annual report see substantial progress accelerate new product sale growth strengthen pharmaceutical vaccine consumer healthcare businessesb gsk annual report strategic report governance remuneration financial statement investor information overview substantial progress accelerate new product sale growth integrate new business vaccine consumer healthcare restructure global pharmaceutical business progress mean group position return core earning growth sir andrew witty chief executive officer performance summary group turnover total operating profit core operate profit cash dividend pay cerup cer cera cerdown proformaa cer proformaa new product salesb total earning share core earning share market operate primarily cer primarily new commercial model reflect impact reflect shortterm dilution transaction gain novartis transactiona potential new medicine potential file estimate internal access medicine vaccine profile asset regulator rate return index event potential firstinclassc footnote use number adjust measure report performance business describe include core result cer growth rate proforma cer growth rate reconciliation total result core result set new product define pharmaceutical relvarbreo ellipta anoro ellipta incruse ellipta arnuity ellipta eperzantanzeum nucala tivicay triumeq vaccine menveo bexsero shingrix approve gsk event november cover story innovation heart katherine picture leave team scientist continue develop nucala year focus include distinct patient study nucala monoclonal antibody stop bind receptor surface eosinophil people asthma eosinophil type white blood cell cause inflammation lung make difficult breathe increase risk asthma attack european regulatory approval nucala firstinclass approve target biologic therapy people eosinophilicdriven severe asthma consolidate gsk lead global position respiratory medicine katherine gsk senior scientist stevenage ukgsk annual report strategic report governance remuneration financial statement investor information content gsk mission strategic report improve quality human investor proposition business chairmans statement life enable people ceo statement global marketplace feel well live long business model strategic priority perform approach risk pharmaceutical vaccine consumer healthcare responsible business group financial review governance remuneration board corporate executive team board governance corporate governance framework committee report audit risk nomination corporate responsibility remuneration report chairman annual statement annual report remuneration remuneration policy summary find wwwgskcom financial statement director statement responsibility independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare gaap cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document investor information write information release oral statement public future behalf group quarterly trend contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current year record fact use word anticipate estimate expect intend project plan believe word product development pipeline term similar meaning connection discussion future operate financial performance particular product competition include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding intellectual property financial result accordance legal regulatory obligation include list risk factor rule disclosure transparency rule financial conduct authority group undertake obligation update forwardlooke statement result new information future event share capital share price reader consult additional disclosure group document dividend publish andor file sec reader locate note disclosure accordingly assurance give particular expectation meet shareholder caution place financial calendar undue reliance forwardlooke statement annual general meeting forwardlooke statement subject assumption inherent risk uncertaintie relate factor tax information shareholder group control precise estimate group caution investor number important factor shareholder service include document cause actual result differ materially express imply forwardlooke statement factor include limit discuss risk factor page contact annual report forwardlooke statement behalf group speak law regulation date base knowledge information available director date group company annual report glossary term expectation target future performance read assumption relate outlook inside cover number adjust measure report performance business measure define reconciliation core result total result set gsk annual report strategic report governance remuneration financial statement investor information investor proposition gsk sciencele global healthcare company aim deliver growth improve return shareholder development innovative pharmaceutical vaccine consumer healthcare product worldleading business broad range pharmaceutical vaccine consumer healthcare growth driver global presence access increase demand healthcare turnover turnover turnover leadership key comprehensive world therapeutic area vaccine portfolio lead global consumer include respiratory industry healthcare company hiv retail sale strong innovation new potential medicine underpin vaccine pipeline business vaccine respiratory rare disease profile eventb disease research focus core therapy area believe potentially firstinclass immuno hivinfectious oncology inflammation disease potential file asset gsk event november efficient global operating model adjust free cash flow exclude incremental annual cost focus cost fund divestmentsc saving deliver optimise operation restructure investment net proceed disposal annual cost saving modernisation generate expect end improve profitability efficiency reduction net debt exclude legal payment noncore billion annual saving restructuring integration cost initial achieve december tax payment sale oncology businessgsk annual report strategic report governance remuneration financial statement investor information earning core ep percentage presence annual revenue growth expect market expect new reach double digit pharmaceutical cer vaccine product sale sale achieve mediumterm outlook group grow core eps midtohigh single digitsg cagr investor event year cerh gsk outline series expectation performance year period inside cover return ordinary dividend share special dividend estimate internal partner rate return organisation world share investment include academic institution billion novartis publicprivate partnership transaction proceed pharmaceutical biotechnology company expect pay ordinary dividend share time supply customer trust key new pharmaceutical gsk respiratory product introduction vaccine usf launch market legacy gsk brand customer trust ranking demonstrate unique visitor gsk gsk annual customer value survey hcp digital portal customer investor event gsk consumer healthcare outline series expectation performance year period supply average service inside cover level otif expect compound annual growth rate time cagr base year inside cover gsk annual report strategic report governance remuneration financial statement investor information business focus research development innovative pharmaceutical medicine vaccine consumer healthcare product business strategy pharmaceutical vaccine strategy design generate consumer healthcare business sustainable sale earning growth generate turnover billion improve return shareholder strategic priority business benefit gsk global research development commercial infrastructure integrate supply grow balanced business network innovative significant product portfolio capable innovation underpin global presence deliver sustainable sale growth business partner business model company academic research develop deliver organisation world ead business opposite high quality innovative product enable increase page offer valuable improvement understand new area science treatment patient consumer global presence share risk development healthcare provider significant global presence deep portfolio innovation employee simplify way operate focus core area market network manufacturing reduce complexity increase efficiency scientific research development site large centre free resource reinvest hiv infectious disease oncology belgium china business return immunoinflammation vaccine shareholder respiratory rare disease attractive return profile new potential balanced geography medicine vaccine turnover region responsible business believe potential responsible business central firstinclass mean offer strategy deliver success benefit current standard important achieve care case radically work underpinned value transform patient treat patient focus integrity respect people transparency read page read strategic priority approach responsible europe business page international potential file asset asset profile balanced business expect group turnover phase iii starts phase start estimate internal rate return investment pharmaceutical vaccine consumer healthcare core expenditure core expenditure allocation pharmaceuticals vaccine consumer healthcare gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine consumer healthcare pharmaceutical business develop vaccine business consumer healthcare business make medicine treat broad large world develop develop market product range acute chronic disease produce distribute million wellness oral health nutrition lead global position vaccine day people skin health portfolio respiratory disease hiv world broad portfolio world trust good portfolio innovative establish paediatric adolescent adult selling brand include sensodyne medicine travel vaccine voltaren horlick panadol read page read page read page total turnover total turnover total turnover group turnover group turnover group turnover sale therapy area sale category sale category respiratory rotavirus wellness cardiovascular metabolic urology pneumococcal oral health immunoinflammation flu nutrition oncology meningitis skin health pharmaceutical tdap establish product hepatitis hiv viiv healthcare represent sale prior disposal tetanus diphtheria acellular pertussis oncology business unit novartis march gsk annual report strategic report governance remuneration financial statement investor information strategic report governance remuneration financial statement investor information chairmans statement group good progress deliver strategy outlook set shareholder group declare pleased report group highlight ordinary dividend penny share demonstrate strength multiple area special dividend pence governance review work oversee audit risk committee current level annual dividend remuneration committee penny exceed cash flow operate accordance bind business board remuneration policy approve say expect maintain level shareholder remuneration payment ordinary dividend special report find important year change dividend period longterm impact cash flow please welcome decline seretideadvair new independent nonexecutive director clear benefit board vindi banga jesse letter shareholder cash generation growth recently goodman senior independent pleased report group launch product expansion director designate scientific good progress deliver strategy vaccine consumer business medical expert respectively please outlook set shareholder reduce restructure expenditure contribution board deliberation good progress clear element group strategy development company operate sir christopher gent retire deal decline sale model pipeline board chairman seretideadvair well important longterm health year helm gsk stand decade big company board encourage time tom swaan source profit group level innovation company je ulrich longserve non considerable challenge pipeline novel asset development executive director stephanie burn investment new core therapy area sir deryck maughan daniel pharmaceutical vaccine product podolsky retire plan priority board manage see effective transition agm complete succession executive management group portfolio year service han wijer nearly year decide seek reelection agm important group secure ceo sir andrew indicate year greatly appreciate sale benefit cost synergies board intention retire dedication experience wealth result recent novartis company early board knowledge insight bring transaction successfully agree retire march board deliberation year complete board closely culmination year service board monitoring integration new service leadership gsk business acquire vaccine industry thank andrew closing behalf board consumer healthcare clear formally tremendous dedication like thank sir andrew executive management substantial contribution year meantime team commitment progress board start formal search performance successor consider internal external candidate role philip hampton chairmangsk annual report strategic report governance remuneration financial statement investor information strategic report governance remuneration financial statement investor information ceo statement progress strongly position group deliver medium term outlook set investor year return core earning growth year launch restructuring modernising highlight number new pharmaceutical vaccine business product sale group ahead schedule reach billion performance integration restructuring programme drive continue excellent uptake realise billion hiv launch tivicay triumeq incremental annual cost saving grow momentum new respiratory track deliver billion portfolio relvarbreo anoro incruse saving end group turnover significant contribution newly modernise business cer cer proforma acquire meningitis vaccine bexsero make significant change menveo commercial model new product sale change compensate sale offset decline seretideadvair representative begin sale january stop pay external new product sale peak doctor speak product industry first time see strong performance invest significantly consumer healthcare business medical expertise develop new sale proforma digital capability improve drive number key brand include interaction physician incremental annual cost saving sensodyne allergy treatment flonase integration restructuring switch prescription status outlook overthecounter progress strongly position group deliver strong innovation mediumterm outlook set marked progress organisation continue deliver investor year return strategy create balanced group significant innovation group core earning growth world lead business key milestone approval pharmaceutical vaccines consumer europe nucala biologic finally year healthcare clear aim deliver growth treatment severe asthma like thank employee improve return shareholder successfully gain approval malaria extraordinary energy passion tenacity vaccine vaccine parasite year complete major transaction novartis good group receive progress integrate new business approval new molecular entity consumer healthcare vaccine nmes november profile restructure pharmaceutical business new potential medicine time sale new vaccine believe product dramatically accelerate firstinclass trading performance year expect sir andrew witty group sale rise proforma significant development milestone chief executive officer billion despite trading condition number asset include filing remain challenge number vaccine shingle shingrix market core earning share sirukumab rheumatoid arthritis pence cer ahead triple combination therapy chronic guidance year total earning obstructive pulmonary disease copd share pence rise addition expect continue progress reflect significant gain mid late stage pipeline core transaction therapy area respiratory immuno inflammation hiv vaccine oncology footnote saving achieve december come year gsk annual report strategic report governance remuneration financial statement investor information global marketplace global healthcare marketplace experience significant change uneven economic recovery farreache global trend evolve commercial environment particularly price transform sector global healthcare market develop economy age global economy remain fragile population improvement macroeconomic overall growth fall medical technology add social trend reflect slow pressure healthcare budget growth certain emerge economy change societal attitude oilexporte country shape healthcare environment despite unsettled economic people take increasingly population growth background global pharmaceutical active role manage ageing population market continue grow global sale health create demand lifestyle change billion period january healthcare product september billion finally heighten geopolitical month uncertainty key region longterm economic growth north america remain large likely impact certain healthcare market emerge market pharmaceutical market share global sale europe represent gsk group world lead asia pacific relatively static business pharmaceutical vaccine rapid scientific emerge market fall consumer healthcare global technological advance japan presence mean position respond opportunity global vaccine market grow billion expect strategic response opposite political instability continue grow year pricing market access fragmentation represent billion pressure public debate industry approach price continue consumer healthcare market increase key market increase expectation gsk operate estimate worth particularly alongside transparency billion project healthcare system focus high standard grow annually assess value medicine business yearsc formal health technology assessment evaluate implication hta continue grow importance business possible exit japan new assessment climate change united kingdom european process pilot resource depletion union view advantage establish system europe continue remain present challenge delay launch group continue easy restrict patient population access significant economic bloc successful market access negotiation global competition able operate established innovative valueadde product talent harmonise regulatory approval system continue country continue benefit advocacy demonstrate continued willingness international trade discussion pay treatment meet genuine unmet leave create patient need see aggressive formulary uncertainty add complexity wide price negotiation exclusion range business activity highlycharge public debate compete product shortterm disruption likely plan price increase influence value place mitigate effect assessment likely continue public commentary issue currently believe continue create able capture complexity pricing material adverse impact uncertainty industry increase structure confidential discount group result financial position collaboration different stakeholder create lack transparency key deliver mutually acceptable stakeholder include policy maker global societal trend pricing access solution presidential election candidate payer impact healthcare provider patient call price emerge market longterm economic reform expect pricing growth increase expectation healthcare healthcare landscape continue focus policy debate provision change diet lifestyle substantial change strong focus increase demand healthcare continue expand healthcare coverage product life stage especially control cost area high growth footnote treat chronic condition include time government international monetary fund world economic respiratory cardiovascular disease implement policy shift payment outlook adjust low commodity price october demand expect grow significantly away traditional feeforservice fast market come arrangement approach orld preview outlook year mature economy intend increase competition internal forecast base nicholas hall create funding challenge incentivise efficiency quality euromonitorgsk annual report strategic report governance remuneration financial statement investor information opportunity challenge healthcare sector rise living standard age population lead grow demand healthcare particularly emerge market change lifestyle lead change disease burden global scientific advance create opportunity healthcare innovation marketplace payer concern cost value lead pressure pricing demand differentiate product expectation high standard behaviour healthcare company strategic response worldleading business global sustainable pricing lead responsible create group world aim improve return business approach lead business pharmaceutical innovation strike balance responsible business vaccine consumer healthcare price volume generation fundamental gsk strategic presence market prioritie business actively work payer provide access global demand important financial result policymaker physician healthcare aim deliver growth deliver lead industry solution address concern improve return shareholder access medicine datum transparency cost healthcare realise evolve commercial model read page maximise value patient ensure patient interest come provider innovator create innovative product centre discussion read innovation underpin business focus core therapy read area scientific understanding help deliver significant medical advance patient read page gsk annual report strategic report governance remuneration financial statement investor information global marketplace continue regulatory environment provision introduce grow population prescription medicine vaccine period time depend highly regulated ensure patient country agreement ratify user access safe effective congress medicine food conclude bilateral people drug administration fda approve new agreement market region medicine approve novel vietnam medicine high improve regulatory environment number approval enhance patient access key medicine pharmaceutical industry vaccine number trade year old healthcare landscape continue agreement negotiation undergo substantial change transpacific trade investment strong focus improve quality partnership eujapan fta controlling cost fda respond challenge work market availability intellectual people outside industry advance alternative approach property right particularly patent data europe help reduce time cost protection limit develop new medicine particularly difficult enforce develop world generic include market example india brazil use biomarker real world data argentina implement new baby consider practice restrict europe european medicine availability patent addition agency ema regulate new medicine country consider widespread issue positive opinion use compulsory licensing medicine contain new active substance vaccine biological product europe ema continue effort help currently face degree generic give significant public funding accelerate patient access valuable competition largely healthcare european country new medicine include progress product research require pressure government budget continue adaptive pathway pilot proposal difficult product complex create challenge industry launch new scheme boost innovation quality dependent technical market grow primarily call prime priority medicine manufacturing process compare use new highpriced medicine small molecule medicine japan new medicine hepatitis put great constraint receive approval intellectual property protection healthcare budget inequality access regenerative cell base medicine available consumer healthcare medicine european product develop product importance country patient population jcr pharmaceutical partner effectiveness different consumer affordability remain significant gsk product obtain healthcare product cover issue despite debate issue designation sakigake fasttrack national regulation test medicine affordability particular review system introduce approval manufacturing labelling affordability member state lower promote early development marketing advertising product gdp practical challenge remain regulatory application japan ahead strong reliance brand loyalty significant reform medicine pricing rest world trade mark protection create protect access value time especially emerge intellectual property patent japan market protection development strong focus pricing ensure reasonable return competition japan government implement investment researchbase healthcare gsk operate highly competitive new approach mitigate fiscal burden company rely protection dynamic marketplace see rapid associate medicine annual intellectual property patent consolidation sector response sale billion yen regulatory data exclusivity right significant market pressure exceed significantly sale forecast industry merger acquisition agree government launch patent expiry early loss patent pharma medical biotech sector hit lead availability generic emerge market new record transaction version product government emerge market reach billion globally billion cheap generic manufacturer region continue seek way improve deal sector typically incur significant cost access healthcare alonee consumer healthcare develop market generic rapidly time manage healthcare expenditure market remain highly competitive capture large share market market high profile deal country dependent oil look erosion emerge market limit spend health result agreement reach significant decrease oil price transpacific partnership give country diverse ghana china footnote inter alia year datum exclusivity india look expand mergermarket global regional population cover governmentfunde nonbiologic pharmaceutical product biologic additional health scheme increase mergermarket global regional year equivalent protection opportunity high volume tender impact pricinggsk annual report strategic report governance remuneration financial statement investor information business model success depend ability research develop innovative healthcare product accessible people possible deliver mission align business model design lead profitable input strategic priority deliver range output patient sustainable performance turn harness primary input set shareholder society addition allow generate value return strengthen ability product direct benefit patient consumer shareholder enable satisfy unmet need offer cost effective shareholder successful business reinvest business healthcare option customer help build strong society increase access vaccine medicine direct indirect contribution consumer healthcare product country operate tax employment charitable support input business operation output unmet medical need pharmaceutical healthcare benefit discover patient develop innovative consumer scientific healthcare product technological expertise sustainable sale growth macro socioeconomic vaccine manufacturing environment make distribute return shareholder quality product financial resource world benefit society include tax collaboration consumer healthcare commercialisation employment partnership distribution charitable support improve access people product profit cashflow culture generation reinvestment gsk annual report strategic report governance remuneration financial statement investor information strategic priority strategy design generate improve sale earning growth sustainable return shareholder benefit patient consumer strategic strategic priority progress novartis transaction complete grow significantly strengthen vaccine consumer healthcare business strong performance new balanced business pharmaceutical vaccine product create balanced business billion sale product portfolio capable deliver sustainable sale earning growth successful otc launch flonase centre business allergy relief pharmaceutical vaccine consumer healthcare read page launch nucala eosinophilic deliver asthma approval europe positive phase iii data shingrix product value candidate shingle vaccine research develop high quality file gene therapy rare disease innovative product offer valuable adascid europe improvement treatment patient consumer healthcare provider read page integration restructuring cost saving simplify track pharmaceutical consumer operating model healthcare market live gsk global erp transform operate reduce system live august complexity increase efficiency free consumer healthcare supply achieve average resource reinvest service level otif time business return shareholder attractive time supply key new return pharmaceutical product introduction launch market read page legacy gsk brand responsible malaria candidate vaccine rtss business receive positive opinion european regulator responsible business central continue transform commercial strategy deliver model drive growth build trust success important reshaping relationship achieve healthcare professional implement new sale force ensure value embed compensation approach culture decision make help well meet expectation society read page gsk annual report strategic report governance remuneration financial statement investor information key challenge performance future priority continue pricing pressure deliver earning guidance europe core ep percentage growth reach double digit cer change market dynamic impact speed uptake new group turnover drive sale new product meet product launch target billion annual turnover slow emerge market economy group core eps midtohigh single digit cagr growth cer basis read global year period marketplace page core earning share investor event gsk reconciliation total result core outline series expectation result set performance year period inside cover ensure continue focus file approval key product include delivery ongoing restructure shingrix benlysta subcutaneous programme include site rationalisation sirukumab close triple integration novartis vaccine new potential medicine vaccine pipeline pipeline profile event deliver phase iii starts phase start summit study statistically gsk event november significant mortality benefit relvar complete integration bms pipeline breo ellipta copd patient hiv medicine estimate internal rate return investment complexity integrating deliver incremental annual saving employee consumer healthcare billion billion vaccine business bring total billion annual saving end roll new system erp incremental annual cost saving scale market continue streamline product portfolio deliver reduce complexity formulation transfer market oncology product novartis packaging format embed common process platform read approach risk integrate reporting system follow page global reduction number pharmaceutical novartis transaction marketplace page pack variant baseline billion saving achieve december reduce value chain carbon emission support delivery malaria demand product high vaccine notforprofit price carbon footprint ventolin key partnership increase dow jones sustainability index score continue enhance governance strengthen valuesbased culture compliance quality encouraging report proactive risk management concern qualityled culture change programme transform lead access medicine continue improve leadership commercial model index effectiveness quality talent gsk annual report strategic report governance remuneration financial statement investor information perform measure performance number key performance indicator remuneration executive base group turnover perform turnover report basis proforma proforma basis high sale hiv vaccine consumer healthcare growth cer partly offset low global pharmaceutical sale report proforma exclude divestment complete new pharmaceutical vaccine product performance definition new product identify investor event expect deliver billion sale annum growth growth cer basis target cer expect reach year early perform sale new product billion represent pharmaceutical vaccine turnover sdnedivid sdnedivid sdnedivid pharmaceutical turnover perform turnover report basis proforma growth hiv product primarily tivicay triumeq offset growth cer continue decline seretideadvair sale price pressure report increase generic competition proforma exclude divestment complete vaccine turnover consumer healthcare turnover perform turnover report perform basis proforma turnover grew report business benefit basis proforma newly acquire meningitis portfolio growth cer business benefit sale growth cer proforma growth drive newly acquire product strong rotarix flulaval report particularly voltaren otrivin report boostrix sale proforma theraflu proforma growth proforma bexsero sale europe predominantly drive oral health wellness category exclude divestment complete cash return shareholder perform gsk return billion shareholder dividend return billion shareholder billion dividend billion share repurchasesgsk annual report strategic report governance remuneration financial statement investor information total operate core operate profit margin profit margina perform definition total operating profit core result exclude number item billion exclude currency total result definition core effect total operating margin growth result find growth cer increase percentage point reconciliation total result cer report primarily reflect core result provide high profit disposal perform proforma oncology business asset partly offset increase core operating profit billion exclude currency effect contingent consideration liability core operating margin decline payable relation viiv healthcare result high sale outlook percentage point primarily sav sta aor tem thq nen ocd tigh imefl tie transaction exclude divestment complete total earning share core earning sharea perform definition total earning share core result exclude number item compare total result definition core primarily reflect increase result find business asset disposal gain growth reconciliation total result growth partly offset increase core result provide contingent consideration liability cer cer perform payable relation viiv healthcare core eps decreased primarily result high sale outlook reflect shortterm dilution tivicay triumeq novartis transaction impact continue transition pharmaceutical business particularly respiratory exclude divestment complete free cash flowa net debt definition definition calculation free cash flow net debt comprise bank loan adjust free cash flow describe overdrafts obligation finance reconciliation lease commercial paper provide growth bond issue gsk cash perform liquid investment exre ins afl tlea ail yli mon tsu tho ete roe efo frd disposal restructuring cost initial tax oncology business payment oncology disposal asset enable accelerate free cash flow billion restructuring integration compare billion programme return billion decline reflect initial impact cash shareholder dividend novartis transaction lower reduce net debt billion operating profit free cash flow exclude payment legal cost restructure tax oncology disposal footnote use number adjust measure report performance business describe include core result management planning reporting purpose directly comparable similarly describe measure company gsk annual report strategic report governance remuneration financial statement investor information approach risk rigorous consistent risk management process system help assure integrity business operation effective risk management key principal risk sustainable business success establish risk management framework definition couple internal control help maintain focus manage principal risk affect business principal risk list table opposite believe cause patient safety result differ materially expect failure appropriately collect review follow report adverse event historical result risk potential source act relevant finding timely manner significantly impact strategic priority grow deliver simplify corporate executive team review intellectual property principal risk annually fourth quarter failure appropriately secure protect intellectual property right assure appropriateness follow year agree consolidate reporting description number principal risk align product quality manage business failure comply current good manufacturing practice cgmp consolidated list report opposite inadequate control governance quality supply chain covering table summarise supplier standard manufacture distribution product define risk assessment change risk assessment base external financial control reporting environment operate failure comply current tax law incur significant loss business operation impact treasury activity failure report accurate financial information compliance internal control severity risk accounting standard applicable legislation failure maintain adequate period risk exposure continually governance oversight thirdparty relationship review senior management subject change result internal external factor future event antibribery corruption abac detail definition failure prevent gsk employee party comply abac context potential impact mitigate principle standard applicable legislation activity page progress establish global risk management office help drive good practice commercialisation standard business remit failure execute business strategy manage competitive opportunity include standardise methodology threat effectively accordance letter spirit legal industry manage principal risk identify company requirement significant emerge risk business continue evolve antibribery corruption team enhance research practice resource focus remit failure adequately conduct ethical sound preclinical clinical research include party oversight tpo addition failure engage scientific activity consistent letter commission external assessor evaluate spirit law industry group requirement high risk supplier distributor build effort enhance environment health safety sustainability ehss standardise approach regional failure manage ehss risk line objective policy review internal control relevant law regulation pharmaceutical business assess new approach annual review enable confirm information protection company standard local law failure protect maintain access critical sensitive computer system regulation understand adhere information place business viability statement set assessment prospect group crisis continuity management year inability recover sustain critical operation include key supply chain reference thing follow disruption respond crisis incident timely manner principal risk managedgsk annual report strategic report governance remuneration financial statement investor information manage risk assessment change risk increase risk change risk decrease risk chief medical officer lead large global safety pharmacovigilance team maintain global policy guide employee risk remain paramount focus mature rigorous control place manage global patent group continually analyse change patent law regulation ensure incorporate process continue focus ensure robust effective process place mean assessment risk change chief product quality officer accountable quality management system include implementation associate policy lead global network quality council view risk continued escalate increase regulation sanction company sector response significantly invest reinforce strengthen quality culture organisation chief financial officer group financial controller oversee internal control relate financial information report tax treasury introduce additional resource monitoring ensure robust financial control maintain effectively manage risk initial phase integrate novartis business control reporting framework implement ongoing transformation upgrade financial system process continue additional risk mitigation introduce amend programme timeline ongoing system upgrade extensive global abac programme policy procedure include train employee whilst risk remain significant gsk continuous improvement compliance training programme review reduction presence number high risk market manage bribery corruption risk exposure present global business operation single global standard promotional marketing activity gsk product employee include party act behalf comply introduce change engage healthcare provider implement new sale force incentive model globally believe decrease level risk business structure provide access fast grow demand healthcare balanced exposure future change industry environment governance system control oversee clinical trial research use biological sample data integrity key system continue focus regulatory inspection place establish quality assurance programme ensure continue adherence regulatory requirement global ehss standard support clear policy employee train believe overall management ehss risk remain effective gsk reduce risk employee harm traditional enterprise disruption category process safety high risk chemical manufacturing facility chief information security officer oversee global information policy programme regularly assess change monitor internal system external environment believe risk increase major company year include prominence external threat internally continue invest improve capability technological solution counter threat crisis continuity management ccm governance board support team ccm expert ensure critical business operation plan place potential disruption business continue risk establish governance board business continue learn plan activation enable continue drive improvement programme gsk annual report strategic report governance remuneration financial statement investor information pharmaceuticalsgsk annual report strategic report governance remuneration financial statement investor information pharmaceutical business discover develop commercialise medicine treat broad range world common acute chronic disease number number employeesa core spend billion pack medicine produce new potential medicine vaccine pipeline profile eventb include gms dedicated support function staff gsk event november gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical pharmaceutical portfolio performance innovative establish strengthen summary medicine hold lead global respiratory portfolio position respiratory disease hiv underpin innovative research nextgeneration pharmaceuticals organisation drive discovery development treatment potential core area research hiv alter fundamental turnover infectious disease oncology immunoinflammation respiratory course disease rare disease respiratory extensive portfolio focus successfully report sale growth cer respiratory product industry transition new portfolio seretideadvair remain world well accelerate growth product sell brand respiratory product expectation proforma sale growth cer continue lead scientific innovation product expect account area work ensure patient approximately sale receive effective therapy possible respiratory compare convenient device target research portfolio past year potential nextgeneration treatment core operating profit significantly broaden strengthen respiratory disease current respiratory portfolio launch approach inhale medicine relvarbreo ellipta anoro ellipta launch nucala mepolizumab gsk incruse ellipta arnuity ellipta injectable biologic severe asthma multiple potential medicine target medicine administer underlie cause respiratory disease easy use patent dry development powder inhaler ellipta strategy action product expect account approximately sale respiratory compare tivicay triumeq new pharmaceutical product sale overall pharmaceutical sale turnovergsk annual report strategic report governance remuneration financial statement investor information hiv strong presence hiv advance treatment benefit people global hiv business manage live hiv viiv healthcare company majority own gsk pfizer shionogi tivicay prescribe access hiv treatment shareholder lead people live hiv major focus reflect hiv company world launch august regulatory strategy take triumeq dolutegravirbase regimen strong recent performance august seek regulatory approval hiv business principally lead product country tivicay dolutegravir innovative strong sale momentum total possible facilitate integrase strand transfer inhibitor positively support approval process generic version singlepill treatment triumeq pharmaceutical business dolutegravir country combination dolutegravir abacavir country need press lamivudine performance overtake previously lead agent see file generic significant hiv pipeline building success japan dolutegravir aurobindo support explore new therapy patient country viiv healthcare viiv healthcare partnership potentially enable longterm establish leadership clinton health access initiative hiv control infrequent dosing position country large viiv healthcare sign early viiv healthcare acquire hiv company innovative manufacturing partnership bristolmyer squibb late stage hiv continue evolve way desano pharmaceutical enable asset portfolio preclinical engage healthcare professional competitive supply dolutegravir discovery stage hiv research asset tivicay triumeq launch china number develop acquisition expect strengthen demonstrate digital country end tivicay group leadership hiv provide communication enhance available country new opportunity growth interaction triumeq specialty establish product rapid digital launch campaign addition respiratory hiv see open click sell innovative rate significantly pharmaceutical product include industry average benlysta treatment lupus digital focus positively tivicay prescribe disease tanzeumeperzan comment customer remain people live hiv type diabete key priority launch august establish product portfolio include mature medicine area antiinfective allergy central nervous system dermatology respiratory urology product important emerge market business sell volume second large competitor sell volume pharmaceutical new potential product emerge medicine vaccine gsk potential market second pipeline profile event file asset large competitor regulator believe potentially firstinclass gsk event november gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical continue grow deliver new pharmaceutical product sale performance summary pharmaceutical pipeline progress new product increase continued progress offset contribution particularly respiratory pharmaceutical pipeline hiv restructuring pharmaceutical believe offer significant opportunity drive decline seretideadvair cost base continue longterm performance group million report pharmaceutical sale late stage pipeline deliver new million cer primarily firstinclass medicine reflect disposal market approval europe oncology product adjust nucala antiil monoclonal antibody disposal proforma turnover decline treatment severe asthma reflect decline respiratory sale eosinophilic inflammation indication decline sale establish breo ellipta expand product largely offset approval treatment adult growth new pharmaceutical product asthma sale million rare disease file european increase million strong approval strimvelis gene therapy performance hiv product triumeq treat patient adenosine deaminase tivicay acceleration severe combine immunodeficiency sale new respiratory product help syndrome adascid approve deliver performance corrective gene therapy new pharmaceutical product sale approve world offset decline seretideadvair immunoinflammation positive result million global seretideadvair achieve phase iii study sale billion approximately investigate subcutaneous benlysta peak lupus sirukumab rheumatoid significant change arthritis regulatory filing expect modernise commercial model medicine stop pay healthcare receive data summit professional hcp speak study understand mortality product instead recruit morbidity copd summit number inhouse medical expert achieve statistical significance addition increase digital primary endpoint datum generate communication hcp study inform overall profile webinar click chat facility medicine expect submit enable hcp talk real time authority label update gsk medical expert reaction customer positive believe change offer gsk source competitive advantage read group financial review page gsk annual report strategic report governance remuneration financial statement investor information begin phase iii study investigate close triple icslama laba combination treatment copd dolutegravir combination janssen rilpivirine hiv infection sirukumab giant cell arteritis retosiban preterm labour stop development losmapimod antiinflammatory agent patient acute coronary syndrome interim analysis datum ongoing phase iii trial fail efficacy signal stepwise trial design interim review enable limit investment study deep portfolio innovation profile portfolio innovative medicine focus core area pharmaceutical research hiv infectious disease respiratory oncology immunoinflammation rare disease vaccine separate section total new potential medicine vaccine profile support group outlook growth period significant opportunity group create value believe approximately decade innovative science deliver medicine review potential biologic treatment severe eosinophilic asthma patient firstinclass novel mechanism action result offer benefit current standard year regulatory asthma patient care case radically approval severe asthma severe asthma proportion transform patient treat treatment nucala mepolizumab severe eosinophilic asthma key milestone long journey struggle control asthma develop portfolio innovative discovery despite medication experience medicine focus target frequent asthma attack regular immune mechanism alter nucala gsk injectable respiratory hospitalisation fundamental course disease modify biologic therapy identify hard treat patient disease progression present potential respiratory treatment condition ociden result opportunity achieve remission time consider disproportionately high burden functional cure develop treatment mild moderate asthma patient healthcare system simplify treatment regimen initial result patient potential new generation longacting group disappoint study involve medicine provide longterm control people research allow team improve treatment outcome patient well understand specific role mepolizumab believe great generation technology platform eosinophil play severe asthma potential use emerge scientist lead approval firstinclass science identify patient increase understand fundamental approve target treatment severe benefit disease mechanism develop eosinophilic asthma patient new approach disease management aid grow understand control cause asthma particular role eosinophil type white blood cell cause inflammation lung focus research look specifically severe eosinophilic firstinclass biologic asthma patient therapy target antibody gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical continue notable advance scientist pharmaceutical portfolio include potential leadingedge molecule generation technology field epigenetic immunooncology platform increase treatment cancer generation respiratory medicine understand inhale treatment portfolio new antibody inflammatory disease fundamental disease include rheumatoid arthritis autoimmune mechanism disease osteoarthritis investigate potential new option develop new approach longterm control prevention hiv disease management opportunity design cure induce longterm remission hepatitis control rare disease potential total potential file breakthrough cell gene therapy asset regulator milestone additional innovative asset expect number clinical development significant development milestone pharmaceutical approach pharmaceutical vaccine pipeline regulatory filing include highly selective shingrix shingle vaccine sirukumab investing area rheumatoid arthritis subcutaneous good opportunity consider benlysta lupus close triple patient need market opportunity icslamalaba combination treatment scientific understanding copd commit improve productivity develop expect phase iii start innovative new medicine vaccine include cabotegravir hiv daprodustat great efficiency anaemia pentavalent candidate vaccine prevention meningococcal commit publish meningitis man abcwy estimate internal rate return irr phase start immunoinflammation base investment late oncology respiratory infectious stage pipeline expectation disease longterm sale performance estimate apply methodology estimate irr remain timeline development stage pharmaceutical research drug regulatory approval postmarkete preclinical clinical trial discovery review launch surveillance phase phase phase compound compound compound year year year investigational new drug application submit investigational new drug application submittedgsk annual report strategic report governance remuneration financial statement investor information collaboration external partner critical component strategy enable access increase understand new area science share risk development early research effort centre discovery performance unit dpus nimble personalised unit budget great accountability project far remove traditional hierarchical business model help maintain flexibility research investment focus promise scientific opportunity drive accelerate drug discovery output cost saving generate today dpus simplify pharmaceutical restructuring support third original unit establish progress simplify business delivery billion annual saving group end significantly reshape responsibility guide pharmaceutical business continue improve performance investigational medicine later reduce supply chain complexity new product restructure development stage file regulator retain commitment quality improve flexibility cost base rest medicine development rescale commercial operation allow offset headwind team small unit global support function operating margin continue people manufacture support business decline seretideadvair old partner product support enhance supply chain improvement programme organisation world investment new product aim deliver industryleade level include academic institution growth key deliver performance programme publicprivate partnership expect mediumterm outlook deliver significant saving pharmaceutical biotechnology pharmaceutical business procurement excellence company collaboration buy logistic distribution portfolio commit meet high external partner critical component optimisation reduce number standard stringent quality control strategy enable access pharmaceutical pack variant quality assurance process increase understand new baseline medicine vaccine manufacture area science share risk streamline external supply accord good manufacturing practice development result network cgmp regulations internal collaborative culture gsk quality management system estimate new strengthen logistic regulatory inspection molecular entity nme currently operation establish regional vast majority conclude clinical development discover supply demand hub enable satisfactory outcome work internally collaboration efficient use warehouse regulator bring inspection external partner transport reduce cost serve remain concern acceptable million great time cost involve conclusion august follow drug discovery development ongoing rollout enterprise food drug administration fda essential highly selective resource planning erp system reinspection warning letter invest focus resource commercial market manufacturing relate cork manufacturing site executive team oversee strategic site critical transformation lift issue overall budget management couple new planning capability robust governance increase endtoend visibility board manage investment technical control help ensure supply demand scientific commercial decision robust align change life cycle help improve service patient new medicine launch consumer gsk annual report strategic report governance remuneration financial statement investor information vaccinesgsk annual report strategic report governance remuneration financial statement investor information vaccine business large world develop vaccine protect wide range disease number number employeesa core spend license vaccine protect disease million vaccine deliver day candidate vaccine pipeline include gms dedicated support function staff gsk annual report strategic report governance remuneration financial statement investor information vaccine vaccine portfolio broad performance grow vaccine company available summary paediatric adolescent adult travel performance summary vaccine protect different report vaccine sale grow disease include hepatitis influenza million europe pneumococcal disease rotavirus international cervical cancer business benefit sale newly turnover addition novartis portfolio acquire product proforma basis gain vaccine prevention sale grow good contribution meningitis menveo approve rotarix fluarixflulaval boostrix baby month addition see rapid sale growth market country worldwide new meningitis vaccine portfolio bexsero new meningitis vaccine menveo bexsero sale report sale growth cer currently available country proforma million notable decision national health new vaccine pipeline bring service include bexsero national proforma sale growth cer expertise virology bacterial immunisation programme overall growth infection different technological partly offset decline proforma platform candidate vaccine sale hepatitis vaccine infanrix development disease include pediarix sale impact shingles meningitis rsv group strep year high trade inventory core operating profit chronic obstructive pulmonary disease inherit newly acquire vaccine copd exacerbation international market expansion portfolio boost offer world read group financial review page notably novartis strong presence track record regulatory approval gsk significant presence emerge develop continued country provide new opportunity introduction progress growth newly acquire vaccine promise pipeline year tiere pricing approach vaccine base support future growth gross national income enable vaccine business country maintain expand commitment immunisation economy grow large contributor gavi vaccine alliance publicprivate partnership improve access vaccine develop country effort improve access medicine vaccine responsible business section strategy action unique world lead expertise adjuvant technology vaccine operate difference margin help protect disease like malaria cervical cancer bexsero menveo pandemic flu combine global sale base proforma cer newly acquire meningitis portfoliogsk annual report strategic report governance remuneration financial statement investor information deliver vaccine pipeline progress vaccine work focus discover develop new prophylactic therapeutic vaccine help protect treat people disease currently candidate vaccine early mid latestage development range disease report positive pivotal phase iii trial data adult advanced candidate shingrix prevention shingle intend file global regulatory application shingrix second half receive positive scientific opinion european regulator malaria vaccine mosquirix child age week month mosquirix vaccine malaria reach milestone additionally regulatory review adjuvant technology shingrix novel candidate vaccine malaria vaccine phase clinical development report positive responsible business section respiratory syncytial virus rsv common pivotal phase iii trial datum cause bronchiolitis pneumonia infant lead hospitalisation adult continue progress paediatric enhance risk severe asthma vaccine measle mump rubella paediatric rsv vaccine use advanced candidate additional phase iii trial genetically engineer recombinant require achieve registration shingrix prevention chimpanzee adenovirus carrier vaccine ebola vaccine candidate shingle intend vaccine innovation second glycoprotein rsv vaccine file global regulatory november profile number give pregnant woman provide promise early stage asset infant protective maternallyderive application shingrix vaccine pipeline pentavalent rsvneutralise antibodies candidate vaccine prevention second half meningococcal meningitis man abcwy combine exist gsk meningococcal meningitis vaccine advanced phase development phase iii study plan start candidate efficacy vaccine development mosquirix malaria advanced late disease include vaccine receive positive stage candidate vaccine shingle meningitis rsv regulatory review shingrix shingles group strep copd phase iii study exacerbation gsk annual report strategic report governance remuneration financial statement investor information vaccine continue explore maternal immunisation approach candidate vaccine phase development prevent group streptococcus gbs leading cause pneumonia meningitis sepsis affect birth addition candidate vaccine phase clinical proof concept study prevention exacerbation chronic obstructive pulmonary disease copd continue work partner accelerate development ebola candidate vaccine help prevent future disease outbreak candidate vaccine test phase clinical trial country west africa discuss potential regulatory pathway file candidate vaccine approval fda agency investment governance highly selective inv focus resource vaccine discovery development prioritise investment meet need patient address big remain global health challenge core vaccine investment million impressive trial result prepare ground scientist work new shingle vaccine vaccine organisation oversight key decision new candidate vaccine shingrix shingrix demonstrate great potential vaccine development process demonstrate longlaste effective trial involve people rest vaccine research protection pain world october pivotal development board vrdb review discomfort shingles pivotal phase iii study result show project strategy advise phase iii study effective shingles scientific technical matter effective phn people vaccine investment board vib shingles sufferer develop painful itchy make final decision rash ociden turn blister finding echo early pivotal invest project commercial opportunity body phase iii study result show portfolio fit develop postherpetic neuralgia phn efficacy shingle intense distressing pain phn over finding continue expand early stage month acider shingles rash show pipeline strengthen expertise appear possible complication candidate vaccine effective age target investment example include scar eyesight problem effectiveness remain acquisition glycovaxyn february secondary infection nerve palsy constant year acider innovative biological administer significant conjugation platform technology support people improvement exist vaccine effort develop new vaccine chicken pox risk effective range bacterial disease shingle disease particularly elderly reduce efficacy time affect adult likely follow successful trial result disease lifetime individual later intend begin file compromise immune system application shingrix cancer patient undergo chemotherapy prevention shingle regulator people hiv especially north america japan europe susceptible shingrix trial ongoing people compromise immune system hope able file regulatory application group patient gsk annual report strategic report governance remuneration financial statement investor information vaccine research development cycle registration identify produce preclinical phase phase proof phase iii file post marketing antigen antigen test concept surveillance research include immunology preclinical development clinical development include post marketing surveillance transfer process manufacturing year year year year invest supply chain simplify gsk vaccine manufacturing progress simplify business site strategically position world broad diversify footprint substantial progress give great manufacturing capacity integrate new novartis business efficiency flexibility act catalyst simplify continue significant investment vaccine operating model strengthen manufacturing network key area manufacture network reduce include start construction new supply cost change help hepatitis facility wavre belgium deliver annual cost saving set major capital investment plan help deliver rosia italy site meningitis target operating margin vaccine incremental annual cost saving helped increase committed quality proforma operating profit margin vaccine manufacture vaccine cer basis high quality standard accord manufacture site current good manufacturing practice complex integration cgmp regulation world programme complete regulatory time take produce vaccine require divestment transaction distribute million dedicated quality control include divestment meningitis vaccines nimenrix mencevax regulatory inspection vaccine day satisfactory outcome november begin restructure ste foy facilitys warning letter people programme remove duplication food drug administration infrastructure role country fda conclude fda find remediation activity complete satisfactorily gsk annual report strategic report governance remuneration financial statement investor information consumer healthcaregsk annual report strategic report governance remuneration financial statement investor information consumer healthcare business portfolio world trust love brand brand underpin sciencebased innovation include panadol voltaren horlick sensodyne develop meet healthcare need consumer worldwide number number employeesa core spend specialist oral care company retail sale serving horlick second india nutritional supplement include gms dedicated support function staff gsk annual report strategic report governance remuneration financial statement investor information consumer healthcare consumer healthcare business brand sell performance world leading represent country world summary consumer healthcare joint venture sale emerge market novartis gsk consumer wellness healthcare list business india wellness big category nigeria exclude overall global leader joint venture number company country business split equally retail sale lead global turnover counter otc medicine position respiratory cold flu nasal fast move consumer good fmcg decongestant allergy smoking cessation brand dedicated healthcare pain management category wellness oral health brand nutrition skin health systemic panadol topical report sale growth cer pain relief voltaren category define specific consumer healthcare requirement complementary range brand allow proforma sale growth cer evolve consumer need core operate profit strategy action consumer healthcare operate margin innovation sale world lead product introduction otc company retail sale specialist year rolling basis oral care companygsk annual report strategic report governance remuneration financial statement investor information oral health power core brand company toothpaste power brand select power brand select number specialist oral newly integrate portfolio newly integrate health leading position sensitivity identify voltaren panadol acid erosion denture care gum sensodyne theraflu otrivin portfolio identify health sensodyne number parodontax poligrip recommend dentist worldwide category leader voltaren panadol sensitivity long track record high sensodyne theraflu average gross margin skin health otrivin parodontax globally core brand include tum medicate skin health focus flonase horlick eno poligrip treat condition affect million similarity power brand category leader long people worldwide cold sore local regional opportunity dry sensitive skin abreva global track record high zovirax brand hold leading position prioritise investment world large market average gross margin innovation marketing nutrition commercial execution nutrition business particular seven power core brand focus indian subcontinent horlick serve nutritional supplement rate time second mainly child horlick rank sixth trust brand india brand indication focus brand strategy innovation generating growth horlick market share india sensodyne double digit growth horlick deliver time share organisation region high trust base emerge market hot beverage brand india gsk annual report strategic report governance remuneration financial statement investor information consumer healthcare continue grow deliver identify dozen market performance summary strong innovation pipeline consumer healthcare sale grow category prioritise investment proforma million continue prioritise investment advertising promotion note sensodyne grow doubledigit region capital expenditure close generate sale billion core investment consumer year successful healthcare billion place talent launch flonase allergy relief follow million market contribute strategy switch product integration process prescription otc invest third growth report growth benefit sale capability integrate marketing newly acquire product particularly scientific regulatory technical medical voltaren otrivin theraflu follow team colocate hubs formation joint venture switzerland india china novartis proforma growth singapore go forward predominantly drive growth organisation base oral health wellness category emerge market consumer healthcare build new sensory sale generate innovation packaging lab capability ensure launch year capitalise trend development newtomarket product flavour application technique launch year present growth opportunity example develop formulation key innovation driver year horlick consumer mix cold include flonase water hot water readily available sensodyne complete japan people indian subcontinent help sensodyne brand example fenbid chewable lead toothpaste country launch china pain relief product need water key launch include continue invest shopper sensodyne repair science lab stateoftheart protect whitening facility allow research sensodyne complete innovative product simulate digital real life environment fenbid chewable retail partner test packaging physiogel calm relief range claim shopper material theraflu warm syrup read group financial review page gsk annual report strategic report governance remuneration financial statement investor information simplify progress simplify business integration process simplify organisation build lean business renew focus deliver performance increase agility develop high performance culture personnel exit consumer healthcare joint venture complete site consolidate make good progress change help deliver annual cost saving expect integration enable deliver target operating margin cer incremental annual cost saving helped increase proforma operating profit margin cer basis careful planning enable maintain stable supply chain novartis integration disruption supply time achieve net reduction pack variant product portfolio debut flonase allergy relief regulatory inspection satisfactory outcome year overthecounter otc launch average service level rise launch flonase allergy relief lead allergy brand supply underline effective dual capability recommend doctor chain improvement programme initiative pharmaceutical fast allergist number investment manufacturing move consumer good fmcg recommend pharmacist site enhancement systems nasal allergy brand capacity reduction singlesource nasal spray raw material available prescription contain strong performance aid number prescribe ingredient flonase expert digital marketing provide temporary relief hay campaign achieve strike careful planning enable fever upper respiratory allergy result lead social medium channel maintain stable supply reflect heritage respiratory medicine otc spray chain novartis relieve nasal ocular symptom allergy treatment integration target histamine inhibit disruption supply key substance month partnership retailer enable launch secure strong presence store flonase capture mile shelf space million pointofsale devices integrate adult allergy consumer marketing campaign work product market simultaneously engage shopper month launch flonase capture adult allergy product market lead brand category gsk annual report strategic report governance remuneration financial statement investor information gsk annual report governance remuneration financial statement investor information gsk annual report governance remuneration financial statement investor information responsible businessgsk annual report strategic report governance remuneration financial statement investor information responsible business fundamental gsk strategic priority business important financial result deliver number million people reach training frontline health worker develop country million child reach lifesave immunisation treatment intervention groundbreake partnership save child market operate new commercial model employee family member country access preventive healthcare partnership prevention programme reduction operational waste hazardous nonhazardous year gsk annual report strategic report governance remuneration financial statement investor information responsible business approach create value society responsible business priority highlight success benefit wide society gsk responsible business priority sit develop innovative healthcare context macroeconomic product directly benefit patient social trend affect company consumer flexible pricing strategy wide society trend present allow price reflect country opportunity challenge ability pay global footprint enable global healthcare company like gsk partnership comic relief great access medicine fight malaria product deliver profitable report progress area sustainable business performance health behaviour people generate value return planet identify priority shareholder reinvest area understand issue business wider important business extend price freeze society benefit healthy people commitment year stakeholder essential building strong sustainable country graduate community longerterm commitment gavi support area reflect global health need significant direct indirect align gsk strategic priority economic contribution country value area community operate support global goal sustainable tax employment development detail progress research proposal submit people charitable support commitment access datum gsk trial detail approach tax responsible business supplement publish detail available wwwgskcomresponsibility position tax wwwgskcom assessment showed read commitment complete responsible business commitment progress wwwgskcom track work show table progress responsible business commitment summary commitment progress summary commitment progress health behaviour innovation unmet medical need ethical conduct well access medicine vaccine promote value sale marketing building product well meet need transparency clinical research reduce child mortality rigorous patient consumer safety strengthen healthcare infrastructure minimise animal testing eliminate control ntds promote human right fight malaria ensure ethical interaction eradicate polio work party access antiretroviral treatment hiv people planet create inspire healthy workplace carbon promote inclusion diversity water community volunteering create change waste work need track progressing completedgsk annual report strategic report governance remuneration financial statement investor information health increase access healthcare approach gsk develop rtss aim extend benefit supply notforprofit price recommend product people matter partnership path malaria malaria candidate live ability pay target vaccine initiative funding area unmet medical need disease bill melinda gates foundation vaccine rtss develop world antibiotic stimulate open innovation addition vaccine medicine introduce comprehensive approach tackle collaborate tackle barrier malaria include wide preventative pilot programme affordability accessibility measure support work strengthen healthcare systems africa malaria partnership promote way seek play use exist intervention tackle global health challenge bed net indoor residual spraying innovation antimalarial treatment january commit innovation launch new million disease disproportionately affect partnership comic relief world poor people malaria ukbased charity fight malaria societys need great endemic country antibiotic make new discovery offer potential commercial return adapt exist product tackle open innovation model core different health challenge october commitment submit regulatory year research application european medicine reach significant milestone agency antiseptic gel prevent journey develop vaccine protect umbilical cord infection newborn young child malaria july reformulate european medicine agency adopt chlorhexidine solution corsodyl positive scientific opinion malaria mouthwash case study candidate vaccine mosquirix rtss increase antibiotic resistance child aged week month emerge urgent public health additionally world health organisation crisis research unit recommend rtss focus develop introduce pilot generation antibiotic active rollout actively work pipeline potential new medicine financing body malaria development vaccine clinical trial partnership include path gsk generate support pilot finalise design pilot implementation programme help newborn survive million newborn baby die year infection ociden newlycut umbilical cord act entry point bacteria issue exacerbate develop country birth place home work reformulate antiseptic chlorhexidine solution corsodyl mouthwash gel prevent umbilical cord infection insight ontheground knowledge save child european medicine agency approve regulatory application offer gel notforprofit price share knowledge manufacture locally nerdlihc eht evas yelworc niloc otohp advanced asset topoisomerase inhibitor gepotidacin gsk develop collaboration government biomedical advanced research development authority barda asset novel mechanism action potential address multiple indication move phase iii study follow positive phase result gsk annual report strategic report governance remuneration financial statement investor information health continue open innovation model give cap advanced research disease malaria tuberculosis price patent neglect tropical disease ntd medicine vaccine affect billion people screen million develop compound help combat deadly infectious disease publish country ldc datum highquality hit ntds develop world price initiate new research project outside gsk long manufacturing invite external researcher utilise cost cover facility resource expertise cash open lab tre canto spain product inkind lab recent progress ntd research time pulse include develop preclinical management candidate treat visceral leishmaniasis promise precandidate drug combat chaga disease increase local access supply open innovation central africa important commitment africa noncommunicable disease ncds open continue evaluate lab launch lab work option manufacture nigeria partnership major funder academic start work million group government conduct pharmaceutical factory india sign research ncds innovative manufacturing partnership extend affordability availability chinas desano pharmaceutical billion people live emerge market allow provide dolutegravir hiv million use healthcare treatment competitive price china time flexible country pricing strategy seeks meet affordability hinder access healthcare need provide develop country broaden access product low price product market find capped price patent flexible way price medicine medicine vaccine retain return investment develop country ldc innovation develop world price long manufacturing cost cover example tiere pricing approach recently launch new medicine poor country pay price parity discount medicine aim supersede offer low vaccine price reach agreement government organisation gavi vaccine britain country alliance support country nationwide vaccination programme low gross national income meningitis agreement offer fair value freeze price country graduate national health service gavi support continue offer sustainable return buy vaccine discount price decade offer type patient assistance help ensure appropriate middleincome country access medicine gsk live poverty flexible programme eligible patient pricing approach enable people prescription drug coverage access product philippine medicare prescription drug gsk introduce card coupon plan offer specialty product patient programme offer discount assistance eligible insure patient select product result new coverage option patient available follow affordable care access product include antibiotic act patient insure few augmentin zinnat require patient assistance seretide inhaler programme programme pap build local capability improve access commitment access continue develop country provide provide service help patient patient consumer locally relevant understand alternative coverage option product enhance domestic manufacturing capacity capabilitygsk annual report strategic report governance remuneration financial statement investor information strengthen healthcare system world develop country ldcs lack train healthcare worker prevent people access lifesave medicine vaccine ldc operate reinvest ldc profit sale pharmaceutical consumer healthcare product train educate community health worker reinveste million ldc profit country training frontline health worker doctor midwive nurse volunteer reach million people expand health worker training ldc country subsaharan africa support million community health worker campaign funding pilot train health worker ghana apart train healthcare worker strengthen healthcare system broadly example improve health facility equip training centre encourage government improve partnership save child complement partnership policy increase investment groundbreake fiveyear support broad range work reduce partnership save child childhood mortality target product financial help save million children live reinvestment programme focus donation help provide healthcare world poor country reduce child maternal mortality vulnerable community partnership involve combine rural community instance nepal global community investment capability supply chain work care international total million compare procurement vaccine government improve maternal neonatal million charitys local expertise democratic reproductive health improve republic congo example skill frontline health worker partnership create model provide health equipment enable essential service neonatal maternal community feedback health centre child health replicate performance support enable develop country health worker nepal train reach estimate reach million people million child fully immunise treat diarrhoea malaria pneumonia screen million malnutrition strategy action publish data highquality hit european medicine ntds initiate new frontline health worker agency adopt positive research project train develop scientific opinion malaria outside gsk country candidate vaccine mosquirix child age week month nerdlihc eht evasbbew nitram otohp gsk annual report strategic report governance remuneration financial statement investor information behaviour put need patient consumer approach sale marketing practice transparency clinical trial datum expect employee act line significantly change way pioneer way share value transparency respect sell market medicine vaccine information datum clinical people integrity patient ensure patient interest come trial provide great access trial consumer well serve customer datum allow conduct believe change provide research maximise contribution value inform approach long term commercial advantage participant study patient consumer safety product development use january complete roll online sell market medicine change way sale team clinical study register train employee address compensate pharmaceutical medical available information trial include misconduct expectation representative long individual summary result party sale target instead compensate pharmaceutical company clinical base technical skill scientific study report basis regulatory patient consumer safety knowledge quality service deliver submission include detailed patient safety priority hcp broad business performance information trial publicly available development testing manufacture approach generate use product medicine company sign strong customer feedback july potential risk benefit alltrial campaign trial survey healthcare professional extensive control detect evaluate register result report gsk rank trust customer communicate benefit risk value second time row set system researcher potential safety concern request access detailed product remain committed ongoing anonymise patientlevel datum dialogue scientific community safety sit clinical trial result peertopeer medical education clinical trial extremely seriously wwwclinicalstudydatarequestcom modernise way engage trial conduct line list global clinical hcp january international conference harmonisation trial conduct formation long pay external hcp speak good clinical practice guideline gsk include clinical trial prescriber medicine independent ethic committee review company wellcome trust continue pay hcp nonpromotional trial protocol study start take management panel advisory service clinical research prevent go ahead consider application access payment govern rigorous datum initially global risk register help research control base fair market value independent expert appoint gsk team track emerge risk change support important step vision quality safety standard risk medical education long choose independent datasharing system identify regular healthcare professional study industry academia selfaudit trial sponsor attend scientific conference end research conduct party behalf instead provide funding proposal submit access perform audits trial independent professional body datum gsk trial core focus safety strict allocate funding individual give research team access quality safety standard uphold detailed trial datum multiple channel include manufacture site digital realtime application provide code conduct product life cycle source information way time hcp code conduct online raw material manufacturing want effective digital resource centre guide people transportation finish product communication support interaction apply value everyday activity strive minimise risk hcp launch new hiv employee complete counterfeit medicine medicine tivicay triumeq mandatory annual training code extend endtoend supply chain online course available healthcare professional scientist serialisation programme fingerprint language include training gsk include global medical packaging line value ethical leadership antibribery expert play important role inform manufacturing site programme corruption reporting issue peer medicine apply unique serial fingerprint concern extend responsible provide right product log complementary information support safe governmentmanage database worker employee complete effective use medicine verify course face disciplinary action point supply chaingsk annual report strategic report governance remuneration financial statement investor information antibribery corruption total discipline receive employee discipline zero tolerance bribery verbal warning employee receive breakdown type policy violation corruption recognise document warning expose bribery corruption dismiss risk give global footprint particularly agree leave company voluntarily market government structure high number dismissal rule law develop relate travel expense policy healthcare system mature violation account dismissal follow dismissal antibribery corruption programme relate code conduct violation include risk assessment standard attendancepayroll violation practical guidance design prevent noncompliance work party employee complimentary worker expect supplier party complete basic level training comply standard ethic attendancepayroll local work employee highrisk role labour right health safety good manufacturing regulation violation complete additional advanced training environment introduce practicesgood unauthorised distribution practice absenteeism roll framework comprehensive programme strengthen engage train party base management risk travel expense ehssafety risk profile supply chain marketing falsification promotional activity document approach design prevent follow review supplier code conduct train completion breach thing wrong act identify high risk promptly decisively centralise assess external risk review committee oversee investigation assessment expert require allegation bribery corruption complete extensive questionnaire engage artificial tax ensure prioritise consistently demonstrate policy management arrangement business company system responsible business issue commercial substance additional diligence follow time responsibility report investigate shareholder financially efficient misconduct assess deliver sustainable tax rate centrally track misconduct allegation distributor key risk antibribery concern security incident receive corruption labour right promotional detail approach tax speak channel monitor activity information protection tax disclosure find route receive assess group financial review report allegation supplier support manufacturing report responsible majority line quality management system business supplement speak channel audit environmental approach human right offer people outside gsk health safety management system gsk signatory global opportunity ask question voice approach tax compact set key principle concern anonymously confidentially understand responsibility pay business human right independent party appropriate tax commit uphold universal phone online robust internal policy process train declaration human right concern raise review compliance programme ensure core labour standard set formal investigation initiate alignment business international labour organization response allegation meet tax obligation human right steering group provide frequent category allegation pay significant tax direction oversight help ensure employee performancerelation product global corporate meet commitment human right promotion interaction hcp fraud function significant manufacturing set human right statement antibribery corruption facility locate available website disciplinary action country world identify seven priority disciplinary action take substantial business employment area human right gsk access employee fail act line presence health care air quality impact relate policy employee year pay propellant clinical trial standard discipline policy violation billion corporation tax globally employment practice patient safety type policy violation pay billion product counterfeiting use chart remain broadly nearly global total party supplier attendance payroll net sale global remain big type violation net sale total follow good manufacturing practice travel expense violation increase increase frequency monitor gsk annual report strategic report governance remuneration financial statement investor information people gsk people essential success approach follow steady reduction year need talented motivate resilient welcome reportable injury illness rate workforce deliver increase slightly large number novartis employee strategy tackle global health semicircular lipoatrophy case brazil challenge effectively achieve gsk clear regular treatable condition associate aim create work environment localise pressure office employee feel value respected communication crucial furniture take step support empower inspire affect prevent recurrence introduce new business experience significant change global business operate particularly important listen colleague value market incident support people expectation occur august employee performance engagement tragically die boiler explosion global performance system site rixensart belgium underpin set clear expectation support belgian authority emphasise result particular emphasis leadership investigation check achieve line development boiler gsk october sale value line leader complete programme employee india travel help manager business sadly die motorcycle provide regular update launch enterprise talent initiative collide vehicle mission strategy progress develop leader potential live broadcast message energy resilience programme aspiration executive ceo corporate executive team continue help employee balance train listen critical personal professional responsibility employee coach help employee people take fulfil leadership potential take employee survey provide employee survey agree valuable feedback health wellbee sufficient energy invest thing survey progressive approach matter work life employee health protect support people provide preventive healthcare workforce business priority restructure complement employee healthcare refresh simplify health welcome novartis benefit establish market safety standard review global employee gsk clear regular partnership prevention health strategy set communication crucial programme aims provide plan gsk employee introduce new colleague employee family access consistent comprehensive value expectation performance unprecedented access preventive health service system local employee practice healthcare service little cost programme major reshaping continue recognise leader implementation prioritise global pharmaceutical business health wellbeing region access preventive occurring time place gsk multinational healthy service unavailable limited equal focus support employee workplace award global centre particularly develop market leave company consult healthy workplace service include immunisation employee representative road safety significant risk cancer screening recommend business change affect employee launch driver safety world health organization talent leadership programme india plan roll available employee number graduate widely emerge market family member country postgraduate join programme place halfway target increase recruit implement globally graduate postgraduate future leader esprit programme globally exceed target welcome apprentice woman volunteer number discipline location look expand create change apprenticeship programme geographie pulse volunteer partnership employee use professional skill create sustainable change nonprofit partner community serve launch pulse enable employee work nonprofit partner country provide nearly million worth skilled servicesgsk annual report strategic report governance remuneration financial statement investor information diversity inclusion value diversity diverse knowledge perspective experience working style global workforce strengthen business help meet need patient consumer aim improve gender balance level december woman represent recruit future leader programme management corporate executive team board female manager begin accelerate difference programme high perform woman leader strive gsk accessible people disability december partner government disability confident campaign raise disability awareness business remove barrier increase understand ensure disability right opportunity inspire generation scientist global organisation serve diverse market nationality need young tell represent corporate executive million new scientist engineer teacher study drama team board employee solve future challenge include enjoy science math emerge market asia pacific japan big health challenge end complete phd virology represent workforce tomorrow research lead immunology parttime whilst gsk aim attract develop local talent healthcare company gsk playing say partner university offer lead role inspire young aim build business opportunity particular people science technology experience create global focus africa strategy new engineering math stem stem education programme regional headquarters singapore provide range career employee tool need inspire help attract develop local people opportunity foster generation emerge market recruit science education early scientist engineer worldwide people country talent team stem future leader graduate programme gsk offer range career opportunity ambassador engage young stem area range summer people demonstrate realworld internship apprenticeships graduate science engineering school woman management position postgraduate programme manage graduate apprenticeship programme apprenticeship programme offer school college leaver opportunity join svpvp rhiannon lowe heads team company variety role director ambassador volunteer gsk employee finance laboratory science manager site ware hertfordshire engineering apprentice learn onthejob total programme value member team begin alongside job progress work employee gender number investigator investigative preclinical nationally recognise qualification male female total toxicology focus disease ultimately transition board develop world gene therapy permanent role managementa team expertise scheme grow steadily total practice inspire people age ambition continually expand school demonstrate scientific programme new geography total experiment host visit gsk lab help nurture new generation management senior manager define student give opportunity talent add diversity company act strategic report involve science connect business director report regulation directly work real world include person responsible planning direct control activity rhiannon encourage girls particular company strategically significant pursue subject young age company board woman represent stem include director undertaking include consolidated account professional gsk annual report strategic report governance remuneration financial statement investor information planet reduce environmental impact approach carbon emission major environmental challenge closely link global health concern climate tonne coea change deforestation example exacerbate inequality health scope emission global healthcare company help scope emission tackle effect environmental scope emission change cause aim carbon neutral value chain intensity ratio ambitious interim goal reduce carbon scope emission water waste past year sale revenue tonne significant progress coem carbon scope fte aim reduce carbon footprint tonne efte value chain baseline way carbon emission calculate accord greenhouse gas protocol goal carbon neutral value chain corporate accounting reporting standard revise edition pursue objective reduce datum include novartis site emission headcount operational emission scope engage supplier patient consumer cut emission link reduce emission raw material water source raw material ingredient engage supplier crucial aim reduce gsk water product scope approach recognise ethical impact value chain corporation responsible business level meet volume medicine award found data collection milestone operation year consumer health product vaccine collaboration recognition ecodesk early reduce send factory online platform gather data carbon achieve high time water waste supplier reduction invest watersaving value chain carbon footprint represent approximately million initiative past year focus grow half annual spend site high water use reduce value chain carbon footprint raw material region water scarcity product ship average versus control direct water emission operation value chain come raw material continue growth sale reduce emission mainly agricultural partner ventolin propellantbase inhaler operation million energy resources institute emit greenhouse gas tonne sustainable development ngo india administration medication cumulative save assess reduce water impact patient continue impact carbon million tonne year rural community supply footprint researching solution achieve energy wheat barley milk manufacture issue include change way efficiently invest renewable horlick manufacture reduce energy provide propellant maintain gsk laboratory manufacture total energy use wind turbine efficacy patient site office facility cork ireland example total water impact make major generate site electricity investment reduce companywide deliver saving million tonne strategy action reduce direct hit water target carbon emission scope year early reduce usage reduce value chain save million tonne save million carbon footprint product year water use ship average year versus gsk annual report strategic report governance remuneration financial statement investor information horlick take green leap india horlick bestknown construct new brand nutritional combine heat power plant supplement india provide rajahmundry fuel essential vitamin minerals waste biomass plant grow child improve efficiency capture heat power generation discover waste lifecycle analysis horlick second large carbon footprint sonepat instal photovoltaic product reason cell generate power horlick factory india nabha solar energy invest rajahmundry sonepat power efficient lead lighting coal site cut energy use invest million project project begin april green leap reduce carbon emission cut carbon emission water use horlick instal effluent treatment factory example continue plant rainwater harvesting system increase waste biomass enable water reuse buy replace coal fuel dispose safely cut water use boiler help replenish groundwater restore local water source consumer use account waste water footprint mainly clean aim reduce operational waste identify huge tooth continue encourage compare people leave water run year cut opportunity brushing sensodyne support operational waste hazardous non reduce carbon emission turn tap campaign hazardous sonepat realise commitment encourage site view waste working expert ngo resource share good practice tonne understand well cut example facility east durham water impact value chain building insight combine datum wwf dungarvan plant ireland install water risk filter area machine recycle fibre drum satyaprakash punia water scarcity local water quality packaging storage transportation utility site energy manager health social risk regulatory save year sonepat india reputational risk identify high produce waste water impact hotspot previous year tonne represent total waste send landfill reduction tonne compare end site send waste landfill gsk pharmaceutical company hold carbon trust cut score carbon standard operational waste climate change disclosure cut carbon emission performance water standard cdps ftse climate reduce water use disclosure leadership index operation globallystrategic report governance remuneration financial statement investor information group financial review ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statement investor information group financial review significant progress leave well positioned deliver financial architecture driving eps growth ahead sale improve cash flow generation significant progress line prioritisation board highlight strategy include closing declare ordinary dividend penny novartis transaction accelerate share say delivery restructuring integration expect pay ordinary dividend programme allow release penny share billion incremental saving transition group business group ahead original target deliver expectation ensure million importantly sufficient financial flexibility continue group turnover create additional flexibility invest invest synergy benefit cer cer proforma pipeline new product growth opportunity launch help build momentum respond potential exercise business option partner viiv healthcare group well position consumer healthcare joint drive sustainable growth give venture retain billion total earning share significant restructuring reshape net proceed receive novartis cer cost base well place deliver number nonstrategic asset financial architecture drive disposal billion return growth earning share ahead shareholder form special sale improve cash generation dividend penny share pay support dividend long term april core earning share cer current level dividend exceed retention disposal proceed cash flow generate business continue focus cash flow management strategy design rebuild protection credit profile restructure cash cost capacity transition mean year able group business away previous fund restructure integration reliance seretideadvair broadly programme declare ordinary dividend base grow cash flow drive penny share reduce net new product pharmaceutical debt billion securing flexibility expansion vaccine consumer need complete transition healthcare business operate cost business deliver strategic saving arise integration objective restructure programme reduction viability statement level restructure spend new requirement year assess programme come end future prospect group period period transition long month require forecastb say intend prioritise available go concern provision corporate cash operational cash flow governance code outcome footnote disposal return ordinary review set viability statement include billion cash cost legacy dividend shareholder accelerate restructuring programme complete investment restructure total charge combine restructure integration programme support integration programme expect rapid delivery synergy benefit approximately billion cash cost new growth opportunity expect approximately billion identify group programme expect largely complete end ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statement investor information group financial review continue clear set priority ensure consistency capital viability statement allocate different business gsk relative return business benchmarke relevant accordance provision revision code external comparative cash flow return investment gsk assess prospect group long period cfroi base framework metric specific capital investment month require go concern provision benchmarke similar way director confirm reasonable expectation gsk continue operate meet liability fall turnover growth year director assessment group turnover performance reflect reference current position prospect strategy progress delivery strategic objective building board risk appetite principal risk balance set growth driver business manage detailed page strategic report continue launch new product pharmaceutical business board review internal control risk management expand vaccine consumer healthcare policy approve governance structure code business novartis transaction new source conduct appraise approve major financing investment growth offset decline seretideadvair licensing decision evaluate monitor performance old product deliver overall turnover prospect gsk focus largely improve growth cer year proforma longterm financial performance simplify operate sale new pharmaceutical vaccine product billion model grow diversified global business deliver year key driver consumer healthcare product value significant contribution proforma new product year review consider exist strategy include recent flonase otc switch drive growth associate principal risk underpin current year plan director review annually director believe operate leverage year assessment appropriate align normal ability deliver improve profitability heavily impact establish year business planning process overall trend sale affect change year period balance long term nature investment mix business regional product contribution growth pharmaceutical industry realistic assessment variability operating profit see significant change mix key driver near term business performance external group follow novartis transaction help create factor regulation impact business reflect view industryleade vaccine consumer healthcare business access capital market funding requirement project alongside divestment market oncology product analysis time divestment oncology business plan stress test series robust operational high operating margin acquire vaccine consumer principal risk downside scenario board review risk healthcare business particularly give heavy investment downside scenario consider gsk cash flow dividend cost structure inherit novartis integration cover funding strategy insurance provision recovery plan address cost structure directly set key financial ratio period metric target significant margin improvement acquire subject sensitivity analysis involve flex number business core operate margin shortterm main assumption underlie forecast individually affect materially transaction total impact combination appropriate analysis stress percentage point sale test ensure robustness viability period evaluate potential impact material negative change report core operating margin decline total macroeconomic healthcare environment increase pricing percentage point substantially additional pressure europe accelerate impact percentage point decline reflect impact benefit generic alternative seretideadvair principal risk actually operate margin structural credit sga occur early potential exercise option million repeat exclude effect partner year review make certain assumption proforma core operating margin broadly flat normal level capital recycling likely occur consider additional financing facility require reflect delivery billion incremental cost respective level funding flexibility headroom saving integration restructuring programme saving contribute offset price pressure old part base result analysis director confirm reasonable expectation group able continue portfolio add cost flexibility operation meet liability fall year build recent year period assessment provide great opportunity reallocate resource group include reinvestment support new launch pipeline improvement manufacture financial architecture capability capacity financial architecture design support consistent integration restructuring programme ahead schedule execution strategy enhance return deliver end programme deliver approximately shareholder billion annual saving remain track deliver focus deliver sustainable sale growth billion annual saving total end company improve operate leverage profitability financial efficiency enhance financial efficiency order drive growth continue focus improve financial efficiency overall eps ahead sale performance convert funding cost protect credit profile particular earning cash invest business shortterm target credit rating return shareholder attractive return gsk annual report strategic report governance remuneration financial statement investor information gsk financial architecture drive improve return shareholder sale growth operate leverage eps return shareholder financial efficiency free cash flow cash flow growth earning share eps approach tax total ep see significant increase primarily drive profit disposal oncology business core understand responsibility pay appropriate eps decline mainly reflect shortterm dilution tax group pay corporate income novartis transaction impact continue transition tax million million profit pharmaceutical business particularly respiratory million million represent cash expect core eps percentage growth reach tax rate correspond accounting double digit cer base growth core tax charge profit million million eps tax risk managed set policy procedure free cash flow seek ensure consistency compliance tax legislation audit risk committee board responsible free cash flow generation impact approve tax policy risk management ongoing transition pharmaceutical portfolio particularly decline seretideadvair shortterm impact seek maintain open positive relationship government novartis transaction particular inherit level tax authority worldwide welcome constructive cost investment address debate taxation policy continue significant synergy integration plan international focus tax reform include oecds base erosion profit shift bep project restructuring cost plan cost novartis european commission initiative propose transaction fund proceed disposal antibep directive increase use fiscal state aid oncology business nonstrategic asset consistent investigation oecd beps report clarify important general approach funding cost restructure principle tax pay profit supply chain commensurate profit make activity exclude cash restructuring charge incur year take place gsk support approach active billion initial tax payment oncology provide relevant business input assist successful disposal legal payment free cash flow generate delivery aim bep project particular support billion compare billion implementation oecds recommendation country adjust comparable basis bycountry reporting cbcr include exchange cbcr addition rebuild cash generation capacity continue datum tax authority key success focus improve efficiency capital investment datum validate exist information hold taxpayer use work capital reduce internal cash requirement support ability ensure multinational group pay right tax expect allow build operate cash flow quickly maintain dividend return group growth engage artificial tax arrangement protect credit profile business commercial substance time responsibility shareholder financially efficient return shareholder deliver sustainable tax rate ongoing alignment group board approve ordinary dividend pence structure reflect mix operation geography help special pence dividend pay net maintain efficient effective tax rate core tax rate proceed oncology business asset disposal similar rate distribute april alongside regular fourth moderate upward pressure rate expect quarter dividend expect pay annual dividend year give group momentum change earning penny mix favour particular core tax rate range expect fuller review financial result set page approach tax set detail public policy position section website detail corporate tax charge year set simon dingemans chief financial officer gsk annual report strategic report governance remuneration financial statement investor information group financial review continue proforma result report financial review novartis transaction complete march report year date result include month turnover result report novartis vaccine consumer healthcare product group financial review discuss operate financial exclude sale gsk oncology business performance group cash flow financial position march follow completion transaction novartis resource compare result year primarily reorganise group reflect great balance result precede year review discuss pharmaceutical vaccine consumer total result group core result healthcare business responsibility part use number adjust measure report respective business realign performance business measure report business separately corporate cost management planning reporting purpose reallocate accordingly profitability discussion presentation investment analyst business reflect accurately restate rating agency define measure segment information consistent realignment define ifrs comparable similarly addition present unaudited proforma growth rate describe measure company turnover core operating profit core operating profit cer growth business proforma growth rate calculate compare order illustrate underlying performance practice report turnover core operating profit year discuss result term constant exchange rate cer december turnover core operating profit growth represent growth calculate exchange rate year december adjust include equivalent determine result overseas company sterle month sale novartis vaccine consumer remain unchanged previous year healthcare product exclude sale gsk cer represent growth constant exchange rate oncology product march december represent growth actual exchange rate free cash flow growth rate include report cer free cash flow net cash inflow operating activity state capital expenditure interest dividend pay noncontrolle interest plus proceed sale property plant core result report equipment dividend receive joint venture total report result represent group overall performance associate undertaking free cash flow growth calculate result contain material unusual non sterle basis reconciliation present operational item obscure key trend factor determine group operational performance result adjust free cash flow report core result adjust free cash flow exclude payment settle legal dispute core result exclude follow item total result amortisation impairment intangible asset exclude work capital conversion cycle computer software goodwill major restructuring cost work capital conversion cycle calculate number include cost follow material acquisition legal charge day sale outstanding plus day inventory outstanding net insurance recovery expense settlement day purchase outstanding litigation government investigation acquisition internal rate return accounting adjustment material acquisition disposal calculation include product launch associate product business operate income january december compound royalty income item tax phase iib iii development process calculation effect item base actual sale forecast sale core result report utilise basis internal adjust reflect expect failure rate performance report alongside total result cash flow broadly line standard industry failure rate cost base generation number metric core result present calculation comprise estimate attributable discuss group financial review believe cost actual project milestone payment core result representative performance appropriate group operation allow key trend factor drive irr estimate factor applicable component performance easily clearly identify novartis transaction include acquisition cost forecast shareholder definition core result set cash flow bexsero man abcwy cash flow align group result majority peer company relevant oncology asset divest product launch report earning akt inhibitor oncology cash flow include reconciliation total core result include detailed estimate attributable cost estimate proportion breakdown key noncore item set aftertax sale proceed proceed product launch provide shareholder ensure visibility exclude consistency overall transparency assess group performance methodology net impact acquisition disposal estimate irr material gsk annual report strategic report governance remuneration financial statement investor information group turnover geographic region group turnover turnover restate growth growth cer europe international group turnover group turnover outside europe represent total group turnover report proforma sale new pharmaceutical vaccine product cer growth cer growth growth growth cer respiratory operating profit relvarbreo ellipta anoro ellipta arnuity ellipta incruse ellipta nucala total operating profit cvmu eperzantanzeum global pharmaceutical report tivicay cer growth triumeq pharmaceutical bexsero menveo restate growth growth vaccine cer global pharmaceuticals hiv investor day identify series pharmaceutical new pharmaceutical vaccine product expect vaccine deliver billion revenue annum cer basis product plus current clinical pipeline asset consumer healthcare shingrix set group define segment turnover new pharmaceutical vaccine product sale new corporate pharmaceutical vaccine product expect reach unallocated turnover billion revenue annum cer basis year group turnover early cer represent growth constant exchange rate represent sale new pharmaceutical vaccine product growth actual exchange rate hiv turnover represent sale million represent approximately viiv healthcare pharmaceutical vaccine turnover year group turnover increase report basis million pharmaceutical vaccine consumer healthcare reflect impact novartis transaction proforma basis group turnover increase pharmaceutical vaccine consumer healthcare sale new pharmaceutical vaccine product million year corporate unallocated turnover million represent sale vaccine consumer healthcare product hold sale number market require dispose product specific market order meet requirement antitrust approval novartis transaction disposal complete august september gsk annual report strategic report governance remuneration financial statement investor information group financial review continue pharmaceutical global pharmaceutical turnover turnover group turnover group turnover report proforma report proforma cer growth cer growth cer growth cer growth operate profit operating profit operating profit operating profit report proforma report proforma cer growth cer growth cer growth cer growth pharmaceutical turnover million global pharmaceutical turnover report basis primarily reflect disposal oncology business adjust impact disposal proforma restate growth growth turnover reflect decline respiratory cer sale decline sale establish product largely respiratory offset growth new pharmaceutical product cardiovascular metabolic particularly hiv product tivicay triumeq urology sale new pharmaceutical product million immunoinflammation increase million offset decline oncology seretideadvair sale million global seretideadvair pharmaceutical sale billion approximately peak establish product global pharmaceutical turnover million report basis primarily reflect disposal oncology business adjust impact disposal proforma turnover reflect decline respiratory sale decline sale establish product sale new global pharmaceutical product million increase million global pharmaceutical report turnover million decline year proforma basis proforma decline primarily reflect fall respiratory sale fall establish product sale respiratory advair sale million volume decline negative impact price mix flovent sale million decline partly offset sale new respiratory product breo ellipta anoro ellipta incruse ellipta arnuity ellipta combine sale million year gsk annual report strategic report governance remuneration financial statement investor information primary driver decline establish product cardiovascular metabolic urology lovaza million follow launch sale category decline million year generic competition april avodart decline avodart franchise fall million growth million reflect launch generic competition sale duodartjalyn offset decline sale october relenza sale double million avodart reflect patent expiry october partly reflect cdc order benlysta continue sale prolia million december strong growth sale million amgen reacquire right prolia gsk europe global pharmaceutical turnover decline immunoinflammation million proforma basis immunoinflammation sale grow million benlysta adjust impact oncology disposal respiratory sale year million benlysta sale decline million decline sale million seretide increase generic competition ongoe oncology transition new ellipta product report total sale sale oncology product million year million year establish product sale million follow disposal oncology million reflect increase generic competition business novartis march capacity constraint supply number product pharmaceutical international global pharmaceutical sale million sale therapy area fall million year report basis proforma augmentin sale million dermatology basis sale emerge market million decline sale decline million adversely affect proforma emerge market respiratory sale decline supply constraint relenza sale million seretide impact increase generic drive cdc order competition price pressure offset flovent ventolin avamys million relvar ellipta sale product rare disease decline million anoro ellipta sale establish product primarily result generic competition mepron dermatology product partly impact establish product supply constraint establish product turnover fall million emerge market china report year sale million primarily proforma respiratory flat establish product reflect fall sale lovaza million primarily reflect significantly increase pricing europe million reflect increase pressure ongoing reshape business include generic competition number product supply number product disposal japan global pharmaceutical constraint seroxat sale fall million sale report basis proforma million increase respiratory sale primarily international million primarily reflect drive relvar ellipta offset low sale relenza reflect low sale seroxatpaxil million weak early flu season continue generic competition japan zeffix competitive pressure number establish product million partly offset increase valtrex sale million follow regain exclusivity respiratory canada late october sales china fall respiratory sale year decline million million primarily reflect significantly increase seretideadvair sale million pricing pressure supply constraint zeffix flixotideflovent sale decrease million ventolin sale fall million combine total ellipta product sale million respiratory sale decline million year volume growth negative impact price mix sale advair million volume decline negative impact price mix include benefit positive adjustment payer rebate provision fourth quarter flovent sale million ventolin sale fall million primarily result net negative movement payer rebate provision new ellipta product record sale million year european respiratory sale million seretide sale million volume decline negative impact price mix reflect expect pressure increase competition generic transition respiratory portfolio new product relvar ellipta record sale million year anoro ellipta record sale million respiratory sale international region flat million emerge market japan emerge market sale seretide decline million ventolin grow million japan sale relvar ellipta million strong avamys xyzal sale growth offset decline adoair sale gsk annual report strategic report governance remuneration financial statement investor information group financial review continue hiv vaccine turnover turnover group turnover group turnover report report proforma cer growth cer growth cer growth operate profit operating profit operating profit operating profit report report proforma cer growth cer growth cer growth vaccine turnover hiv turnover growth growth cer growth growth combivir cer epzicomkivexa bexsero lexivatelzir infanrix pediarix selzentry boostrix tivicay fluarix flulaval hepatitis triumeq menveo trizivir rotarix synflorix worldwide hiv sale increase million europe international vaccine sale grow million growth region drive primarily europe international business benefit strong performance triumeq tivicay sale sale newly acquire product primarily meningitis million million respectively year portfolio europe proforma growth epzicomkivexa sale decline million mainly drive bexsero sale europe strong rotarix selzentry decline million combivir lexiva fluarixflulaval boostrix sale growth sale fall respectively partly offset decline infanrixpediarix sale return competitor market increase competitor activity europe supply constraint international hepatitis vaccine sale decline supply constraint international impact high trade inventory newly acquire vaccine cervarix sale decline follow introduction new competitor vaccine gsk annual report strategic report governance remuneration financial statement investor information sale grew report basis proforma consumer healthcare million proforma growth drive mainly strong performance fluarixflulaval result conversion turnover quadrivalent formulation rotarix benefit cdc stockpile replenishment boostrix market share gain meningitis portfolio drive primarily launch bexsero growth partly offset infanrixpediarix sale decline primarily result return market group turnover competitor vaccine combine low cdc stockpile purchase europe sale grew report basis proforma million proforma growth primarily reflect increase report proforma sale meningitis portfolio bexsero gain cer growth cer growth private market include italy spain germany portugal follow inclusion nhs immunisation programme menveo deliver incremental sale result tender award italy growth partly offset operating profit sale decline infanrixpediarix supply constraint increase competitor activity hepatitis vaccine supply constraint cervarix follow introduction new competitor vaccine germany grow strongly mmrv portfolio boostrix infanrixpediarix well operating profit supply competitor supply shortage international sale grew report basis decline proforma basis million proforma performance mainly drive low tender volume latin report proforma america particularly synflorix partly offset increase cer growth cer growth market access demand synflorix africa bangladesh cervarix sale decrease mexico south africa low demand infanrixpediarix hepatitis vaccine sale consumer healthcare turnover reflect supply constraint newly acquire vaccine decline phase shipment high trade inventory level inherit acquisition restate growth growth cer wellness oral health nutrition skin health restate growth growth cer europe international consumer healthcare business represent consumer healthcare joint venture novartis gsk consumer healthcare list business india nigeria exclude joint venture turnover grow million benefit significantly sale newlyacquire product include joint venture proforma basis growth volume price primarily reflect strong growth follow launch otc flonase buoyant sale india drive horlick global specialist oral health growth partly recovery supply disruption sale new gsk innovation product introduction year rolling basis represent approximately sale higher prior year primarily flonase switch otc early year key launch include sensodyne repair protect whiten germany voltaren hour rollout sensodyne mouthwash gsk annual report strategic report governance remuneration financial statement investor information group financial review continue sale grew report basis million total result proforma basis flonase region principal growth driver oral health sale continue drive total result group set reconciliations sensodyne launch sensodyne repair total result core result present protect whiten supply recovery distribution gain sensodyne pronamel excedrin grow follow launch growth gel tablet format combine momentum tension turnover turnover cer headache variant theraflu post strong growth turnover relaunch new warming syrup format price increase cost sale nicorette lozenge nicorette mini lozenge alli return sell general market tum impact supply constraint increase competitive pressure year administration research sales europe grew report basis million development grow proforma proforma performance drive royalty income oral health product report growth reflect operate strong performance sensodyne gum health income product follow improved supply position compare operate profit new advertising key market roll new sensodyne variant region wellness pain relief net finance cost record strong doubledigit proforma performance drive profit disposal voltaren benefit new marketing campaign interest associate brand record high market share major share tax european market include germany italy poland france profit associate strong performance partly offset adverse joint venture performance nutrition skin health category profit taxation realignment resource brand portfolio follow taxation integration business termination number total profit party supply arrangement supply chain taxation year simplification initiative total profit attributable international sale million grew report basis shareholder proforma oral health sale grow strongly earning share region doubledigit growth sensodyne denture earning ad care product wellness sale decline proforma basis largely result impact excess channel inventory part acquire consumer business notably china cost sale russia middle east generic competition cost sale percentage turnover impact panadol osteo australia economic political percentage point high percentage uncertainty venezuela india lead growth point high cer basis increase reflect disposal priority market report doubledigit performance eno high margin oncology business acquisition sensodyne horlick drive distribution gain new low margin vaccine consumer healthcare business marketing campaign relaunch improve chocolate novartis addition adverse price movement flavour horlick sale brazil lowsingle digit particularly pharmaceutical increase investment business transition new product formulation vaccine improve reliability capacity supply sun care business chain increase intangible asset amortisation impairment charge high integration restructuring cost partly offset improved product mix particularly result growth hiv sale benefit group ongoing cost reduction programme sell general administration sga cost percentage sale percentage point high percentage point high cer basis increase primarily reflect impact novartis transaction million credit sga release reserve follow simplification entity structure high integration restructuring cost increase promotional product support particularly new launch respiratory consumer healthcare vaccine hiv partly offset benefit pharmaceutical cost reduction programme synergy vaccine consumer healthcare low legal charge research development expenditure increase cer million turnover compare million turnover benefit cost reduction programme pharmaceutical vaccine consumer healthcare offset high integration restructuring cost gsk annual report strategic report governance remuneration financial statement investor information operating income net finance cost net operating income million million expense include profit disposal oncology finance income business million ofatumumab million interest finance income partly offset increase liability fair value movement contingent consideration acquisition shionogiviiv healthcare joint venture million million follow improve sale performance finance expense tivicay triumeq liability million interest expense december represent present value expect future unwind discount liability payment shionogi detail consideration remeasurement fair value movement shionogi relation viiv healthcare set finance expense operating profit total operating profit million compare million increase primarily reflect profit profit disposal interest associate disposal oncology business novartis equity profit disposal associate million investment asset disposal partly offset nil arise disposal half investment increase integration restructuring cost adverse impact aspen pharmacare remeasurement remain margin disposal high margin oncology business hold market value reclassification investment acquisition low margin vaccine consumer healthcare share tax profit associate joint venture business novartis increase contingent share profit associate joint venture consideration liability payable acquisition million million profit include million shionogiviiv healthcare joint venture gain share profit disposal investment intangible asset amortisation decrease million recognise associate share profit million intangible asset impairment million associate principally arise hold aspen million include impairment pharmacare commercial asset charge noncash item profit taxation major restructuring charge accrue year million take account net finance cost profit disposal million reflect acceleration number interest associate share profit associate profit integration project follow completion novartis transaction taxation million compare million charge pharmaceutical restructure programme cash payment year taxation million million programme deliver approximately billion incremental benefit compare current year charge charge date combine restructure integration rest world current year charge programme billion total cash charge combine charge respect prior period programme expect approximately billion total current taxation noncash charge billion end total defer taxation programme deliver approximately billion annual taxation total profit saving remain track deliver billion annual saving total programme expect largely complete charge taxation total profit amount million end represent total effective tax rate legal charge million million include gsk payment million corporation settlement number exist matter litigation cost tax january gsk payment million charge include million fine payable relation corporation tax amount chinese government cash payment million corporation tax include business million taxis bear gsk year taxation detail acquisitionrelate adjustment result net charge million million include remeasurement earning share liability unwind discount effect total eps compare increase contingent consideration acquisition shionogi primarily reflect profit disposal oncology viiv healthcare joint venture million million business aspen pharmacare share partly offset contingent consideration relate acquisition increase liability contingent consideration novartis vaccine business million net hedging gain acquisition shionogiviiv healthcare joint venture nil consumer healthcare joint venture option accelerate charge major restructuring expenditure million nil detail consideration dividend shionogi relation viiv healthcare set board declare interim dividend result total disposal item result net credit million dividend year penny line dividend million charge include profit disposal addition board declare special dividend oncology business novartis million profit penny pay proceed disposal disposal ofatumumab equity investment oncology business asset note financial asset disposal equity investment impairment reflect statement dividend current market valuation oneoff require regulatory charge certain adjust item gsk annual report strategic report governance remuneration financial statement investor information group financial review continue core result reconciliation december intangible intangible total asset asset major legal acquisition disposal core result amortisation impairment restructuring charge accounting result turnover cost sale gross profit sell general administration research development royalty income operating income operating profit net finance cost profit disposal associate share tax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation lossprofit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million core result reconciliation december intangible intangible total asset asset major legal acquisition disposal core result amortisation impairment restructuring charge accounting result turnover cost sale gross profit sell general administration research development royalty income operating income operating profit net finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million gsk annual report strategic report governance remuneration financial statement investor information operation pharmaceutical broadly split core result discovery activity completion phase iia trial development work phase iib onwards support use core result metric include total result specific common infrastructure share service cash flow generation manage performance appropriate phase cost administrative group definition core result set expense report sga include cost sale table table analyse core expenditure growth category turnover turnover cer cost sale discovery cost sale percentage turnover development percentage point high proforma basis facility central support function cost sale percentage increase percentage point pharmaceutical percentage point cer basis reflect adverse price movement particularly pharmaceutical vaccine increase investment vaccine improve reliability consumer healthcare capacity supply chain partly offset research development improve product mix particularly result growth hiv proportion pharmaceutical investment sale benefit ongoing cost reduction programme latestage portfolio decrease pharmaceutical sell general administration cost reflect completion number latestage programme growth royalty income turnover turnover cer royalty income million million sell general administration core operating profit business sga cost percentage sale percentage restate growth point high percentage point high margin margin cer basis proforma basis sga cost percentage cer sale increase percentage point percentage point global cer basis increase primarily reflect impact pharmaceutical million credit sga release reserve hiv follow simplification entity structure exclude pharmaceutical sga cost percentage sale decrease percentage pharmaceutical point cer basis drive decline global vaccine pharmaceutical include benefit pharmaceutical consumer cost reduction programme synergies vaccines healthcare consumer healthcare largely offset promotional product support particularly new launch respiratory consumer healthcare vaccine hiv corporate unallocated cost research development core operate profit growth core operate profit million low turnover turnover cer cer term turnover increase core operating research margin percentage point low development exclude adverse impact currency movement particularly euro emerge market currency core expenditure decline cer million operating margin percentage point low cer turnover compare million turnover basis decline include percentage point impact proforma basis expenditure decline novartis transaction reflect disposal high margin reflect benefit cost reduction programme oncology business acquisition low margin pharmaceutical vaccine consumer healthcare different cost structure vaccine consumer healthcare business novartis gsk annual report strategic report governance remuneration financial statement investor information group financial review continue proforma basis core operating profit low net finance cost cer term compare turnover increase primarily reflect decline proforma core operating finance income margin percentage point decline interest income include percentage point impact adverse fair value movement comparison include million credit sga release reserve follow simplification group entity structure trading arrangement exclude finance expense effect core operating margin decline percentage interest expense point reflect balance continue impact unwind discount liability decline sale seretideadvair include contracting price reduction low sale establish product remeasurement fair value movement investment require multiple new launch finance expense pharmaceutical vaccine consumer healthcare transition product portfolio offset saving release restructure integration programme benefit net finance expense million compare improve product mix particularly growth hiv sale million pharmaceutical share tax loss associate joint venture pharmaceutical operate profit million low share loss associate joint venture million cer term turnover decrease million profit march reduce core operating margin percentage point lower shareholde significant associate aspen pharmacare percentage point low cer basis holding limit issue share capital proforma basis core operating margin decrease result long account aspen associate percentage point cer basis reflect adverse core profit taxation price movement global pharmaceutical particularly respiratory product increase promotional growth manufacture investment new product launch turnover turnover cer respiratory hiv target investment core profit tax manufacturing capacity stability portfolio partly offset favourable product mix primarily drive taxation growth hiv sale benefit group cost tax core profit amount million represent reduction programme core operating margin global effective core tax rate reflect pharmaceutical hiv resolution number item benefit year noncontrolle interest vaccine allocation earning noncontrolle interest amount vaccine operate profit million low million million include non cer term turnover increase core control interest allocation consumer healthcare segment operating margin percentage point low profit million million allocation percentage point low cer basis primarily viiv healthcare profit increase million drive inclusion cost base novartis million detail economic interest vaccine business proforma core operating profit grow profit viiv healthcare set turnover increase cer basis proforma operating margin improve percentage point core earning share reflect increase cost sale percentage turnover core eps declined cer term compare additional supply chain investment benefit cost decline operating profit primarily reflect great sale number inventory adjustment contribution growth business offset reduction sga restructure significant noncontrolle interest integration benefit consumer healthcare consumer healthcare operate profit million high cer term turnover increase core operate margin percentage point lower improve percentage point cer basis proforma basis operating margin increase percentage point cer basis drive reduction cost sale percentage turnover reflect benefit improve supply pricing delivery integration synergy offset additional investment growth target power brand particularly oral health wellness gsk annual report strategic report governance remuneration financial statement investor information reconciliation net cash inflow operating activity cash generation conversion close equivalent ifrs measure free cash flow show summary consolidated cash flow set reconciliation free adjust cash flow net cash inflow operating activity net cash inflowoutflow investing activity net cash inflow operating activity net cash outflow financing activity purchase property plant equipment increasedecrease cash bank overdraft purchase intangible asset proceed sale property plant equipment cash bank overdraft begin year interest pay increasedecrease cash bank overdraft interest receive exchange adjustment dividend associate joint venture cash bank overdraft end year distribution noncontrolle interest cash bank overdraft end year free cash flow comprise legal payment cash cash equivalent adjust free cash flow overdraft investment appraisal formal process assess potential investment adjust net cash inflow operating activity proposals order ensure decision align overall strategy process include assessment cash flow net cash inflow operating activity year return investment cfroi net present value million million exclude legal settlement npv internal rate return irr timeline million million adjust net cash inflow project long term consider impact earning operating activity million credit profile relevant million payment noncore restructure integration cost million million discount rate perform financial analysis decide initial tax payment arise sale oncology business internally allow determination extent investment amount million fund cover cost capital specific investment discount rate divestment proceed exclude item adjust net cash adjust account country risk weighting inflow operating activity million capital expenditure financial investment million reduction million cash payment tangible intangible fix asset amount decrease primarily result initial impact million million disposal realise novartis transaction reflect disposal gsk high million million cash payment acquire margin oncology business impact acquire low equity investment million million margin vaccine consumer healthcare business year sale equity investment realise million low operating profit primarily global pharmaceutical million impact negative currency movement year addition future cash flow cash payment shionogi relation viiv healthcare long term expect future cash generate contingent consideration liability recognise operate cash operation sufficient fund operating debt flow increase million total cash payment servicing cost normal level capital expenditure obligation shionogi relation viiv healthcare contingent exist licensing agreement expenditure arise consideration liability million restructuring programme routine outflow include tax million recognise cash flow operating activity pension contribution dividend subject risk factor million recognise purchase business discuss page time time invest cash flow additional demand finance acquisition share free cash flow repurchase access source liquidity free cash flow cash generate business short longterm capital market financial institution meet obligation interest tax dividend pay addition cash flow operation need noncontrolle interest capital expenditure property work capital plant equipment intangible asset work capital percentage turnover work capital conversion cycle day free cash outflowinflow adjust free cash flow work capital programme continue progress improvement collection receivable free cash outflow million year exclude legal well inventory management payment million million adjust free cash report work capital conversion cycle day distort flow million million temporary favourable impact day arise noncore restructure integration cost initial tax novartis transaction exclude impact conversion cycle payment sale oncology business exclude day reduction day compare item adjust free cash inflow million predominantly increase million decrease reflect factor denominator increase restructuring cost offset net cash inflow operating activity describe beneficial impact exchange reduce receivables improve collection reduce inventory level gsk annual report strategic report governance remuneration financial statement investor information group financial review continue property plant equipment financial position resource business sciencebase technologyintensive highly regulate governmental authority allocate significant financial resource renewal maintenance property asset plant equipment minimise risk interruption production noncurrent asset achieve compliance regulatory standard number property plant equipment process use chemical hazardous material goodwill total cost property plant equipment intangible asset december million net book value investment associate joint venture million land building represent million plant equipment million asset investment construction million invest million defer tax asset new property plant equipment mainly related noncurrent asset large number project renewal improvement total noncurrent asset expansion facility worldwide site property mainly hold freehold new investment finance current asset liquid resource december contractual inventory commitment future capital expenditure million current tax recoverable operating lease commitment million believe trade receivables facility adequate current need derivative financial instrument observe stringent procedure use specialist skill liquid investment manage environmental risk activity environmental cash cash equivalent issue date operation modify asset hold sale discontinue report planet total current asset note financial statement legal proceeding total asset goodwill goodwill increase year million liability december million increase reflect current liability goodwill arise acquire novartis vaccine business shortterm borrowings creation consumer healthcare joint venture trade payable intangible asset derivative financial instrument intangible asset include cost intangible acquire current tax payable party computer software net book value shortterm provision intangible asset december total current liability million million increase reflect impact acquire vaccine business noncurrent liabilitie million creation consumer healthcare longterm borrowing joint venture million capitalise development cost defer tax liability million partly offset amortisation impairment pension postemployment benefit exist intangible million million respectively provision investment associate joint venture derivative financial instrument hold investment associate joint venture noncurrent liability carry value december million total noncurrent liability million market value december total liability million million large net asset investment theravance inc innoviva inc book value december million market equity value december million september share capital theravance inc account equity investment share premium account consider group exert significant influence company point note retain earning financial statement investment associate joint venture reserve shareholder equity investment noncontrolle interest hold investment carry value december million million total equity significant investment aspen pharmacare holding limited book value december million previously investment aspen treat associate march sell half hold aspen result long able exert significant influence company investment report investment date investment include equity stake company research collaboration provide access biotechnology development potential interest interest company arise business divestment gsk annual report strategic report governance remuneration financial statement investor information derivative financial instrument asset noncurrent liability current derivative financial instrument hold fair value noncurrent liability million december million million majority million include million relate foreign exchange contract designate million contingent consideration payable designate accounting hedge million million respect acquisition shionogiviiv healthcare joint inventory venture million payable novartis relation inventory million increase million vaccine acquisition addition million increase primarily reflect impact novartis relate present value estimate payable acquisition partly offset exchange movement event exercise novartis right require trade receivables acquire shareholde consumer healthcare trade receivables million increase joint venture impact novartis acquisition partly offset net debt exchange movement derivative financial instrument liability hold current derivative financial instrument fair value cash cash equivalent liquid investment million million current million non borrowing repayable year current primarily relate foreign exchange contract borrowing repayable year designate nondesignate intercompany loan trade net debt receivables accounting hedge trade payable december net debt billion compare trade payable amount million increase billion december comprise gross debt million reflect effect novartis billion cash liquid investment billion acquisition increase accrual customer return decrease net debt primarily reflect impact novartis rebate transaction sell oncology business net cash proceed billion pay billion net cash provision acquire purchase novartis vaccine business carry defer tax provision shortterm noncurrent provision million december tax payment novartis transaction amount million million million addition sell million relate legal dispute million shareholding aspen cash proceed million million relate operational excellence pay dividend shareholder million net debt provision provision legal dispute reflect exchange loss translation cash hold indemnify disposal liability employee relate liability group venezuelan subsidiary cost restructure programme extent continue political economic uncertainty balance sheet date legal constructive obligation exist venezuela december change reliably estimate exchange rate translate subsidiary venezuela pensions postemployment benefit point apply official rate available account pension postemployment vef december change arrangement accordance ias deficit vef vef change significant net surplus allow deferred taxation impact group income statement give rise million million pension arrangement exchange loss translation cash hold venezuelan million million unfunded post subsidiary million employment liability decrease deficit december cash liquid investment hold predominantly drive high discount rate follow discount value liability partly offset increase inflation rate net obligation acquire result novartis transaction bank balance deposit december scheme purchase insurance treasury treasury repo contract guarantee payment specify pensioner money market fund liability contract value million liquidity fund december government security cash liquid investment billion hold centrally december gsk annual report strategic report governance remuneration financial statement investor information group financial review continue maturity profile gross debt equivalent gbp bonds eur bond usd bond bank borrowing lease analysis cash gross debt effect hedge total equity follow december total equity increase million december million increase arise impact operating profit business asset disposal profit partly offset cash liquid investment remeasurement viiv healthcare contingent consideration gross debt fix dividend pay year float noninterest bear summary movement equity set net debt total equity beginning year movement net debt total comprehensive income year dividend shareholder ordinary share issue net debt begin year gain transfer net asset increasedecrease cash bank overdraft consumer healthcare increasedecrease liquid investment consumer healthcare option net increase longterm loan loss transfer equity investment net repayment shortterm loan investment associate exchange movement change noncontrolle interest movement forward contract relate noncontrolle net debt end year interest share purchase cancel hold treasury share share acquire esop trust sharebase incentive plan tax sharebase incentive plan distribution noncontrolle interest total equity end year gain transfer net asset consumer healthcare joint venture million reflect difference book value gsk consumer healthcare net asset contribute joint venture fair value apply consideration novartis contribute asset consumer healthcare joint venture option million reflect recognition initial value liability group balance sheet change non control interest primarily reflect recognition novartis share consumer healthcare joint venture gsk annual report strategic report governance remuneration financial statement investor information share purchase enter number research collaboration employee share ownership plan esop develop new compound pharmaceutical company trust acquire million share glaxosmithkline plc term arrangement include upfront fee equity million share hold trust satisfy investment loan commitment fund specify level future exercise option award group share research addition agree payment option award scheme proportion share hold future milestone achieve trust respect award rule scheme agreement relate compound early require satisfy exercise market purchase stage development potential obligation milestone issue new share share hold trust payment continue number year compound match option award grant successfully development process generally december esop trust hold million close product marketing approval great million gsk share future exercise probability success amount show share option share award carry value intangible asset represent maximum pay million million deduct milestone achieve include billion reserve market value share relate externalised project discovery portfolio million million number new commitment licensing agreement offset amendment share repurchase december exist agreement hold million share treasury share million share cost million reach agreement trustee million deduct pension scheme additional contribution retain earning year period include eliminate pension deficit identify december actuarial funding company expect ordinary share valuation deficit persist contribution repurchase ordinary share purchase payable follow year depend level deficit period january february table include commitment exclude normal commitment contingent liability ongoing annual funding requirement approximately financial commitment summarise note financial million information pension obligation statement commitment contingent liability note financial statement pension post obligation respect short longterm debt set employment benefit note financial statement contingent liability contingent liability note financial statement net debt follow table set contingent liability comprise amount provide pension postretirement benefit discount bill performance guarantee letter credit set note financial statement pension item arise normal course business postemployment benefit amount provide restructuring expect expire programme legal environmental dispute set note financial statement provision total yrs yrs yrs contractual obligation commitment guarantee follow table set contractual obligation contingent liability commitment december fall payment total total yrs yrs yrs normal course business provide indemnification guarantee respect business disposal loan legal dispute subsequently arise interest loan provision outflow resource consider finance lease obligation probable reliable estimate likely outcome finance lease charge dispute include note financial operating lease statement provision commitment provide outcome tax legal dispute intangible asset outflow resource consider probable reliable property plant equipment estimate outflow december investment dispute provision possible reliable estimate potential purchase commitment outflow fund require settle dispute pension possibility outflow remote commitment total ultimate liability matter vary significantly amount provide dependent outcome commitment respect loan future interest payable litigation proceeding negotiation relevant tax loan disclose take account effect authority discuss risk factor page derivative note financial statement taxation legal proceeding gsk annual report strategic report governance remuneration financial statement investor information group financial review continue follow recent review prospect viiv noncontrolle interest viiv healthcare healthcare business conclusion intend retain viiv healthcare decide option hold trading profit allocation pfizer shionogi recognise group viiv healthcare subsidiary group balance sheet liability option recognise operating result turnover operate profit profit tax group balance sheet ifrs require agreement include group income statement portion give right withhold consent change remove earning allocate noncontrolle interest own right notify pfizer shionogi shareholders line respective equity irrevocably give right recognise shareholding pfizer shionogi liability option group balance sheet shareholder include gsk entitle preferential estimate present value liability option dividend determine performance certain product approximately billion adjustment value shareholder contribute relative performance preferential dividend shareholder product change time proportion overall earning viiv healthcare allocate shareholder change consistent revise treatment expect particular increase sale tivicay triumeq recognise liability group balance sheet future favourable impact proportion preferential dividend preferential dividend anticipate payable pfizer allocate entitle approximately shionogi estimate aggregate present value liability core earning viiv healthcare preferential preferential dividend pfizer shionogi approximately dividend allocate pfizer shionogi include million noncontrolle interest line acquisitionrelate arrangement critical accounting policy agreement reach acquire shionogis interest shionogiviiv healthcare joint venture consolidated financial statement prepare accordance agree pay additional consideration shionogi contingent ifrs adopt use european union performance product develop joint ifrs issue iasb follow accounting policy venture principally dolutegravir december fair approve board describe note financial value contingent consideration represent statement accounting principle policy discount value total estimate payable require estimate assumption affect million recognise group amount asset liability revenue expense report balance sheet million show trade payable financial statement actual amount result differ million noncurrent liability estimate payment shionogi quarter reduce liability critical accounting policy information instalment payment calculate base sale judgement estimate give note financial performance relevant product previous quarter statement key accounting judgement estimate reflect cash flow statement partly operate cash relevant detailed note financial statement indicate flow partly purchase business invest relate follow area activitie payment relate original estimate fair value contingent consideration acquisition turnover shionogiviiv healthcare joint venture taxation note million report purchase business legal dispute note payment relate increase liability goodwill intangible asset impairment note acquisition report operate cash flow cash payment amount million total business combination note million report operate cash flow million pension postemployment benefit note purchase business information judgement estimate area exit right given note financial statement key accounting certain circumstance pfizer shionogi require judgements estimate acquire shareholding price base likely valuation turnover viiv healthcare conduct initial public offering respect turnover accounting policy large business ipo pfizer request ipo viiv healthcare time pharmaceutical vaccine market consent ipo offer complex arrangement rebate discount complete month pfizer require acquire allowance follow briefly describe nature shareholding shionogi request gsk acquire arrangement existence pharmaceuticals shareholde viiv healthcare certain circumstance vaccine business month window commencing arrangement certain indirect customer original agreement unconditional right customer able buy product wholesaler long subsequent distribution shareholder reduce price chargeback represent difference withhold consent exercise pfizer invoice price wholesaler indirect shionogi option result accordance ifrs customer contractual discount price accrual estimate recognise liability option chargeback calculate base term balance sheet agreement historical experience product growth rate gsk annual report strategic report governance remuneration financial statement investor information customer rebate offer key manage care group monthly process operate monitor inventory level purchase organisation gpo direct indirect wholesaler abnormal movement process use gross customer arrangement require customer achieve sale volume prescription volume base party datum certain performance target relate value product source information receive key wholesaler aim purchase formulary status predetermine market share maintain inventory consistent level year relative competitor accrual customer rebate year base pattern consumption estimate base specific term agreement basis pharmaceutical vaccine inventory level historical experience product growth rate wholesaler distribution channel december medicaid programme stateadministere estimate approximately week programme provide assistance certain poor vulnerable turnover calculation use party information accuracy patient medicaid drug rebate program totally verify believe sufficiently establish reduce state federal expenditure reliable purpose prescription drug patient protection legal dispute affordable care act law participate provide respect accounting policy legal dispute rebate state accrual medicaid rebate calculate follow briefly describe process determine base specific term relevant regulation level provision necessary patient protection affordable care act accordance requirement ias provision cash discount offer customer encourage prompt contingent liability contingent asset provide payment accrue time invoicing anticipate settlement cost outflow resource adjust subsequently reflect actual experience consider probable reliable estimate record accrual estimate sale return apply likely outcome dispute legal expense arise historical experience customer return amount invoice claim group involved market relate information stock level significant legal proceeding respect possible wholesaler anticipate price increase competitor activity reliable estimate expect financial effect result ultimate resolution proceeding reconciliation gross turnover net turnover case appropriate disclosure case pharmaceutical business include puerto rico follows include annual report provision restate restate position change time margin margin margin assurance loss result outcome legal proceeding exceed material gross turnover provision report group financial statement like pharmaceutical company face market drive complex product liability antitrust patent litigation segment investigation operation conduct governmental government regulatory agency year general counsel mandate state group head group legal function program senior vice president head global litigation group responsible litigation government investigation cash discount routinely brief chief executive officer chief financial customer officer board director significant litigation return pende group governmental investigation prior year group adjustment meeting appropriate detail status significant item litigation government investigation review matter total deduction number claim notify information potential net turnover claim notify assessment validity claim progress settle claim recent settlement level market drive segment consist primarily manage care potential reimbursement insurer medicare plan gsk negotiate contract pricing honour rebate chargeback mandate segment meeting include assessment consist primarily medicaid federal government program sufficient information available able receive government mandate pricing rebate reliable estimate potential outcome dispute chargeback external counsel assist litigation matter investigation assist briefing board balance sheet accrual rebate discount allowance senior management follow discussion return pharmaceutical vaccine business matter possible reliable estimate manage combined basis december total provision require level accrual amount million million provision legal dispute review adjust appropriate matter discuss note financial statement legal proceeding gsk annual report strategic report governance remuneration financial statement investor information group financial review continue foreign exchange risk management treasury policy foreign currency transaction exposure arise internal external trade flow typically hedge objective report sterling pay dividend sterling profit minimise exposure overseas operating subsidiary role corporate treasury monitor manage transaction risk match local currency income local external internal funding requirement financial risk currency cost possible internal trading transaction support strategic objective operate global match centrally manage intercompany payment basis primarily subsidiary company manage term reduce foreign currency risk foreign currency cash flow capital ensure subsidiary able operate hedge selectively management treasury go concern optimise return shareholder tmg include hedge foreign exchange risk appropriate balance debt equity treasury activity arise acquisition disposal asset possible govern policy approve annually board director manage cash surplus borrowing requirement recently july treasury management group subsidiary company centrally forward contract hedge tmg meeting chair chief financial officer take place future repayment originate currency monthly basis review treasury activity member receive management information relate activity order reduce foreign currency translation exposure seek denominate borrowing currencie principal asset treasury operation cash flow primarily denominate dollar objective treasury activity minimise posttax euro sterle certain borrowing swap net cost financial operation reduce volatility order currency require benefit earning use variety financial instrument finance operation derivative financial instrument borrowing denominate swap foreign currency manage market risk operation derivative match investment overseas group asset treat principally comprise forward foreign currency contract foreign hedge relevant asset forward contract major currency option interest rate swap swap currency reduce exposure investment borrowing liquid asset currency require group overseas group asset tmg review ratio borrowing purpose manage exposure financial risk change asset major currency monthly foreign exchange rate interest rate counterparty risk management hold issue derivative speculative purpose set global counterparty limit banking treasury policy specifically prohibit activity investment counterpartie base longterm credit rating transaction financial instrument undertake manage moodys standard poor corporate treasury usage risk arise underlie business activity limit monitor daily corporate compliance officer speculation cco operate independently corporate treasury breach limit report cfo immediately capital management financial strategy implement financial cco monitor credit rating counterpartie architecture support group strategic priority change rating occur notifie corporate treasury regularly review board manage capital structure change investment level authority group appropriate mix debt equity limit appropriate addition relationship bank credit rating review regularly report present annually longterm credit rating standard poor tmg approval stable outlook moodys investor service moodys negative outlook shortterm credit rating standard poor moodys respectively liquidity risk management policy borrow centrally order meet anticipate strategic report funding requirement cash flow forecast funding requirement monitor tmg monthly basis strategic report approve board director strategy diversify liquidity source range march sign behalf facility maintain broad access funding market day sweep cash number global subsidiary central treasury account liquidity management purpose interest rate risk management simon dingemans chief financial officer objective minimise effective net interest cost march balance mix debt fix float interest rate time policy interest rate risk management limit float interest payment prescribe percentage operating profit gsk annual report gsk annual report strategic report governance remuneration financial statement investor information governance remuneration section board corporate executive team board governance corporate governance framework committee report audit risk nomination corporate responsibility remuneration report chairman annual statement annual report remuneration remuneration policy summary gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board sir philip hampton skill experience nonexecutive chairman prior join gsk sir philip chair major ftse company include royal bank scotland group plc sainsbury plc nationality serve group finance director lloyds tsb group british group plc group plc british gas british steel plc appointment date sir philip previously appoint executive director lazard january deputy nonexecutive director rmc group plc belgacom chairman april chairman financial investment limited nonexecutive chairman manage government shareholding bank external appointment committee membership sir philip currently senior independent director anglo nominations committee american plc chairman remuneration committee chairman finance member audit committee sir philip chair woman board review independent review increase representation woman executive level ftse company sir andrew witty skill experience chief executive officer sir andrew joined gsk work south africa singapore senior role nationality appoint president europe join gsk corporate british executive team andrew serve numerous advisory role appointment date government world include south africa singapore january guangzhou china member chief executive officer prime minister business advisory group award knighthood service economy pharmaceutical industry new year honour list committee membership finance external appointment sir andrew appoint business ambassador group chinabritain business council advisory council school economic management advisory board sem tsinghua university beijing china sir andrew chancellor university nottingham simon dingemans skill experience chief financial officer prior join gsk simon year experience investment banking warburg goldman sachs nationality time advise broad range large corporate number british industry sector include pharmaceutical consumer healthcare appointment date simon advise gsk decade appointment january chief closely involve number gsk key strategic project financial officer april external appointment committee membership simon chairman group finance director finance moncef slaoui skill experience chairman global vaccines moncef join gsk vaccine engineer development robust vaccine pipeline lead worldwide nationality business development pharmaceutical product moroccan belgian american appointment lead give overall responsibility appointment date gsk oncology business gsk vaccine global franchise moncef advise president council advisor science technology committee membership member board agency science technology finance research astar january phd molecular biology immunology universit libre bruxelle publish scientific paper presentation prior join gsk moncef professor immunology university mon belgium external appointment moncef member biotechnology industry organization board member advisory committee director national institutes health adviser qatar foundation member qatar biomedical research institute scientific advisory committee moncef serve nonexecutive director international aids vaccine initiative iavigsk annual report strategic report governance remuneration financial statement investor information sir deryck maughan skill experience senior independent sir deryck wealth international corporate investment nonexecutive director banking experience previously serve chairman chief executive officer citigroup international salomon nationality brothers inc serve vice chairman new york stock british exchange sir deryck senior adviser appointment date partner kohlberg kravis roberts previously serve june senior nonexecutive director thomson reuters independent nonexecutive external appointment director sir deryck nonexecutive director blackrock inc committee membership trustee british museum audit risk nomination remuneration finance professor sir roy anderson skills experience independent nonexecutive professor sir roy worldrenowne medical scientist advanced director scientific expert knowledge infectious disease epidemiology currently professor infectious disease faculty medicine imperial nationality college london fellow royal society academy british medical sciences royal statistical society honorary appointment date fellow institute actuary foreign associate member october national academy medicine national academy sciences french academy sciences professor sir roy committee membership bring scientific expertise board deliberation nomination finance external appointment professor sir roy member international advisory board holdingham group chairman science advisory board natural history museum london member vaccine international advisory board vacciab pharma hold sdn bhd malaysia manvinder singh vindi skill experience banga prior join gsk vindi spend year unilever plc independent nonexecutive role senior position president global director food home personal care business member unilever executive board vindi sit prime minister indias nationality council trade industry board indian governors indian institute management iim ahmedabad appointment date vindi recipient padma bhushan india high september civilian honour committee membership external appointment audit risk nomination vindi partner private equity investment firm clayton dubili remuneration finance rice chairman supervisory board mauser group senior independent director mark spencer group plc member nomination remuneration committee nonexecutive director thompson reuters corp member committee vindi govern board indian school business isb hyderabad stephanie burn skill experience independent nonexecutive stephanie recognise global business leader serve director chairman president ceo dow corning corporation retirement end strong scientific background nationality phd organic chemistry organosilicon speciality american advocate science education stephanie previously sit appointment date president export council officer society february chemical industry american section past honorary president ukbased parent society stephanie committee membership officer chairman american chemistry council corporate responsibility remuneration finance external appointment stephanie nonexecutive director corning inc kellogg company appoint board inc november gsk annual report strategic report governance remuneration financial statement investor information board continue stacey cartwright skill experience independent nonexecutive stacey charter accountant significant experience director global consumer business corporate finance serve executive vice president chief financial officer burberry group plc nationality july prior join burberry group plc stacey hold british role chief financial officer egg plc appointment date work financerelated position april granada group plc committee membership board determine stacey recent relevant financial audit risk finance experience agree appropriate qualification background audit committee financial expert external appointment stacey chief executive officer harvey nichols group company lynn elsenhans skill experience independent nonexecutive lynn wealth experience run global business director significant knowledge global market gsk operate serve chair president chief executive officer sunoco nationality inc prior join sunoco president american chief executive officer lynn work royal dutch shell appointment date join hold number senior role include july executive vice president global manufacturing committee membership external appointment corporate responsibility lynn nonexecutive director baker hughes inc committee chairman flowserve corporation director texas medical center audit risk nomination nonexecutive director tee great houston finance trustee united way great houston jesse goodman skill experience independent nonexecutive goodman previously serve senior leadership position director scientific expert food drug administration fda include recently fdas chief scientist previously deputy commissioner science nationality public health director center biologics evaluation american research cber appointment date goodman play leadership role develop fda regulatory january science medical countermeasure initiative work committee membership collaboratively industry academia government global public finance health regulatory partner prepare respond major public health threat include emerge infectious disease disaster terrorism lead fdas response west nile virus influenza pandemic serve senior leadership team white house medical countermeasure review goodman bring scientific public health expertise board deliberation external appointment goodman currently professor medicine georgetown university direct georgetown university center medical product access safety stewardship compass active clinician serve attend physician infectious disease serve president member board united states pharmacopeia usp judy lewent skill experience independent nonexecutive judy extensive knowledge global pharmaceutical industry director corporate finance join merck serve chief financial officer retire judy nationality previously nonexecutive director purdue pharma inc napp american pharmaceutical holding limit certain mundipharma international appointment date limit company december judy previously serve april nonexecutive director dell inc quaker oats company committee membership board determine judy recent relevant financial audit risk committee experience agree appropriate qualification chairman nomination background audit committee financial expert remuneration finance external appointment judy nonexecutive director thermo fisher scientific inc motorola solutions inc trustee rockefeller family trust chairperson audit committee rockefeller financial service life member massachusetts institute technology corporation member american academy arts sciencesgsk annual report strategic report governance remuneration financial statement investor information daniel podolsky skill experience independent nonexecutive daniel worldrenowne researcher advanced knowledge director scientific expert underlie mechanism disease new therapy gastrointestinal disorder mallinckrodt professor nationality medicine chief gastroenterology massachusetts general american hospital harvard medical school previously serve appointment date chief academic officer partner healthcare system daniel july current responsibility lead large academic medical centre relevant insight healthcare delivery daniel bring scientific committee membership expertise board audit risk committee deliberation audit risk corporate responsibility finance external appointment daniel president university texas southwestern medical center hold philip obryan montgomery distinguish presidential chair academic administration doris bryan wildenthal distinguish chair medical science member national academy medicine national academy sciences member board southwestern medical foundation director antibe therapeutics inc member national academies sciences board army science technology urs rohner skill experience independent nonexecutive urs broad range business legal experience serve director chairman number board recently credit suisse world lead financial service company prior join credit nationality suisse urs serve chairman executive board swiss ceo prosieben prosiebensat media follow appointment date number year private practice major law firm switzerland january admit bar canton zurich state new york committee membership remuneration committee external appointment chairman finance urs currently appoint chairman board credit suisse group chairmans governance committee appoint chairman member board trustee credit suisse research institute credit suisse foundation urs appoint vicechairman govern board swiss bankers association han wijer skill experience independent nonexecutive han broad range business economic political director experience serve chief executive officer chairman akzo nobel hans long nationality distinguish career academia public service strategy dutch consulting serve senior partner boston consulting appointment date group april external appointment committee membership han chairman supervisory board heineken corporate responsibility deputy chairman nonexecutive director royal dutch shell remuneration finance chairman supervisory board afc ajax member supervisory board hal holding gsk annual report strategic report governance remuneration financial statement investor information corporate executive team ceo assistance corporate executive team responsible management business develop group strategic direction consideration approval board implement agree strategy sir andrew witty simon dingemans moncef slaoui chief executive officer chief financial officer chairman global vaccine biographical detail roger connor nick hiron abbas hussain president global manufacturing supply senior vice president global ethic president global pharmaceuticals compliance roger join cet appoint abbas join cet appoint president global manufacturing supply nick appoint cet september president global pharmaceuticals october gms working year senior vice president global ethic join company president president designate gms compliance responsible emerge market asia pacific june compliance risk management corporate joined viiv healthcare ltd board roger join gsk astrazeneca security investigation october work finance manufacturing strategy role include gsk site cork nick join gsk international previously spend year eli lilly ireland ware prior auditor later head audit hold position include president europe position gms roger vice president assurance combine vice president europe office ceo corporate strategy separate audit function independent hold position eli lilly australia february team operate common riskbase india turkey germany methodology june nick take role include business development sale hold degree mechanical role china establish new marketing management manufacturing engineering queen governance model china business university belfast masters degree medicinal chemistry create consistent approach compliance manufacturing leadership cambridge pharmacology loughborough university university charter accountant nick fellow chartered institute bear madras india management accountantsgsk annual report strategic report governance remuneration financial statement investor information david redfern claire thomas phil thomson chief strategy officer senior vice president human resource senior vice president communication government affair david join cet chief strategy officer claire appoint cet senior vice responsible corporate president human resource phil join cet appoint development strategic planning senior vice president communication claire join company senior addition appoint chairman government affair manager human resource sale board viiv healthcare ltd april responsibility medium relation investor marketing group pharmaceutical nonexecutive director aspen relation corporate responsibility internal director human resource pharmacare ltd board february communication product communication pharmaceutical government affair gsk global brand previously senior vice president appoint senior vice president human northern europe responsibility gsk resource pharmaceuticals europe join glaxo wellcome trainee pharmaceutical business region senior vice president human resource move pharmaceutical brand marketing prior senior vice president international product communication central eastern europe david join director medium relation glaxo wellcome prior join company work gsk finance director plc director investor relations ford motor company hold european business return position human resource corporate medium relation vice president david bachelor science degree claire bachelor science degree phil work numerous corporate bristol university charter economics management industrial product reputational matter gsk accountant relation university wale phil earn degree english history durham university dan troy patrick vallance emma walmsley senior vice president general counsel president pharmaceuticals ceo gsk consumer healthcare dan joined gsk cet senior patrick join cet emma ceo gsk consumer healthcare vice president general counsel appoint president pharmaceutical include joint venture novartis september january prior senior list consumer healthcare vice president medicine discovery business india nigeria business previously partner development split equally otc washington law firm sidley austin llp medicine fast move consumer good represent mainly pharmaceutical patrick join company head brand category wellness company trade association matter drug discovery prior join gsk oral health nutrition skin health relate food drug patrick clinical academic lead administration fda government division medicine university college prior emma president gsk regulations dan chief counsel london year experience consumer healthcare fda serve primary research clinical medicine general internal member cet joined liaison white house medicine cardiovascular medicine clinical gsk department health human service pharmacology elect prior emma work loreal academy medical sciences dan graduate cornell universitys year degree classic school industrial labor relations patrick board modern language oxford university earn law degree columbia office strategic coordination health emma nonexecutive director university school law dan name research oschr diageo plc effect january legend law burton awardsstrategic report governance remuneration financial statement investor information corporate governance board governance strategy progress delivery set strategic report follow page provide information board oversight group activity board board please report compliance requirement financial reporting council frc corporate governance code code exception code provision require audit contract tender undertake year set detail year audit contract tender process copy code available frc website wwwfrcorguk board responsible longterm success company accountable shareholder ensure group appropriately manage govern believe governance structure provide right base help deliver strategy grow diversified business deliver product value simplify operating model create additional longterm value shareholder board programme board meet face face time board member attend schedule board meeting board agenda shape create time strategic discussion debate closely manage time allocate routine item ensure focused consideration strategic priority agenda board meeting include follow business month strategy board risk oversight governance january review ceo objective review financial result secretary report include outlook regulatory governance update review investor activity reappointment auditor activity novartis transaction update approval budget plan march review reshape consumer review financial result secretary report include healthcare global pharmaceutical year date regulatory governance update business ebola vaccine update mandatory annual corporate integrity deep dive pharmaceutical agreement cia training pricing formulary access review revise plan review financial result secretary report include long range forecasting follow year date regulatory governance update completion novartis transaction global manufacturing supply preparation agm annual update novartis transaction update review annual cia agreement compliance resolution july annual review talent leadership eview financial result secretary report include development strategy year date regulatory governance update review fund strategy vaccine annual update include treasury policy integration pipeline review pension insurance strategy propose agenda annual board cet strategy meeting review go concern assumption october nnual board cet strategy meeting eview financial result secretary report include regulatory review output annual year date governance update board cet strategy meeting annual update quality update healthcare professional hcp model update december review budget eview financial result secretary report include regulatory plan year date governance update supply chain update nucala launch plan pricing update ure year board member invite attend audit risk committee meeting risk matter routinely discuss gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board governance continue board performance action point progress conclusion board evaluation review independently facilitate tracy long boardroom review limited set key findingsaction point progressachievement composition board change year board composition assessment exercise require carefully plan thoughtfully execute refreshment programme undertake enable nomination committee plan board chairman designate nomination committee seek enhance change occur year governance process relate board composition tenure size ensure board review seek develop objective specification plan board role necessary skill alignment strategy external landscape company evolve circumstance director identify gap board current composition relate board please vindi banga pricing healthcare emerge market consumer healthcare knowledge jesse goodman sid designate sme respectively agree join board closing knowledge experience gap consider process appointment help fill recruitment new nonexecutive director combine refreshment designate identify skill gap nomination specialist role board scientific medical expertise sme senior committee continue refresh board independent director sid meet company future need give speed complexity external landscape change potential characteristic factor surprise highly experienced nonexecutive director crucial component individual search profile selection board composition process recruit new nonexecutive director critical skill set potential candidate international market cultural experience crisis stakeholder management consider composition choice peer group board benchmarke replacement current sid retire agm priority issue vindi banga background experience fulfil requirement chairman designate lead search involve internal external candidate sid specification appoint sid role designate september sid specification develop balance replacement exist knowledge succeed sir deryck maughan current sid ability work chairman designate conduct robust board evaluation conclusion agm interact shareholder able commit necessary time role consideration give reduce size board judge board recommendation strong composition dynamic nomination committee agreed work ideal board size aspiration consider refresh board competenceskill matrix director board refreshment programme link company strategy consideration give enhance nonexecutive director evaluation process chairman conclude review agree introduce peer evaluation chairman designate lead process consider good practice technique inform annual review meeting combination annual individual peer evaluation board director board performance action point agree action point arise board evaluation review internally facilitate company secretary victoria whyte progress disclose gsk annual report set executive succession deep dive board material strategy ne refreshment site visit shareholder logistic assist new director increase focus consider deep review look continue drive additional background executive succession dive particularly enhance boardcommittee material briefing material ahead plan ensure strategy pipeline company communicate concise debate strategy effectiveness product launch shareholder effective highlight disaster recovery plan price joint venture issue concern arrange regular new business model discussion medium consider alternative aim gms long term strategy suggestion non presentation time fresh insight different executive director consider hold site time discussion perspective refreshment visit operational site debate meeting year implement suggestion allow social time enhance board member effectiveness annual know well board cet strategy give number new meeting board member gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue corporate governance framework board coherent corporate governance framework clearly define responsibility accountability design safeguard enhance longterm shareholder value provide robust platform realise group strategy grow deliver simplify internal control risk management arrangement describe page integral gsk governance framework board committee board operate effectively consideration key matter board committee establish board summary role board committee set table term reference committee available wwwgskcom report membership work undertake audit risk nomination corporate responsibility remuneration committee give page board chief executive officer corporate executive team corporate corporate administration audit risk remuneration nomination responsibility finance transaction committee committee committee committee committee committee review review review review review review responsible recommend recommend external issue approves approve financial internal board board potential annual report matter report process overall executive structure size impact form connection integrity remuneration policy composition gsk business convene administration financial statement reference board reputation agm group include remuneration appointment management quarterly result business annual report employee director committee announcement certain corporate annual governance quarterly result appropriate fee member cet oversight gsk certain major transaction announcement chairman member responsible business licensing capital system internal succession commitment transaction control determine board cet change identification term service group investment management remuneration instrument risk external executive director counterparty limit internal audit member process cet initiate audit tender review selection approve appointment remuneration external auditor report remuneration oversight workgsk annual report strategic report governance remuneration financial statement investor information leadership effectiveness chairman role chairman lead manage business board provide direction focus ensure clear structure effective operation board committee set agenda board discussion promote effective constructive debate support sound decisionmake process sir philip hampton succeed sir christopher gent chairman work closely chief executive officer sir andrew witty ensure strategy action agree board effectively implement provide support advice sir andrew respect executive responsibility manage group division responsibility chairman ceo agree board set governance section website sir philip satisfy frc code independence test appointment board responsible shareholder performance group lead discussion nonexecutive director nonexecutive director provide strong independent element board place constructively challenge support management shape proposal strategy succession planning bring independent judgement breadth skill experience gain senior level international business operation academia nonexecutive director letter appointment set term condition directorship nonexecutive director expect devote time necessary proper performance duty precise timing give vary year year depend company activity expect attend board meeting additional meeting require board consider nonexecutive director include tenure year demonstrate appropriate degree independence character judgement free business relationship materially interfere exercise judgement independence commitment nonexecutive director serve board year subject rigorous review senior independent sir deryck maughan senior independent nonexecutive director sid nonexecutive director sir derycks role act sound board chairman trust intermediary director sid work process selection new chairman appropriate chair nominations committee agree recommendation board chairmans successor sir deryck maintains understand issue concern major shareholder meeting report investor relation team briefing company secretary corporate governance issue vindi banga succeed sir deryck sid retires board agm ceo sir andrew responsible management business develop group strategic direction consideration approval board implement agree strategy assist member corporate executive team cet meet time year require short biography member cet give corporate executive team page company secretary company secretary victoria whyte solicitor fellow institute charter secretary administrator victoria deputy secretary secretary remuneration committee act secretary board board committee appointment company secretary january victoria whyte support chairman design induction new director delivery corporate governance agenda particular planning agenda annual cycle board committee meeting ensure information available board member timely basis advise director board procedure corporate governance matter arrange nonexecutive director meet investor discuss aspect corporate governance arrangement request arrange attend internal management meeting visit business operation enhance knowledge understanding business company secretary respond consultation evolve global governance corporate reporting agenda behalf group engage shareholder ensure fully understand gsk governance remuneration arrangement request chairman undertake evaluation board committee collaboration committee chairman year evaluation conduct internally gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue diversity experience international experience composition tenure nonexecutive scientific global executive year finance nonexecutive year industry europe male year emap female year board addition schedule meeting board meet board meet face face time member quorate basis occasion consider corporate attending follow transaction include novartis transaction number board member meeting attend board induction sir philip hampton january number new nonexecutive director join sir andrew witty january board year undertaken board induction programme commence appoint simon dingemans january programme devise new chairman base moncef slaoui principle company new nonexecutive director sir deryck maughan june programme outline customise account leadership role gsk core element professor sir roy anderson october individual meeting hold listen tour gsk major vindi banga september shareholder understand firsthand view perspective group company strategy leadership business model stephanie burn february performance trading environment stacey cartwright april enhance programme set gsk lynn elsenhans july annual report judy lewent april induction programme urs rohner vindi banga jesse goodman daniel podolsky july ndividually design facilitate chairman urs rohner january company secretary hans wijers april design purpose orientate familiarise sir christopher gent june industry organisation governance strategy grow deliver simplify tom swaan january iii ustomised account respective experience je ulrich july different geographical background business perspective light particular role jesse goodman appoint nonexecutive director effect january perform committee serve board member seek reelection gsk agm key element induction programme include onetoone attend schedule board meeting briefing teachin session site visit undertaken director retired board urs rohner vindi banga jesse goodman set board composition diversity seek build effective complementary board executive director discuss gsk strategic financial capability appropriate scale complexity strategic priority position business process board appointment cet member cover principal pharmaceutical lead nomination committee describe consumer healthcare vaccine business page gms organisation underpin operating model mindful need balance composition board committee refresh progressively time senior executive cover core operation draw experience long serve director strategic development finance tax treasury audit tap new external perspective insight assurance investor relation global ethic recent appointee bring board deliberation compliance nonexecutive director draw wide range industry site visit gms vaccine facility background include pharmaceutical healthcare nvestor meeting particularly customise medical research academia retail insurance financial vindi banga role sid service appropriate experience complex organisation cia new director receive hour train global reach considerable experience cia obligation pharmaceutical industry recent appointee bring new approach group board discussion board diversity policy set detail gender diversity gsk global workforce strategic report governance remuneration financial statement investor information board business awareness training accountability ensure nonexecutive director develop maintain great insight understand business internal control framework invite attend internal management meeting include board recognise responsibility present fair meeting cet research development executive balance understandable assessment group position radex product executive scientific review board prospect board accountability review portfolio investment board commercial accountability approve effectiveness internal control operate board risk oversight compliance council rocc group include financial operational compliance control meet employee informally visit group risk management operation reception hold board meeting gsk internal control framework framework chairman meet director annually oneto mean gsk assure compliance law basis discuss ongoing training development regulation reliability financial reporting requirement board keep uptodate legal regulatory effectiveness risk management framework assists governance matter regular paper company ongoing process board identification evaluation secretary presentation internal external adviser management company principal risk require board member undertake specific refresher training frcs code design manage eliminate provision cia march new board risk achieve business objective fitforpurpose internal member require induction programme control framework conjunction embed gsk value receive comprehensive training cia philip hampton speak reporting line ensure principal risk urs rohner january vindi banga september actively effectively control information jesse goodman january take approach risk page train session induction programme framework design ensure risk associate conduct business activity effectively control line internal evaluation board gsk risk appetite believe framework provide board carry evaluation performance reasonable absolute assurance material committee year evaluation facilitate misstatement loss externally year progress board ensure effective governance ethical culture gsk agree action point evaluation externally facilitate tracy long boardroom review limited establish risk oversight compliance council rocc disclose team senior leader authorise board assist audit risk committee committee oversee risk board committee evaluation process management internal control activity provides conduct internally secretary request business framework risk management upward reporting chairman ceo significant risk gsk value policy business unit prepare survey complete board member global support function risk board structure hold interview director report rocc risk management compliance board rmcb responsible local tone risk discuss outcome recommendation management internal control chairman rocc rmcbs assist global ethic follow discussion board identify area improvement agreed board compliance gec responsible support risk management development implementation area review board oversight issue practice facilitate employee compliance law shareholder stakeholder relationships board culture policy gec provide assistance help employee meet balance challenge support ethic strategy high ethical standard operating accordance value priority comply applicable law regulation corporate board view member effective strong responsibility able equipped navigate challenge ahead action gsk audit assurance provide objective view point arise evaluation disclose assurance senior management board risk chairman nonexecutive director evaluation manage group line agree assurance senior independent nonexecutive director sid seek plan assurance helps meet oversight advisory feedback chairman performance canvass view responsibility fulfil strategic operational ambition chairman performance nonexecutive director build trust patient stakeholder collectively result chairmans effectiveness review dual reporting line cfo committee discuss chairman sid committee receive report business unit head gec chairman meet nonexecutive director discuss area significant risk group relate individual contribution performance train internal control report provide summary change development need share peer feedback control environment principal risk area following provide evaluation process addition consideration report committee report annually chairman meet nonexecutive director independently board effectiveness control executive director gsk annual report gsk annual report strategic report governance remuneration financial statement investor information corporate governance continued board committee conduct robust accordance provision frc code assessment group principal risk framework provide board responsible determine consider effectiveness system internal nature extent principal risk willing control operation group year cover achieve strategic objective board provide oversight annual report date approval board help ensure group maintain sound risk management board review focus company subsidiary internal control system framework operation extend material associate undertaking joint year continue operate venture investment consider risk date approval annual report company participation activity establish review group risk management approach procedure control place identify entity result discuss approach risk section strategic report consolidated group result page management mitigation believe process follow board principal risk explain principal risk uncertaintie committee review regularly system internal control page group viability discuss risk management arrangement accordance group financial review section strategic report guidance risk management internal control relate financial business reporting issue frc ongoing review monitor arrangement expand year include impact novartis transaction close march detail internal control framework terprise oversight ira ofe gfo rnr ete strategy risk management independent assurance financial performance disi epn fond eap ede ntnden seu csn nai tnt row lsar dti sten cou mdi esk roo mcroi eiv nie ntr nai tde eow nqi business ble ser ding activity train xerp cuor ivt team anu ago cir ioh eue uso itg ine gnt communication risk oversight authorise board compliance assist audit risk council committee oversee risk management internal control activity group gsk value business unit responsible identify key assess manage risk individual accountability business line management accountability compliance business management accountability compliance risk oversight ensure appropriate audit assurance compliance internal control effective risk council management implement complement country executive risk board ensure consistent approach risk management local geography gnirotinom rof ytilibatnuocca gnitnemelpmi rof ytilibisnopser governance structure risk managementstrategic report governance remuneration financial statement investor information remuneration remuneration report comprise remuneration committee chairman annual statement annual report remuneration set page addition produce summary shareholder approve remuneration policy report set page relation shareholder work engage effectively shareholder regular communication agm investor relation activity particularly busy year term shareholder engagement transformational year company result novartis transaction addition continuous dialogue ceo cfo maintain institutional shareholder hold individual meeting host group event number key shareholder engagement event year include new chairman undertaking listening tour institutional investor understand firsthand view perspective issue challenge face industry gsk hold investor day ceo leader pharmaceutical vaccine consumer healthcare business outline strategic proposition reshape group profile medium longterm shape opportunity gsk hold event november ceo leader pharmaceutical vaccine business profile potential new medicine vaccine offer significant opportunity drive longterm performance deliver new benefit patient consumer hold annual investor meeting november new chairman remuneration committee chairman audit risk committee chairman sid company secretary discuss corporate governance remuneration matter institutional investor committee report report audit risk nomination corporate responsibility committee describe activity committee year set page gsk annual report gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue follow centre excellence establish audit risk committee report lobal risk office accountability strengthen risk management standardise methodology manage principal risk include combined abac party risk programme identify emerge risk scan external internal environment serve steward internal control framework model proactively communicate monitor effective judy lewent implementation audit risk committee trategy planning operation accountability chairman ensure global system governance embed maintain proactively deliver standard policy dear shareholder training value assurance programme gsk committee agenda continue build investigation independent business monitoring offer usual review financial result ensure tier service deliver regional hub provide ongoing effectiveness company internal control risk consistent framework deliver effective independent management arrangement year business monitoring align gsk value particular focus impact novartis transaction close march transaction result relate initiative oversee committee include material change core business mprove coordination investigatory effort require significant integration restructuring effort embed establishment enterprise investigation committee acquire business vaccine consumer extract accelerate management speakup antibribery oncology market product pharmaceutical regular corruption abac computer security incident response review hold committee ensure control issue assign issue investigation appropriate enable framework reporting requirement maintain great collaboration gec legal computer security response team addition committee continue monitor group onitore progress implement programme action key ongoing transformation simplification programme underway enhance control abac risk ultimately include particular global support function incorporate abac requirement regular business practice continue simplify operating model employee management accountability improve programme finance transformation establishment network abac owner undertake major upgrade group system global business unit broaden abac training process include core erp supply chain platform communication enterprise introduction committee regularly review group cyber periodic certification reinforcement linkage security progress infoprotect programme gsk value performance implementation new design address risk specifically policy senior management financial recoupment new standard introduce frcs code ompletion general manager confirmation require additional focus committee year ensure operation internal control framework market compliance requirement probably pharmaceutical vaccine business exclude significant change year new requirement different system review complete relate company viability report assessment process annual process time operate standardise consistent approach finally committee approve formal commencement output review consolidate provide audit tender autumn result new clear view current trend assist identification audit firm replace pricewaterhousecooper llp pwc potential gap facilitate share good practice begin significant important step consumer healthcare implement similar process committee board detail audit tender confirmation operation internal control process governance timescale find framework key risk minimum control internal framework control risk management novartis integration enhancement internal control framework oversight novartis transaction key priority help build strong culture compliance enable committee give importance success transaction multifacete approach strengthen control group committee receive regular report principal risk extensive training presentation integration management acquire communication implement compliance novartis business operational internal control function turn key risk group business accounting risk management perspective run unit progress support global ethic close transaction march regularly compliance gec function activity gec year integration associate restructuring reorganise enhanced place network programme began implement addition onboarde expert sit centre excellence manage key novartis employee successfully complete mandatory element principal risk internal control framework training code conduct abac corporate integrity new governance model design standardise prioritise agreement obligation drive integrate compliance control principal risksstrategic report governance remuneration financial statement investor information global support function simplification programme membership attendance committee continue review regularly multiyear membership committee appointment programme underway simplify support function date attendance meeting set standardise operating model new upgrade platform programme establish committee attendance peak activity currently new platform process member member meeting roll group compound additional judy lewent requirement integrate novartis business chairman january april group operate report infrastructure significant vindi banga january progress report completion new global lynn elsenhans january supply chain forecasting system multiple cut over stacey cartwright april local operating company new erp platform deliver year target control level maintain sir deryck maughan january committee pay particular attention parallel daniel podolsky january transformation programme underway number support tom swaan january function especially finance transformation initiative jing ulrich ensure control reporting requirement affect infoprotect tom swaan jing ulrich retired board committee continue multiyear programme enhance secure strengthen cyber security defence addition schedule meeting committee meet close scrutiny review process cyber quorate basis occasion review approve matter security report submit chief information security associate annual report form preliminary officer schedule meeting please quarterly result announcement number key risk reduction initiative deliver year detail member financial accounting scientific experience expertise give biography board corporate governance code page follow issue frc update code associate guidance come effect financial reporting company secretary secretary committee attend year committee devoted time satisfy meeting entire board invite attend committee internal control risk management arrangement meeting attendee include monitor practice accord new enhance requirement particular area investment year regular attend attendee attendee require development recommendation board new viability statement examine company long general counsel cid term solvency viability set agree financial controller cid analytical assurance work management underpin head audit assurance cid statement consider year appropriate head global ethic compliance cid timeframe base assessment longterm viability align regular business planning period chief medical officer cid committee review outcome stress test chief product quality officer cid perform management recommend director external auditor cid confirm reasonable expectation group able continue operation meet liability accordance frcs code board determine fall year period assessment stacey cartwright judy lewent recent relevant financial experience board agree stacey committee continue work encourage support cartwright judy lewent appropriate qualification enhancement group internal control audit background audit committee financial expert define assurance arrangement addition look forward report sarbanesoxley act determine conclusion external audit tender process independent mean securities exchange act explain plan manage transition pwc amend new auditor operate addition vindi banga judy lewent sir deryck maughan member remuneration committee allow provide input committee review group performance oversight risk factor relevant remuneration matter judy lewent audit risk committee chairman march gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue principal activity matter address global internal control governance month financial reporting compliance external auditor risk matter january integrity draft review risk assessment external china investigation compliance frc financial statement management auditor effectiveness abac update code appropriateness internal control report external audit emerge risk review corporate governance accounting policy litigation report process global support update draft annual corporate integrity reappointment function change committee evaluation report form agreement cia auditor propose programme impact private meeting annual summary update report approval agm rocc meeting update external auditor leaflet review annual audit external auditor novartis transaction head audit assurance plan yearend audit finding update assurance respectively report auditnonaudit committee member expenditure meet privately february go concern sarbanesoxley auditnonaudit assumption compliance expenditure preliminary result confirmation external auditor announcement sarbanesoxley control director expense finding approval external auditor annual annual report report form annual finding summary leaflet march approach performance china investigation audit assurance sarbanesoxley expectation abac update rating system compliance external auditor emerge risk review private meeting litigation report commercial practice external auditor cia update report enterprise risk committee member global ethic vaccine update meet privately compliance report rocc meeting update global pharma novartis transaction business unit report update quarter result litigation report external auditor china investigation private meeting announcement consumer healthcare quarter result review abac update external auditor gm business unit finding novartis transaction committee member report external audit plan update meet privately fee proposal erp annual update rocc meeting update emerge risk review july go concern litigation report external auditor china investigation corporate governance assumption cia update report quarter result review abac update update include frc viability statement assessment key finding rocc meeting update code change approach internal control cyber security report private meeting quarter result principal risk emerge risk review external auditor announcement vaccine business unit novartis transaction committee member review accounting report update meet privately issue development ehss party impact oversight tpo enterprise risk treasury tax pension insurance risk october quarter result litigation report external auditor abac update frc code announcement cia update report quarter result review rocc meeting update guidance change operational excellence finding cyber security report private meeting update novartis external emerge risk review external auditor business unit audit plan novartis transaction committee member report update meet privately scientific engagement patient safety product quality tpo enterprise risk december viability statement litigation report external audit phase abac update private meeting update cia update report result annual cyber security report external auditor management report global support report disclosure rocc meeting update corporate accounting issue function business unit requirement novartis transaction compliance officer appropriateness report preapproval external update respectively accounting policy internal control auditor budget non emerge risk review corporate governance framework assessment audit service information protection disclosure update external terrorism risk committee member auditor fee budget assessment meet privately audit tender review gsk annual report strategic report governance remuneration financial statement investor information committee financial reporting activity significant issue relate financial statement respect financial reporting activity committee review significant issue consider relation financial recommend board approval financial result statement year end december set announcement consider quarterly financial result follow table summary financial announcement financial result contain outcomes appropriate addition committee annual report committee review significant issue external auditor discuss significant issue address judgement management determine result committee year area particular audit committee review paper prepare management set focus describe independent auditor report page key area risk action undertake quantify effect relevant issue judgement management appropriate accounting require address issue financial statement significant issue consider committee relation financial statement issue address committee go concern basis committee consider outcome management halfyearly review current forecast net debt preparation financial position financing facility option available group following review risk statement potential impact unforeseen event committee confirm application go concern basis preparation financial statement continue appropriate revenue recognition include committee review management approach time recognition revenue accrual return rebate rar customer return rebate pharmaceutical vaccine accrual return rebate accrual billion december committee review basis accrual concurred management judgement amount involved full description process operate pharmaceutical vaccine business determine level accrual necessary set critical accounting policy provision legal matter committee receive detailed report actual potential litigation internal external include investigation legal counsel number detail update investigation group commercial group commercial practice practice management outlined level provision correspond disclosure consider necessary respect potential adverse litigation outcome area possible determine provision necessary december provision legal matter billion set note financial statement provision provision uncertain tax committee consider current tax dispute area potential risk concur position management judgement level tax contingency require december group balance sheet include tax payable liability billion impairment intangible committee review management process review testing goodwill intangible asset asset potential impairment committee accept management judgement intangible asset require writing result impairment charge million note financial statement intangible asset detail valuation contingent committee consider management judgement follow improve sale performance consideration relation tivicay triumeq necessary increase liability pay contingent consideration acquisition viiv healthcare shionogiviiv healthcare joint venture december group balance sheet include net contingent consideration liability billion note financial statement acquisition disposal detail novartis transaction item committee receive regular report year progress novartis transaction include vaccine contingent committee review basis valuation asset liability acquire novartis consideration consumer particular calculation liabilitie vaccine contingent consideration consumer healthcare option healthcare option committee concur management judgement amount recognise gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue audit tender pwc auditor company group inception performance review annually audit partner rotation requirement observe time director seek tender pwcs contract result uks implementation eus mandatory firm rotation requirement company require replace pwc auditor later financial year commence january january committee usual review pwcs performance previous year recommend reappointment year consider initiate defer external audit contract tendering process committee agreed give level change experience business appropriate audit tender review relative merit conduct tender recent change regulation area committee consider good interest shareholder plan undertake tender process second half target appoint new auditor effect january coincide end current pwc partner year tenure group audit engagement leader company reappoint pwc january new pwc partner need appoint pwc require rotate audit consequently pwc ask participate anticipate tender exercise second half audit tender governance december committee agree achieve new audit firm audit financial year audit contract tender conduct autumn final recommendation committee audit firm preference express appointment firm anticipate december final approval board end committee direct supervise tender process agree implementation robust audit tender governance structure deliver successful audit contract tender process minimal disruption group main element governance structure follow audit tender operation steer executive steering audit risk board planning team committee committee committee remit design plan remit remit leadoversee remit direct remit appoint new implement run coordinateexecute audit tender process supervise audit auditor effect audit tender process audit tender process implementation tender process january meet weekly consider shortlist assess candidate recommend agree seek arrangement liaise arc new auditor shareholder approval meet monthly process board appointment fortnightly final evaluation agm end process member arc chair cfo group financial controller company secretary meet monthly gsk annual report strategic report governance remuneration financial statement investor information ongoing effectiveness quality external audit process committee commit ensure ongoing basis gsk receive high quality effective audit evaluate effectiveness audit process prior make recommendation reappointment external auditor committee review effectiveness performance criterion agree conjunction management begin year audit cycle activity committee typically undertake year satisfy external audit quality effectiveness timeline set audit reappointment auditor expectation formal auditor appointment ommittee evaluation process set audit plan budget setting matter address matter address matter address matter address review effectiveness external agree performance shareholder vote agm review feedback auditor expectation expectation auditor resolution appoint committee member set previous year upcoming audit auditor fix independently review auditor independence remuneration annual committee evaluation appropriate level review agree audit plan cover qualification expertise upcoming audit relationship auditor resource consider auditor quality quality insight consider auditor control procedure provide committee exhibit appropriate level agree set statutory work challengescepticism audit fee work receive management sufficient access consider initiate feedback prior year auditor management defer audit contract tender audit process preapprove budget satisfied recommend survey cover nonaudit service ideally board auditor reappointment robustness audit statutory agm process audit fee follow year quality delivery people service january march december detailed criterion committee use judge effectiveness external auditor override responsibility deliver smooth run thorough efficiently execute audit set performance expectation gsk external auditor specific auditor responsibility wide auditor responsibility discuss approach area focus advance early provide uptodate advice new viability statement engagement understanding implication gsk new requirement operating model provide uptodate knowledge technical governance ensure sarbanesoxley scope additional procedure issue provide accurate timely advice discuss endorse management communicate serve industry resource communicate good practice timely basis gsk pwc industry trend report avoid surprise timely reporting issue level adhere independence policy include gsk policy group financial reporting council isa applicable ensure clarity role responsibilitie securities exchange commission standard auditor local management deliver focus consistent audit approach globally respond issue raise management timely basis reflect local risk materiality meet agree deadline liaise gsk audit assurance team avoid duplication work global ethic compliance team ensure provide continuity succession planning key employee common understanding audit outcome auditor provide consistency advice level organisation provide sufficient time management consider draft auditor ultimately provide high quality service board report respond request query scrupulous scrutiny group act employ consistent communication local central utmost integrity audit team gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue nonaudit services fair balanced understandable assessment sarbanesoxley act prohibit engagement key compliance requirement group financial external auditor provision certain service statement annual report fair balanced legal actuarial internal audit outsource financial understandable coordination review groupwide information system design external auditor contribution annual report follow establish permit provide nonaudit service auditrelate document process perform parallel tax service committee ensure auditor formal process undertake external auditor objectivity independence safeguard policy committee receive summary approach take require preapproval committee service management preparation gsk annual report contractual similar obligation restrict ensure meet requirement frc code group choice external auditor enable committee board confirm nonaudit service competitive gsk annual report take fair tender financial service provider external balance understandable auditor line group procurement process code conduct report line skill experience external auditor number establish policy include suitable supplier nonaudit service consideration code conduct available governance section case request proposal submit relevant website confidential speak reporting line cet member cfo approval nonaudit service report investigation unlawful conduct update spending monitor committee quarterly basis version code conduct publish january discuss committee chairman cma order statement compliance follow policy guideline engage external auditor committee confirm company provide nonaudit service observe comply mandatory audit process audit committee ascertain skill experience external responsibility provision competition market authority auditor suitable supplier nonaudit services statutory audit service order outline report ensure adequate safeguard place objectivity describe work committee discharge independence group audit threaten responsibility compromise committee evaluation ensure total fee level exceed annual committee annual evaluation internally facilitate audit fee special circumstance company secretary supplement questionnaire clear advantage company auditor undertaking circulate committee member behalf committee additional work chairman conclude committee continue operate effectively term enhancement committee fee pay company auditor associate set deliberation follow improvement point agree detail give note financial statement operating profit continue improve paper content focus ensure brevity possible accounting firm engage undertake nonaudit service increase focus set monitoring adjust risk appetite auditnonaudit service year comparison graph incorporate new risk oversight compliance council reporting update new emerge issue committee agenda aid anticipation potential risk audit issue consider division meeting half focus traditional financial audit relate matter committee member risk litigation issue face group committee subsequently debate organisation meeting agree board member wish continue attend entire meeting audit assurance service service include tax regulatory compliance treasuryrelate service service relate novartis transaction fee audit assurance service include million arise novartis transaction subsequent increase complexity group approximately half expect recur gsk annual report strategic report governance remuneration financial statement investor information senior independent director sid succession nomination committee report sir deryck maughan bring style role sid discharge responsibility great diligence include lead conclude recent chairman succession search process please sir deryck agree extend tenure board step agm bring continuity board composition give significant knowledge experience gsk business affair period significant change board philip hampton membership sir deryck help facilitate transition nomination committee sir christopher chairman addition committee member help search recruitment successor sid committee dear shareholder please recommend board appointment vindi key priority join board start banga sid designate vindi join board september year succeed sir christopher gent nominations appoint committee sir deryck committee chairman year year significant transition january nomination audit risk remuneration mean focus immediately tailor work closely ensure smooth transition refreshment board line vindi succeed sir deryck sid conclusion agree principle action set tracy long agm external evaluation review scientific medical expert sme succession requirement reshape group create maximise daniel podolsky serve board usbased longterm value novartis transaction shareholder designate sme great distinction tenure board stepping board plan nominations committee committee busy year agm serve year commencing search good progress aim consider successor highly specialist role begin board size composition replace number year committee please recommend board plan retirement nonexecutive board member appointment jesse goodman nonexecutive addressing identify skill gap committee focus director sme join board january effective management succession executive management appoint corporate responsibility committee progress respect element set effect board size composition detail role criterion recruitment process central element current board refreshment programme sid sme role rationale committee consideration appropriate size recommend vindi banga jesse goodmans composition board give scale complexity appointment give strategic positioning business perform analysis committee enhanced board competence committee membership experience matrix link company strategy underpin lynn elsenhans appoint committee january board refreshment programme make good progress join judy lewent new appointee ensure identify ideal future size board likely committee achieve good balance long serve reduction second half analysis committee member new appointee support shaping committee factor increase target size board long term grateful sir christopher female representation outline lord davy share insight deep understand evolution final woman board report publish october board culture composition period stewardship ceo management succession committee continue scrutinise robustness committee key focus progression succession planning arrangement executive director management succession plan work collaboration executive management role adequacy ceo addition continue refresh nonexecutive pipeline leadership talent cet representation board aim reduce overall nearly year ceo sir andrew indicate board size member board intention retire company early board agree retire march committee start formal search successor consider internal external candidate role end philip hampton egon zehnder korn ferry engage nomination committee chairman march gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue membership refreshment specialist role board membership committee appointment orderly refreshment board date attendance meeting set particular area focus committee search successor sir deryck maughan sid daniel podolsky attendance usbased sme retire stand committee meeting board agm member member sir philip hampton committee feel determine key essential chairman january january sid desirable ukbased director fail travel spend majority time professor sir roy anderson october think important individual vindi banga january strong understand corporate governance lynn elsenhans january environment judy lewent korn ferry provide recruitment service company sir deryck maughan july engage conduct search sid provide long short list potential candidate sir christopher gent december interview suitable sid candidate feedback seek tom swaan october support receive certain investor committee recommend board vindi banga potential sir christopher gent committee chairman january january retired board independent nonexecutive director sid designate appoint board september board tom swaan retired board consider strong operational bias bring company secretary secretary committee attend year commercial experience track record meeting attendee committee meeting include deliver outstanding performance highly competitive global consumerfocuse industry invaluable regular attend company currently serve nonexecutive director attendee attendee require board ftse company vindi succeed chief executive officer cid sir deryck maughan sid steps board head human resource cid close agm appropriate external adviser cid committee draw role specification new sme role consider podolskys successor ideally strong business perspective usbased work committee understand healthcare environment medic main responsibility close patient run operation scale main responsibility committee set hospital institution understand vaccine preferably respiratory consider stand gsk ceo management succession vaccine portfolio novartis transaction complete committee ceo assistance head internal sounding take vaccine human resource work managing succession identify potential external candidate egon zehnder undertake arrangement executive director executive external market search suitable candidate management role secure good leadership company specification role consider detail egon zehnder provide recruitment service current future need change environment company engage conduct search usbased company operate compile succession plan internal sme role dossier potential nonexecutive appointee external talent consider review consider committee candidate shortlist specification draw interview merit objective criterion assess relevant qualification time commitment term executive team ensure focus management company consumer healthcare vaccine interview suitable sme candidate committee pharmaceutical business result transformational recommend board jesse goodman potential novartis transaction nonexecutive director sme appoint board january jesse goodman leader public health emma walmsley previously president consumer bring wealth expertise span science medicine healthcare appoint ceo consumer healthcare joint vaccine regulation public health prove record venture business member board addressing press public health need academic novartis transaction successfully complete march federal sector invaluable gsk board follow announcement deirdre connelly president north america pharmaceuticals february intention retire gsk role replace cet addition bill louv senior vice president core business service retire plan gsk successor report cfo member cet gsk annual report strategic report governance remuneration financial statement investor information board committee chairman membership change refreshment board lead follow orderly change board committee membership director committee membership appointment date retirement date sir philip hampton nominations committee chairman january urs rohner remuneration committee member january remuneration committee chairman lynn elsenhans corporate responsibility committee chairman member october vindi banga audit risk remuneration january nominations committee member professor sir roy corporate responsibility committee member anderson jesse goodman corporate responsibility committee member sir christopher gent corporate responsibility committee chairman remuneration nomination committee member tom swaan remuneration committee chairman audit risk nomination committee member jing ulrich audit risk committee member board committee change commit diversity boardroom ongoing refreshment board result orderly similarly commit equal opportunity employee plan change composition board level organisation diversity inclusiveness committee year recommendation workforce promote gsk committee change include plan retirement key requirement effective board comprise range stephanie burn sir deryck maughan daniel podolsky balance skill experience knowledge gender han wijers board close agm independence individual prepare challenge set work team need back board appointment retirement diversity personal attribute include character intellect sound refreshment board lead follow orderly judgement honesty courage change board member committee responsible develop measurable objective support implementation board diversity director appointment date retirement date policy include gender monitor progress achievement objective term balance board sir philip hampton january gender diversity exceed target urs rohner january set current female vindi banga september board level representation stands note lord jesse goodman january davy new target increase female board representation set woman board year sir christopher gent summary report publish october tom swaan good representation woman management jing ulrich position illustrate gender stephanie burn diversity gsk global workforce continue support sir deryck maughan effort increase pipeline woman senior position gsk support engagement daniel podolsky executive search firm mwm egon zehnder korn hans wijer ferry sign voluntary code conduct executive search firm gender diversity good practice board composition diversity mindful need balance composition board committee evaluation committee refresh progressively time committee annual evaluation internally facilitate draw experience long serve director company secretary behalf committee chairman tap new external perspective insight supplement questionnaire circulate committee recent appointee bring board deliberation member conclude committee continue operate effectively nonexecutive director draw wide range industry background include pharmaceutical healthcare term enhancement committee work agree medical research academia retail insurance financial focus direct forward planning service appropriate experience complex organisation executive succession replenishment board anticipation global reach considerable experience director rotate board key priority pharmaceutical industry recent appointee bring new approach group board discussion gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue membership corporate responsibility committee report membership committee appointment date attendance meeting set attendance meeting member committee member lynn elsenhans october chairman lynn elsenhans corporate responsibility stephanie burns december committee chairman daniel podolsky july hans wijers october dear shareholder sir christopher gent december like thank predecessor sir christopher gent sir christopher gent serve committee chairman strong leadership committee year retired board stewardship oversee development refinement gsk principle current responsible professor sir roy anderson jesse goodman business commitment addition committee act appoint committee effect custodian policy practice define safeguard company secretary secretary committee reputation company new chair committee attend meeting attendee committee meeting seek build legacy committee continue include challenge shape company responsible business agenda committee member bring wide range experience regular attend attendee attendee require insight different sector provide oversight company responsible business opportunity risk chief executive officer cid invaluable relation committee assessment company chairman cid corporate responsibility challenge integrate novartis chairman global vaccine cid assets company acquire year substantial change general counsel cid particularly pleased work committee head communication government affair cid year focus issue material gsk mission strategy value discussion focus head pharmaceutical cid company seek balance need return investment head pharmaceutical cid innovation need price product appropriately head human resource cid drive access broad range patient addition head external market communication cid consider way gsk continue build commitment operate transparently integrity head global corporate responsibility cid commercial model transformation executive cid please continue enjoy positive engagement independent external corporate cid investor responsible business commitment responsibility adviser include particular focus approach address antibribery corruption abac issue reputational independent external corporate responsibility adviser perspective change sell market medicine healthcare professional access innovation clinical augment engagement stakeholder opinion trial transparency disclosure sophia tickell appoint independent external adviser committee position previously hold march july tickell extensive experience pharmaceutical industry improve health system productivity lynn elsenhans sustainability energy supply distribution climate change corporate responsibility committee chairman policy shorttermism financial market march cofounder director meteo direct pharma future series aim align well societal shareholder value hold number board advisory role tickell attend meeting committee provide independent advice guidance corporate social responsibility matter chairman ceo gsk annual report gsk annual report strategic report governance remuneration financial statement investor information main responsibility people enable people thrive develop main responsibility committee set individual deliver mission committee rolling agenda receive report planet grow business reduce member cet senior manager ensure progress environmental impact value chain meeting responsible business commitment addition meeting committee consider possible area focus review annual basis follow emerge issue bear company health innovate address currently unmet health reputation interaction stakeholder committee need improve access product irrespective review approve responsible business supplement people live ability pay control eliminate available reference wwwgskcomresponsibility disease affect world vulnerable people behaviour put interest patient consumer drive value back robust policy strong compliance process work committee committee focus core remit matter set report receive highlight evolving challenge area include particular impact novartis transaction focus area committee area focus health flexible open approach disease develop world area great medical need antibiotic dementia gsk approach price particular balance return investment innovation alongside need support access medicine vaccine strategy support global public health priority include pricing model malaria vaccine ebola response behaviour global incentive compensation program sell competency model change gsk engage healthcare professional embed valuesbased decision make organisation include training compliance progress work align party gsk standard expectation conduct public disclosure clinical research transparency detail datum trial result patient safety replacement refinement reduction use animal research development people organisational change employee relation inclusion diversity leadership development approach performance management employee health safety wellbeing insight staff survey employee health safety wellbee planet environmental performance carbon water waste impact committee evaluation committee annual evaluation internally facilitate company secretary supplement questionnaire circulate committee member behalf committee chairman conclude committee continue operate effectively term enhancement committee deliberation agree committee regular basis look advanced longterm perspective company impact external environment gsk annual report strategic report governance remuneration financial statement investor information corporate governance continue nominations committee review register potential director conflict authorisation january report board director power determine legislation conflict appropriately authorise article association contain rule appointment process authorisation continue operate effectively replacement director provide director describe note financial statement relate party appoint ordinary resolution member transaction end financial year director resolution director provide instance connect person material interest contract director appoint way retire agm follow significance group company appointment independent advice article provide director normally subject company agree procedure director reelection agm interval year annually independent legal andor financial advice company hold office continuous period year expense deem necessary board agree director wish indemnification director continue member board seek reelection qualify party indemnity provision define annually accordance corporate governance code company act force benefit director director cease director director hold office signing bankrupt annual report cease director virtue company change control essential contract act article contract arrangement individually suffer mental physical ill health board resolve fundamental ability business operate effectively shall cease director company party material agreement miss director meeting continuous period effect altered terminate change control follow month permission board resolve takeover bid agreement director shall cease director provide compensation loss office employment prohibit director law result takeover provision company resign offer resign board accept offer share plan cause option award grant plan vest takeover detail termination provision require resign board company framework contract executive director director conflict interest give version company remuneration policy report director duty company act avoid available wwwgskcom investor section situation direct indirect conflict interest possible conflict company article provide general power board authorise conflict nominations committee authorised board grant regularly review potential actual conflict authorisation record company secretary note board director count quorum authorisation actual potential conflict ongoing basis director responsible inform company secretary new actual potential conflict arise change circumstance affect authorisation previously give provide authorisation director absolve statutory duty promote success company actual conflict arise postauthorisation board choose exclude director receipt relevant information participation debate suspend director board resort require director resigngsk annual report strategic report governance remuneration financial statement investor information director continue director report purpose company act director report glaxosmithkline plc year end december comprise page corporate governance report director responsibility statement page page investor information strategic report set matter require disclose director report consider strategic importance company follow risk management objective policy page likely future development company strategic report research development activity page diversity inclusion provision information consultation employee carbon emission follow information incorporate director report location annual report financial statement interest capitalise note publication unaudite financial information group financial review detail longterm incentive scheme remuneration report waiver emolument director applicable waiver future emolument director applicable non preemptive issue equity cash applicable non preemptive issue equity cash applicable unlisted major subsidiary undertaking parent company participation place applicable list subsidiary provision service control applicable shareholder financial statement shareholder waiver dividend note financial statement shareholder waiver future dividend note agreement control shareholder applicable director report draw present accordance reliance english company law liability director connection report shall subject limitation restriction provide law director report approve board director march sign behalf philip hampton chairman march gsk annual report strategic report governance remuneration financial statement investor information remuneration report chairman annual statement dear shareholder committee believe significant shareholding remain key mechanism align personal interest executive follow agm succeed tom swaan chair interest longterm shareholder sir andrews shareholding remuneration committee committee please time base salary gsk share present remuneration report excess share ownership requirement time base like opportunity thank tom behalf salary committee leadership time chairman disclose remuneration report set remuneration decision respect adjust free cash flow new product target lti mark substantial progress strategy award grant delay pende completion create balanced group world lead business novartis transaction target award pharmaceutical vaccine consumer healthcare clear agree detail adjust free cash flow target aim deliver growth improve return shareholder communicate stock exchange announcement july group strong position succeed longterm business give significance transaction committee global scale exposure risk volatility past consider impact change target year accelerate new product sale growth integrate outstanding lti awards key principle new business vaccine consumer healthcare ensure incentive continue operate originally restructure pharmaceutical business financial result intend committee focusse ensure stretch ahead guidance set start year performance target retain incentive continue believe position return core earning measure performance strategic objective originally share growth identify grant detail decision reach set background key decision follow report committee respect remuneration follow agenda bonus outcome executive director material change executive remuneration propose determine reference performance agree committee decide salary level executive financial measure committee assessment director increase effective january individual performance gsk achieve performance consistent salary increase budget broad excess relevant financial target year employee population give improved performance assessment remuneration policy expire agm year individual performance contribution result bonus committee undertaking review gsk remuneration award ahead previous year arrangement review continue regular draw shareholder attention detailed disclosure dialogue shareholder hold annual meeting follow report annual bonus plan bonus gsk large investor later year listen view earn enhanced report annual feedback shareholder feedback bonus plan bonus pay help shareholder current remuneration arrangement view understand award earn hope focus review hesitate pass shareholder join welcome enhance comment attention company secretary disclosure victoria whyte agm vest performance share plan defer annual bonus plan award base agree measure finally like thank shareholder input relative tsr adjust free cash flow new product engagement year chairman committee business diversification performance welcome shareholder feedback report look year december overall vest level achieve forward receive support remuneration lti awards detail report agm achievement present follow report urs rohner remuneration committee chairman march gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration executive director remuneration summary remuneration principle policy principle committee believe pay performance executive director remuneration design promote longterm success company committee seeks ensure performancerelate element executive director remuneration transparent stretching rigorously apply policy committee consider company shareholder approve remuneration policy executive director pay comparator group pay level wide employee population group determine total individual pay package executive director balance fix shortterm variable longterm variable element pay carefully review overall package weight heavily closely align executive director interest shareholder table summarise committee set element remuneration package executive director fix pay base salary salary review annually support datum relevant comparator group take account executive director role experience performance average increase broad gsk workforce salary level respect follow sir andrew witty simon dingemans moncef slaoui benefit principally healthcare car personal financial advice life assurance assignment travel expense pension executive sir andrew witty join group certain executive member legacy final salary plan close new entrant increase pensionable earning limit annum gsk operate define contribution plan executives simon dingemans member plan pension contribution instead receive cash lieu contribution executive gsk operate cash balance pension plan gsk plan saving scheme supplemental cash balance pension plan executive supplemental saving plan essp saving scheme open moncef slaoui certain executive accrue benefit government limit impose plan cash balance pension plan pay performance safeguard company long stand clawback malus arrangement lti bonus plan executive risk director executive enable company recover sum pay withhold payment management sum occurrence trigger event significant misconduct way violation regulation law significant gsk policy code conduct annual bonus target maximum bonus opportunity executive director follow majority bonus base achievement target maximum challenging financial target core groupbusiness unit operating profit core group profit interest tax salary salary agree board committee ceo individual performance predetermine personal cfo objective chairman global vaccine defer individual defer defer psp dapb matching award base follow annual total bonus earn equally weight performance measure bonus plan defer bonus match year period dabp oneforone subject performance criterion new product performance adjust free cash flow relative tsr vest threshold rise stretching performance exceed set threshold performance performance share award specify margin share plan executive director follow comparator group comprise gsk psp salary pharmaceutical company base vest schedule vest median rise ceo vest upper quartile performance cfo psp award subject threeyear performance period chairman global vaccine additional twoyear vest period gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue total remuneration audit value earn annual longterm total salary benefit pension bonus incentive remuneration award fix pay pension pay performance total remuneration executive director set table sir andrew witty simon dingemans moncef slaoui ceo cfo chairman global vaccine total total total total total total fix pay salary benefit total fix pay pension pay performance annual bonus include defer value earn lti awards matching award defer annual bonus plan performance share plan total value earn lti awards total pay performance total remuneration deferral annual bonus number number number share share ad bonus defer number share ad purchase detail element total remuneration give follow page report fix pay pension pay performance base salary page annual bonus page benefit page value earn lti award page onwards notes note value show differ disclose annual report dabp value base estimate vest price value base fair market value closing share price business day prior vest date committee specific circumstance line state principle apply clawbackmalus determine appropriate follow consideration committee recovery sum pay clawback reduction outstanding award vest level malus apply respect executive director difference pension value slaoui movement interest rate assumption ira projection age ira decrease increase slightly gsk annual report strategic report governance remuneration financial statement investor information total remuneration fix pay audit follow section provide detail element total salary remuneration include committee implement table set base salary executive approve remuneration policy apply director year base salary comparator group pay performance change committee use primary pay comparator group sir andrew witty consider executive pay simon dingemans crossindustry global pharmaceutical moncef slaoui comparator group comparator group benefit audit anglo american france sanofi follow table show breakdown gross cash astrazeneca switzerland novartis value benefit receive executive director group roche holdings bhp billiton astrazeneca sir andrew simon moncef abbvie witty dingemans slaoui british american tobacco amgen benefit diageo bristolmyers squibb employee benefit reckitt benckiser eli lilly travel rio tinto johnson johnson benefit royal dutch shell merck total benefit sab miller pfizer benefit tesco employee benefit unilever travel vodafone benefit total benefit amgen abbvie include remuneration benchmarking include tsr comparator group employee benefit include employee share plan healthcare car global pharmaceutical comparator group allowance personal financial advice life assurancedeath basis tsr comparator group feature longterm service incentive award primary pay comparator group travel expense include car travel spousepartn cost executive director show table associate accompany director gsk business primary pay comparator group deem taxable benefit individual global benefit comprise expense incur ordinary course director crossindustry pharmaceutical business deem taxable benefit sir andrew witty cid individual include table simon dingemans cid slaoui include accommodation moncef slaoui cid review ceo remuneration committee reference pay group lead european company selection base size complexity summary total remuneration competitive positioning ceo total remuneration benchmarke crossindustry global pharmaceutical european crossindustry group group group low quartile median median upper quartile current position benchmarking include salary expect value incentive base committee agree benchmarke methodology gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue pension audit pension arrangement sir andrew sir andrew witty member glaxo wellcome define benefit pension plan close new entrant witty section plan sir andrew member provide normal retirement age maximum pension value rd pensionable salary april pensionable earning increase limit annum member include sir andrew simon simon dingemans member gsk pension plan pension contribution instead receive cash payment lieu dingemans pension base salary line gsk define contribution pension plan rate simon dingemans receive death service illhealth insurance provide pension plan include employee benefit moncef slaoui member cash balance pension plan supplemental cash balance pension plan provide slaoui executive pension credit gsk make annual contribution slaouis pension plan base salary plan provide cash sum retirement fund increase interest rate set annually advance base year treasury bond rate plan entitlement spouse pension pension increase active member belgium insurance exfortis plan belgian plan defer member plan define benefit plan lump sum payable normal retirement age company contribution plan slaoui member plan open employee essp saving scheme open executive accrue benefit government limit impose plan contribution plan invest range fund combine contribution rate plan core contribution plus match total base salary bonus bonus defer dabp follow table show breakdown pension value set sir andrew witty simon dingemans moncef slaoui pension remuneration value define benefit define benefit belgian define benefit employer cash contribution member contribution define benefit plan total pension remuneration value pension remuneration figure calculate accordance methodology set large mediumsize company group account report amendment regulation remuneration regulation calculate define benefit pension value difference accrue pension december accrue pension december increase inflation define benefit define benefit belgian define benefit multiply result negative value deem zero calculate total value amount translate euro dollar exchange rate sir andrew detail pension value set table accrue pension accrue pension pension remuneration sir andrew witty december december value fund unfunded total sir andrew join gsk predecessor company progress role increase seniority gsk appoint ceo time build pensionable service different tier glaxo wellcome pension plan current pension entitlement product service progression gsk moncef slaoui detail pension value set table accrue pension accrue pension pension remuneration moncef slaoui december december value fund unfunded belgium fund essp total slaoui join gsk predecessor company progress number senior role gsk appoint chairman research development chairman global vaccine time build pensionable service belgian plan cash balance supplemental pension plan annual employer cash contribution plan essp current pension entitlement product service progression gsk difference pension value movement interest rate assumption ira projection age ira decrease increase slightly gsk annual report strategic report governance remuneration financial statement investor information pay performance audit annual bonus majority annual bonus opportunity base formal review performance stretch financial target outcome adjust reflect individual performance apply individual performance multipli ipm ipm set committee take account performance individual objective multipli set generally year executive director perform strongly objective expect receive ipm range annual bonus base follow financial measure weighting performance target core group operating profit core group pbit vaccine performance weight sir andrew witty simon dingemans moncef slaoui performance target million million million outcome million million million core group operating profit core group pbit target outcome purpose annual bonus differ core group operating profit pbit disclose annual report primarily target outcome number calculate apply gsk budget exchange rate actual exchange rate core group operating profit measure exclude corporate cost cost include core group pbit follow table show actual bonus earn compare opportunity bonus opportunity total bonus bonus earn base salary target maximum bonus salary salary salary salary sir andrew witty simon dingemans moncef slaoui table set matter committee consider respect financial measure weighting set executive director financial performance core group group turnover increase cer report basis million cer proforma basis core operating profit group operating profit core group profit interest tax ahead target set profit benefit core group acceleration sale new product cost saving release group restructure profit integration programme offset benefit decline sale seretideadvair low sale establish interest tax product investment support new product launch shortterm dilution novartis transaction adverse comparison include sga credit impact core operating profit exclude core operating margin decline percentage point vaccine vaccine sale million cer proforma basis proforma growth performance primarily drive bexsero sale europe strong rotarix fluarixflulaval boostrix sale vaccine operate profit million cer primarily reflect inclusion cost base acquire novartis vaccine business proforma basis vaccine operating profit substantial progress integration acquire business initial restructure integration benefit help deliver improvement percentage point proforma core operating margin cer basis gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue pay performance continue table set matter committee consider respect individual objective set executive director personal performance sir andrew witty sir andrew successfully deliver number key strategic priority group include complete highly complex novartis transaction create group worldleading business pharmaceutical vaccine consumer healthcare significant progress integration new business vaccine consumer healthcare integration ahead schedule billion incremental cost saving deliver cost billion track deliver billion annual saving end restructuring pharmaceutical business include commercial reorganisation accelerate new product performance sale billion revise expectation achieve target billion annual sale new product year ahead previous plan core eps ahead financial guidance high teen decline profile innovative portfolio approximately asset focus oncology immunoinflammation vaccine infectious respiratory rare disease portfolio expect deliver multiple significant milestone month worldwide implementation business model change cover sale force incentivisation hcp interaction successful progress delivery responsible business commitment notable advance access medicine approval new malaria vaccine ordinary dividend special dividend pay net proceed novartis transaction expectation pay year ordinary dividend simon dingemans dingemans deliver strong financial leadership group restructure integration ahead schedule billion incremental cost saving deliver cost billion track deliver billion annual saving end reduce net debt billion despite significant cash restructuring cost core eps ahead financial guidance high teen decline effective core tax rate group substantial progress deployment new core business system supply chain improvement ordinary dividend special dividend pay net proceed novartis transaction expectation pay year ordinary dividend moncef slaoui slaouis leadership vaccine business deliver strong performance plan vaccine sale grow billion business benefit sale newly acquire product primarily meningitis portfolio menveobexsero europe strong sale growth legacy gsk vaccine fluarixflulaval rotarix boostrix slaoui deliver number strategic priority follow completion novartis transaction march slaoui lead effective integration gsk novartis vaccine organisation accelerate commercialisation acquire portfolio particularly meningitis portfolio significant contribution global public health agenda extensive research development progress candidate vaccine malaria ebola lead successful vaccine organisation success year include positive phase iii trial success candidate vaccine shinglesgsk annual report strategic report governance remuneration financial statement investor information value earn longterm incentive ltis award performance period end december audit committee review performance psp dabp matching award grant executive director target set performance achieve year december vest level set table committee previously provide estimate vest award gsk annual report estimate base performance achieve time follow reflect performance achieve course performance period line committee agree principle measure actual performance target review adjustment appropriate reflect impact novartis transaction business ensure vest outcome reflect genuine underlie business performance performance vest measure relative weighting performance target performance achieve maximum award new new product performance measure base aggregate threeyear revenue product target new product sale new product define product launch performance performance period precede year product launch year include aggregate sale period billion vest schedule show straightline vest point vest schedule adjust exclude impact novartis transaction revenue divest oncology product remove target outcome determine performance acquire vaccine product bexsero judge meet condition new product include target outturn target vest maximum threshold business target originally set element time grant base aggregate revenue diversification vaccine consumer healthcare emerge market japan purpose incentivising performance reward growth globally diversify business remuneration committee determine original target sustainable light transformational threepart transaction novartis committee review original target performance light additional sale acquire vaccine business consumer healthcare joint venture overall progress strategic goal diversification committee note strong performance business initiative period include relation fluarixflulaval follow launch quadrivalent formulation strong emerge market sale product synflorix rotarix progress japan transition respiratory portfolio new ellipta portfolio successful otc switch flonase consumer healthcare factor support group ambition create longterm business global scale reduce exposure risk volatility consistent strategic target identify start performance period subsequently determine light progress performance period vest element threshold maximum element award vest adjust free adjust free cash flow afcf vest schedule disclose time grant cash flow vest threshold billion maximum vest achieve billion performance committee review target vest schedule light completion novartis transaction determine adjust reflect impact transaction restructure adjust vest schedule target vest maximum threshold afcf year billion line committee agree principle include adjustment number material distort item include legal settlement exchange rate movement special pension contribution threshold level performance meet element lapse relative tsr gsk tsr rank position comparator group pharmaceutical company performance gsk company element lapse vest schedule comparator group set award adjustment reflect novartis transaction total vest respect award gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue update performance ongoing lti awards committee review performance psp dabp matching award grant executive director follow table provide estimate vest take account performance date actual vest level determine base performance threeyear performance period indication regard prediction final vest level line committee agree principle measure estimate vest include adjustment require reflect impact novartis transaction business ensure outcome reflect genuine underlie business performance detail adjustment provide time vest award performance period end december performance measure relative weighting performance update new product new product sale performance measure aggregate threeyear sale new product launch performance threeyear performance period precede year threshold performance result vest maximum performance threshold result vest strong sale new product year end december base aggregate sale new product year base performance measure definition vest currently estimate maximum adjust free adjust free cash flow afcf vest schedule disclose time grant vest threshold cash flow billion maximum vest achieve billion committee review target performance vest schedule light completion novartis transaction determine adjusted reflect impact transaction restructure adjust vest schedule threshold award vest achieve afcf billion achieve billion achieve billion maximum achieve billion straightline vest point base afcf year end december performance measure definition vest currently estimate threshold relative tsr period january december gsk tsr rank position comparator group performance pharmaceutical company gsk company vest schedule comparator group set award rank position remain level vest threshold current estimate potential total vest award vest award performance period end december performance measure relative weighting performance update new product new product sale performance measure aggregate threeyear sale new product launch performance threeyear performance period precede year threshold performance result vest maximum performance threshold result vest strong sale new product year end december base aggregate sale new product year base performance measure definition vest currently estimate maximum adjust free adjust free cash flow afcf vest schedule award determine follow completion cash flow novartis transaction disclose announcement stock exchange july performance order fully assess discipline use restructure fund period committee add plan restructuring cost period billion separately fund retain divestment proceed order incentivise management deliver restructure plan cost overspend underspend versus billion translate adjustment determine adjust free cash flow performance relative target vest schedule award threshold award vest achieve afcf billion achieve billion achieve billion maximum achieve billion straightline vest point base afcf year performance measure definition vest currently estimate threshold maximum relative tsr period january december gsk tsr rank position comparator group performance pharmaceutical company gsk company vest schedule comparator group set award rank position remain level vest threshold current estimate potential total vest award vestinggsk annual report strategic report governance remuneration financial statement investor information executive director remuneration audit salary average salary increase budget employee level cet approximately committee decide increase executive director salary benefit significant change provision benefit propose detail policy relation benefit refer remuneration policy wwwgskcom investor section operation annual bonus plan change propose operation annual bonus plan inevitably target link directly financial strategic plan commercially sensitive committee consider appropriate disclose annual bonus target year result competitive harm detail performance achieve disclose annual report longterm incentive awards level participation defer annual bonus plan dabp respect executive director show table maximum matching award grant respect deferral bonus table show performance share plan psp award level executive director dabp matching awards psp award subject performance continue employment dabp matching awards psp award match total bonus defer award award level award level award share ad base salary base salary sir andrew witty shares share simon dingemans share share moncef slaoui adss adss performance target award performance target vest schedule set table measure link directly strategy commercially sensitive particular committee consider appropriate disclose target range new product performance grant result competitive harm target range disclose gsk annual report end performance period detail extent target meet committee provide update estimate vest target performance period gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue executive director remuneration continue award performance period end december performance measure relative weighting link strategy vest schedule new recognise importance future business growth performance product revenue target base new product sale incentivise well threshold vest performance performance commercialisation new product define maximum product launch performance period precede year performance period product threshold launch year include target adjust use cash flow performance measure intend adjust free free recognise importance effective work capital management cash flow vest cash flow generate cash fund group operation investment maximum billion performance ordinary dividend shareholder free cash flow target represent billion operating profit business adjust noncash item billion deducting cost benefit work capital capital expenditure taxation add plan restructuring cost threshold billion period billion separately fund retain billion divestment proceed order incentivise management deliver restructure plan cost overspend underspend versus billion translate adjustment determine adjust free cash flow performance relative target adjustment free cash flow set target purpose performance measure include legal settlement special pension contribution foreign exchange divestment acquisition measure postadjustment adjust free cash flow relative tsr focus delivery value shareholder tsr ranking performance relative tsr comparator group comprise gsk comparator global pharmaceutical company relative tsr measure group vest year twelvemonth averaging period tsr maximum measured local currency threshold median comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck novartis pfizer roche holding sanofi vest schedule base deliver vest median performance comparator group company median fall company threshold vest achieve median performancegsk annual report strategic report governance remuneration financial statement investor information remuneration performance disclosure ceo remuneration table performance graph table follow graph set performance company relative ftse index pharmaceutical performance comparator group sevenyear period december graph prepared accordance single figure remuneration regulation indication likely remuneration vest award grant company incentive plan index select comparison purpose annual bonus reflect index gsk constituent award industry operate maximum vest lti awards maximum bonus amount include amount pay operational efficiency bonus place year overall maximum bonus receivable subject limit base salary respect psp award sir andrew outstanding awards share option grant respectively lapse include total vest percentage distort effect aggregate conditional share share option gsk total return gsk pharma peer ftse total return index total return index index comprise astrazeneca bristolmyers squibb eli lilly johnson johnson merck novartis pfizer roche holding sanofi historical vest gsk ltis follow table show historical vest level companys longterm incentive plan defer annual bonus plan matching award performance share plan share option plan respect award executive share defer annual bonus plan performance share plan option plan vest vest vest vest vest total adjust free new business total year vest tsr cash flow product diversification vest eps grant performance period dabp award subject wholly tsr performance award subject performance measure psp award malus clawback policy disclosure matter subject company policy malus clawback set public report misconduct fully resolve company remuneration policy report available legally permissible disclose wwwgskcom investors section committee unduly prejudice company shareholder line jurisdiction malus clawback respect executive disclosure guideline committee event trigger event significant misconduct recoupment committee exercise malus clawback way violation regulation law significant gsk policy code conduct company ability claw committee determine release share year annual defer bonus lti plan delay case leaver vested unvested ltis recoupment committee exercise reinforce implementation malus clawback policy authority wide employee base comprise senior case defer bonus award dabp executive relevant oversight appropriate experience grant executive retire redundant include senior vice president global ethic compliance vest award normally delay vest senior vice president general counsel original timescale vest early end january respect financial year committee year termination date fall disclose recoupment committee exercise clawback malus gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue remuneration performance disclosure continue allemployee share plan percentage change remuneration ceo executive director participate allemployee share sir andrew witty employee plan include sharesave sharereward sharesave plan revenue customs approve plan open change change employee participant save month salary net salary fix term year end benefit saving period option buy gsk share annual bonus discount market price set launch saving contract sir andrew witty simon dingemans reflect salary earn benefit receive annual contribute maximum month sharesave plan bonus earn respect compare wide employee population salary increase include sharereward plan revenue customs approve annual salary review additional change year plan open employee term participant promotion increase benefit ceo contribute month gross salary purchase result change benefit arrangement employee gsk share company match number gsk share benefit unchanged previous year buy month arrangement sir andrew witty change benefit policy level reflect simon dingemans contribute maximum month change level benefit individual receive buy share sharereward plan result change role promotion population dilution limit consider relevant comparison closely award plan incorporate dilution reflect economic environment encounter ceo limit consistent guideline publish investment external appointment executive director association form follow merger board encourage executive director hold external abi limit roll year period directorship establish plan roll year period executive share role broaden experience development help plan estimate dilution exist award increase pool nonexecutive director candidate year december follow outside appointment consider nomination committee ensure cause conflict interest gsk employee share plan executive share plan approve chairman behalf board company policy remuneration earn appointment keep individual executive director moncef slaoui receive fee relation membership qatar biomedical research institute scientific advisory committee meeting take place period earn honorarium attend board meet advisory committee director national institute health external appointment receive remuneration sir andrew witty simon dingemans hold external appointment remunerate actual limit service contract table set relevant date current relative importance spend pay executive director service contract available table show percentage change group dividend review company register office office hour pay shareholder share buyback total employee pay date effective contract date expiry date note change sir andrew contract amend total employee pay witty remove entitlement bonus dividend termination share buyback simon dingemans figure table set page dividend declare respect million moncef contract replace slaoui principally million increase give impact remove entitlement sustain strength sterle free cash flow bonus termination company suspend share repurchase programme follow completion novartis transaction gsk payment past director audit return approximately billion net proceed way payment past director special dividend payable time payment loss office audit dividend special dividend include payment loss office director amount company expect ordinary share repurchase total employee pay base employee average number people employ gsk annual report strategic report governance remuneration financial statement investor information overview total pay summary remuneration follow show breakdown total remuneration pay executive director respect ceo cfo chairman global vaccine fix pay salary benefit pension performance pay annual bonus ltis earn annual bonus lti award summary outcome chart illustrate annual bonus outcome financial year end december vest level psp dabp matching award grant executive director performance period end december award base equally weight performance measure new product performance adjust free cash flow relative tsr business diversification financial performance lti outcomes maximum business diversification new product target threshold adjust relative core group core group vaccine free cash flow tsr operating pbit performance profit maximum performance target performance achieve award lapsed award vest executive director shareholding audit current share ownership align interest executive director shareholder require build maintain significant ceo holding share gsk time executive director require continue satisfy shareholding requirement minimum month follow retirement company cfo current share ownership requirement sor follow share ownership requirement ceo base salary chairman global vaccine executive director base salary cet member base salary base salary current shareholding illustrate chart opposite sor shareholding gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue remuneration governance remuneration committee adviser committee remuneration committee chairman urs rohner join board committee access external advice require appoint committee january committee carry formal review independent adviser appoint committee chairman effect committee result review committee follow retirement tom swaan committee chairman reappointe deloitte llp provide independent advice nonexecutive director executive remuneration committee chairman agree protocols deloitte provide advice committee role committee satisfied advice receive deloitte role committee set company remuneration objective independent policy gsk able recruit retain motivate executive remuneration policy regularly review deloitte member remuneration consultant group ensure consistent company scale scope voluntarily operate code conduct relation operation support business strategy growth plan executive remuneration consulting code conduct help drive creation shareholder value find wwwremunerationconsultantsgroupcom term reference deloitte provide independent commentary matter committee term reference available consideration committee update market practice company website term reference review legislative requirement deloitte fee advice provide annually revise january reflect good committee fee charge practice corporate governance development time material basis deloitte llp provide consult tax assurance service gsk year governance committee satisfied compromise board consider member committee independence advice receive deloitte independent nonexecutive director accordance corporate governance code willis tower watson provide additional market datum committee committee meet time schedule meeting shareholder vote remuneration matter member attending follow vote total vote total vote total vote withhold agm cast billion million committee attendance member member meeting remuneration report urs rohner january chairman vote total vote total vote total vote withhold vindi banga january agm cast billion million stephanie burn remuneration report judy lewent january remuneration policy sir deryck maughan july consideration shareholder view hans wijers october committee engage regular dialogue shareholder sir christopher gent january hold annual meeting gsk large investor discuss feedback remuneration policy governance matter tom swaan chairman annual meeting hold november urs rohner committee chairman share update remuneration sir christopher gent tom swaan retired board matter month proposal onwards addition schedule meeting committee meet particular cover propose enhance annual bonus quorate basis occasion approve formal grant disclosure inclusion annual report addition longterm incentive award employee cet investor initial view seek future development address lti administrative matter approve remuneration policy advance anticipate submission company bind shareholder resolution committee meeting usually include closed session approve new remuneration policy agm member committee present individual invite attend committee meeting committee evaluation year executive committee attendee committee annual evaluation internally facilitate involved decision present company secretary supplement questionnaire discussion remuneration circulate committee member behalf committee chairman conclude committee continue company secretary secretary committee operate effectively term enhancement committee attend meeting attendee committee include deliberation agree committee focus attention review company remuneration regular attend attendee attendee require policy ceo cid cfo cid head human resource cid head reward cid committee adviser deloitte llp cidgsk annual report strategic report governance remuneration financial statement investor information remuneration governance continue principal activity matter address remuneration item specific governance month overall annual bonus ltis matter january approve cet salary increase eview approve annual bonus eview draft remuneration report recommendation target metric eview shareholder feedback eview approve executive annual investor meeting bonus review committee external evaluation ceo bonus objective report pdate defer annual bonus plan rule pdate lti performance lti awards february eceive update remuneration eview lti performance outcomes eview remuneration report relate implication novartis approve vest lti awards transaction cet cet review approve lti grant cet grant interim share value plan awards cet march emuneration environment update update performance share plan update remuneration consideration employee cet grant award certain eligible novartis employee july review ceo cfo pay approve adjust free cash flow target eview agm remuneration report competitiveness award follow completion feedback external remuneration eview remuneration benchmark novartis transaction environment performance target comparator group disclosure incentive plan pprove committee evaluation process review chairman fee nvironmental update august rant interim main share value plan awards cet october onsider remuneration pdate lti vest award pdate remuneration report report disclosure disclosure update ceo cfo review adjustment principle lti reparation annual investor cet remuneration competitiveness measure respect novartis meeting draft plan review remuneration transaction policy agm november annual meeting investor december annual cet benchmarking grant award certain eligible review investment association competitiveness review novartis employee principle remuneration approve executive director salary update remuneration report increase disclosure review shareholder feedback annual investor meeting gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue nonexecutive director fee chairman nonexecutive director letter appointment company aim provide chairman non term engagement nonexecutive director executive director fee competitive pay set letter appointment available inspection company equivalent size complexity subject company register office agm limit contain gsk article association nonexecutive director initial appointment subsequent reappointment subject election chairman fee periodic reelection shareholder chairman sir philip hampton appoint nonexecutive director january receive standard annual nonexecutive director letter appointment fee nonexecutive director april contain provision notice period compensation receive fee annum deputy appointment terminate chairman appointment chairman conclusion follow table show date initial letter agm fee increase appointment nonexecutive director annum elect fee gsk share nonexecutive director fee date letter nonexecutive director fee increase january nonexecutive director appointment increase supplemental fee minimum sir philip hampton september fee continue deliver share defer professor sir roy anderson september nonexecutive director step board vindi banga nonexecutive director fee apply january stephanie burns february set stacey cartwright march annum lynn elsenhans standard annual fee jesse goodman december supplemental fee chairman audit risk committee judy lewent march senior independent director scientificmedical expert sir deryck maughan chairman remuneration corporate daniel podolsky july responsibility committees urs rohner october nonexecutive director undertake intercontinental travel meeting meeting han wijer january table audit set value fee benefit receive nonexecutive director form cash share ad detail nonexecutive director share allocation plan set nonexecutive director fee fee emolument audit cash sharesad benefit total cash sharesad benefit total professor sir roy anderson vindi banga stephanie burn stacey cartwright lynn elsenhans sir christopher gent sir philip hampton judy lewent sir deryck maughan daniel podolsky urs rohner tom swaan jing ulrich han wijers sir robert wilson benefit primarily consist travel subsistence cost incur normal course business relation meeting board committee matter gskhoste event consider taxable overseasbase nonexecutive director include travel meeting nonexecutive director fee pay gbp convert exchange rate set annually base average rate quarter year prior payment rate review move significantly year sir philip hampton urs rohner join board january vindi banga join board september sir christopher gent tom swaan jing ulrich retired board sir robert wilson retired board sir christopher gents benefit number include travel hospitality cost incur whilst attend gsk host event previously agree request company retire gsk annual report strategic report governance remuneration financial statement investor information director interest share audit interest director company office december connect person show table total share plan interest december total director interest sharesad option aunveste unvested aunveste unvested march december january subject subject subject subject vest exercise performance performance performance performance exercise year executive director share sir andrew wittybcdfgi simon dingemansbcdfi moncef slaouig ad moncef slaouicdeh share allocation plan nonexecutive director total director interest sharesad number share ad december january march date date december dividend allocate december resignation appointment pay reinveste elect nonexecutive director sharesj professor sir roy anderson vindi banga stephanie burn stacey cartwright sir christopher gentk sir philip hampton urs rohner tom swaank hans wijers adsj stephanie burns lynn elsenhans judy lewent sir deryck maughan daniel podolsky jing ulrichk unvested share ad unvested option hold executive director subject performance reflect bonus deferral dabp sharesave share value plan svp awards total director interest march include defer annual bonus award relate matching award vest february awards participant structure nil cost option follow gross interest include table tax point exercise sir andrew witty defer annual bonus award vest matching award simon dingemans defer annual bonus award vest matching award total director interest include share purchase glaxosmithkline sharereward plan sir andrew witty simon dingemans award share plan balance share plan follow sharereward plan share march december january sir andrew witty simon dingemans moncef slaoui eligible participate sharereward plan open employee gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director interest share continue total director interest include share ad result deferral bonus subsequent reinvestment dividend dabp total show table include bonus deferral exclude unvested matching award subject ongoing performance criterion amount represent gross share ad balance prior sale share ad satisfy tax liability defer annual bonus plan bonus deferral march december january sir andrew witty shares simon dingemans share moncef slaoui ad total director interest march include share ad vest performance meet element psp award sell satisfy tax liability vest amount page detail moncef slaoui total director interest include ad purchase plan executive supplemental saving plan essp ad award slaouis connect person svp relevant balance follow moncef slaoui ad march december january retirement saving plan share value plan executive director moncef slaoui eligible receive award svp svp award show reflect holding slaouis connect person employee gsk award subject threeyear vest period vest contingent continue employment gsk gain arise vest include moncef slaouis total remuneration figure year connect person grant ad august grant price face value slaouis total share plan interest include psp award hold connected person award subject performance criterion relevant employee cet december connect person hold ad psp comprise award ad ad ad amount include dividend reinvestment unvested option subject performance sir andrew witty simon dingemans unvested option subject performance include holding respectively sharesave plan participate term employee sharesave option grant sir andrew witty simon dingemans grant option plan october remainder unvested option subject performance relate bonus deferral structure nilcost option dabp vest exercise option executive director follow table provide detail vest unexercised option december share option plan sop lapse february gsk grant option plan executive director annual basis share option plan number share option date grant lapse date grant price sir andrew witty moncef slaoui ad vest unexercised option totalling moncef slaoui represent ad option hold moncef slaouis connect persongsk annual report strategic report governance remuneration financial statement investor information director interest share continue follow table set detail option include nilcost option dabp exercise executive director moncef slaoui exercise option year number share market gain exercise type award date grant option date exercise grant price price exercise sir andrew witty sharesave dabp deferral dabp match simon dingemans sharesave dabp deferral dabp match respect option sop sharesave plan remuneration receivable executive director calculate date option vest remuneration difference executive director require pay buy share ad total value share ad vest date executive director choose exercise option vest date subsequent increase decrease realise movement share ad price vest date date exercise increase decrease value result investment decision executive director record remuneration option vest executive director respect nilcost option dabp bonus defer director record remuneration annual bonus year relate gain record exercise nilcost option comprise remuneration total amount receive reinveste dividend prior vest gain loss result movement share price date grant exercise initial bonus defer date dividend reinvestment exercise reinveste dividend matching element dabp remuneration executive director record year performance criterion end represent number vest share multiply price vest gain record exercise nilcost option comprise total remuneration gain loss result movement share price vest exercise sir andrew witty total gain follow exercise option grant sharesave plan gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment loss relate movement share price vest exercise date simon dingemans total gain follow exercise option grant sharesave plan gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment loss relate movement share price vest exercise date nonexecutive director total interest include share ad receive fee nonexecutive director share allocation plan note dividend receive share ad plan convert share ad december christopher gent tom swaan jing ulrich retired board elect receive share nonexecutive director share allocation plan immediately retire board dividend entitlement respect dividend pay cash accordance plan rule gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director interest share continue deferred annual bonus plan matching award defer annual bonus plan dabp matching award annually executive director base individual mandatory deferral voluntary bonus deferral election company match share ad oneforone depend company performance threeyear performance period performance condition vest level describe page report award ukbase executive director form nilcost option award vest ukbased executive director choose exercise award time year date grant awards usbased executive director conditional award ad remuneration receivable respect matching share ad calculate share ad price date relevant award vest award vest date remuneration report calculation perform average share ad price quarter financial year executive director choose exercise nilcost option vest date subsequent increase decrease realise movement share price vest date date exercise increase decrease value result investment decision record remuneration dividend reinveste nilcost option conditional award share ad executive director date vest follow table provide detail executive director respect dabp matching awards market price grant vest represent closing share price date performance period sir andrew witty share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration value show column award vest march value base fair market value closing share price business day prior vest date note value show differ disclose annual report value base estimate vest price gsk annual report strategic report governance remuneration financial statement investor information director interest share continue deferred annual bonus plan matching award continue performance period simon dingemans share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration value show column award vest march value base fair market value closing share price business day prior vest date note value show differ disclose annual report value base estimate vest price performance period moncef slaoui ad market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested march vest ad number ad market price vest gain remuneration remuneration value show column award vest march value base fair market value closing share price business day prior vest date note value show differ disclose annual report value base estimate vest price gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director interest share continue performance share plan award performance share plan psp award executive director annual basis term psp number share ad vest determined follow end relevant performance period dependent gsk performance period performance condition vest level describe page dividend reinveste performance share ad award executive performance period date vest vest participant receive relevant number share participant defer receipt vested award remuneration receivable respect performance share calculate share ad price date relevant psp award vest psp award sir andrew witty threeyear performance period deed award specify award subject twoyear vest period year total twoyear period additional performance criterion awards lapse sir andrew dismissed cause remuneration respect award consider realise follow determination remuneration committee vest level initial award remuneration recognise end threeyear performance period award executive director threeyear performance period additional twoyear vest period award vest year final year vest period award director lapse dismiss cause remuneration respect award dividend equivalent point recognise end threeyear performance period remuneration report follow table provide detail executive director respect psp award market price grant vest represent closing share price date performance period sir andrew witty share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration gsk annual report strategic report governance remuneration financial statement investor information director interest share continue performance share plan award continue performance period simon dingemans share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration performance period moncef slaoui ad market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested march vest ad number ad market price vest gain remuneration remuneration gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director senior management information provide compensation interest director senior management group group purpose group define nonexecutive executive director members cet company secretary financial year follow table set aggregate remuneration group period serve capacity remuneration total compensation pay aggregate increase accrue pension benefit net inflation aggregate payment define contribution scheme member group award share ad company share plan set table award dividend reinvestment award award share ad share ad defer annual bonus plan performance share plan defer investment awardsa share value planb march group follow interest share ad company holding issue executive share plan describe note financial statement employee share scheme interest march share ad own unexercised option defer annual bonus plan performance share plan defer investment awardsa share value planb notional share ad executive director eligible receive defer investment award participate share value plan basis preparation remuneration report prepare accordance company act large mediumsize company group account report amendment regulation regulation accordance regulation follow part annual report remuneration subject audit total remuneration figure executive director include detail element remuneration salary benefit annual bonus longterm incentive award pension nonexecutive director fee emolument receive year director interest share include interest gsk share plan payment past director payment loss office share ownership requirement holding opinion thereon express remain section remuneration report subject audit page refer audit section remuneration report approve board director sign behalf urs rohner remuneration committee chairman march gsk annual report strategic report governance remuneration financial statement investor information remuneration policy summary executive director remuneration policy company remuneration policy report approve gsk annual general meeting policy available wwwgskcom investor section annual report follow summary policy value earn annual longterm total salary benefit pension bonus incentive remuneration award fix pay pension pay performance element purpose link strategy operation salary provide core reward role individual role experience performance independently source datum relevant comparator group consider determine salary level set level appropriate secure retain high calibre individual need deliver group strategic priority benefit level set recruit retain executive director generally eligible receive benefit line policy high calibre individual execute employee vary location include travel allowance business strategy include spousepartn travel healthcare life assurancedeath service provide individual pension arrangement personal financial advice contractual postretirement benefit pension pension arrangement provide pension arrangement structure accordance plan operate competitive level retirement country individual likely retire individual income choose member pension plan cash lieu relevant pension contribution pay instead new executive director entitle join define contribution pension plan receive cash payment lieu pension contribution individual member gsk legacy define benefit plan define contribution plan alternative pension plan arrangement subsequently appoint board remain member plan annual bonus incentivise recognise financial operational business target set start year execution business strategy committee bonus level determine committee base annual basis performance target reward achievement individual objective set start year committee stretch annual financial performance objective assess committee strategic business target executive director require defer bonus earn share delivery personal objective ad appropriate year defer additional bonus earn overall maximum deferral defer share vest end year performance period longterm incentivise recognise delivery defer annual bonus plan incentive award long term business defer share match subject achievement performance prioritie financial growth condition year matching award conditional share increase shareholder value nilcost option eligible dividend equivalent respect compare pharmaceutical performance period company performance share plan addition provide alignment conditional award annually vest dependent shareholder interest retention achievement performance condition year vested award element encourage longterm subject additional twoyear vest period award eligible shareholding discourage dividend equivalent date vest excessive risk take detail policy clawbackmalus recruitment remuneration loss office termination payment refer remuneration policy report gsk annual report strategic report governance remuneration financial statement investor information remuneration policy summary continue nonexecutive director remuneration policy element purpose link strategy overview chairmans fee provide inclusive flat rate fee formal maximum fee review annually set competitive pay reference review chairman performance independently company equivalent sourced market datum size complexity subject remuneration committee responsible evaluating make limit contain gsk article recommendation board fee payable chairman association chairman participate discussion respect fee fee pay combination cash andor gsk share ad basic fee formal maximum fee review annually set reference independently source market datum chairman ceo responsible evaluating make recommendation board fee payable company nonexecutive director minimum deliver form gsk share ad supplemental provide additional compensation additional fee committee chairman intercontinental travel fee nonexecutive director senior independent director medicalscientific expert current fee exclude chairman take level set annual report additional board responsibility undertake intercontinental travel meeting benefit facilitate execution travel subsistence cost nonexecutive director incur responsibility duty normal course business relation meeting board committee require role matter gskhoste event include nonexecutive director undertake intercontinental travel meeting nonexecutive director time time accompany spouse partner meeting event cost associate meet company instance deem taxable treat benefit nonexecutive director nonexecutive enhance link nonexecutive director total fee exclude director share director shareholder chairman pay form gsk share ad allocate share allocation plan gsk require nonexecutive ad account director receive significant nonexecutive director opportunity invest fee form balance fee share ad account gsk share ad gsk share ad notionally award nonexecutive director allocate interest account set director interest table annual report accumulate balance gsk share ad notional dividend accrue pay nonexecutive director leave board leave nonexecutive director receive gsk share ad cash equivalent value gsk share ad date leave date payment later letter nonexecutive director nonexecutive director subject annual election reelection appointment chairman term engagement normally serve long year date election set letter appointment shareholder general meeting set table chairman subject annual appointment shareholder annual report serve long year date election shareholder general meetingstrategic report governance remuneration financial statement investor information financial statement section director statement responsibilitie independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare gaap gsk annual report gsk annual report strategic report governance remuneration financial statement investor information director statement responsibilitie director responsible prepare annual report disclosure information auditor remuneration report group financial statement director office date annual report accordance applicable law regulation confirm company law require director prepare financial far aware relevant audit information statement financial year law director company auditor unaware require prepare group financial statement take step ought accordance international financial reporting standard take director aware ifrs adopt european union prepare group relevant audit information establish company financial statement director elect comply auditor aware information ifrs issue international accounting standard board iasb company law director approve confirmation give interpret accordance group financial statement satisfied provision section company act true fair view asset liability financial position go concern basis profit loss group period page contain information performance prepare financial statement director group financial position cash flow net debt position require borrowing facility information include treasury risk management policy exposure market credit risk select suitable accounting policy apply hedging activity give note financial statement consistently financial instrument relate disclosure assess judgement accounting estimate principal risk matter consider connection reasonable prudent viability statement director consider appropriate adopt go concern basis accounting prepare state group financial statement comply ifrs financial statement adopt european union ifrs issue iasb subject material departure disclose internal control explain group financial statement board audit risk committee review assessment risk internal control framework operate prepare financial statement go concern basis gsk consider effectiveness system inappropriate presume group internal control operation group year cover continue business annual report date approval board director responsible keep adequate accounting director record sufficient explain company corporate governance code transaction disclose reasonable accuracy time board consider glaxosmithkline plc apply financial position group enable ensure principle complie provision corporate group financial statement remuneration report governance code maintain financial reporting council comply company act article ias describe corporate governance section page regulation responsible safeguarding asset board consider annual report take group take reasonable step fair balanced understandable provide prevention detection fraud irregularity information necessary shareholder assess group group financial statement year end december position performance business model strategy comprise principal statement support note require financial conduct authority list rule set financial statement page auditor consider director statement report responsibility auditor relation group compliance relation point corporate financial statement set independent auditor report governance code specify review page annual report group financial statement year end december annual report year end december include annual report publish comprise report director remuneration report print form available website director financial statement additional information investor responsible maintenance integrity annual report approve board director sign website accordance legislation govern behalf preparation dissemination financial statement access website available outside comparable legislation different current director name function philip hampton list corporate governance section annual report chairman confirm good knowledge march group financial statement prepare accordance ifrs adopt ifrs issue iasb true fair view asset liability financial position profit group strategic report risk section annual report represent management report include fair review development performance business position group description principal risk uncertaintie facesgsk annual report strategic report governance remuneration financial statement investor information independent auditor report members glaxosmithkline plc report group financial statement area focus threepart transaction novartis opinion rebate discount allowance return opinion glaxosmithkline plcs group financial statement pharmaceutical vaccine business true fair view state group affair investigation group commercial practice december profit cash flow year end litigation properly prepare accordance international carrying value goodwill intangible asset financial reporting standard ifrss adopt remeasurement shionogiviiv healthcare contingent european union consideration prepare accordance requirement uncertain tax position company act article ias regulation context separate opinion relation ifrss issue iasb context audit set group major activity explain note group financial statement significant event month group addition apply ifrss adopt european completion group threepart transaction union apply ifrss issue international novartis new area focus accounting standard board iasb audit give number significant management opinion group financial statement comply ifrss estimate judgement require account transaction issue iasb include valuation acquire asset liability impact acquisition accounting recognition measurement audit option liability certain tax judgement broad range group financial statement include annual report financial statement line item impact comprise time few market migrate compare consolidated balance sheet december group common enterprisewide consolidated income statement consolidate statement resource planning platform erp move financial transaction comprehensive income year end accounting service business process outsourcing location bpo inhouse business service centre consolidate cash flow statement year end bsc decision take consciously management consolidate statement change equity year give compete pressure organisation complete end integrate novartis transaction result transformation group finance process highlight area focus note group financial statement include report area low risk summary significant accounting policy include area focus report explanatory information expect area feature area focus certain require disclosure present newly acquire novartis business start migrate annual report note financial gsk centralise platform statement crossreference financial add new area focus group estimation statement identify audit fair value shionogiviiv healthcare contingent financial reporting framework apply consideration reflect significant estimation uncertainty preparation group financial statement applicable law inherent calculation balance give continue ifrss adopt european union increase size balance response change management estimate address well expect audit approach performance acquire product revision certain overview assumption follow resolution investigation materiality group chinese pharmaceutical business september overall group materiality million represent consider output audit work risk approximately profit tax add certain focus principally direct nonrecurre item adjust profit tax financial reporting judgement relate active investigation audit scope department justice doj fraud audit include scope audits report component office sfo specific audit procedure perform area focus refine reflect development report component group business include consideration expansion take component audit work healthcare reform continue competitive pricing pressure perform account consolidated revenue discount progress litigation consolidated profit tax adjust profit group expose impact change group segmental tax cover component individually contribute reporting follow novartis transaction determination revenue profit tax adjust profit tax cash generating unit cgus impairment testing purpose management assessment uncertain tax position gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue scope audit area focus procedure verify proper cutoff revenue expense conduct audit accordance international testing existence accuracy revenue transaction standard audit ireland isas ireland addition incorporate element unpredictability audit work year design audit determine materiality assess risk material misstatement financial statement risk material misstatement great effect particular look director subjective audit include allocation resource effort judgement example respect significant accounting identify area focus table set estimate involve make assumption consider future tailor audit address specific area order event inherently uncertain audits provide opinion group financial statement address risk management override internal control comment result procedure include evaluate evidence bias read context area focus director represent risk material misstatement appropriate evaluate design test operating fraud risk fraud revenue recognition procedure effectiveness key internal control financial reporting design execute address risk include use datum include testing operation system financial enable auditing technique test journal entry postclose information generate complete list risk adjustment test evaluate management key accounting identify audit estimate reasonableness consistency undertake cutoff area focus audit address area focus threepart transaction novartis deploy valuation specialist audit methodology refer note group financial statement underlying assumption mechanical accuracy valuation model significant acquire intangible asset consideration pay march group complete threepart transaction include contingent consideration settlement preexist novartis group acquire novartis exist vaccine business relationship challenge cash flow projection underpin cash consideration billion disposed oncology valuation include consumer option compare business cash consideration billion party historical cash flow understand reason growth contribute exist consumer healthcare business new profile projection venture group control interest deploy tax specialist evaluate external tax opinion focus area accounting component obtain management verify technical accuracy validate threepart transaction give rise follow significant audit risk step take group effecting transaction recognition goodwill million intangible asset consistent external advice opinion million acquisition vaccine novartis consumer healthcare business instruct component team location undertake certain substantive procedure acquire opening balance sheet accounting establishment consumer healthcare joint vaccine consumer healthcare include attendance inventory venture complicate require fair valuing portion count close acquisition date physical verification asset acquire gsk exist business contribute million non substantive procedure focus revenue cost cutoff controlling interest arise acquisition million result work determine provisional purchase number internal restructuring step undertake prior price allocation vaccine consumer healthcare acquisition oncology disposal consumer healthcare vaccine outline note group financial statement reasonable acquisition order support transaction tax efficient connection oncology disposal verify cash proceed manner reperforme management calculation resultant gain group recognise liability present value expect disposal find pretax gain disposal oncology redemption price write option novartis noncontrolle million associate tax charge million interest new consumer healthcare venture consumer reasonably state reflect management well estimate option value subject significant judgement incremental tax risk arise result threepart transaction estimation uncertainty december liability determine carrying value consumer option carry value million calculate accordance agreement novartis base board approve projection business reasonably state finally find disclosure respect aspect transaction reasonable provide fair reflection accounting valuation judgementsgsk annual report strategic report governance remuneration financial statement investor information area focus audit address area focus rebate discount allowance return obtain management calculation accrual applicable pharmaceutical vaccine business scheme validate assumption reference group refer note group financial statement state commercial policy term applicable contract party datum relate patient enrolment government fund benefit scheme group make sale customer fall historical level product return certain commercial government mandate contract reimbursement arrangement significant medicaid compare assumption contract price historical rebate medicare group provide right return customer discount allowance return level relevant current certain product payment trend consider historical accuracy group estimate previous year include certain change management arrangement result deduction gross sale arrive estimate update medicaid rebate new pricing methodology turnover rise obligation group provide customer respond impact competitive pricing pressure particularly rebate discount allowance right return advair greater discount market generally form unsettled amount recognise accrual independent expectation large element accrual focus area rebate discount allowance december party datum compare expectation return arrangement complex establish appropriate actual accrual recognise group accrual require significant judgement estimation director base procedure perform identify material judgement particularly complex healthcare environment difference independent expectation accrual competitive pricing pressure product discount grow trend director determine accrual million necessary december december million investigation group commercial practice meet director management inhouse legal counsel speak refer note group financial statement group external advisor assess risk occurrence group remain subject ongoing investigation doj similar act previously allege china status ongoe sfo group commercial practice investigation potential fine penalty include number market december group conclude understand evaluate group internal investigation process sufficient clarity likely time assess risk allegation report channel completion investigation able sufficiently include whistleblowe hotline evaluate ongoing reliable estimate fine penalty doj enhancement change control sfo impose group completion respective process business practice original allegation china investigation result group state note unable recognise provision estimate eventual outcome deploy forensic specialist assess scope finding investigation investigative work perform group risk assessment addition group carry investigation number exercise management perform party interaction market ascertain activity similar previously allege engagement broadly output assessment instruct china occur component team include certain market include group audit scope undertake riskfocuse audit procedure address focus follow risk material impact audit risk group financial statement materially group financial statement misstate potential financial implication allege illegal act fine penalty forthcoming respect ongoing respect doj sfo investigation independently circularise investigation group commercial practice include external legal counsel engage group obtain view status doj sfo rise need material investigation ascertain reasonableness management provision asset impairment assertion respect likely outcome investigation discuss response receive directly external legal counsel find illegal act similar previously allege china consistent representation receive management occur group satisfied group provision decision december adequacy disclosure give status investigation litigation discuss status significant know actual potential litigation refer note group financial statement inhouse legal counsel obtain substantively test evidence support decision rationale provision hold decision pharmaceutical industry heavily regulate increase record provision include correspondence legal counsel inherent litigation risk group engage number legal counterpartie litigation monitor consider external action include product liability antitrust relate private litigation information source identify potential legal action significant disclose note develop independent expectation litigation provision base focused area eventual outcome claim uncertain product litigation history available evidence challenge position take director base application valuation completeness provision recognise group material judgement estimation accordingly unexpected adverse obtain confirmation external legal counsel confirm outcome significantly impact group report profit understanding settle outstanding litigation assert claim balance sheet position evaluate significant adjustment legal provision record year significant increase group litigation year determine indicative management bias respect provision respect paxil product liability refer increase provision paxil product liability litigation obtain note reassess follow unsuccessful sufficient evidence conclude increase reasonable include mediation plaintiff give rise subsequent revision review external legal advice management well estimate settle claim increase disclose note group financial statement eventual offset utilisation exist provision million outcome legal proceeding dependent outcome future event december group hold provision million position take group inherently judgemental find respect legal action december million context group financial statement take judgement management reasonable disclosure respect provision contingent liability appropriate gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continued area focus audit address area focus carry value goodwill intangible asset deploy valuation specialist obtain group impairment refer note group financial statement analysis test reasonableness key assumption include profit cash flow growth terminal value impact expiry patent group billion intangible asset december potential product obsolescence selection discount rate billion comprise significant license patent acquire trade challenge management substantiate assumption include mark exclude computer software addition group compare relevant assumption industry economic forecast billion goodwill december december billion group recognise impairment intangible interrogate integrity support calculation corroborate asset amount million year certain information party source include expectation performance certain asset component business obtain carry value goodwill intangible asset contingent evaluate management sensitivity analyse ascertain impact future cash flow risk cash flow meet reasonably possible change key assumption perform group expectation asset impair impairment independent sensitivity calculation quantify downside change review perform group contain number significant management model require result impairment judgement estimate include revenue growth success new product launch patent expiry date profit margin cash conversion result work determine quantum impairment terminal value discount rate change assumption recognise appropriate intangible asset include lead change carry value intangible asset goodwill goodwill management determine impairment require find judgement support reasonable assumption year group reduce number individual cash require unreasonable downside change additional generating unit cgus goodwill impairment testing purpose material impairment necessary comprise global pharmaceutical consumer healthcare vaccine viiv healthcare exercise undertaken align respect aggregation cgus confirm low cgus group operate segment change follow level management monitor goodwill internal purpose group restructure follow novartis transaction consistent way group leadership team exercise vaccine treat separate cgu structure group result financial position time global pharmaceutical cgu aggregate pharmaceutical report cet cgu goodwill impairment testing business previously separate europe japan emerge purpose large group new operating segment market focus acquire intangible asset significant individually aggregate number indefinite life include significant intangible asset acquire novartis group recognise goodwill number acquisition include threepart transaction novartis remeasurement shionogiviiv healthcare contingent deploy valuation specialist evaluate management fair value consideration computation model include projection key assumption refer note group financial statement compare group projection dolutegravir product certain party expectation find group subsidiary viiv healthcare acquire remain reasonable particular consider reasonably possible alternative interest shionogiviiv healthcare joint venture scenario comprise downside case event product launch million recognise contingent consideration competitor cannibalise group market share anticipate represent fair value expect payment shionogi management base case upside case competitor contingent future sale dolutegravir product liability launch successful scenario result contingent require remeasure fair value report date consideration liability materially lower higher respectively initial recognition increase response actual notwithstanding believe group reasonable basis future sale significantly exceed original expectation determination fair value december value december associate financial liability million reflect management good estimate december million validate methodology consistent previous year focus area fair value contingent consideration certain input change discount tax rate determine number significant unobservable input validate appropriate trigger occur support management judgement estimate include forecast future sale change verify update assumption reasonable tivicay triumeq overall market size hiv therapy validate group disclosure respect liability potential impact competitor product launch expect include disclosure estimation uncertainty impact fair launch future addition valuation sensitive value liability reasonable change assumption include discount tax rate revise determine valuation december uncertain tax position conjunction international tax transfer pricing refer note group financial statement specialist evaluate challenge management judgement respect estimate tax exposure contingency order assess group operate complex multinational tax environment adequacy group tax provision include obtain open tax transfer pricing matter overseas tax evaluate certain party tax opinion group obtain authority addition time time group enter assess appropriateness assumption transaction complicated accounting tax consequence include threepart transaction novartis judgement understand evaluate management judgement consider required assess level provision require respect status recent current tax authority audits enquiry outturn uncertain tax position december group previous claim judgemental position take tax return current year recognise provision million respect uncertain tax estimate development tax environment evidence position million obtain consider level provision acceptable context group financial statement take note assumption judgement require formulate provision mean range possible outcome broadgsk annual report strategic report governance remuneration financial statement investor information tailor audit scope component team largely focus impact threepart tailor scope audit ensure perform transaction novartis alongside plan risk work able opinion group financial assessment activity addition visit share statement take account geographic structure service centre support reporting component group audit group accounting process control scope component group audit scope site visit industry group operate undertaken involvement include regular dialogue component team review component auditor work paper group financial statement consolidation participation certain component audit clearance meeting report component identify reporting component view require audit complete financial information specific audit procedure central function group size risk characteristic specific audit procedure consolidation area significant judgement include taxation significant balance transaction perform goodwill intangible asset treasury postretirement benefit report component appropriate coverage litigation elimination unrealise intercompany profit material balance report component inventory directly lead group audit team support share financial service centre centre take territory function perform include group audit scope report audit work account consolidated revenue component include group audit scope individually consolidated profit tax adjust profit tax contribute consolidated revenue profit consider contribution audit evidence tax adjust profit tax perform audit work divisional group level work perform component auditor include test monitoring control disaggregate analytical determined level involvement need audit review procedure cover significant portion group work report component unit result overseas small low risk component directly include component visit senior member group audit group audit scope addition obtain audit evidence team include group financially significant certain outofscope component procedure component visit annually alongside undertake group share service centre encompass belgium japan switzerland germany india hold bpos bsc centralise infrastructure day audit plan workshop london attend process standardise materiality scope audit influence application materiality set certain quantitative threshold materiality qualitative consideration help determine scope audit nature timing extent audit procedure individual financial statement line item disclosure evaluate effect misstatement individually financial statement base professional judgement determine materiality financial statement follow overall group materiality million million determine approximately profit tax million add certain nonrecurre item include remeasurement charge shionogiviiv healthcare contingent consideration million remeasurement charge consumer healthcare option million major restructuring cost million legal cost million equity investment impairment million impairment intangible asset million deducting nonrecurre net income relate major acquisition disposal activity net million rationale benchmark apply group principal measure earning comprise core result add statutory result number item income expenditure include detailed management use measure believe eliminate volatility inherent oneoff item take measure account determine materiality adjust profit tax add amortisation intangible asset certain small noncore item view recur item introduce volatility group earning materiality low year primarily effect low profit agree audit risk committee report misstatement identify audit million million misstatement view warrant reporting qualitative reason go concern note director statement director conclude list rule require review director appropriate adopt go concern basis prepare statement set relation going concern group financial statement go concern basis report perform review presume group adequate resource remain operation director intend isa ireland require report year date group financial statement sign material add draw attention relation audit conclude director use director statement consider go concern basis appropriate appropriate adopt go concern basis prepare group financial statement material add future event condition draw attention predict statement guarantee group ability continue go concern gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue require reporting consistency information company act opinion opinion information give strategic report director report financial year group financial statement prepare consistent group financial statement isas ireland report isas ireland require report opinion information annual report exception materially inconsistent information audit group financial statement report apparently materially incorrect base materially inconsistent knowledge group acquire course perform audit misleading statement give director accordance provision corporate governance exception code code consider annual report take fair balanced understandable report provide information necessary member assess group position performance business model strategy materially inconsistent knowledge group acquire course perform audit section annual report require provision code describe work exception audit committee appropriately address matter communicate audit committee report director assessment prospect group principal risk threaten solvency liquidity group isas ireland require report material add draw attention relation director confirmation annual report accordance provision code material carry robust assessment principal risk face group include threaten add draw attention business model future performance solvency liquidity disclosure annual report describe risk explain manage mitigate material add draw attention director explanation annual report accordance provision code material assess prospect group period consider period add draw attention appropriate statement reasonable expectation group able continue operation meet liability fall period assessment include related disclosure draw attention necessary qualification assumption list rule require review director statement carry robust assessment principal risk face group director statement relation longerterm viability group set review substantially scope audit consist make enquiry consider director process support statement check statement alignment relevant provision code consider statement consistent knowledge acquire course perform audit report perform review adequacy information explanation receive corporate governance statement company act require report list rule require review opinion receive information corporate governance statement relate provision explanation require audit exception corporate governance code report report arise responsibility perform review director remuneration company act require report opinion certain disclosure director remuneration specify law exception report arise responsibilitygsk annual report strategic report governance remuneration financial statement investor information responsibilitie financial statement matter audit report separately parent company financial responsibility director statement glaxosmithkline plc year end december information director explain fully director statement remuneration report describe audit responsibility set director responsible preparation group financial statement company pass resolution accordance section satisfied true fair view company act senior statutory auditor state responsibility audit express opinion group financial statement accordance applicable law isas ireland standard require comply auditing practice board ethical standard auditor report include opinion prepare pricewaterhousecooper llp company member body accordance charter accountant statutory auditor chapter company act london purpose give opinion accept assume march responsibility purpose person report show hand come save expressly agree prior consent writing note audit financial statement involve maintenance integrity glaxosmithkline plc audit involve obtain evidence amount website responsibility director work carry disclosure financial statement sufficient reasonable auditor involve consideration assurance financial statement free material matter accordingly auditor accept responsibility misstatement cause fraud error include change occur financial assessment statement initially present website accounting policy appropriate group egislation united kingdom govern preparation circumstance consistently apply dissemination financial statement differ adequately disclose legislation jurisdiction reasonableness significant accounting estimate director overall presentation financial statement primarily focus work area assess director judgement available evidence form judgement evaluate disclosure financial statement test examine information sampling auditing technique extent consider necessary provide reasonable basis draw conclusion obtain audit evidence testing effectiveness control substantive procedure combination addition read financial nonfinancial information annual report identify material inconsistency audit financial statement identify information apparently materially incorrect base materially inconsistent knowledge acquire course perform audit aware apparent material misstatement inconsistency consider implication report gsk annual report strategic report governance remuneration financial statement investor information financial statement consolidate income statement year end december note turnover cost sale gross profit sell general administration research development royalty income operating income operate profit finance income finance expense profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year lossprofit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny consolidate statement comprehensive income year end december profit year item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary defer tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement gainslosse define benefit plan defer tax remeasurement gainslosse define benefit plan comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report strategic report governance remuneration financial statement investor information consolidate balance sheet december note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax liability pension postemployment benefit provision derivative financial instrument noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity financial statement page approve board march sign behalf philip hampton chairman gsk annual report strategic report governance remuneration financial statement investor information financial statement continue consolidated statement change equity year end december shareholder equity non share share retain control total capital premium earning reserve total interest equity january profit year comprehensive incomeexpense year total comprehensive income year distribution noncontrolle interest dividend shareholder change noncontrolle interest ordinary share issue ordinary share purchase cancel hold treasury share ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive expenseincome year total comprehensive incomeexpense year distribution noncontrolle interest dividend shareholder change noncontrolle interest forward contract relate noncontrolle interest ordinary share issue ordinary share purchase cancel hold treasury share ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profitloss year comprehensive expenseincome year total comprehensive incomeexpense year distribution noncontrolle interest dividend shareholder gain transfer net asset consumer healthcare joint venture consumer healthcare joint venture option change noncontrolle interest loss transfer equity investment investment associate ordinary share issue ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december gsk annual report strategic report governance remuneration financial statement investor information consolidated cash flow statement year end december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment purchase business net cash acquire disposal business investment associate joint venture proceeds disposal subsidiary interest associate increasedecrease liquid investment interest receive dividend associate joint venture net cash inflowoutflow investing activity cash flow financing activity share acquire esop trust issue share capital purchase share cancellation hold treasury share purchase noncontrolle interest increase longterm loan repayment shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder distribution noncontrolle interest finance cash flow net cash outflow financing activity increasedecrease cash bank overdraft cash bank overdraft begin year exchange adjustment increasedecrease cash bank overdraft cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft gsk annual report strategic report governance remuneration financial statement investor information note financial statement presentation financial statement implementation new accounting standard amendment ia define benefit plan employee description business contribution issue november implement gsk major global healthcare group engage gsk january amendment provide additional creation discovery development manufacture marketing guidance treatment contribution define benefit pharmaceutical product include vaccine overthecounter plan employee party material impact otc medicine healthrelate consumer product gsk current period principal pharmaceutical product include medicine financial period follow therapeutic area respiratory antiviral central nervous system cardiovascular urogenital metabolic antibacterial financial statement cover financial year january dermatology rare disease immunoinflammation vaccine december comparative figure financial hiv year january december appropriate january december compliance applicable law ifrs parent company financial statement financial statement prepare accordance company act article ias regulation financial statement parent company glaxosmithkline international accounting standard ias international plc prepare accordance gaap financial reporting standard ifrs relate interpretation accounting presentation company balance sheet present adopt european union accounting policy give financial statement compliance ifrs issue international accounting standard board accounting principle policy composition financial statement consolidation consolidated financial statement draw sterling consolidated financial statement include functional currency glaxosmithkline plc accordance asset liability result cash flow ifrs accounting presentation financial statement company subsidiary include esop trust comprise group share result net asset associate consolidate income statement joint venture consolidate statement comprehensive income group share asset liability revenue expense consolidate balance sheet joint operation consolidated statement change equity financial statement entity consolidate december year consolidated cash flow statement entity group power direct relevant note financial statement activity affect return group generally composition group control financial operating policy account list subsidiary associate undertaking subsidiary group ability exercise joint opinion director principally affect profit control right net asset entity entity net asset group give note principal account joint venture group group company ability exercise joint control arrangement right specify asset obligation specify liability accounting principle policy arrangement arrangement account joint financial statement prepare historical operation group ability exercise significant cost convention modify revaluation certain item influence entity account associate state accounting policy go concern basis result asset liability associate joint financial statement prepare accordance venture incorporate consolidated financial group accounting policy approve board statement equity method accounting describe note accounting principle policy group right asset liability revenue expense information application accounting policy joint operation include consolidated financial include area estimation judgement give note statement accordance right obligation key accounting judgement estimate interest acquire entity consolidated date preparation financial statement conformity group acquire control interest sell deconsolidate generally accept accounting principle require management date control cease estimate assumption affect report amount asset liability disclosure contingent asset liability date financial statement report amount revenue expense report period actual result differ estimatesgsk annual report strategic report governance remuneration financial statement investor information accounting principle policy continue revenue revenue recognise income statement good transaction balance subsidiary eliminate service supply available external customer profit tax take sale subsidiary order receive title risk loss pass product sell customer outside group customer reliable estimate relevant deduction relevant proportion profit transaction joint venture relevant obligation fulfil joint operation associate defer product earning process regard complete sell party transaction noncontrolle interest record directly equity defer tax relief unrealise turnover represent net invoice value deduction intragroup profit account extent discount allowance give accrual estimate future consider recoverable rebate return methodology assumption estimate rebate return monitor adjust regularly goodwill capitalise separate item case light contractual legal obligation historical trend subsidiary cost investment case past experience project market condition market joint venture associate goodwill denominate condition evaluate wholesaler thirdparty currency operation acquire analysis market research datum internally generate cost acquisition fair value information value add tax sale taxis exclude net asset acquire difference recognise directly revenue income statement group copromote product counterparty business combination record sale group record share revenue business combination account acquisition copromotion income turnover nature copromotion accounting method identifiable asset liabilitie contingent activity group record cost sale liability acquire measure fair value acquisition date pharmaceutical turnover include copromotion revenue consideration transfer measure fair value million million million addition include fair value contingent consideration initial eventbase milestone income exclude royalty income consideration transfer noncontrolle arise development marketing collaboration group interest exceed fair value net asset liability compound product party recognise contingent liability acquire excess record goodwill turnover milestone income nil include turnover cost acquisition charge income statement million million period incur royalty income recognise accrual basis accordance equity subsidiary acquire non term relevant licensing agreement control interest recognise fair value expenditure noncontrolle interest share net asset subsidiary expenditure recognise respect good service casebycase basis change group ownership receive supply accordance contractual term percentage subsidiary account equity provision obligation exist future liability foreign currency translation respect past event obligation foreign currency transaction book functional reliably estimate manufacturing startup cost currency group company exchange rate rule validation achievement normal production expense date transaction foreign currency monetary asset incur advertising promotion expenditure charge liability retranslate functional currency rate income statement incur shipment cost inter exchange rule balance sheet date exchange difference company transfer charge cost sale distribution include income statement cost sale customer include sell general administrative expenditure consolidation asset liability include related goodwill overseas subsidiary associate joint venture restructure cost recognise provide translate sterling rate exchange rule balance appropriate respect direct expenditure business sheet date result cash flow overseas subsidiary reorganisation plan sufficiently detail associate joint venture translate sterling advanced appropriate communication average rate exchange affect undertaken exchange adjustment arise open net asset profit year retain overseas subsidiary associate joint venture translate sterling exchange difference arise related foreign currency borrowing hedge group net investment operation take separate component equity translating sterling asset liability result cash flow overseas subsidiary associate joint venture report currency hyperinflationary economy adjustment material reflect current price level loss net monetary asset charge consolidated income statement gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue employee share plan incentive form share provide employee research development share option share award scheme research development expenditure charge income statement period incur development fair value option award calculate expenditure capitalise criterion recognise grant date blackschole option pricing model asset meet usually regulatory filing charge income statement relevant vesting period major market approval consider highly probable property group provide finance esop trust purchase company plant equipment research development share meet obligation provide share employee capitalise depreciated accordance group policy exercise option award cost run esop environmental expenditure trust charge income statement share hold environmental expenditure relate exist condition result esop trust deduct reserve transfer past current operation current reserve retain earning vest future benefit discernible charge income statement period relate share option award reflect group recognise liability sitebysite basis ultimate proceed receivable employee exercise reliably estimate liability include group property plant equipment portion total cost portion potentially property plant equipment ppe state cost responsible party cost probable purchase construction provision depreciation able satisfy respective share cleanup obligation impairment financing cost capitalise cost recovery reimbursement record asset qualify asset construction virtually certain depreciation calculate write cost residual value legal dispute ppe exclude freehold land straightline basis provision anticipated settlement cost legal expect useful life residual value life review dispute group outflow resource appropriate adjust annually normal expect consider probable reliable estimate useful life major category ppe likely outcome addition provision legal expense arise claim receive dispute freehold building year respect product liability claim relate certain product leasehold land building lease term year sufficient history claim settlement plant machinery year enable management reliable estimate provision equipment vehicle year require cover unasserted claim certain case incur report ibnr actuarial technique determine disposal ppe cost relate accumulate estimate depreciation impairment remove financial statement net proceed take group involved legal proceeding respect income statement possible reliable estimate lease expect financial effect result ultimate resolution proceeding case appropriate leasing agreement transfer group substantially disclosure case include provision benefit risk ownership asset treat cost associate claim group finance lease asset purchase outright party charge income statement asset include ppe computer software capital incur element leasing commitment show obligation finance lease asset hold finance lease pension postemployment benefit depreciate basis consistent similar own asset cost provide pension define benefit scheme lease term short interest element lease rental calculate project unit credit method spread include income statement lease operating period benefit expect derive lease rental cost charge income statement employee service consistent advice qualified straightline basis lease term actuary pension obligation measure present value goodwill estimate future cash flow discount rate reflect yield high quality corporate bond pension scheme asset goodwill state cost impairment goodwill deemed measure fair value balance sheet date indefinite useful life test impairment annually cost postemployment liability calculate similar way define benefit pension scheme spread fair value interest acquire entitys asset period benefit expect derive liability contingent liability exceed consideration pay employee service accordance advice excess recognise immediately gain income qualified actuary statement actuarial gain loss effect change actuarial assumption recognise statement comprehensive income year arise group contribution define contribution plan charge income statement incurredgsk annual report strategic report governance remuneration financial statement investor information accounting principle policy continue availableforsale investment liquid investment investment classify intangible asset availableforsale investment initially record fair intangible asset state cost provision amortisation value plus transaction cost remeasure subsequent impairment report date fair value unrealised gain loss licence patent knowhow marketing right separately availableforsale investment recognise directly acquire acquire business combination comprehensive income impairment arise significant amortise estimate useful life generally exceed prolong decline fair value equity investment reduce year straightline basis time carry asset directly charge available use estimate useful life determine income statement amortisation charge account patent life disposal impairment investment gain applicable value obtain period non loss defer comprehensive income exclusivity asset life review appropriate reclassify income statement dividend equity adjust annually contingent milestone payment recognise investment recognise income statement point contingent event probable group right receive payment establish equity investment development cost incur group associate record noncurrent asset expect acquire licence patent knowhow marketing right sell year write income statement incur criterion recognition internally generate intangible asset purchase sale equity investment account meet usually regulatory filing major trade date purchase sale availableforsale market approval consider highly probable investment account settlement date inventory acquire brand value independently fair value business acquire party brand inventory include financial statement low value substantial long term brand cost include raw material direct labour direct cost contractual legal nature sell separately relate production overhead net realisable value cost rest business acquire brand amortise generally determine basis prelaunch estimate useful life year inventory hold asset high probability consider useful economic life indefinite regulatory approval product point provision carry value recoverable cost acquire develop computer software provision reverse point high probability internal use internet site external use capitalise regulatory approval determine intangible fix asset software site support trade receivable significant business system expenditure lead creation durable asset erp system software amortise trade receivables carry original invoice seven year computer software provision doubtful debt provision year evidence risk nonpayment take account age previous experience general economic condition impairment noncurrent asset trade receivable determine uncollectable write carry value noncurrent asset review firstly provision available income impairment standalone basis large statement cash generating unit indication asset impair additionally goodwill intangible asset subsequent recovery amount previously provide indefinite useful life intangible asset credit income statement longterm receivable available use test impairment annually provision discount effect material impairment charge income statement year borrowing concern borrowing initially record proceed impairment goodwill reverse impairment loss receive net transaction cost borrowing subsequently noncurrent asset reverse carry amortise cost difference change estimate determine recoverable amount proceed net transaction cost extent revise recoverable amount redemption recognise charge income exceed carry value exist net statement period relevant borrowing depreciation amortisation impairment recognise investment associate joint venture joint operation investment associate joint venture carry consolidated balance sheet group share net asset date acquisition postacquisition retain profit loss goodwill arise acquisition group recognise right asset liability revenue expense joint operation gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue key accounting judgement estimate taxation prepare financial statement management require current tax provide amount expect pay estimate assumption affect amount apply tax rate enact substantively enact asset liability revenue expense report financial balance sheet date statement actual amount result differ estimate follow consider key accounting defer tax provide temporary difference arise judgement estimate tax basis asset liability carry amount financial statement defer tax asset turnover recognise extent probable future taxable revenue recognise title risk loss pass profit available temporary difference customer reliable estimate relevant deduction utilise defer tax provide temporary difference relevant obligation fulfil arise investment subsidiary associate joint earning process regard complete venture time reversal temporary gross turnover reduce rebate discount allowance difference control probable temporary product return give expect give vary difference reverse foreseeable future defer tax product arrangement buy group arrangement provide rate tax enact substantively purchase organisation dependent submission enact balance sheet date claim time initial recognition derivative financial instrument hedge sale accrual time sale estimate derivative financial instrument manage exposure rebate discount allowance payable return market risk principal derivative instrument gsk base available market information historical experience foreign currency swap interest rate swap foreign exchange amount estimate fully reflect forward contract option group hold issue final outcome amount subject change dependent derivative financial instrument trade speculative thing type buy group product purpose sale mix derivative financial instrument classify heldfortrading level accrual review adjust regularly carry balance sheet fair value derivative light contractual legal obligation historical trend past designate hedge instrument classify inception experience project market condition market condition cash flow hedge net investment hedge fair value hedge evaluate wholesaler thirdparty analysis change fair value derivative designate cash flow market research datum internally generate information hedge recognise comprehensive income future event cause assumption extent hedge effective ineffective portion accrual base change affect future recognise profit loss immediately amount defer result group comprehensive income reclassify income statement hedge item affect profit loss taxation current tax provide amount expect pay net investment hedge account similar way defer tax provide temporary difference cash flow hedge tax basis asset liability carry amount change fair value derivative designate fair value rate enact substantively enact hedge record income statement balance sheet date change fair value hedge asset liability defer tax asset recognise extent change fair value derivative instrument probable future taxable profit available qualify hedge accounting recognise immediately temporary difference utilise base income statement management assumption relate amount time future taxable profit factor affect tax charge discount future year set note taxation change time value money material balance group effective tax rate change discount current value appropriate rate interest total tax charge year approximately million unwind discount record finance income finance expense group open tax issue number revenue authority outflow fund believe probable reliable estimate outcome dispute management provide good estimate liability calculate liability gsk apply risk base approach take account appropriate probability group able obtain compensatory adjustment international tax treaty estimate account specific circumstance dispute relevant external advice inherently judgemental change substantially time new fact emerge dispute progress gsk continue believe adequate provision liability likely arise open assessment open issue exist ultimate liability matter vary amount provide dependent outcome negotiation relevant tax authority necessary litigation proceedingsgsk annual report strategic report governance remuneration financial statement investor information key accounting judgement estimate business combination contingent consideration include consideration continue payable business combination record fair value legal dispute date acquisition fair value generally base group provide anticipate settlement cost riskadjuste future cash flow discount appropriate outflow resource consider probable reliable interest rate fair value review regular basis estimate likely outcome dispute annually change reflect income legal expense arise claim group statement estimate account specific circumstance december liability contingent consideration dispute relevant external advice inherently amount million million note judgmental change substantially time new acquisition disposal million fact emerge dispute progress detail status million arise acquisition uncertainty involve significant unresolved shionogiviiv healthcare joint venture million dispute set note legal proceeding arise acquisition vaccine business novartis company director take legal advice establish provision take account relevant group grant option novartis fact circumstance matter accordance respect novartis shareholde consumer healthcare accounting requirement respect product liability claim joint venture certain circumstance novartis right relate certain product sufficient history claim require gsk acquire shareholde consumer settlement enable management reliable healthcare joint venture marketbase valuation right estimate provision require cover unasserted claim exercisable certain window group involved legal proceeding respect exercise respect novartis entire shareholding possible reliable estimate instalment gsk recognise financial liability expect financial effect result ultimate million noncurrent liability december resolution proceeding case appropriate represent present value estimate disclosure case include provision payable gsk event exercise right novartis contingent liability quantify calculate apply marketbase multiple forecast december provision legal dispute future profit accordance shareholder agreement amount billion billion sensitivity analysis give note noncurrent ultimate liability legal claim vary amount liability provide dependent outcome litigation assumption relate future cash flow discount rate proceeding investigation possible settlement negotiation base business forecast inherently position change time judgemental future event cause assumption assurance loss result outcome projection marketbase multiple change legal proceeding exceed provision consequent adverse effect future result group report group financial statement material pension postemployment benefit goodwill intangible asset impairment cost provide pension postemployment goodwill deem indefinite life benefit charge income statement accordance amortise annual impairment test cash generating ias employee benefit period benefit unit goodwill allocate performed impairment derive employee service cost assess test base established market multiple riskadjuste basis assumption select management future cash flow discount appropriate interest rate assumption include future earning pension increase assumption impairment test set discount rate expect longterm rate return asset note goodwill mortality rate disclose note pension case valuation indicate sufficient headroom postemployment benefit surplus define benefit reasonably possible change key assumption unlikely scheme arise potential surplus arise result impairment relate goodwill commit future contribution right trustee prevent group obtain refund surplus future impairment test intangible asset undertake consider determine necessary restrict event occur question carry value surplus recognise asset brand intangible asset available use amortise subject annual expect longterm rate return bond determine impairment test valuation impairment test base base portfolio mix indexlinke government establish market multiple riskadjuste future cash flow corporate bond equity risk premium add estimate useful life asset limited equity discount appropriate interest rate set discount rate derive rate corporate bond yield note intangible asset country deep market corporate assumption relate future cash flow estimate useful bond government bond yield sensitivity analysis live discount rate base business forecast provide note pension postemployment inherently judgemental future event cause benefit reduction discount rate lead assumption impairment test change increase net pension deficit approximately million consequent adverse effect future result group increase annual pension cost approximately million selection different assumption affect future result group gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue new accounting requirement exchange rate follow new amend accounting standard group use average exchange rate prevail issue iasb likely affect future annual report period translate result cash flow overseas amendment ifrs expect material subsidiary joint venture associate undertaking impact result financial position group sterling period end rate translate net asset impact ifrs ifrs ifrs result undertaking currency influence financial position group currently assess translation relevant exchange rate amendment ifrs joint arrangement issue implement group january average rate amendment require acquisition joint operation meet definition business account euro accordance ifrs business combination yen ifrs revenue contract customer issue implement group january period end rate standard provide single principlesbased approach recognition revenue contract customer euro focus identification performance obligation yen contract require revenue recognise performance obligation satisfy ifrs financial instrument issue final form july implement group january standard replace majority ia cover classification measurement derecognition financial asset financial liability impairment financial asset provide new hedge accounting model ifrs lease issue january implement group january standard replace ias lease require lease liability right use asset recognise balance sheet leasesgsk annual report strategic report governance remuneration financial statement investor information segment information operating segment report base financial information provide chief executive officer responsibilitie corporate executive team cet completion novartis transaction march change balance group gsk change segment reporting reflect effect january gsk report result segment global pharmaceutical hiv pharmaceutical vaccine consumer healthcare individual member cet responsible segment comparative information restate accordingly addition segment turnover profit restate exclude divestment complete group management reporting process allocate intragroup profit product sale market sale record profit analysis present basis pharmaceutical segment responsibility head research development report separate segment corporate unallocated turnover cost include result vaccine consumer healthcare product hold sale number market order meet antitrust approval requirement cost corporate function january global pharmaceuticals hiv segment combine operating segment pharmaceutical restate restate turnover segment global pharmaceutical hiv pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover divestment complete restate restate global pharmaceutical turnover therapeutic area respiratory cardiovascular metabolic urology immunoinflammation oncology pharmaceutical establish product gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue segment information continue restate restate consumer healthcare turnover category wellness oral care nutrition skin health element global pharmaceutical hiv vaccine sale wholesaler approximately million million million million million million million million million respectively allocate finalcustomer discount wholesaler segment profit restate restate global pharmaceutical hiv pharmaceutical pharmaceutical vaccine consumer healthcare segment profit corporate unallocated cost reconcile item segment profit operating profit operating profit finance income finance costs profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year reconcile item segment profit operating profit comprise item specifically allocate segment profit include impairment amortisation intangible asset major restructuring charge legal charge expense settlement litigation government investigation disposal business product associate certain item relate major acquisition disposal activity depreciation amortisation segment restate restate global pharmaceutical hiv pharmaceutical pharmaceutical vaccine consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconcile item segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report strategic report governance remuneration financial statement investor information segment information continue ppe intangible asset goodwill impairment segment restate restate global pharmaceutical hiv pharmaceutical pharmaceutical vaccine consumer healthcare segment impairment corporate unallocated impairment reconcile item segment impairment total impairment total impairment ppe intangible asset impairment reversal segment restate restate global pharmaceutical hiv pharmaceutical pharmaceutical vaccine consumer healthcare segment impairment reversal corporate unallocated impairment reversal total impairment reversal restate net asset segment global pharmaceutical hiv pharmaceuticals pharmaceutical vaccine consumer healthcare segment net operating asset corporate unallocated net operating asset net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale net asset hiv segment include shionogiviiv healthcare contingent consideration liability million million consumer healthcare segment include option liability million nil gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue segment information continue geographical information regard group country domicile restate restate turnover location customer international external turnover turnover location subsidiary international turnover include intersegment turnover international intersegment turnover international external turnover operate profit location international total operating profit noncurrent asset location international noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivablesgsk annual report strategic report governance remuneration financial statement investor information operating income impairment equity investment disposal equity investment disposal business asset fair value remeasurement contingent consideration recognise business combination remeasurement consumer healthcare option liability fair value adjustment derivative financial instrument incomeexpense disposal business asset include disposal oncology business novartis million million divestment ofatumumab include gain disposal treximet fair value remeasurement contingent consideration recognise business combination comprise million related acquisition shionogiviiv healthcare joint venture million net hedging gain relate acquisition vaccine business novartis fair value adjustment derivative financial instrument arise foreign exchange forward contract option take hedge foreign currency movement sale purchase denominate foreign currency note financial instrument relate disclosure include unrealised loss million arise number forward exchange contract enter follow announcement propose novartis transaction protect sterling value net dollar proceed group completion transaction gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal amortisation intangible asset impairment intangible asset net reversal net foreign exchange lossesgain inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration include operate profit major restructuring charge million million million note major restructuring cost fee payable company auditor associate audit parent company consolidated financial statement audit company subsidiary auditrelate assurance service include attestation sarbanesoxley act audit auditrelated service taxation compliance taxation advice assurance service service addition fee pay respect gsk pension scheme audit service gsk annual report strategic report governance remuneration financial statement investor information employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance charge pension postemployment cost include credit million follow restructure postretirement medical obligation set note pension postemployment benefit cost sharebase incentive plan analyse follow share value plan performance share plan share option plan plan average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial record average number person employ glaxosmithkline plc nil nil compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue major restructuring cost major restructuring cost charge arrive operating profit include restructure cost arise major change programme initiate pharmaceutical restructuring programme announce october follow novartis transaction complete gsk report programme combine programme total restructuring cost billion incur follow area restructuring pharmaceutical business north america emerge markets europe lead staff reduction sale force administration restructuring organisation predominantly unite kingdom north america japan project simplify eliminate process lead staff reduction support function transformation manufacture vaccine business deliver step change quality cost productivity integration novartis consumer healthcare business new consumer healthcare joint venture analysis cost charge operating profit programme follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise noncash charge cash cost asset impairment million nil million noncash charge total million million million noncash item principally fix asset write down manufacture research facility accelerate depreciation asset lives shorten result major restructuring programme charge settle cash include termination lease site closure cost consultancy project management fee finance income interest income arise cash cash equivalent availableforsale investment derivative fair value profit loss loan receivables fair value adjustment derivative fair value profit loss derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ias gsk annual report strategic report governance remuneration financial statement investor information finance expense interest expense arise financial liability amortise cost derivative fair value profit loss fair value hedge fair value movement derivative designate hedge instrument fair value adjustment hedge item fair value movement derivative fair value profit loss reclassification cash flow hedge comprehensive income unwind discount provision movement amount owe noncontrolle interest finance expense derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia interest expense arise derivative fair value profit loss relate swap interest expense associate joint venture group share tax profit loss associate joint venture set share tax profit associate share tax loss joint venture december group hold significant associate theravance inc innoviva inc investment account investment associate september describe note investment associate joint venture previously include investment group share tax profit associate include loss million respect theravance innoviva march group divest half shareholde aspen pharmacare holding limit cease account remain investment associate investment aspen include investment note aspen group significant associate summarise income statement information respect aspen set period group account investment aspen associate group share tax profit associate comprehensive income include profit million comprehensive income million respect aspen march turnover profit taxation comprehensive income total comprehensive income result aspen include summarise income statement information represent estimate earning aspen group relevant period adjust transaction gsk aspen aggregate financial information respect associate undertaking joint venture set share turnover share tax profitslosse share comprehensive income share total comprehensive income group sale associate joint venture million million million profit disposal interest associate million year arise group divestment half shareholde aspen pharmacare holding limit march include gain million result change measurement basis group retain investment aspen reclassification investment follow divestment retain investment transfer investment associate equity account investment measure fair value gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue taxation taxation charge base profit year current year charge rest world current year charge charge respect prior period total current taxation total defer taxation gsk payment million corporation tax january gsk payment million relation corporation tax amount corporation tax include business taxis bear gsk year significant component defer tax credit prior period arise respect remeasurement contingent consideration relation shionogiviiv healthcare joint venture credit include unwind defer tax liability disposal group oncology business novartis credit include recognition defer tax asset capital loss anticipate utilise completion novartis transaction follow table reconcile tax charge calculate statutory rate group profit tax actual tax charge year reconciliation taxation group profit profit tax statutory rate taxation difference overseas taxation rate benefit intellectual property incentive credit intercompany inventory profit impact sharebase payment loss recognisedpreviously unrecognise loss permanent difference disposal acquisition permanent difference reassessment prior year estimate disposal associate tax unremitte earning defer tax adjustment restructure tax charge tax rate gsk substantial business presence country globe impact difference overseas taxation rate arise profit earn country tax rate high statutory rate significant india france germany partially offset increase benefit intellectual property incentive patent box belgian patent income deduction regime regime provide reduce rate corporate income tax profit earn qualifying patent impact overseas tax rate offset permanent difference disposal subject substantial shareholding exemption tax anticipate oncology disposal result recognition defer tax asset capital loss subsequently utilise reduction benefit provide credit reflect change regime record benefit expense income statement reassessment prior year estimate include benefit million resolution number tax matter country future tax charge effective tax rate affect factor acquisition disposal restructuring location research development activity tax regime reform resolution open matter continue bring tax affair date world tax item charge equity statement comprehensive income current taxation sharebase payment define benefit plan defer taxation sharebase payment define benefit plan exchange movement fair value movement cash flow hedge fair value movement availableforsale investment total chargecredit equity statement comprehensive income item charge statement comprehensive income tax share base paymentsgsk annual report strategic report governance remuneration financial statement investor information taxation continue issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket gsk big risk respect taxation different tax authority seek attribute profit activity undertake jurisdiction potentially result double taxation gsk apply oecd establish principle matching profit generate legal entity risk borne value add value chain inherently subjective challenge tax authority give rise complexity delay resolve audits revenue authority profit individual group company liable tax calculate tax liability group gsk apply risk base approach determine transaction likely subject challenge probability group able obtain compensatory adjustment international tax treaty continue significant international focus tax reform include oecds bep project european commission initiative propose antibep directive increase use fiscal state aid investigation domestic initiative world result significant change establish tax principle increase tax authority dispute turn affect adversely effective tax rate result high cash tax liability group continue believe adequate provision liability likely arise period open agree tax authority ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate aggregate unremitte profit balance sheet date approximately billion billion legislation relate company distribution provide exemption tax overseas profit subject certain exception provision defer tax liability million million respect withholding taxation arise distribution profit certain overseas subsidiary unremitte profit defer tax provide billion billion defer tax distribution profit provide ground group able control timing reversal remain temporary difference probable reverse foreseeable future ovement defer tax asset liability pension share accelerate post option net capital intangible contingent intragroup employment tax award temporary allowance asset consideration profit benefit loss scheme difference total january exchange adjustment creditcharge income statement charge equity charge statement comprehensive income acquisition disposal december recognise tax loss comprise million trading loss million trading loss million capital loss net temporary difference include accrue expense tax deduction available pay basis defer tax asset recognise territory probable group continue generate taxable profit future asset utilise offset defer tax asset liability appropriate territory net defer tax asset comprise defer tax asset defer tax liability gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue taxation continue unrecognised tax loss trading loss expire year year available indefinitely december capital loss december defer tax asset recognise probable future taxable profit available utilise loss unrecognised capital loss revise follow reassessment available loss defer tax recognise earning share pence pence pence basic earning share dilute earning share basic earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right dividend share hold esop trust diluted earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award dilute dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable penny pay penny pay pence interim july july july second interim october october october interim january january january fourth interim april april april total special dividend april ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder gsk annual report strategic report governance remuneration financial statement investor information property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december exchange adjustment addition business combination addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december depreciation january exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december exchange adjustment charge year disposal writeoff transfer tofrom asset hold sale depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment impairment december exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december follow completion novartis transaction group revise segmental reporting allocation cost asset process review conduct ensure consistent appropriate classification report group segment result number classification adjustment property plant equipment reclassification impact net book value property plant equipment report yearend income statement year stated total ppe reduce opening balance asset construction january million increase opening balance land building plant equipment vehicle million million respectively equivalent adjustment reclassification report gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue property plant equipment continue net book value december group land building comprise freehold property million million property lease year million million property lease year million million include land building december lease asset cost million million accumulate depreciation million million impairment nil million net book value million million include plant equipment vehicle december lease asset cost million million accumulate depreciation million million impairment nil million net book value million million lease agreement include renewal purchase option escalation clause impairment loss principally arise decision rationalise facility calculate base fair value cost disposal value use fair value cost disposal valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate relevant specific risk value use calculation impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately net impairment loss charge cost sale million million million million sga million million include million nil arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale carrying value december asset impairment charge reverse year million million goodwill cost january exchange adjustment addition business combination note transfer asset hold sale movement contingent consideration balance cost december net book value january net book value december gsk divest novartis market oncology portfolio acquire novartis vaccine business exclude influenza vaccine create consumer healthcare joint venture novartis gsk control equity interest acquisition result recognition additional goodwill allocate vaccine million consumer healthcare million disposal oncology business result transfer goodwill asset hold sale reduction goodwill global pharmaceutical million disposal complete carry value goodwill translate yearend exchange rate allocate follow cash generating unit global pharmaceutical hiv vaccine consumer healthcare net book value december goodwill balance december reallocate reflect revise cash generating unit gsk annual report strategic report governance remuneration financial statement investor information goodwill continue recoverable amount cash generating unit assess fair value cost disposal model fair value cost disposal calculate discount cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy detail relate discount cash flow model impairment test global pharmaceutical hiv vaccine consumer healthcare cash generating unit follow valuation basis fair value cost disposal key assumption sale growth rate profit margin terminal growth rate discount rate taxation rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate taxation rate base appropriate rate region period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate global pharmaceutical hiv vaccines consumer healthcare terminal growth rate exceed longterm project growth rate relevant market reflect impact future generic competition account new product launch case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill goodwill monitor segmental level global pharmaceutical cash generating unit comprise collection small cash generating unit include asset indefinite live carry value million million consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value billion billion detail indefinite life brand give note intangible asset gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue intangible asset computer licence amortise indefinite life software patent etc brand brand total cost january exchange adjustment capitalise development cost capitalise borrowing cost addition reclassification disposal asset writeoff transfer asset hold sale cost december exchange adjustment capitalise development cost capitalise borrowing cost addition business combination addition reclassification disposal asset writeoff transfer asset hold sale cost december amortisation january exchange adjustment charge year disposal asset writeoff amortisation december exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december impairment january exchange adjustment impairment loss disposal asset writeoff impairment december exchange adjustment impairment loss disposal asset writeoff transfer asset hold sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december net book value computer software include million million internally generate cost charge impairment year include impairment magea asset maxinutrition carry value december intangible asset impairment charge reversed year follow impairment reversal million milliongsk annual report strategic report governance remuneration financial statement investor information intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development licence patent etc include large number acquire licence patent knowhow agreement marketing right market use development note acquisition disposal give detail addition business combination year book value large individual item follow dolutegravir benlysta menveo bexsero man abcwy fluarixflulaval selzentry okairos technology platform indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business number pharmaceutical brand acquisition stiefel laboratories inc book value major brand follow voltaren otrivin fenistil theraflu panadol sensodyne lamisil breathe right stiefel trade excedrin physiogel polident brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment amortise intangible asset test indicator impairment arise testing apply fair value cost disposal methodology generally posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate country currency specific risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply nil management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment intangible asset gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue investment associate joint venture joint joint ventures associates total ventures associates total january exchange adjustment addition disposal transfer fromto investment distribution receive movement profitloss tax recognise consolidated income statement comprehensive income recognise consolidated statement comprehensive income december group hold significant associate december theravance inc change innoviva inc january december group own million share theravance inc innoviva inc biopharmaceutical company list nasdaq company partner gsk development relvarbreo ellipta anoro ellipta receive royalty income sale product eligible receive royalty income sale vilanterol monotherapy approve commercialise retain economic interest future payment gsk earlierstage programme partner theravance biopharma inc gsk recognise theravance associate september follow expiry governance agreement relate group investment company term governance agreement group require certain limited exception vote share support recommendation independent director board proportion shareholder vote cast expiry governance agreement removal voting right restriction consider provide group ability exert significant influence activity company investment market value million december movement primarily reflect recognition gsk share theravance past loss transfer theravance investment associate december group significant investment associate hold aspen pharmacare holding limit march group sell half hold aspen result group long ability exert significant influence aspen group remain investment aspen account investment summarise balance sheet information base preliminary result information respect theravance innoviva december aspen december set theravance aspen december december noncurrent asset current asset current liability noncurrent liability net liabilitiesasset interest associate undertake goodwill fair value adjustment carry value december gsk annual report strategic report governance remuneration financial statement investor information investment january exchange adjustment addition fair value gain reclassification investment associate net fair value movement impairment loss transfer investment associate joint venture disposal december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument discount cash flow underlie net asset group hold number equity investment entity group enter research collaboration investment include list investment million million increase arise addition fair value adjustment transfer group investment aspen pharmacare holding limited investment associate investment offset transfer group investment theravance inc investment associate disposal impairment principally relate aspen december group hold common stock theravance biopharma inc group investment theravance biopharma account equity investment group power exert significant influence activity company group theravance biopharma enter governance agreement expire agreement group right appoint director theravance biopharma board certain limited exception vote share support recommendation independent director board proportion shareholder vote cast september similar governance agreement investee theravance inc innoviva inc expire expiry agreement consider provide group ability exert significant influence activity company group account shareholde investment associate date march group sell half shareholde aspen pharmacare holding limited investment previously account associate result sale group long consider ability exert significant influence aspen group remain investment transfer investment associate investment december investment fair value million disposal investment fair value movement reclassify equity income statement base average cost share acquire different time impairment loss record recognise income statement year operate income amount reclassify fair value reserve recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement carry value december investment impaired follow original cost cumulative impairment recognise income statement subsequent fair value increase carry value december noncurrent asset amount receivable insurance contract pension scheme surplus receivables gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue inventory raw material consumable work progress finish good trade receivable trade receivables net provision bad doubtful debt accrue income prepayment interest receivable employee loan advance receivables trade receivable include million million associate joint ventures receivables include nil million associate joint venture increase receivable primarily arise novartis transaction bad doubtful debt provision january exchange adjustment charge year subsequent recovery amount provide utilise december cash cash equivalent cash bank hand shortterm deposit asset hold sale property plant equipment goodwill intangible inventory noncurrent asset disposal group transfer asset hold sale expect carry amount recover principally disposal sale consider highly probable hold low carrying fair value cost sell include asset hold sale asset write fair value cost sell million million valuation methodology use significant input base observable market datum valuation classify level fair value hierarchygsk annual report strategic report governance remuneration financial statement investor information trade payable trade payable wage salary social security payable defer income customer return rebate accrual contingent consideration accrual customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer include million million respect pharmaceutical vaccine accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption accrual base change affect future result group trade payable include million million associate joint venture pension postemployment benefit pension postemployment cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme net reduction postretirement healthcare scheme cost arise restructure postretirement medical obligation detail cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service hybrid define benefit scheme include define contribution section gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue pension cost define benefit scheme accounting purpose calculate project unit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement comprehensive income discount rate derive rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt mortality rate determine adjust sap standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line cmi projection longterm rate improvement year male female mortality rate calculate white collar table adjust reflect recent experience rate project scale bbd allow future improvement life expectancy average life expectancy assume individual age project apply individual age follow male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment group review investment strategy plan asset allocation plan adjust approximately return seek asset liability match asset target asset allocation plan update return seek asset liability match asset pension plan expose risk arise estimate market value plan asset decline investment return reduce estimate value plan liability increase line agree mix return seek asset generate future return liability match asset well match future pension obligation group define overall longterm investment strategy plan investment broad range asset main market risk asset hedge portfolio credit risk interest rate longterm inflation equitie property bank counterparty risk plan liability series future cash flow relatively long duration ias basis cash flow sensitive change expect longterm inflation rate discount rate corporate bond yield curve increase longterm inflation correspond increase liability increase discount rate correspond decrease liability define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme glaxo wellcome smithkline beecham define benefit scheme merge addition group operate number postretirement healthcare scheme principal group apply follow financial assumption assess define benefit liability rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit rest world group group amount charge operating profit current service cost past service costcredit net interest cost gain settlement expense remeasurement record statement comprehensive income postretirement pension benefit rest world group group amount charge operating profit current service cost past service costcredit net interest creditcost gain settlement expense remeasurement record statement comprehensive income postretirement pension benefit rest world group group amount charge operating profit current service cost past service costcredit net interest cost expense remeasurement record statement comprehensive income past service credit million include million relation restructure postretirement medical obligation active retired member age amount include past service cost include million million nil augmentation cost arise major restructuring programme note provision gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table recognise noncurrent asset pension scheme surplus recognise pension postemployment benefit pension scheme deficit postretirement benefit fair value asset liability define benefit pension scheme aggregate datum define benefit pension scheme group follow rest world group december equity list unlisted property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net obligation include noncurrent asset include pension postemployment benefit actual return plan asset indexlinke gilt hold repo programme include government bond relate loan include asset value million illion million rest world group december equity list unlisted property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net obligation include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue rest world group december equity list unlisted property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net assetobligation include noncurrent asset include pension postemployment benefit actual return plan asset postretirement pension benefit rest world group group movement fair value asset asset january exchange adjustment interest income expense remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment addition business combination interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december define benefit scheme include define contribution section account balance total million december million million group special funding contribution pension scheme total million million million million nil nil scheme gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation base funding agreement follow valuation additional contribution expect million contribution base government bond yield curve approach select discount rate rate choose include allowance expect investment return reflect asset mix scheme employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue postretirement pension benefit rest world group group movement define benefit obligation obligation january exchange adjustment service cost past service cost interest cost movement remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment movement remeasurement scheme participant contribution benefit pay obligation december exchange adjustment addition business combination service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december define benefit scheme include define contribution section obligation total million december million million define benefit pension obligation analyse follow fund unfunded liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade december postretirement healthcare scheme obligation million million million postretirement benefit unfundedgsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue movement net define benefit liability follow january exchange adjustment addition business combination service cost past service cost interest incomecost settlement curtailment remeasurement return plan asset exclude amount include interest gainloss change demographic assumption gainloss change financial assumption experience loss employer contribution expensesother movement december remeasurement include postretirement benefit detailed gainloss change demographic assumption gainloss change financial assumption experience lossesgain gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue define benefit pension obligation analyse membership category follow active retire defer postretirement benefit obligation analyse membership category follow active retired defer weight average duration define benefit obligation follow year year year pension benefit postretirement benefit sensitivity analysis effect change assumption benefit obligation annual define benefit pension post retirement cost decrease discount rate follow approximate effect increase annual pension cost decrease annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation increase rate future healthcare inflation follow approximate effect increase annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation gsk annual report strategic report governance remuneration financial statement investor information provision legal major employee restructure relate dispute programme provision provision total january exchange adjustment charge year reverse unused unwind discount utilise reclassification movement transfer pension obligation december settle year settle year december legal dispute major restructuring programme group involve substantial number legal group initiate major change restructure dispute include notification possible claim set programme focus opportunity simplify supply chain note legal proceeding provision legal process build group capability manufacture dispute include amount relate product liability antitrust restructure european pharmaceutical business government investigation principally relate secdoj pharmaceuticals restructuring programme announce sfo relate investigation contract termination self october rescale commercial operation global support insurance environmental cleanup function relevant rdmanufacturing operation charge year million million net pharmaceutical addition integration restructure programme reversal estimate insurance recovery primarily relate initiate follow completion novartis provision product liability case paxil transaction restructure integration programme product commercial dispute government report combine major restructuring investigation programme discount provision decrease million provision staff severance payment nil calculate riskadjuste project management formal decision eliminate certain cash flow riskfree rate return movement position communicate group include increase million million arise employee affect appropriate consultation procedure change discount rate year complete appropriate provision staff severance payment immediately respect product liability claim relate certain product sufficient history claim settlement enable pension augmentation arise staff redundancie management reliable estimate provision require million million charge year cover unasserted claim ultimate liability matter transfer pension obligation provision show vary amount provide dependent note pension postemployment benefit outcome litigation proceeding investigation possible asset writedown recognise impairment settlement negotiation property plant equipment note property plant equipment majority amount provide expect nature group business number utilise year matter subject negotiation litigation year litigation proceeding include employee relate provision appeal procedure year reach resolution employee relate provision include obligation certain outofcourt settlement discussion protract medical benefit disabled employee spouse december provision benefit group potential settlement discussion number amount million million employee dispute amount provide base benefit reflect variety provision severance cost jubilee current assessment progress dispute award longservice benefit estimate billion provide december settle year december provision expect nil provision legal include provision insurance provision dispute reimburse party insurer million million onerous property lease discussion legal issue note legal proceeding provision million million number provision include vehicle insurance regulatory matter gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue noncurrent liability accrual defer income contingent consideration note consumer healthcare option liability payable consumer healthcare option liability relate ability novartis share consumer healthcare joint venture gsk certain point future commencing liability record present value expect redemption calculate multiple approach base forecast revenue earning consumer healthcare joint venture table show indicative basis income statement balance sheet sensitivity reasonably possible change sale forecast sale multiple valuation liability increasedecrease financial liability lossgain income statement change key input increase sale forecast sale multiple apply decrease sale forecast sale multiple apply net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing commercial paper bank loan overdraft obligation finance lease medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange longterm borrowing medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange obligation finance lease net debt gsk annual report strategic report governance remuneration financial statement investor information net debt continue current asset longterm borrowing liquid investment classify availableforsale investment yearend gsk longterm borrowing billion december include treasury note billion billion billion government bond effective interest rate liquid fall year average effective preswap investment december approximately interest rate note issue december approximately liquid investment balance approximately approximately december earn interest float rate longterm borrowing repayable year carry interest million million liquid investment balance effective rate repayment december earn interest fix rate date range million nil pledge asset effective interest rate cash cash equivalent group pledge investment treasury note december approximately par value million million million approximately cash cash equivalent million security irrevocable letter credit december earn interest float fix rate issue group behalf respect group self million nil respectively insurance activity provision respect selfinsurance million million include provision legal dispute gsk policy credit quality cash cash discuss note provision addition million equivalent refer note financial instrument million asset include note relate disclosure noncurrent asset form net debt pledge collateral future rental payment shortterm borrowing operate lease arrangement enter human genome gsk billion billion commercial paper sciences inc prior acquisition group programme undrawn december billion billion draw gsk billion year commit mediumterm facility billion billion day commit facility facility place september undrawn december liquid investment cash cash equivalent show table weight average interest rate current bank loan overdraft december finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation contingent liability december contingent liability comprise guarantee discount bill item arise normal course business amount million million december nil nil financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow december dispute provision possible reliable estimate potential outflow fund require settle dispute possibility outflow remote description significant tax legal dispute group party set note taxation note legal proceeding gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue share capital share premium account share ordinary share premium number share capital authorise december december december share capital issue fully pay january issue employee share scheme share capital cancel december issue employee share scheme december issue employee share scheme december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share schemesgsk annual report strategic report governance remuneration financial statement investor information movement equity retain earning reserve amount million december million million million million million relate joint venture associate undertaking cumulative translation exchange equity follow net translation exchange include non total retain fair value control translation earning reserve interests exchange january exchange movement overseas net asset december exchange movement overseas net asset reclassification exchange liquidation disposal overseas subsidiary december exchange movement overseas net asset december analysis comprehensive income equity category follow non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement gain define benefit plan defer tax remeasurement gain define benefit plan comprehensive expenseincome year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary defer tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge defer tax fair value movement cash flow hedge share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement loss define benefit plan defer tax remeasurement loss define benefit plan comprehensive expenseincome year gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue movement equity continue non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge defer tax fair value movement cash flow hedge share comprehensive income associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement gain define benefit plan defer tax remeasurement gain define benefit plan comprehensive incomeexpense year analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserve total january transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust writedown share hold esop trust december transfer income expense year disposal net fair value movement year ordinary share acquire esop trust writedown share hold esop trust forward contract noncontrolle interest december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million milliongsk annual report strategic report governance remuneration financial statement investor information relate party transaction gsk hold interest aspen pharmacare holding limit december follow sale half group hold aspen march investment long account associate december gsk own million share theravance inc innoviva inc biopharmaceutical company list nasdaq gsk begin recognise theravance associate september royalty revenue pay gsk theravance period september december million nil december balance payable gsk theravance million december gsk hold interest japan vaccine ltd jvc subsidiary glaxosmithkline joint venture daiichi sankyo ltd primarily responsible development marketing certain prophylactic vaccine japan gsk sell million million vaccine product joint venture december trading balance gsk jvc million balance payable gsk jvc nil addition loan million jvc year remain gsk december aggregate compensation director cet give note employee cost adjustment reconcile profit tax operating cash flow profit tax tax profit share tax profit associate joint venture finance income net finance expense depreciation amortisation intangible asset impairment asset write profit sale business profit sale intangible asset profit sale investment associate profit sale equity investment change work capital increase inventory decrease trade receivables increasedecrease receivables increase trade payable increase payable increasedecrease pension provision sharebase incentive plan fair value adjustment cash generate operation gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue reconciliation net cash flow movement net debt net debt begin year increasedecrease cash bank overdraft decreaseincrease liquid investment net increase longterm loan net repayment shortterm loan net repayment obligation finance lease net noncash fund subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year january reclass december exchange ification cash flow analysis change net debt liquid investment cash cash equivalent overdraft debt year commercial paper european medium term note debt year european medium term note net debt information significant change net debt note net debtgsk annual report strategic report governance remuneration financial statement investor information acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give acquisition novartis consumer healthcare vaccine business threepart interconditional transaction novartis involve consumer healthcare vaccine oncology business complete march gsk novartis contribute respective consumer healthcare business consumer healthcare joint venture noncash transaction gsk equity interest majority control joint venture addition gsk acquire novartis global vaccine business exclude influenza vaccine initial cash consideration billion billion contingent consideration represent subsequent potential milestone payment billion billion arise achievement specify development target ongoing royalty base future sale performance certain product total payable unlimited milestone million million pay march business acquisition addition gsk complete small vaccine business acquisition cash consideration million net cash acquire fair value exist investment million represent goodwill million intangible asset million net liability million fair value asset acquire business combination include goodwill set table amount provisional subject change novartis consumer novartis healthcare vaccine business business net asset acquire intangible asset property plant equipment inventory trade receivables asset include cash cash equivalent trade payable defer tax liability liability noncontrolle interest goodwill consideration settle share gsk consumer healthcare holding cash consideration pay purchase adjustment fair value equity investment disposal contingent consideration defer tax contingent consideration loss settlement preexist relationship total consideration noncontrolle interest consumer healthcare joint venture calculate apply goodwill method represent novartis share net asset joint venture attributable goodwill goodwill business acquire represent potential synergy arise combine acquire business gsk exist business value workforce acquire majority goodwill recognise expect deductible tax purpose total transaction cost recognise acquisition novartis amount million acquisition march turnover million arise novartis consumer healthcare vaccine business include group turnover business acquire beginning year estimate group turnover approximately million high business integrate group exist activity practicable identify impact group profit period disposal oncology gsk divest market oncology business relate activity right akt inhibitor grant commercialisation partner right future oncology product novartis consideration billion million purchase adjustment gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue acquisition disposal continue business disposal gsk number small business disposal period net cash consideration million profit disposal business determine follow oncology cash consideration include currency forward purchase adjustment net asset sell goodwill intangible asset property plant equipment inventory cash net asset loss currency forwards book disposal cost profit disposal investment associate joint venture march gsk sell half shareholding aspen represent issue share capital company million cash result sale group long consider ability exert significant influence aspen group remain investment transfer investment associate investment cash consideration net book value share reclassification exchange comprehensive income transaction fee item profit disposal associate business business acquisition disposal disposal total cash flow cash consideration paidreceive purchase adjustment cash cash equivalent acquireddiveste defer cash proceed contingent consideration pay transaction cost cash outflowinflow addition gsk cash investment million associate joint venture contingent consideration payable consideration certain acquisition include amount contingent future event development milestone sale performance group provide fair value contingent consideration follow shionogi viiv novartis healthcare vaccine total january remeasurement goodwill remeasurement income statement settlement december addition business combination remeasurement income statement settlement movement december million contingent consideration payable december expect pay year million consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccine business expect pay number year information sensitivity income statement balance sheet reasonably possible change key input valuation contingent consideration payable shionogiviiv healthcare business novartis vaccine business provide note financial instrument relate disclosuresgsk annual report strategic report governance remuneration financial statement investor information acquisition disposal continue cash payment settle shionogiviiv healthcare joint venture contingent consideration payable amount million total million report operate cash flow million cash flow purchase business acquisition acquisition acquisition integration cost million arise propose threepart interconditional transaction novartis expense million pay cash year disposal year million receive deferred consideration sale anticoagulant business complete million disposal associate gsk cash investment million associate business associate acquisition joint disposal venture total cash flow cash consideration pay transaction cost pay purchase business associate net cash proceed disposal acquisition gsk complete acquisition business cash include okairos european base biopharmaceutical company focus development specific vaccine technology prophylactic therapeutic field acquire total purchase price business million include million cash acquire million contingent consideration fair value net asset acquire intangible property plant equipment inventory trade receivables asset include cash cash equivalent defer tax provision trade payable goodwill cash consideration pay contingent consideration total consideration acquisition beginning year estimate group turnover increase approximately million year okairo fully integrate gsk business practicable separately identify impact group profit year acquisition occur shortly end year material impact group profit year goodwill arise acquisition reflect potential business synergy value workforce acquire majority goodwill expect deductible income tax purpose result acquisition report europe emerge market japan trade unallocated pharmaceutical vaccine consumer healthcare operating segment transaction account acquisition accounting method acquisition cost expense total million gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue acquisition disposal continue disposal lucozade ribena december gsk complete sale lucozade ribena business include manufacturing site relate inventory suntory beverage food ltd million cash recognise profit disposal operate income million lucozade ribena sale exclude retain market total million year end december cash consideration net asset sell inventory property plant equipment goodwill disposal cost profit disposal anticoagulant business december gsk complete sale anticoagulant business comprise worldwide intellectual property right exclude china india pakistan fraxiparine arixtra relate inventory manufacture site aspen group consideration million million receive cash million defer profit disposal million recognise operating income worldwide sale fraxiparine arixtra exclude retain market million year end december cash consideration cash consideration receivable net asset sell inventory property plant equipment intangible asset goodwill disposal cost total profit disposal deferral profit profit recognise year investment associate joint venture november gsk sell shareholding aspen represent issue share capital company million cash december gsk hold aspen continue recognise investment aspen associate cash consideration net book value share reclassification exchange comprehensive income reclassification fair value movement comprehensive income profit disposal gsk annual report strategic report governance remuneration financial statement investor information acquisition disposal continue business associate acquisition joint disposal venture total cash flow cash consideration pay cash cash equivalent acquire cash consideration pay net cash acquire total cash consideration payable net cash acquire contingent consideration cash consideration pay net cash acquire total cash proceed receivable cash proceed defer net cash proceed disposal noncontrolle interest group subgroup material noncontrolle interest viiv healthcare limited subsidiary gsk consumer healthcare holding limit subsidiary summarise financial information respect viiv healthcare group gsk consumer healthcare joint venture set viiv healthcare turnover lossprofit taxation comprehensive incomeexpense total comprehensive expenseincome noncurrent asset current asset total asset current liability noncurrent liability total liability net liability net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity increasedecrease cash bank overdraft year financial information relate viiv healthcare group standalone basis impact grouprelate adjustment primarily relate recognition preferential dividend loss taxation million loss taxation million profit taxation million state charge million million million remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year follow amount attributable viiv healthcare group include gsk consolidate statement comprehensive income consolidate statement change equity consolidate balance sheet total comprehensive expenseincome year attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue noncontrolle interest continue consumer healthcare joint venture turnover loss taxation comprehensive income total comprehensive income noncurrent asset current asset total asset current liability noncurrent liability total liability net asset net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity decrease cash bank overdraft year financial information relate consumer healthcare joint venture standalone basis formation march impact grouprelate adjustment follow amount attributable consumer healthcare joint venture include gsk consolidate statement comprehensive income consolidate statement change equity consolidate balance sheet total comprehensive income year attributable noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report strategic report governance remuneration financial statement investor information commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment pension commitment interest loan finance lease charge commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount number commitment licensing agreement new arrangement offset reduced commitment prior year transaction include amendment agreement ionis shionogi gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation payment million future payment base deficit position scheme maximum million table include commitment exclude normal ongoing annual funding requirement approximately million group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap commitment noncancellable operating lease disclose million million provide commitment group balance sheet commitment noncancellable operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment noncancellable operating lease gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue inancial instrument relate market risk disclosure interest rate risk management gsk objective minimise effective net interest cost gsk use variety financial instrument finance balance mix debt fix float interest rate operation derivative financial instrument manage market time policy interest rate risk management limit risk operation derivative principally float interest payment prescribe percentage comprise forward foreign currency contract foreign currency operate profit option interest rate swap swap borrowing foreign exchange risk management liquid asset currency require group purpose foreign currency transaction exposure arise internal manage exposure financial risk change foreign external trade flow typically hedge group exchange rate interest rate objective minimise exposure overseas operating gsk hold issue derivative speculative purpose subsidiary transaction risk match local currency income treasury policy specifically prohibit activity local currency cost possible gsk internal trading transaction financial instrument undertake manage transaction match centrally intercompany payment risk arise underlie business activity term manage reduce foreign currency risk foreign speculation currency cash flow hedge selectively include hedge foreign exchange risk arise acquisition disposal capital management asset gsk financial strategy support group strategic priority regularly review board gsk manage capital possible gsk manage cash surplus borrowing structure group appropriate mix debt requirement subsidiary company centrally forward equity contract hedge future repayment originate currency order reduce foreign currency translation exposure capital structure group consist net debt group seek denominate borrowing currency billion note net debt shareholder equity principal asset cash flow primarily billion consolidated statement change equity denominate dollar euro sterle certain borrowing total capital include provide noncontrolle swap currency require borrowing interest billion denominate swap foreign currency match longterm credit rating standard poor investment group overseas asset treat hedge stable outlook moodys investor service moodys relevant asset forward contract major currency negative outlook group shortterm credit rating reduce exposure group investment standard poor moodys overseas asset net investment hedge section note respectively detail liquidity risk management gsk policy borrow centrally order meet anticipate funding requirement strategy diversify liquidity source range facility maintain broad access funding market december gsk billion borrowing repayable year hold billion cash cash equivalent liquid investment billion hold centrally gsk access shortterm finance billion billion commercial paper programme gsk billion year commit mediumterm facility billion billion day commit facility facility place september undrawn december gsk consider level committed facility adequate give current liquidity requirement gsk billion european medium term note programme december billion note issue programme group shelf registration statement december billion billion note issue programme gsk longterm borrowing mature date gsk annual report strategic report governance remuneration financial statement investor information inancial instrument relate follow completion novartis transaction march disclosure continue gsk cash liquid investment balance increase materially significant proportion fund place credit risk number aaaaaa rate treasury treasury repo group consider maximum credit risk december money market fund aaaaaa rate liquidity fund million december million credit rating number group total group financial asset exception relationship bank downgrade notably deutsche investment comprise equity investment bear bank downgrade bbbbaa equity risk credit risk detail possible measure take reduce exposure group total financial asset december gsk lower rate counterpartie include active management great concentration credit risk billion citibank cash balance gsk european cash pool billion hsbc aaaa december million cash categorise hold treasuryrelate credit risk unrated subinvestment grade rate counterpartie low gsk set global counterparty limit gsk banking bbbbaa million cash transit investment counterpartie base longterm credit rating remain exposure concentrate overseas bank moodys standard poor usage limit monitor local cash management investment purpose include daily million nigeria hold zenith bank united bank gsk actively manage exposure credit risk reduce surplus africa million btv austria million cash balance possible gsk strategy islandsbanki iceland regionalise cash management concentrate cash centrally million bank balance deposit hold possible table set credit exposure bbbbaa rate counterpartie million hold counterpartie rate liquid investment cash cash bbbbaa rate counterpartie include bank balance equivalent derivative gross asset position deposit million state bank india million derivative contract consider purpose table hdfc bank india bank local isda agreement risk net cash management purpose local investment purpose position counterparty table set group financial asset liability offset basis bbba aaaaaa aaaa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security party financial derivative total bbba aaaaaa aaaa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund government security party financial derivative total table restate include detail counterparty credit rating credit rating assign standard poor moodys respectively opinion rating agency differ gsk assign low rating counterparty local rating agency fitch datum source available rating convert global rating equivalent standard poor moodys publish conversion table gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue inancial instrument relate follow method assumption estimate disclosure continue fair value cash cash equivalent approximate carry gsk centrally manage cash reserve amount billion december available month exclude billion centrally manage cash hold viiv liquid investment base quote market price healthcare own subsidiary group invest calculate base observable input case marketable centrally manage liquid asset bank deposit aaaaaa rate security base principal amount case non treasury treasury repo money market fund marketable security short repricing period aaaaaa rate liquidity fund investment equity investment trade active wholesale retail credit risk market determine reference relevant stock exchange outside customer account quote bid price equity investment determine group trade receivable balance reference current market value similar instrument reference discount cash flow underlie net line pharmaceutical company group asset sell product small number wholesaler addition hospital pharmacie physician group shortterm loan overdraft commercial paper sale large wholesaler approximately approximate carry short sale element global maturity instrument pharmaceutical hiv vaccine segment december longterm loan base quote market price case group trade receivable european medium term note fix rate wholesaler total million million borrowing level fair value measurement approximate group expose concentration credit risk respect carry case float rate bank loan wholesaler encounter loan financial difficulty materially adversely affect group financial result contingent consideration business acquisition base present value expect future cash flow group credit risk monitoring activity relate wholesaler include review quarterly financial information interest rate swap foreign exchange forward contract standard poor credit rating development gsk internal option base present value contractual cash flow risk rating establishment periodic review credit limit option valuation model market source datum exchange group believe credit risk rate interest rate balance sheet date provision require excess normal provision bad receivables payable approximate carry doubtful debt note trade receivables fair value financial asset liability companyowne life insurance policy base cash table present carry amount surrender value fair value group financial asset liability december december lease obligation approximate carry fair value financial asset liability include fair value investment gsk share price receive sell asset pay transfer december employee share ownership plan liability orderly transaction market participant esop trust held gsk share carry value measurement date million million fair value million million base quote market price share hold esop trust satisfy future exercise option award employee incentive scheme carry value low cost expect proceed share recognise deduction reserve december gsk hold treasury share cost million million deduct retain earningsgsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue carry fair carry fair value value value value note cash cash equivalent availableforsale investment liquid investment government bond investment loan receivables trade receivables certain noncurrent asset scope ia financial asset fair value profit loss noncurrent asset scope ias derivative designate fair value profit loss ade derivative classify held trading ia ade total financial asset financial liability measure amortise cost borrowing exclude obligation finance lease bond designate hedge relationship bond bank loan overdraft commercial paper total borrowing exclude obligation finance lease obligation finance lease total borrowing trade payable provision certain noncurrent liability scope ias financial liability fair value profit loss trade payable provision certain noncurrent liability scope ia derivative designate fair value profit loss ade derivative classify held trading ia ade total financial liability net financial asset financial liability valuation methodology measure fair value table describe categorise trade receivables noncurrent asset trade payable provision noncurrent liability reconcile relevant note page gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue financial instrument hold fair value follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment emerge life science company trade payable noncurrent liability classify level comprise contingent consideration business acquisition level level level total december financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss trade payable noncurrent liability derivative designate fair value profit loss derivative classify held trading ias level level level total december financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss trade payable noncurrent liability derivative designate fair value profit loss derivative classify hold trading ia movement year financial instrument measure level valuation method present january net loss recognise income statement net gain recognise comprehensive income contingent consideration liability business acquire year payment contingent consideration liability addition disposal transfer level exchange december gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue include net loss million million attributable level financial instrument recognise income statement net loss million million respect financial instrument hold end year net loss report operate income million million arise remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture million arise remeasurement contingent consideration payable acquisition novartis vaccine business net gain million million attributable level equity investment report comprehensive income fair value movement availableforsale investment include net loss million net gain million respect equity investment hold end year financial liability measure level valuation method december include million million respect contingent consideration payable acquisition shionogiviiv healthcare joint venture increase fair value include impact revision discount rate tax rate year consideration expect pay number year vary line future performance specify product include million respect contingent consideration acquisition novartis vaccine business consideration expect pay number year vary line future performance specify product achievement certain milestone target table show indicative basis income statement balance sheet sensitivity reasonably possible change key input valuation liability shionogi viiv novartis healthcare vaccine increasedecrease financial liability lossgain income statement change key input increase sale forecast decrease sale forecast increase market interest rate decrease market interest rate increase probability milestone success decrease probability milestone success trade receivables noncurrent asset scope ias follow table reconcile financial instrument trade receivables noncurrent asset fall scope ia relevant balance sheet amount financial asset predominantly noninterest earn financial instrument noncurrent asset balance include companyowne life insurance policy nonfinancial instrument include tax receivables pension surplus balance prepayment outside scope ias fair value non fair value non loan financial financial loan financial financial profit loss receivables instrument instrument total profit loss receivables instrument instrument total trade receivable note noncurrent asset note follow table show age financial asset past provision bad doubtful debt past day past day past day past day past day gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue trade payable provision noncurrent liability scope ias follow table reconcile financial instrument trade payable provision noncurrent liability fall scope ia relevant balance sheet amount financial liability predominantly noninterest bear accrue wage salary include financial liability nonfinancial instrument include payment account tax social security payable provision arise contractual obligation deliver cash financial asset outside scope ia fair value non fair value non financial financial financial financial profit loss liability instrument instrument total profit loss liability instrument instrument total trade payable note provision note noncurrent liability note derivative financial instrument hedge programme follow table set fair value derivative hold gsk fair value fair value asset liability asset liabilitie net investment hedge foreign exchange contract principal million million cash flow hedge foreign exchange contract principal million million derivative designate fair value profit loss foreign exchange contract principal million million embed derivative derivative classify hold trading ia total derivative instrument analyse current noncurrent total foreign exchange contract classify held trading ia principal foreign exchange contract absolute total outstanding position balance sheet date group foreign exchange contract period month december group hold outstanding foreign exchange contract net asset fair value million million asset million liability december fair value million net liability million asset million liability follow announcement novartis transaction april gsk enter number forward exchange contract protect sterling value net dollar proceed group completion transaction december contract loss position result liability million unrealise loss million maturity march contract loss position million result realise loss million year loss partly offset gain sterling value proceed receive group divestment oncology business result favourable exchange movement inception forward contract overall increase net asset fair value maturity hedge year increase hedge intercompany loan designate accounting hedge fair value movement take income statement period offset exchange gain loss relate intercompany loan balancesgsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue fair value hedge december group designate fair value hedge net investment hedge year certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment european euro japanese yen foreign operation show table net asset swiss franc south african rand foreign operation designate net investment hedge remain outstanding december carry value bond include million million designate hedging instrument net investment hedge cash flow hedge group enter forward foreign exchange contract designate cash flow hedge foreign exchange exposure arise euro dollar denominate coupon payment relate group european medium term note addition group carry balance reserve arose prehedge fluctuation longterm interest rate pricing bond issue prior year balance reclassify finance cost life bond offset financial asset liability follow table set financial asset financial liability subject offset enforceable master netting arrangement similar agreement amount set financial asset liability group balance sheet set trade receivables trade payable derivative financial asset derivative financial liability amount offset balance sheet offset certain circumstance set gross net financial gross financial asset relate financial liability liability amount asset asset balance set liability set sheet balance sheet net december trade receivables derivative financial asset cash cash equivalent trade payable derivative financial liability bank loan overdraft gross net financial gross financial asset relate financial liability liability amount asset asset balance set liability set sheet balance sheet net december trade receivables derivative financial asset cash cash equivalent trade payable derivative financial liability bank loan overdraft gross financial asset liability set balance sheet primarily relate cash pooling arrangement bank amount meet criterion offset balance sheet settle net certain circumstance principally relate derivative transaction isda international swap derivative association agreement party option settle amount net basis event default party gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue debt interest rate repricing table follow table set exposure group interest rate debt include commercial paper maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing obligation finance lease total debt total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bear sensitivity analysis foreign exchange interest rate sensitivity analysis prepare assumption net debt ratio fix float interest rate debt derivative portfolio proportion financial instrument foreign currency constant basis hedge designation december financial instrument affect market risk include cash cash equivalent borrowing trade receivables payable derivative financial instrument follow analysis intend illustrate sensitivity financial instrument change foreign exchange interest rate foreign exchange sensitivity foreign currency exposure arise translation financial asset liability functional currency entity hold cash cash equivalent bank loan overdraft intercompany loan deposit receivables payable trade receivables payable derivative financial instrument hedge legal provision activity arise acquisition disposal asset group primarily expose foreign exchange risk relation sterling movement dollar euro japanese yen base group net financial asset liability december weaken sterling currency variable hold constant illustrate table table exclude financial instrument expose group foreign exchange risk risk fully hedge financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currency cause follow increasedecrease income million million million million million nil dollar euro yen exchange rate respectivelygsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue equity impact show foreign exchange sensitivity relate derivative nonderivative financial instrument hedge group net investment european euro japanese yen foreign operation cash flow hedge foreign exchange exposure arise euro dominate coupon payment relate group european medium term note increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currency cause follow increasedecrease equity nil million million million million million dollar euro yen exchange rate respectively table present group sensitivity foreign exchange rate base composition net debt show note adjust effect foreign exchange derivative net debt affect future foreign currency cash flow increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currency follow impact net debt million million million dollar euro yen exchange rate respectively million million million interest rate sensitivity group expose interest rate risk outstanding borrowing investment change interest rate affect future cash flow fair value financial instrument majority debt issue fix interest rate change float rate interest significantly affect group net interest charge majority cash liquid investment earn float rate interest table hypothetically show group sensitivity change interest rate relation sterling dollar euro variable rate financial asset liabilitie interest rate applicable float rate financial asset liability increase basis point assume variable remain constant estimate group finance income increase approximately million million increase basis point movement interest rate deem material effect equity increasedecrease increasedecrease income income income statement impact interest rate movement basis point increase sterling interest rate basis point increase dollar interest rate basis point increase euro interest rate contractual cash flow nonderivative financial liability derivative instrument follow table provide analysis anticipate contractual cash flow include interest payable group non derivative financial liability undiscounte basis impact interest rate swap exclude purpose table debt define class borrowing obligation finance lease interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december contractual cash flow respect operating lease vacant space provision exclude table include commitment non cancellable operating lease table note commitment finance charge trade payable obligation obligation interest finance finance liability debt debt lease lease net debt total december year year year year year year great year gross contractual cash flow gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue contractual cash flow nonderivative financial liability derivative instrument finance charge trade payable obligation obligation interest finance finance liability debt debt lease lease net debt total december year year year year year year great year gross contractual cash flow increase contractual cash flow nonderivative financial liability billion year result principally addition consumer healthcare option liability contingent consideration payable novartis vaccine business acquire year addition increase billion forecast future cash flow respect contingent consideration payable acquisition shionogiviiv healthcare joint venture increase partially offset reduction billion forecast future cash flow repayment debt debt interest table provide analysis anticipate contractual cash flow group derivative instrument exclude embed derivative equity option material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument amount receivable payable year decrease compare december maturity foreign exchange contract hedge dollar proceed novartis transaction receivables payable receivables payable year year gross contractual cash flow employee share scheme gsk operate employee share scheme include share value plan award grant employee acquire share ad glaxosmithkline plc cost year vest period performance share plan award grant employee acquire share ad glaxosmithkline plc cost subject achievement group specify performance target grant restrict share award replace grant option employee cost scheme readily equate potential gain employee group operate saving relate share option scheme option grant employee acquire share glaxosmithkline plc discount price grant restrict share award normally exercisable end year vest performance period award performance share plan normally grant employee acquire share ad glaxosmithkline plc circumstance settle cash grant savingsrelate share option scheme normally exercisable year save accordance practice majority option savingsrelate share option scheme grant price market price ruling date grant option historical share option scheme grant market price ruling date grant total charge sharebase incentive plan million million million million million million arise share value plan note employee cost detailsgsk annual report strategic report governance remuneration financial statement investor information employee share scheme continue glaxosmithkline share award scheme share value plan share value plan share award grant certain employee cost award vest half year performance criterion attach fair value award determine base closing share price day grant deduct expect future dividend yield duration award share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december performance share plan performance share plan share award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant director member cet performance condition base equally weight measure year performance period adjust free cash flow tsr new product performance award eligible employee performance condition base gsk ep growth compare increase retail price index year measurement period adjust free cash flow addition business element award base strategic operational business measure year measurement period specific employee business area fair value award determine base closing share price day grant tsr performance element adjust likelihood condition meet assess time grant award million share weight fair value million ad weight fair value december outstanding award million share million ad share option savingsrelate option purpose value option savingsrelate option arrive share base payment charge blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life year year year savingsrelate option grant price include discount gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue employee share scheme continue share option share option savingsrelate option outstanding scheme share scheme ad share option scheme weight weight weight number exercise number exercise number exercise price price price december range exercise price option outstanding year end weight average market price exercise year weight average remain contractual life year year year option million share grant year savingsrelate share option scheme weight average fair value december million savingsrelate share option exercisable share option ad option currently exercisable expire exercise july change effective exercise price outstanding option year employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share finance provide group way loan contribution treasury share carry value million purchase esop trust satisfy future award shareholder approve performance share plan cost run esop trust charge income statement share hold esop trust deduct reserve amortise value proceed receivable employee exercise transfer retain earning trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value post balance sheet event certain circumstance pfizer shionogi gsk partner viiv healthcare historically able require gsk acquire shareholding price base likely valuation viiv healthcare conduct initial public offer original agreement gsk unconditional right long subsequent distribution shareholder withhold consent exercise option february gsk notify pfizer shionogi irrevocably give right lead recognition liability option group balance sheet estimate present value liability option approximately billion adjustment value preferential dividend shareholder consistent revise treatment gsk recognise liability group balance sheet future preferential dividend anticipate payable pfizer shionogi estimate aggregate present value liability preferential dividend pfizer shionogi approximately million february viiv healthcare complete previously announce transaction bristolmyers squibb bms viiv healthcare acquire latestage asset bms initial upfront payment million follow development commercial sale milestone million tiere royalty sale viiv healthcare acquire bmss preclinical discovery stage hiv research business upfront payment million follow development commercial sale milestone million consideration contingent future sale performancegsk annual report strategic report governance remuneration financial statement investor information principal group company follow represent principal subsidiary country incorporation group december equity share capital entity wholly own group percentage interest show company incorporate principal country operation state england glaxo group limited block drug company inc glaxo operation limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare glaxosmithkline consumer healthcare trading limited glaxosmithkline holdings americas inc glaxosmithkline export limited glaxosmithkline llc glaxosmithkline finance plc human genome sciences inc glaxosmithkline holdings limited novartis consumer health inc glaxosmithkline research development limit stiefel laboratories inc glaxosmithkline service unlimited viiv healthcare company glaxosmithkline limited setfirst limited smithkline beecham limited viiv healthcare limited viiv healthcare limited europe glaxosmithkline biological belgium glaxosmithkline argentina argentina glaxosmithkline pharmaceuticals belgium glaxosmithkline australia pty ltd australia glaxosmithkline biological sas france glaxosmithkline brasil limitada brazil groupe glaxosmithkline sas france glaxosmithkline inc canada laboratoire glaxosmithkline sas france biomedical corporation quebec canada viiv healthcare sas france glaxosmithkline china investment ltd china glaxosmithkline consumer healthcare gmbh glaxosmithkline limited china germany glaxosmithkline pharmaceuticals suzhou limited china glaxosmithkline gmbh germany sinoamerican tianjin smith kline french laboratories ltd china novartis consumer health gmbh germany glaxosmithkline consumer healthcare limited india glaxosmithkline consumer healthcare spa italy glaxosmithkline pharmaceuticals limited india glaxosmithkline spa italy glaxosmithkline consumer healthcare japan japan glaxosmithkline netherlands glaxosmithkline japan glaxosmithkline pharmaceuticals poland glaxosmithkline mexico mexico gsk services spzoo poland glaxosmithkline pakistan limited pakistan glaxosmithkline trading services limited republic ireland glaxo wellcome manufacturing pte ltd singapore glaxosmithkline spain glaxosmithkline pte ltd singapore novartis consumer health switzerland glaxosmithkline korea limited south korea glaxosmithkline llaclari sanayi ticaret turkey exempt provision section company act ireland accordance exemption note section act subsidiary disclose page exempt provision consolidate group financial statement directly hold wholly own subsidiary glaxosmithkline plc subsidiary associate list principally affect figure group financial statement glaxosmithkline capital inc glaxosmithkline capital plc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc page complete list subsidiary undertaking associate joint venture form financial statement gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue legal proceeding intellectual property advair hfa flovent hfa ventolin hfa group involve significant legal administrative september mylan pharmaceuticals mylan file proceeding principally product liability intellectual property petition inter part review ipr united states tax antitrust governmental investigation relate patent trademark office uspto seek invalidate private litigation group make provision proceeding patent cover surfactantfree formulation use regular basis summarise note accounting principle hydrofluoroalkane hfa meter dose inhaler advair flovent policy note provision group ventolin group exclusively license patent involved significant legal proceeding respect right enforce defend patent possible reliable estimate expect expire december list orange book financial effect result ultimate resolution group file patent owner preliminary response oppose proceeding case appropriate disclosure institution ipr january decision institution case include provision april patent mylan challenge respect legal proceeding describe number patent cover advair flovent ventolin provision group use hfa meter dose inhaler unable reliable estimate expect financial man vaccinesbexsero effect stage group believe information follow acquisition novartis vaccine business seek plaintiff know group take litigation originally file novartis meaningful respect legal proceeding pfizer inc pfizer italy united states relate number factor include limited stage meningococcal man vaccine february proceeding entitlement party appeal decision novartis file suit pfizer high court patent clarity theory liability damage govern law court declaration european patent own pfizer intellectual property claim include challenge validity infringe bexsero invalid group assume enforceability group patent product responsibility matter april pfizer file process assertion noninfringement statement defence counterclaim patent loss case result loss patent infringement trial matter commence march protection product issue consequence february novartis file suit pfizer loss significant decrease sale product court rome declaration european patent own materially affect future result operation group pfizer infringe bexsero invalid group legal expense incur provision relate legal claim assume responsibility matter group charge sell general administration cost provision prosecute lawsuit pfizer originally file novartis take appropriate legal specialist declaration european patent issue pfizer relate advice outflow resource consider probable meningitis vaccine infringe bexsero reliable estimate likely outcome february novartis file suit pfizer dispute certain product liability claim group district court district new jersey patent provision sufficient history claim infringement complaint assert patent pfizer settlement enable management reliable estimate allege pfizer sale trumenba infringe patent provision require cover unasserted claim december trumenba indicate active immunization prevent invasive group aggregate provision legal dispute disease cause neisseria meningitidis serogroup include tax matter describe note taxation april group file amend complaint billion ultimate liability legal claim vary pfizer reassert patent originally assert novartis amount provide dependent outcome litigation assert additional recentlygranted patent proceeding investigation possible settlement negotiation infringement contention serve group october group position change time pfizer serve noninfringement invalidity contention assurance loss result december group respond pfizer invalidity outcome legal proceeding exceed material contention february date set provision report group summary judgment motion trial financial statement happen material adverse impact result operation group report period judgment incur settlement enter significant matter describe belowgsk annual report strategic report governance remuneration financial statement investor information legal proceeding continue mylan file action patent court allege patent cover combination lamivudine coreg abacavir kivexa invalid allege spc base mylan send paragraph certification date august patent invalid marketing group flamel ireland ltd flamel state authorisation combination allege instead prior submit abbreviate new drug application anda approval trizivir trial schedule food drug administration fda seek approval addition mylan challenge combination patent generic version coreg notice assert patent associate spc france italy portugal trial date list orange book coreg invalid set jurisdiction infringe mylan product october flamel file lexiva civil complaint district court northern district west virginia allege mylan product infringe flamel december lupin file petition uspto orange bookliste extend release formulation patent ipr allege patent cover active ingredient expire march group exclusive licensee lexiva invalid viiv healthcare file patent owner preliminary patent coreg mylan answer december response oppose petition april july assert flamels patent invalid infringe mylan uspto grant inpart deny inpart petition file party complaint group request ipr significantly uspto deny petition basic declaration group patent carvedilol phosphate compound claim cover lexiva grant petition hemihydrate invalid infringe scheduling conference claim patent july lupin request set reconsideration decision initiate review claim specifically cover lexiva october viiv healthcare epzicomkivexatrizivir request adverse judgment claim review february viiv healthcare receive notice lupin grant effectively cancel claim november limited lupin file anda contain paragraph uspto deny lupin motion reconsideration certification epzicom allege patent list november uspto cancel request claim orange book epzicom invalid unenforceable terminate ipr leave claim cover lexiva intact infringe viiv healthcare file suit lupin march february lupin file new petition ipr allege infringement patent cover remain claim patent owner preliminary response combination lamivudine abacavir patent covering hemisulfate salt abacavir viiv healthcare settle lupin product liability june case dismiss august preclinical clinical trial conduct june apotex file petition request inter parte development potential product determine safety review ipr combination patent cover epzicom efficacy product use human follow approval trizivir uspto grant petition december regulatory body notwithstanding effort drug initiate ipr january teva file petition vaccine introduce marketplace unanticipated safety uspto join proceeding viiv healthcare file issue claim evident opposition tevas joinder motion april tevas group currently defendant number product liability motion join deny june july lawsuit relate group pharmaceutical vaccine viiv healthcare apotex settle case uspto consumer healthcare product significant terminate ipr august matter describe teva canada apotex file notice allegation group able reliable estimate challenge patent kivexa lamivudineabacavir list expect financial effect matter discuss category canadian patent register viiv healthcare file suit include provision appropriate matter infringement teva september provision legal dispute matter patent cover abacavir hemisulfate combination group provision note note lamivudine abacavir viiv healthcare file suit apotex provision january patent covering abacavir hemisulfate march infringement patent cover combination lamivudine abacavir viiv healthcare settle case teva april apotex july teva challenge claim combination patent cover kivexa germany france italy united kingdom combination patent expire europe addition viiv healthcare correspond supplementary protection certificate spc kivexa expire late teva challenge validity spc viiv healthcare reach settlement teva litigation terminate gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue legal proceeding continue act violence february pende matter concern avandia allegation patient take paroxetine paxil commit group name product liability lawsuit behalf attempt commit suicide act violence trial individual assert personal injury claim arise use case schedule september avandia federal case file group multidistrict litigation proceed pende district court discontinuation eastern district pennsylvania mdl court case late poor prospect success file number state court public funding seroxat claimants allege withdrawal reaction cease majority claimant discontinue february group reach agreement settle claim claimant appeal decision substantial majority federal state case pende special case review panel special case review purport class action avandia pende panel deny appeal public funding certificate canada discharge legal aid agency january purport class action seek economic damage case remain subject behalf party payer tpps assert claim arise hearing hold december judgement state federal law include racketeer hearing publish february allow influence corrupt organization act rico state unfair remain claim continue court management trade practice andor consumer protection law mdl court case management conference expect summer consolidate action pretrial proceeding zofran appoint plaintiff steering committee group filing plaintiff allege child suffer birth defect result petition writ certiorari united states supreme court mother ingestion zofran andor generic ondansetron seek review circuit decision tpps state pregnancyrelate nausea vomit plaintiff assert valid cause action group sell zofran know unsafe pregnant woman sole remain consumer class action bring behalf fail warn risk illegally market zofran offlabel missouri resident dismiss mdl court use pregnant woman february group circuit affirm mdls decision dismiss action defendant personal injury lawsuit bring behalf result consumer class action remain individual plaintiff federal case multidistrict litigation proceeding mdl district seroxatpaxil paxil massachusetts group defendant propose group receive numerous lawsuit claim allege class action canada early stage class use paxil paroxetine cause variety injury certification issue case address lawsuit contain follow january mdl court issue order deny allegation use paxil pregnancy cause group motion dismiss claim ground congenital malformation persistent pulmonary hypertension preempt federal law group renew motion paxil treatment cause patient commit suicidal later date mdl continue monthly status conference violent act iii group fail warn patient issue sufficiency pleading experience certain symptom discontinue paxil scope discovery address treatment pregnancy group reach agreement settle majority claim relate use paxil pregnancy february number claim relate use pregnancy pende court matter dismiss payment currently trial schedule propose certify class action canada action certify national class action british columbia relate cardiovascular defect appeal certification decision dismiss october case schedule try october gsk annual report strategic report governance remuneration financial statement investor information legal proceeding average wholesale price continue state attorney general wisconsin illinois file suit sale marketing regulation group number pharmaceutical group able reliable estimate company claim damage restitution average expect financial effect matter discuss category wholesale price awp andor wholesale acquisition cost wac include provision matter provision price report pharmaceutical product cover state legal dispute note matter medicaid programme case allege group group provision note note report cause report false awp wac price provision turn allegedly cause state medicaid agencies secdoj sfo anticorruption enquiry reimburse provider money cover medicine securities exchange commission sec agency intend state seek recovery behalf department justice doj initiate industrywide enquiry state payer case behalf instate pharmaceutical company engaged patient consumer group reach settlement violation foreign corrupt practice act fcpa relate state wisconsin resolve claim matter sale pharmaceutical include argentina brazil illinois case ongoing trial date set canada china germany italy poland russia saudi arabia cidra thirdparty payer litigation group company ask respond july number major healthcare insurer enquiry cooperate sec doj file suit group philadelphia pennsylvania group inform doj sec investigation county court common plea seek compensation china operation chinese government initiate reimbursement medicine manufacture outcome investigation group group cidra plant puerto rico insurers brief doj sec country issue claim group knowingly illegally market sell group advise fraud office sfo adulterate drug manufacture condition noncompliant investigation china operation chinese cgmp current good manufacturing practice government outcome investigation sfo thirdparty insurer unlawfully induce pay request information group commercial suit allege federal state law cause operation number country action sfo informed group formally open criminal case stay pending decision court investigation group practice group respond appeal circuit overlap potentially sfos request group unable reliable dispositive issue group thirdparty payer litigation estimate expect financial effect investigation avandia result circuit denial provision group petition judge litigation lift stay vaccine subpoena party file supplemental briefing group february group receive subpoena motion dismiss await rule court group attorney office southern district new york provision matter request document relate group vaccine business antitrustcompetition group respond subpoena group unable group able reliable estimate reliable estimate expect financial effect expect financial effect matter discuss category matter provision include provision matter provision subpoena relate imitrex amerge legal dispute note matter march group receive subpoena group provision note note attorney office southern district new york request provision document relate group contract imitrex competition market authority investigation amerge group respond subpoena group february competition market authority unable reliable estimate expect financial effect cma issue decision fine group matter provision pharmaceutical company infringement competition avandia act cma impose fine million group group defend action county santa clara fine total million company california bring californias consumer relate agreement settle patent dispute protection law seek civil penalty restitution result group potential supplier generic paroxetine formulation group marketing avandia group file number enter group terminate dispositive motion pende mdl court agreement issue group believe strong county santa clara recently file motion dismiss argument defend action currently examine action federal court lack federal jurisdiction cma find legal advisor view appeal motion brief argue party competition appeal tribunal fine overturn substantially reduce accordingly provision matter gsk annual report strategic report governance remuneration financial statement investor information legal proceeding continue addition private litigant suit december securities exchange commission sec file formal lamictal complaint stiefel charles stiefel district purport class direct indirect purchaser file suit court district florida allege stiefel district court district new jersey allege principal violate federal security law induce stiefel group teva pharmaceuticals unlawfully conspire delay employee sell share employee stock plan generic competition lamictal result overcharge company greatly undervalue price disclose purchaser enter allegedly anticompetitive reverse employee company sell case payment settlement resolve patent infringement litigation stay return active status early summer separate count accuses group monopolising market november court enter order ask june court appeal reverse trial court party rebrief summary judgment motion set decision dismiss case remand action pretrial conference august group trial court october trial court deny group provision stiefel litigation motion stay set schedule early dispositive motion environmental matter discovery group file petition certiorari united states supreme court february group notify potential responsibility relate past operation past waste disposal practice certain wellbutrin site primarily matter subject plaintiff claim antitrust injury relate allegedly sham patent litigation include proceeding initiate federal state litigation file biovail generic company pursue government waste disposal site remediation cost tort andas generic wellbutrin group name action bring private party party plaintiff patent infringement action later withdraw matter group party remain group advise responsible party patent infringement action relate wellbutrin plaintiff approximately site appear national allege conspiracy delay generic approval exist priority list create comprehensive environmental biovail group court grant summary response compensation liability act superfund judgment favour group claim proceeding seek require operator hazardous waste facility transporter waste site generator sole remain claim relate plaintiff allegation hazardous waste dispose site clean site group enter anticompetitive reverse payment settlement reimburse government cleanup cost resolve patent infringement litigation court grant instance group involve allege generator summary judgment favour group claim hazardous waste matter currently pende appeal court appeal circuit court superfund provide defendant jointly severally liable cleanup cost proceeding commercial corporate frequently resolve basis nature quantity group able reliable estimate waste dispose generator site group expect financial effect matter discuss proportionate liability cleanup cost substantially category include provision respect matter determine site refer provision legal dispute set note provision group potential liability vary greatly site site cost investigation study remediation securitieserisa class action stiefel site time significant group routinely accrue currently outstanding lawsuit bring amount relate share liability matter stiefel laboratories inc stiefel employee allege stiefel officer director violate employee retirement income security act erisa federal state security law induce stiefel employee sell share employee stock plan stiefel greatly undervalue price disclose employee stiefel sell group fry case currently appeal court appeal eleventh circuit oral argument take place february stiefel complete defence verdict matter jury trial federal court florida october plaintiff appeal trial second florida case stay pende resolution fry matter discovery continue case pende new york federal courtgsk annual report strategic report governance remuneration financial statement investor information financial statement glaxosmithkline plc prepare gaap include frs reduce disclosure framework director statement responsibility disclosure information auditor relation company financial director office date annual report confirm statement far aware relevant audit information director responsible prepare parent company company auditor unaware glaxosmithkline plc financial statement remuneration take step ought report accordance applicable law regulation take director aware company law require director prepare financial relevant audit information establish companys statement financial year law director auditor aware information elect prepare parent company financial statement confirmation give interpret accordance accordance united kingdom accounting standard provision section company act applicable law united kingdom generally accept accounting practice company law director approve go concern basis parent company financial statement satisfied assess principal risk matter consider true fair view asset liabilitie financial connection viability statement director consider position profit loss company period appropriate adopt go concern basis accounting prepare financial statement prepare financial statement director require corporate governance code board consider glaxosmithkline plc apply select suitable accounting policy apply principle complie provision corporate consistently governance code maintain financial reporting council judgement accounting estimate reasonable describe corporate governance section page prudent board consider annual report take fair balanced understandable provide state regard parent company financial statement information necessary shareholder assess group applicable accounting standard follow position performance business model strategy subject material departure disclose explain parent company financial statement require financial conduct authority list rule auditor consider director statement prepare financial statement go concern basis compliance relation point corporate inappropriate presume group continue governance code specify review business director responsible keep adequate accounting record sufficient explain companys transaction disclose reasonable accuracy time financial position company enable ensure philip hampton parent company financial statement remuneration report chairman comply company act responsible march safeguard asset company take reasonable step prevention detection fraud irregularity parent company financial statement year end december comprise balance sheet year end december support note set page report responsibility auditor relation parent company financial statement set independent auditor report financial statement year end december include annual report publish print form available website director responsible maintenance integrity annual report website accordance legislation govern preparation dissemination financial statement access website available outside comparable legislation different strategic report risk section annual report represent management report include fair review development performance business position company group take description principal risk uncertainty face gsk annual report strategic report governance remuneration financial statement investor information independent auditor report members glaxosmithkline plc report parent company financial company act report statement company act require report opinion certain disclosure director remuneration opinion specify law exception report opinion glaxosmithkline plcs parent company financial arise responsibility statement financial statement true fair view state parent company responsibilitie financial statement affair december audit properly prepare accordance united kingdom generally accept accounting practice responsibility director prepare accordance requirement explain fully director statement company act responsibility set director responsible preparation financial statement audit satisfied true fair view financial statement include annual report comprise responsibility audit express opinion financial statement accordance applicable law isa company balance sheet december ireland standard require comply company statement change equity year auditing practice board ethical standard auditor end note financial statement include summary report include opinion prepare significant accounting policy explanatory information company member body accordance chapter company act purpose certain require disclosure present give opinion accept assume annual report note financial responsibility purpose person statement crossreference financial report show hand come save statement identify audit financial reporting expressly agree prior consent writing framework apply preparation financial statement applicable law united kingdom accounting audit financial statement involve standard united kingdom generally accept accounting conduct audit accordance isas ireland practice include frs reduce disclosure framework audit involve obtain evidence amount disclosure financial statement sufficient reasonable assurance require report financial statement free material misstatement cause fraud error include assessment consistency information company act opinion accounting policy appropriate parent opinion information give strategic report company circumstance consistently apply director report financial year adequately disclose financial statement prepare consistent reasonableness significant accounting estimate financial statement director isas ireland report overall presentation financial statement international standard audit ireland primarily focus work area assess director isas ireland require report judgement available evidence form judgement opinion information annual report evaluate disclosure financial statement materially inconsistent information audit financial statement test examine information sampling apparently materially incorrect base materially auditing technique extent consider necessary inconsistent knowledge company acquire provide reasonable basis draw conclusion obtain course perform audit audit evidence testing effectiveness control mislead substantive procedure combination exception report arise responsibility addition read financial nonfinancial information annual report identify material inconsistency adequacy accounting record information audit financial statement identify information explanation receive apparently materially incorrect base materially inconsistent company act require report knowledge acquire course perform opinion audit aware apparent material misstatement receive information explanation inconsistency consider implication report require audit adequate accounting record keep parent matter company return adequate audit report separately group financial statement receive branch visit glaxosmithkline plc year end december financial statement director remuneration report audit agreement company pass resolution accordance section accounting record return company act senior statutory auditor state exception report arise responsibility director remuneration director remuneration report company act opinion pricewaterhousecooper llp opinion director remuneration report charter accountant statutory auditor audit properly prepare accordance london company act march gsk annual report strategic report governance remuneration financial statement investor information company balance sheet gaap include frs reduce disclosure framework december note fix asset investment current asset trade receivable cash bank total current asset trade payable net current asset total asset current liability provision noncurrent liabilitie net asset capital reserve call share capital share premium account reserve retain earning equity shareholder fund financial statement page approve board march sign behalf philip hampton chairman glaxosmithkline plc register number company statement change equity share share premium retain capital account reserve earning total january profit attributable shareholder dividend shareholder share issue employee share scheme share purchase hold treasury share treasury share transfer esot hold subsidiary company december profit attributable shareholder dividend shareholder share issue employee share scheme december gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet accounting policy gaap include frs reduce foreign currency transaction disclosure framework foreign currency transaction record exchange rate ruling date transaction foreign currency asset presentation financial statement liability translate rate exchange rule balance sheet date description business glaxosmithkline plc parent company gsk major global dividend pay receive healthcare group engage creation discovery dividend pay receive include financial development manufacture marketing pharmaceutical statement period relate dividend product include vaccine overthecounter otc medicine actually pay receive healthrelate consumer product expenditure preparation financial statement expenditure recognise respect good service financial statement prepare historical receive supply accordance contractual term cost convention go concern basis prepare provision obligation exist future liability accordance financial reporting standard reduce respect past event obligation disclosure framework accounting presentation reliably estimate december comparative figure december investments subsidiary company comparative figure require change investment subsidiary company hold cost result current year adoption frs provision impairment permit section company act impairment investment income statement company present annual carrying value investment review impairment report indication investment impair company include group financial statement provision result impairment review charge glaxosmithkline plc publicly available income statement year concern follow exemption requirement ifrs share base payment apply preparation financial statement issuance company subsidiary grant accordance frs company share represent additional capital contribution company subsidiarie additional investment paragraph ifrs sharebase subsidiary result correspond increase shareholder payment equity additional capital contribution base fair value ifrs financial instrument disclosure grant issue allocate underlying grant vest paragraph ifrs fair value measurement period paragraph ias presentation financial statement taxation comparative information requirement respect current tax provide amount expect pay paragraph ia apply tax rate enact substantively paragraph enact balance sheet date ia presentation financial statement defer tax provide liability method ias statement cash flow temporary difference arise tax basis asset liability carry amount financial statement paragraph ias accounting policy change defer tax asset recognise extent accounting estimate error consider recoverable future taxable profit paragraph ias relate party disclosure requirement ia disclose related party defer tax measure average tax rate expect transaction enter member apply period temporary difference group expect realise settle defer tax liability accounting convention standard asset discount balance sheet prepare historical financial guarantee cost convention complie applicable accounting liability relate guarantee issue company behalf standard subsidiary initially recognise fair value accounting principle policy amortise life guarantee preparation balance sheet conformity generally legal dispute accept accounting principle require management company provide anticipate settlement cost estimate assumption affect report amount outflow resource consider probable reliable asset liability disclosure contingent asset estimate likely outcome dispute liability date balance sheet actual amount legal expense arise claim company differ estimate december provision legal dispute balance sheet prepare accordance amount million million company accounting policy approve board describe note bgsk annual report strategic report governance remuneration financial statement investor information note company balance sheet gaap include frs reduce disclosure framework continue key accounting judgement estimate contingent consideration contingent consideration include consideration legal dispute payable business combination record fair value company provide anticipate settlement cost date acquisition fair value generally base outflow resource consider probable reliable riskadjuste future cash flow discount appropriate estimate likely outcome dispute interest rate december liability contingent legal expense arise claim company consideration amount million acquisition estimate account specific circumstance vaccine business novartis dispute relevant external advice inherently judgmental change substantially time new fact assumption relate future cash flow discount rate emerge dispute progress base business forecast inherently judgemental future event cause assumption company director take legal advice projection change consequent adverse effect establish provision take account relevant fact future result company circumstance matter accordance accounting requirement december provision perate profit legal dispute amount million fee relate audit million company charge operate profit ultimate liability legal claim vary amount dividend provide dependent outcome litigation proceeding investigation possible settlement negotiation director declare interim dividend result position change time dividend year penny line dividend assurance loss result outcome legal special dividend penny declare proceeding exceed provision report year detail note group financial company financial statement material statement dividend fix asset investment share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relate share base payment contribution relate contingent consideration trade receivables amount year corporation tax recoverable receivables defer tax recoverable amount owe group undertaking amount year amount group undertaking defer tax balance million report reverse arise result recognition defer tax asset tax loss expect follow completion novartis transaction march gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet gaap include frs reduce disclosure framework continue trade payable amount year creditor contingent consideration payable amount owe group undertaking company guarantee debt issue subsidiary company receive annual fee aggregate company outstanding guarantee billion debt instrument amount subsidiary company relation guarantee fee recover life bond disclose trade receivable note provision january charge year utilise movement december provision relate number legal dispute company currently involve noncurrent liability contingent consideration payable contingent consideration relate payable acquisition novartis vaccine portfolio current year liability include trade payable call share capital share premium account share premium ordinary share account number share capital authorise december december share capital issue fully pay january issue employee share scheme december issue employee share scheme december december december number share issuable outstanding option number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme reserve profit glaxosmithkline plc year million million dividend million million gave retain loss million million profit treasury share purchase year million treasury share transfer subsidiary million december retain earning stand million million million unrealised million group company page complete list subsidiary associate joint venture form financial statementsgsk annual report strategic report governance remuneration financial statement investor information investor information section quarterly trend pharmaceutical vaccine turnover year record product development pipeline product competition intellectual property risk factor share capital share price dividend financial calendar annual general meeting tax information shareholder shareholder service contact law regulation group company glossary term gsk annual report gsk annual report strategic report governance remuneration financial statement investor information financial record quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month report proforma report proforma cer cer cer cer turnover pharmaceutical vaccine consumer healthcare corporate unallocated turnover total turnover cost sale sell general administration research development royalty income operating income operate profitloss net finance cost profitloss disposal interest associate joint venture share tax profitslosse associate joint venture profitloss taxation taxation tax rate profitloss taxation period lossprofit attributable noncontrolle interest profitloss attributable shareholder basic earningsloss share penny dilute earningsloss share pence income statement core total turnover cost sale sell general administration research development royalty income operating profit net finance cost share tax lossesprofit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny calculation core result describe gsk annual report strategic report governance remuneration financial statement investor information report proforma report proforma report proforma cer cer cer cer cer cer gsk annual report strategic report governance remuneration financial statement investor information financial record continue pharmaceutical turnover therapeutic area total europe international restate growth growth growth growth therapeutic areamajor product cer cer cer cer respiratory anoro ellipta avamysveramyst flixotideflovent relvarbreo ellipta seretideadvair ventolin cardiovascular metabolic urology cvmu avodart immunoinflammation benlysta oncology pharmaceutical dermatology augmentin antibacterial rare disease innovative pharmaceutical establish product coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix global pharmaceutical hiv combivir epzicomkivexa lexivatelzir selzentry tivicay triumeq trizivir pharmaceutical vaccine turnover total europe international restate growth growth growth growth major product cer cer cer cer bexsero boostrix cervarix fluarix flulaval hepatitis infanrix pediarix menveo rabipurrabavert rotarix synflorix vaccine cer represent growth constant exchange rate represent growth actual exchange ratesgsk annual report strategic report governance remuneration financial statement investor information pharmaceutical turnover therapeutic area total europe international restate restate growth restate growth restate growth restate growth therapeutic areamajor product cer cer cer cer respiratory avamysveramyst flixotideflovent relvarbreo ellipta seretideadvair ventolin cardiovascular metabolic urology cvmu avodart immunoinflammation benlysta oncology pharmaceutical dermatology augmentin antibacterial rare disease innovative pharmaceutical establish product coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix global pharmaceutical hiv combivir epzicomkivexa lexivatelzir selzentry tivicay trizivir pharmaceutical vaccine turnover total europe international restate growth growth growth growth major product cer cer cer cer boostrix cervarix fluarix flulaval hepatitis infanrix pediarix rotarix synflorix vaccine cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board effect january gsk report turnover segment global pharmaceutical hiv vaccine consumer healthcare comparative turnover information year restate accordingly comparative information restate reflect current breakdown group geographic region comparative information report include effect divestment complete information report exclude effect divestment restate restate restate restate group turnover geographic region europe international divestment total turnover include divestment group turnover segment global pharmaceutical hiv pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover divestment complete pharmaceutical turnover therapeutic area respiratory cardiovascular metabolic urogenital immunoinflammation oncology pharmaceutical establish product global pharmaceutical hiv pharmaceutical vaccine turnover consumer healthcare turnover wellness oral care nutrition skin health gsk annual report strategic report governance remuneration financial statement investor information year record continue financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share million million million million million weight average number share issue basic diluted financial result core turnover operate profit profit taxation profit taxation pence pence pence pence pence core earning share return capital employ return capital employ calculated total profit taxation percentage average net asset year gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record continue balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity number employee europe international manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report bank england buy rate average average rate year calculate average buy rate day year mar feb jan dec nov oct sep high low buy rate march usgsk annual report strategic report governance remuneration financial statement investor information pipeline product competition pharmaceutical vaccine product development pipeline key inlicence alliance relationship party month submission viiv healthcare global specialist hiv company gsk bla biological licence application pfizer inc shionogi limited shareholders responsible maa marketing authorisation application europe develop deliver hiv medicine nda new drug application develop indication therapeutic area phase evaluation clinical pharmacology usually conduct volunteer optionbase alliance ionis pharmaceuticals phase determination dose initial evaluation efficacy conduct optionbase alliance adaptimmune ltd small number patient optionbase alliance oncome pharmaceutical phase iii large comparative study compound versus placebo andor establish optionbase alliance telethon ospedale san raffaele treatment patient establish clinical benefit safety optionbase alliance valneva maa ndabla regulatory review milestone show table achieve future filing date include list achieve regulatory review milestone compound type indication phase maa ndabla hiv infectious disease dolutegravir hiv integrase inhibitor nonnucleoside hiv infection drug maintenance regiman iii rilpivirine reverse transcriptase inhibitor nnrti hiv attachment inhibitor hiv infection iii tafenoquine aminoquinoline plasmodium vivax malaria iii relenza neuraminidase inhibitor influenza iii cabotegravir hiv integrase inhibitor longacte hiv preexposure prophylaxis parenteral formulation cabotegravir hiv integrase inhibitor nonnucleoside hiv infections rilpivirine reverse transcriptase inhibitor nnrti longacte parenteral formulation gepotidacin type topoisomerase inhibitor bacterial infection danirixin chemokine cxc motif receptor influenza cxcr antagonist hiv maturation inhibitor hiv infections hiv maturation inhibitor hiv infection hbv antisense oligonucleotide hepatitis hbv lica antisense oligonucleotide hepatitis nonstructural protein nsb hepatitis polymerase inhibitor respiratory fluticasone furoate glucocorticoid agonist longacting beta chronic obstructive pulmonary disease copd iii vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin monoclonal antibody copd iii muscarinic acetylcholine antagonist beta copd agonist maba muscarinic acetylcholine antagonist beta copd fluticasone furoate agonist maba glucocorticoid agonist tolllike receptor tlr agonist asthma phosphatidylinositol kinase delta pikcid asthma copd inhibitor recombinant human angiotensin convert acute lung injury enzyme rhace tumour necrosis factor receptor tnfr acute lung injury domain antibody danirixin chemokine cxc motif receptor cxcr copd antagonist fluticasone furoate glucocorticoid agonist longacte beta asthma vilanterol agonist muscarinic acetylcholine umeclidinium antagonist losmapimod kinase inhibitor copd mepolizumab interleukin monoclonal antibody nasal polyposis mepolizumab interleukin monoclonal antibody hypereosinophilic syndrome sirukumab interleukin human monoclonal antibody severe asthma alpha beta integrin antagonist idiopathic pulmonary fibrosis gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical vaccine product development pipeline continued achieve regulatory review milestone compound type indication phase maa ndabla oncology nyeso autologous engineer sarcoma multiple myeloma nonsmall cell lung tcrt cell engineer tcr cancer melanoma ovarian cancer tarextumab notch monoclonal antibody small cell lung cancer brontictuzumab notch monoclonal antibody solid tumour haematological malignancy agonist monoclonal antibody solid tumour haematological malignancy lysinespecific demethylase lsd acute myeloid leukemia small cell lung cancer inhibitor beta cell maturation antigen antibody multiple myeloma drug conjugate erbb receptor tyrosine kinase solid tumour erbb monoclonal antibody enhancer zeste homologue solid tumour haematological malignancy ezh inhibitor phosphatidylinositol kinase castration resistant prostate cancer pik beta inhibitor focal adhesion kinase inhibitor mesothelioma bet family bromodomain inhibitor solid tumour haematological malignancy immunoinflammation sirukumab interleukin human monoclonal rheumatoid arthritis iii antibody sirukumab interleukin human monoclonal giant cell arteritis iii antibody benlysta lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody benlysta lymphocyte stimulator monoclonal vasculitis iii antibody benlysta lymphocyte stimulator monoclonal transplant rejection antibody benlysta rituxan lymphocyte stimulator monoclonal sjogren syndrome antibody cluster differentiation monoclonal antibody granulocyte macrophage colony rheumatoid arthritis stimulate factor monoclonal antibody oncostatin osm monoclonal antibody systemic sclerosis interleukin receptor monoclonal sjogren syndrome antibody spleen tyrosine kinase syk inhibitor chronic urticaria topical lymphocyte activation gene lag autoimmune disease protein monoclonal antibody receptorinteracte protein rip psoriasis rheumatoid arthritis ulcerative colitis kinase inhibitor chemokine motif ligand psoriatic arthritis ccl monoclonal antibody macrophage target histone rheumatoid arthritis deacetylase inhibitor rearrange transfection ret inflammatory disorder bowel kinase inhibitor rare disease exvivo stem cell gene therapy adenosine deaminase severe combine immune submit deficiency adascid transthyretin ttr production inhibitor transthyretinmediate amyloidosis iii mepolizumab interleukin monoclonal antibody eosinophilic granulomatosis polyangiitis iii serum amyloid component sap amyloidosis monoclonal antibody sap depleter cphpc exvivo stem cell gene therapy metachromatic leukodystrophy exvivo stem cell gene therapy wiscottaldrich syndrome exvivo stem cell gene therapy betathalassemia igsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine product development pipeline continued achieve regulatory review milestone compound type indication phase maa ndabla vaccine shingrix recombinant herpe zoster prophylaxis iii zoster vaccine mmr live attenuate measle mump rubella prophylaxis iii ebola recombinant viral vector ebola haemorrhagic fever prophylaxis group conjugate group streptococcus prophylaxis streptococcus maternal immunisation pneumoniae recombinant conjugate streptococcus pneumoniae disease prophylaxis generation copd recombinant reduction frequency copd exacerbations associate nontypeable haemophilus influenzae moraxella catarrhali hepatitis recombinant viral vector hepatitis virus prophylaxis malaria generation recombinant malaria prophylaxis plasmodium falciparum man abcwy recombinant conjugate meningococcal abcw disease prophylaxis adolescent pseudomonas recombinant pseudomona infection prophylaxis shigella conjugate outer membrane shigella diarrhea prophylaxis tuberculosis recombinant tuberculosis prophylaxis rsv recombinant respiratory syncytial virus prophylaxis maternal immunisation rsv replicationdefective recombinant respiratory syncytial virus prophylaxis viral vector hiv recombinant protein hiv infection prophylaxis pharmaceutical metabolic retosiban oxytocin antagonist spontaneous preterm labour iii daprodustat prolyl hydroxylase inhibitor anaemia associated chronic renal disease ileal bile acid transport ibat inhibitor cholestatic pruritus camicinal motilin receptor agonist delay gastric empty eperzantanzeum glucagonlike peptide glp type diabete albiglutide receptor agonist losmapimod kinase inhibitor focal segmental glomerular sclerosis otelixizumab cluster differentiation new onset type diabete daprodustat prolyl hydroxylase inhibitor topical wound healing monoclonal antibody transient receptor potential cation heart failure channel trpv antagonist selective androgen receptor modulator muscle waste oxytocin inhale oxytocin postpartum hemorrhage dermatology chlorhexidine cationic polybiguanide topical prevention omphalitis submit oct nonsteroidal antiinflammatory topical atopic dermatitis nonsteroidal antiinflammatory topical psoriasis ror gamma inverse agonist topical psoriasis umeclidinium muscarinic acetylcholine antagonist topical hyperhidrosis mepolizumab interleukin monoclonal antibody severe atopic dermatitis neuroscience beta amyloid monoclonal antibody geographic retinal atrophy benlysta lymphocyte stimulator monoclonal myasthenia gravis antibody rilapladib lipoproteinassociate phospholipase alzheimer disease lppla inhibitor ocular target lica antisense geographic atrophy agerelate macular disease oligonucleotide gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brand respiratory anoro ellipta umeclidinium bromide copd spiriva handihaler vilanterol terfenatate respimat stiolto nce nce spiolto respimat ultibro breezhaler device device duaklir genuair formulation formulation arnuity ellipta fluticasone furoate asthma qvar pulmicort asmanex nce alvesco device formulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expire diskus device diskus device hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat nce nce eklira genuair device device formulation formulation nucala mepolizumab severe eosinophilic asthma xolair relvarbreo fluticasone furoate asthmacopd symbicort foster ellipta vilanterol terfenatate flutiform dulera nce nce device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expire fluticasone propionate flutiform dulera diskus device diskus device hfadevice hfadevice serevent salmeterol xinafoate asthmacopd foradil spiriva expire handihalerrespimat diskus device diskus device onbrez hfadevice ventolin hfa albuterol sulphate asthmacopd generic company hfadevice hfadevice antiviral valtrex valaciclovir genital herpe coldsore famvir expire expire shingles zeffixepivirhbv lamivudine chronic hepatitis hepsera expired expire central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expire expire imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire seroxatpaxil paroxetine depression effexor cymbalta expire expire anxiety disorder lexapro cardiovascular urogenital eperzantanzeum albiglutide type diabete victoza byetta bydureon lyxumia trulicity avodart dutasteride benign prostatic hyperplasia proscar flomax expire finasteride coreg carvedilol phosphate mildtosevere heart failure toprol hypertension leave ventricular formulation dysfunction post risk factor detail uncertainty time followon competition note financial statement legal proceeding generic competition possible include supplementary protection certificate patent term extension grant data exclusivity expire usgsk annual report strategic report governance remuneration financial statement investor information pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brand antibacterials augmentin amoxicillinclavulanate common bacterial generic product expire potassium infection rare disease volibris ambrisentan pulmonary hypertension tracleer revatio immunoinflammation benlysta belimumab systemic lupus erythematosus hiv epzicomkivexa lamivudine abacavir hivaids truvada atripla stribild combination combination compleraeviplera lexivatelzir fosamprenavir hivaid prezista kaletra reyataz selzentrycelsentri maraviroc hivaids isentress intelence prezista tivicay dolutegravir hivaid isentress prezista reyataz kaletra triumeq dolutegravir lamivudine hivaids truvada atripla abacavir stribild compleraeviplera trizivir lamivudine zidovudine hivaids truvada atripla abacavir stribild combination combination compleraeviplera vaccine product competition intellectual property patent expiry date major product compound indication competitor brand bexsero meningococcal groupb meningitis group prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel pertussis pertussis booster vaccination infanrix hexa diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expire pediarix polio hepatitis tetanus pertussis polio pentaxim pentavac haemophilus influenzae hepatitis haemophilus hexaxim type influenzae type cervarix hpv virus like human papilloma virus gardasil silgard particle vlp type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza intenza flumist qiv virus subtype prophylaxis vaxigrip qiv subtype antigen fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza vaxigrip mutagrip virus subtype prophylaxis fluzone influvac subtype antigen aggripal fluad intenza flumist menveo meningococcal group meningitis group mencevax menactra conjugate vaccine prophylaxis prepandrix derive split inactivated pandemic aflunov vepacel influenza virus antigen influenza prophylaxis adjuvant rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugate pneumococcal prophylaxis invasive prevenar prevnar polysaccharide disease pneumonia acute otitis medium note financial statement legal proceeding generic competition commence include supplementary protection certificate patent term extension grant gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue consumer healthcare product competition brand product application market competition wellness panadol tablet caplet paracetamolbase global advil pfizer panadol cold infant syrup drop treatment headache aspirin bayer flu joint pain fever tylenol johnson johnson cold symptom voltaren topical gel nonsteroidal diclofenac global advil pfizer base antiinflammatory aspirin bayer tylenol johnson johnson otrivin nasal spray nasal decongestant germany poland afrin merck russia sweden nasivin merck ukraine theraflu tablet syrup cold flu relief russia poland tylenol cold flu ukraine johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser flonase nasal spray allergy relief china ireland claritin bayer flixanase rhinocort astra zeneca flixonase nasacort sanofi piriteze eno effervescent immediate relief antacid global estomazil hypermarca gelusil pfizer tum chewable tablet immediate relief antacid alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi nicorette lozenge gum treatment nicotine global nicorette johnson johnson nicoderm transdermal patch withdrawal aid niquitin perrigo nicotinell smoking reduction australia cessation oral health sensodyne toothpaste toothbrushe relief dentinal global colgate sensitive prorelief pronamel mouth rinse hypersensitivity colgatepalmolive pronamel additionally elmex colgatepalmolive protect acid oral procter gamble erosion parodontax toothpaste helps prevent bleed germany ireland colgate total gum health corsodyl medicate mouthwash gum treat prevent italy united kingdom colgatepalmolive gel spray gingivitis yunnan baiyao state enterprise china polident denture adhesive denture improve retention global fixodent kukident poligrip cleanser comfort dentures procter gamble corega clean denture steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental global colgate colgatepalmolive mouthwash cavity maintain healthy crest procter gamble tooth gum fresh breath oralb procter gamble skin health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicate patch onset cold sore carmex carma labs blistex blistex incorporate retail label nutrition horlick malt drink food nutritional indian subcontinent bournvita mondelez beverages food united kingdom ireland complan heinzgsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor principal risk discuss risk uncertainty similarly business expose litigation government relevant business financial condition result operation investigation include limited product liability litigation patent affect performance ability achieve objective antitrust litigation sale marketing litigation litigation factor believe cause actual government investigation include related provision result differ materially expect historical result unfavourable outcome increase related cost insurance premium materially adversely affect financial result adapt comply broad range law regulation requirement apply research development detail status uncertainty involve manufacturing testing approval distribution sale market significant unresolved dispute potential litigation set pharmaceutical vaccine consumer healthcare product affect note legal proceeding page cost product development time require regulation require discussion mitigating activity company reach market likelihood successfully take address principal risk uncertaintie summary rule regulation change governmental activity group take manage principal risk interpretation rule regulation evolve nature accompanie description principal risk principal particular risk change change certain regulatory regime risk factor uncertaintie list order significance substantial change failure comply applicable law regulation materially adversely affect financial result patient safety risk definition individual medical officer group substantial global failure appropriately collect review follow report adverse safety pharmacovigilance organisation track adverse event potential source act relevant finding issue report product course clinical study timely manner group product approve marketing group risk impact extensive postmarkete surveillance signal detection system impact risk potentially compromise ability information possible effect medicine receive conduct robust safety signal detection interpretation source include unsolicited report health ensure appropriate decision take respect professional patient regulatory authority medical riskbenefit profile product include completeness scientific literature medium policy employee accuracy product label pursuit additional require report immediately issue relate safety studiesanalyse appropriate lead potential harm quality product country manager responsible patient reputational damage product liability claim monitor exception tracking training help assure litigation governmental investigation regulatory action collection safety information report information fine penalty loss product authorisation relevant central safety department accordance group policy legal requirement context preclinical clinical trial conduct development information change benefitrisk profile group investigational pharmaceutical vaccine consumer healthcare medicine result certain action characterise communicate product determine safety efficacy product use minimise risk propose action discuss human notwithstanding effort determine regulatory authority include modify prescribing safety product appropriate preclinical clinical information communication physicians healthcare trial unanticipate effect evident provider restriction product prescribingavailability help product widely introduce marketplace question assure safe use carry clinical trial raise ongoing safety surveillance certain case appropriate stop clinical trial postmarkete study governmental agency withdraw medicine market group global safety thirdpartie analyse publicly available clinical trial result board gsb comprise senior physician representative support function integral component system group currently defendant number product liability gsb include subsidiary board dedicate consumer lawsuit include class action involve significant claim healthcare product vaccine review safety damage relate product litigation particularly investigational market product group inherently unpredictable class action seek sweep authority stop clinical trial continue conduct trial person prescribe product increase potential ethically scientifically justify light information liability claim pain suffer punitive damage emerge start trial frequently assert product liability action allow represent potentially openende exposure materially addition medical governance framework group adversely affect group financial result describe group use mechanism foster early evaluation mitigation resolution dispute mitigate activity arise potential claim arise goal chief medical officer cmo responsible medical programme create culture early identification governance group global policy policy evaluation risk claim actual potential order safeguard human subject clinical trial patient minimise liability litigation product paramount importance cmo authoritative role evaluate addressing matter human safety gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor continue intellectual property risk definition generic drug manufacturer exhibit readiness failure appropriately secure protect intellectual property market generic version important product prior right expiration patent effort involve challenge validity enforceability patent assertion risk impact generic product infringe patent result failure obtain subsequent loss patent protection continue involve legal proceeding involve patent include reduce availability scope patent right challenge materially adversely affect financial compulsory licensing government force manufacturer result increasingly common license patent specific product competitor patent infringement action prompt claim antitrust law materially adversely affect financial result market violate prosecution patent litigation absence adequate patent datum exclusivity protection limit involve defence patent claim direct opportunity rely market future sale growth indirect purchaser payer typically file class product materially adversely affect action relief seek include treble damage restitution financial result claim similarly antitrust claim bring government context entity private party follow settlement patent litigation innovative pharmaceutical vaccine consumer healthcare allege settlement anticompetitive violation product company seek obtain appropriate intellectual antitrust law successful antitrust claim private party property protection product ability obtain enforce government entity materially adversely affect financial patent proprietary right regard product result critical business strategy success pharmaceutical expiration date patent major product vaccine product usually protect copied affect date generic version product generic manufacturer period exclusivity provide introduce set page legal proceeding issue patent relate intellectual property right involve patent challenge set note financial regulatory data protection orphan drug status follow statement legal proceeding expiration certain intellectual property right generic manufacturer lawfully produce generic version product mitigating activity global patent group focus secure protect operate market intellectual property law patent patent right global group maintain internal process office develop government unwilling design seek ensure successful procurement enforcement grant enforce intellectual property right fashion similar defence patent goal maintain exclusive develop region japan rights market product develop country limit threatened limit effective patent protection pharmaceutical product order facilitate global patent group monitor new development early competition market generic manufacturer international patent law seek ensure appropriate protection asset act trade association work face competition manufacturer proprietary generic local government seek secure effective balanced pharmaceutical product major market introduction intellectual property protection design meet need generic product particularly high patient payer support longterm investment turnover margin typically lead rapid dramatic loss innovation sale reduce revenue margin proprietary product depend certain key product significant portion sale product respiratory pharmaceutical product seretideadvair account significant group sale worldwide timing impact entry generic product contain combination active substance seretideadvair uncertain patent composition contain combination active substance seretideadvair expire patent component advair diskus device continue august generic product contain combination active substance seretide advair meter dose inhaler dry powder inhaler launch manufacturer number european market time impact entry major market europe followon product seretideadvair uncertaingsk annual report strategic report governance remuneration financial statement investor information product quality risk definition single external global quality standard system failure comply current good manufacturing practice govern lifecycle medicinal product requirement cgmp inadequate control governance quality complex fragmented national regional supply chain cover supplier standard manufacturing boundary ich guideline pharmaceutical quality distribution product system provide model comprehensive quality framework take account international quality concept risk impact design implement product lifecycle failure ensure product quality far reach framework adopt gsk augmented implication term patient consumer safety result consolidation multiple regulatory requirement product launch delay supply interruption product recall world order seek ensure gsk pqs meet external potential damage reputation expectation product quality market supply pqs associate regulatory legal financial consequence regularly update seek ensure keep pace external materially adversely affect reputation financial result regulatory change reflect operational improvement context new scientific understanding support delivery patient consumer healthcare professional trust quality consistent reliable product product failure ensure product quality enterprise extensive global network quality compliance risk applicable business activity professional align business unit provide product quality influence factor include oversight assist delivery quality performance product process understand consistency manufacture operational compliance site level senior management level component compliance gmp accuracy labelling management oversight activity accomplish reliability external supply chain embodiment hierarchy quality council independent chief overarching quality culture internal external environment product quality officer global product quality office continue evolve new product new market new legislation introduce increase scrutiny supply gsk implement riskbase approach assess continuity focus improve distribution practice manage thirdparty supplier provide material introduction novel cell gene base therapy review finish product contract manufacturer make product inspection conduct industry national regulatory expect comply standard identify gsk authority highlight ongoing focus datum audit help provide assurance expect standard integrity contamination prevention rigour quality meet investigation include robustness decision make staff member regularly train seek ensure timely escalation pertinent issue regulatory authority cgmp standard behaviour base gsk value mitigate activity follow additionally advocacy communication programme develop implement single pharmaceutical routinely deploy seek ensure consistent message quality system pqs define quality standard convey gsk originate change system business associate pharmaceutical regulation learning inspection regulatory submission vaccine consumer healthcare product clinical trial continue emphasis value quality performance material system broad scope applicable metric facilitate improvement foster culture right lifecycle product mature time commercial supply gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor continue financial control report risk definition party critical business delivery failure comply current tax law incur significant integral solution improve productivity quality loss treasury activity failure report accurate financial service innovation rely thirdpartie include information compliance accounting standard applicable supplier distributor individual contractor license legislation failure maintain adequate governance oversight pharmaceutical biotechnology collaboration partner thirdparty relationship discovery manufacture marketing product important business process risk impact noncompliance exist new financial reporting party business relationship present material risk disclosure requirement change recognition income example share critical sensitive information expense expose litigation regulatory action marketing plan clinical datum employee datum specific materially adversely affect financial result party conduct relevant outsourced business change tax law application respect matter operation inadequate protection misuse information transfer pricing foreign dividend control company party significant business impact similarly tax credit taxation intellectual property restriction tax use distributor agent range activity relief allow interest intragroup debt impact promotion tender inherent risk effective tax rate significant loss arise inconsistent inappropriate promotion corruption insufficient internal application treasury policy transactional settlement error compliance control distributor affect counterparty default change substance reputation risk increase complexity application govern tax law failure comply tax work large number party law significant loss treasury activity materially mitigate activity adversely affect financial result group maintain control environment design identify failure adequately manage thirdparty relationship result material error financial reporting disclosure design business interruption exposure risk range suboptimal operating effectiveness key financial reporting control contractual term condition severe business sanction regularly test management independent business andor significant reputational damage consequence monitoring provide assurance control materially adversely affect business operation key financial reporting disclosure process operate financial result effectively context uptodate late development financial group require law jurisdiction report requirement work external auditor disclose publicly financial result event legal advisor materially affect financial result group regulator share accountability financial result routinely review financial statement list company business financial result review approve compliance new revise exist accounting regulatory regional management review financial requirement group believe complie controller chief financial officer cfo allow appropriate regulatory requirement concern financial financial controller cfo assess evolution statement disclosure material information include business time evaluate performance plan transaction relate business restructuring acquisition significant judgment review confirm senior divestiture subject investigation management business reorganisation newly acquire potential noncompliance accounting disclosure activity novartis acquire business oncology requirement lead restatement previously report divestiture integrate risk assessment appropriate result significant penalty control review apply treasury group deal high value transaction foreign introduce additional resource monitor ensure exchange cash management transaction daily basis robust financial control maintain effectively group effective tax rate reflect rate tax manage risk initial phase integrate jurisdiction group operate high novartis business control reporting framework low rate account regime implement ongoing transformation upgrade encourage innovation investment science provide tax financial system process continue additional risk incentive change affect group tax rate mitigation introduce amend programme timeline ongoing system upgrade tax charge include financial statement good estimate tax liability pende audits tax authority group maintain disclosure committee report worldwide nature operation crossborder supply board review group quarterly result annual route complex lead question tax audit report determine year consultation legal advisor necessary disclose publicly continue significant international focus tax information group stock exchange reform include oecds bep project european announcement commission initiative propose antibep directive increase use fiscal state aid investigation treasury management group tmg meet regular domestic initiative world result basis seek ensure liquidity interest rate foreign currency significant change establish tax principal increase transaction foreign currency translation risk manage tax authority dispute regardless merit line conservative approach detail associate outcomes costly divert management attention risk strategy policy adopt adversely impact reputation boardgsk annual report strategic report governance remuneration financial statement investor information financial control report continue oversight treasury role manage counterparty risk seek guide enforce global principle interaction line agree policy perform corporate compliance party place policy framework applicable officer cco operate independently treasury buying good service manage external spend pay work party policy framework detail mitigation treasury risk find apply employee complementary worker worldwide note financial instrument relate disclosure framework complement technical local standard tax risk manage set policy procedure seek design seek ensure alignment nature ensure consistency compliance tax legislation party interaction good manufacturing practice adherence local law regulation independent business seek maintain open positive relationship government monitor key financial operational control place tax authority worldwide monitor government debate supplement periodic check company tax policy key jurisdiction deal proactively independent audit assurance function potential future change tax law engage advisor legal counsel review tax legislation implication continuous monitoring performance party business relevant active provide relevant enhance party oversight team global business input tax policy maker ethic compliance organisation team commence implementation global programme take enterprise centralised team dedicate specialist responsible view party relate risk programme strengthen manage transactional tax reporting compliance risk assessment diligence effort party submit tax return accord statutory time limit improve overall management party risk engage tax authority seek ensure tax affair lifecycle party engagement oversight current enter arrangement continuous audit programme provide newly create global risk office programme advance pricing agreement provide gsk global ethic compliance group longterm certainty tax treatment appropriate exceptional case matter settle agreement tax authority resolve dispute formal appeal proceeding business unit leadership team retain ultimate accountability manage party interaction risk work party gsk employee expect manage external interaction commitment responsibly expectation embed value code conduct responsibility activity perform safely compliance applicable law gsk value standard code conduct gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor continue antibribery corruption risk definition mitigate activity failure prevent gsk employee party comply code conduct value behaviour commitment abac principle standard zero tolerance integral mitigate risk light applicable legislation complexity geographic breadth risk constantly enhance oversight activity datum reinforce risk impact employee contractor clear expectation failure mitigate risk expose group associate acceptable behaviour maintain ongoing communication person governmental investigation regulatory action civil group centre headquarters local market criminal liability damage group reputation shareholder value licence operate particular group enterprisewide abac programme design jurisdiction materially adversely affect respond threat risk bribery corruption financial result build group value exist standard form comprehensive practical approach compliance context flexible evolve nature business example expose bribery corruption risk global scale acquisition abac diligence specific business operation market government structure novartis transaction rule law develop bear bribery corruption risk exposure addition global abac programme support toplevel commitment nature business healthcare sector highly competitive group board director leadership subject regulation increase instance business ongoing risk assessment global abac policy expose activity interaction bribery write standard address commercial practice corruption risk rise abac risk diligence high risk party ongoing training communication confidential reporting line authority lead extraterritorial abac monitor compliance investigation team addition enquirie certain group operation programme mandate enhance control interaction investigation discuss note legal proceeding government official undertake business development transaction programme governance provide group abac governance board include representation key functional area business unit additionally dedicated abac team responsible implementation evolution programme response development internal external environment complement abac investigation abac audit independent business monitoring team separate reporting line continually benchmark abac programme large multinational company use external expertise review help improve element abac programme result china country investigation group increase resource centrally locate abac team regional abac team complete abac review reduce presence number highrisk marketsgsk annual report strategic report governance remuneration financial statement investor information commercialisation risk definition mitigate activity failure execute business strategy manage competitive strategic objective design ensure group opportunity threat effectively accordance achieve mission help people feel well letter spirit legal industry company requirement live long group continue transform strengthen presence key emerge market restructure simplify risk impact core business operation reduce manufacturing failure manage risk relate commercialisation footprint recent transaction novartis helped materially adversely affect ability grow diversified accelerate pace change strengthen global business deliver product value core business pharmaceutical vaccine consumer failure comply applicable law rule regulation healthcare result governmental investigation regulatory action legal change allow global proceeding bring group governmental relevant need world aim reach private plaintiff failure provide accurate complete patient consumer improve health information relate product result incomplete wellbeing use product deliver awareness benefitrisk profile product possibly goal important achieve value provide suboptimal treatment patient consumer guide lead decision constantly strive consequence materially adversely affect group right thing deliver quality product seek ensure practice find misaligned value behaviour reflect value mission company result reputational damage dilute trust establish key stakeholder corporate executive team set share objective describe important priority need deliver context group set enterprisewide project operate global basis industry highly critical achieving objective strategic objective competitive highly regulate competitor cascade group ensure enterprisewide significant product innovation technical advance alignment process place regularly review achievement intensify price competition light competitive environment objective continue development commercially viable new product development additional use exist product critical take action level group enhance achieve strategic objective improve standard procedure promotional interaction base value transparency respect integrity patient develop new pharmaceutical vaccine consumer healthcare focus policy standard govern promotional product costly lengthy uncertain process activity undertake group behalf product candidate fail stage include activity conduct worldwide conform high ethical significant group economic human resource regulatory industry standard local standard differ invest competitor product pricing strategy global standard stringent apply failure develop commercially successful product develop additional use exist product materially group harmonise policy procedure guide adversely affect ability achieve strategic objective country commercial practice process clarify applicable standard engage market commit ethical responsible commercial practice activity oversight business commercialisation product support mission unit risk management compliance board rmcbs improve quality human life enable people country executive board cebs manage risk feel well live long accomplish mission engage incountry business activity healthcare community way provide important information medicine promotional material activity review approve accord group policy standard promotion approve product seeks ensure hcp globally conduct accordance local law regulation seek access information need patient consumer ensure material activity fairly represent access product need product product service group necessary prescribe recommend manner provide discipline include termination employee maximum healthcare benefit patient consumer engage misconduct broaden ability claw commit communicate information relate approve remuneration senior management event product responsible legal ethical manner misconduct time researcher hcp healthcare organisation hcos gsk implement globally change external expert engage compensate compensation model sale professional service expertise provide payment manager interact hcp change eliminate excessive perceive reward base sale market share individual territory inducement reward prescribing recommend favour reward base quality individual product consistent abac policy interaction healthcare professional start gsk comply market abac law recipient payment implement prior commitment stop pay hcp deliver government official promotional presentation gsk directly sponsor pay billion billion resolve government travel medical educational conference investigation focus large promotional practice pay rmb billion million resolve government investigation china focus offer money property nongovernment personnel order obtain improper commercial gain gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor continue research practice risk definition mitigate activity failure adequately conduct ethical sound preclinical establish office animal welfare ethic strategy clinical research addition failure engage scientific activity oawes lead chief animal welfare ethic strategy consistent letter spirit law industry seek ensure humane responsible care animal group requirement increase knowledge application nonanimal alternative group oawes embeds framework animal welfare risk impact governance promote application replacement refinement impact risk include harm patient reputational damage reduction animal research explore opportunity failure obtain necessary regulatory approval product crossindustry datum sharing conduct quality assessment governmental investigation legal proceeding bring group governmental private plaintiff product liability suit report result human subject research claim damage regulatory action fine medicine vaccine publicly accessible clinical study penalty loss product authorisation register website governmentrequire repository consequence materially adversely affect financial submit human research result manuscript publication result peer review scientific journal disclose clinical study report market terminate medicine context research result publish scientific literature research relate animal raise ethical concern register bring total report available attempt proactively address animal study remain vital end list clinical trial gsk research case method online system wwwclinicalstudydatarequestcom investigate effect potential new medicine living complete commitment list complete global study body test human generally mandate conduct formation gsk online system regulator ethically imperative animal research provide allow researcher request access anonymise patientlevel critical information cause disease datum group clinical trial medicine develop country require additional animal testing approve terminate trial publish medicine approve use global human biological sample management hbsm clinical trial healthy volunteer patient assess governance framework place oversee ethical lawful demonstrate investigational product efficacy safety acquisition management human biological sample evaluate product approve global hbsm network champion hbsm activity provide marketing work human biological sample experience group support internal sample custodian good sample fundamental discovery development safety practice monitor product remain important priority enhance datum integrity integrity datum essential success stage control begin work new write standard research datum lifecycle design generation recording seek ensure integrity datum research management analysis report storage retrieval development data integrity committee place research datum govern legislation regulatory requirement year provide oversight datum integrity research datum support document core component quality assurance team begin conduct assessment intend stage pipeline progression decisionmake provide independent business monitor internal control form content regulatory submission poor datum integrity activity compromise research effort chief regulatory officer oversee activity innate complexity interdependency require regulatory governance board include promote regulatory filing particularly give global research compliance regulatory requirement groupwide development footprint rapid change submission requirement standard make regulatory service efficient agile develop country continue increase complexity align regulatory capability international worldwide product registration business need enterprise local level scientific engagement essential scientific group strictly prohibit promotional practice prior marketing discourse define interaction exchange information authorisation care take seek ensure scientific gsk external community order advance engagement activity perceive promotional scientific medical understanding include appropriate specific accountability authorisation scientific engagement development use product nonpromotional reside medical governance framework oversee engagement external stakeholder group vital gsk medical governance executive committee mgec accountable mission necessary scientific medical advance chief medical officer mgec responsible oversight scope activity include advisory board scientific applicable policy seek ensure high level integrity consultancy preplanne informal discussion healthcare continuous development scientific engagement gsk professional hcp share medical information publication framework seeks ensure right level accountability clear include abstract congresse scientific interaction programme guidance country business unit payer patient government medium support local operating company loc independent medical education nonindependent educational group take integrated approach manage scientific activity cover commercial practice engagement commercial practice relate risk include activity essential present legal regulatory combine guidance document promotional code scientific reputational risk sharing datum invite medium coverage engagement standard way consideration risk payment service provider perceive common scientific engagement commercial inappropriate promotional intent risk particularly high practice abac healthcare professional hcp hcp engagement associate financial andor transfer engagement manage right context place value disclosure require gsk seek ensure clarity clear line accountabilitygsk annual report strategic report governance remuneration financial statement investor information environment health safety sustainability risk definition mitigate activity failure manage ehss risk line objective corporate executive team responsible ehss policy relevant law regulation governance group global policy policy cet seeks ensure control framework place risk impact manage risk impact legal compliance issue relate failure manage ehss risk lead significant harm ehss assign responsibility senior manager people environment community operate provide maintain control individual manager seek fine failure meet stakeholder expectation regulatory ensure ehss control framework effective requirement litigation regulatory action damage implement respective business area fully group reputation materially adversely affect compliant applicable law regulation adequately financial result resource maintain communicate monitor context additionally employee personally responsible ensuring group subject health safety environmental law applicable local standard operating procedure jurisdiction law impose duty protect people follow expect responsibility ehss matter environment community operate riskbase proactive approach articulate refresh potential obligation remediate contaminate site global ehs standard support ehss policy identify potentially responsible party objective discover develop manufacture supply sell comprehensive environmental response compensation product harm people environment addition liability act number site remediation cost relate design provision safe facility plant equipment use ownership site failure manage operate rigorous procedure help eliminate hazard environmental risk properly result litigation regulatory practicable protect employee health wellbee action additional remedial cost materially adversely affect financial result note financial continue effort improve environmental statement legal proceeding discussion sustainability reduce value chain carbon intensity environmental relate proceeding involve pack water consumption waste generation actively routinely accrue amount relate liability matter manage environmental remediation obligation seek ensure practice environmentally sustainable compliant ehss performance result share public year responsible business supplement information protection risk definition mitigate activity failure protect maintain access critical sensitive group global information protection policy computer system information support dedicated programme activity increase focus information security group establish risk impact information protection privacy function provide strategy failure adequately protect critical sensitive system direction oversight enhance global information information result loss commercial strategic security capability advantage damage reputation litigation business disruption include regulatory sanction materially assess change information protection risk environment adversely affect financial result briefing government agency subscription commercial threat intelligence service knowledge share context pharmaceutical crossindustry company rely critical sensitive system datum corporate strategic plan sensitive personally identifiable aim use industry good practice information information intellectual property manufacturing system trade security policy process technology invest secret potential malicious careless action strategy commensurate change nature expose computer system information misuse security threat landscape unauthorised disclosure subject law govern process gsk employee indict theft gsk research personally identifiable information pll group bind information charge individual corporate rule bcrs approve concern base know believe information commissioner office human resource breach material impact company activity research activity datum bcrs sign european ongoing business gsk conduct internal review state allow transfer pii internationally group occur planning continue enhance multiple entity individual privacy agreement european layers data protection place union country gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie risk factor continue crisis continuity management risk definition improve linkage commercial forecasting failure deliver continuous supply compliant finished manufacturing possible core commercial cycle product inability recover sustain critical operation methodology time decrease risk associate include key supply chain follow disruption respond demand fluctuation impact ability supply writeoff crisis incident timely manner associate product exceed expiry date node supply chain optimise seek ensure risk impact adequate safety stock balance work capital associate recognise failure supply product adversely endtoend supply chain impact consumer patient rely material interruption supply exclusion healthcare programme safety stock backup supply arrangement medically expose litigation regulatory action incur fine critical highrevenue product place help mitigate disgorgement materially adversely affect group risk addition compliance manufacture external financial result group international operation supplier routinely monitor order identify manage partner maintain vast global footprint expose supply base risk practical dependency single workforce facility operation information technology source critical item remove reliance single potential disruption result natural event storm source component reduce certain key earthquake manmade event civil unrest terrorism product qualification alternative material help global emergency ebola outbreak flu pandemic improve supply chain robustness case dual source important gsk robust crisis management recovery possible inventory strategy develop protect plan place manage event supply chain unanticipated disruption context continue implement anticounterfeit system supply chain operation subject review approval product serialisation accordance emerge supply chain regulatory agency effectively provide licence requirement world operate failure manufacture distribution facility ccm governance group set forth global policy supplier key service material lead litigation policy business unit functional area head regulatory action product recall seizure interruption ensure effective crisis management business supply delay approval new product suspension continuity plan place include authorise response manufacture operation pende resolution manufacturing recovery strategy key area responsibility clear logistic issue communication route business disruption occur material service provide thirdparty supplier additionally represent ccm governance board necessary commercial production product perform risk oversight provide vital information include active pharmaceutical ingredient api antigen ccm programme team new threat acquisition intermediate commodity component necessary significant business organisational change manufacture package pharmaceutical dedicated team ccm expert support business vaccine consumer healthcare product responsibility include chairing governance board thirdparty service procure service provide coordinate crisis management business continuity training contract manufacturing organisation clinical research facilitate exercise monitor provide global organisation support development key product consistency alignment centrally store monitor important ensure continuous operation business update plan support critical business process undertake business continuity plan single activity help ensure appropriate level readiness source certain component bulk api finish product response capability maintained develop maintain service create risk failure supply event partnership external body like business continuity regulatory noncompliance physical disruption institute international strategy disaster risk manufacturing site logistic system reduction helps improve business continuity initiative failure small number singlesource thirdparty supplier disaster prone area support development service provider fulfil contractual obligation timely community resilience disasters manner result regulatory noncompliance physical continue evaluate implication business disruption logistic manufacturing site result delay possible exit united kingdom european union service interruption leave create uncertainty effective crisis management business continuity potentially add complexity wide range business planning commit provide health safety activity currently believe people minimise damage impact group material adverse impact group result long term maintain functional operation follow natural manmade continually improve ccm risk management programme disaster public health emergency tool base learn plan activation example mitigating activity group implement global system provide gsk supply chain model design seek ensure supply leader access vital information need effectively quality security product globally closely monitor respond disruption monitor status supply chain governance committee inventory preparedness response capability regularly solicit status delivery product seek ensure recommendation improvement different customer medicine vaccine product need sourcessupplier charge responsibility assist manage gsk risk introduce new tool improve ccm practicesgsk annual report strategic report governance remuneration financial statement investor information shareholder information share capital control share buyback programme board authorise issue allot ordinary share detail issue share capital number share article company article association hold treasury december find power article authority company note financial statement share capital share purchase share subject shareholder authority premium account seek annual basis annual general ordinary share list london stock exchange meeting agm share purchase company quote new york stock exchange nyse cancel hold treasury share satisfy form american depositary share ad ad share option grant group employee share plan represent ordinary share detail list debt programme cover purchase share cancellation list refer note financial statement hold treasury share accordance authority net debt renew shareholder agm holder ordinary share ad entitle receive company authorise purchase maximum dividend declare company annual report million share detail share purchase cancel attend speak general meeting company appoint hold treasury share disclose note proxy exercise voting right financial statement share capital share premium account restriction transfer limitation determine specific share repurchase level company hold ordinary share ad requirement consider development free cash flow year give obtain approval prior transfer ordinary share ad impact sustained strength sterle free cash flow carry special right regard control company company suspend share repurchase programme restriction vote right major shareholder share purchase financial year voting right share shareholder end know arrangement financial right hold company confirm currently intend person holder share know market purchase company review agreement restriction share transfer voting right potential future share buyback line share acquire share scheme plan rank usual annual cycle subject return rating criterion equally share issue special right market capitalisation trustees employee share ownership plan trust market capitalisation base share issue exclude waive right dividend share hold trust treasury share gsk december billion exchange control limitation affect security date gsk large company market holder capitalisation ftse index certain economic sanction force time time currently applicable law decree share price regulation restrict import export capital affect remittance dividend payment holder january company share nonresident similarly december certain economic sanction force time decreaseincrease time limitation relate nonresident high year english law company article association low year right holder vote respect company share table set middle market closing price company share price decrease interest voting right compare decrease ftse index state far aware year share price march person significant direct indirect holding company information provide company pursuant financial conduct authoritys fca disclosure transparency rule dtrs publish regulatory information service company website march company receive notification accordance fca dtrs follow notifiable interest voting right company issue share capital percentage issue share capital blackrock inc legal general group plc percentage ordinary share issue exclude treasury share acquire disposed interest share price ad price share period review gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue nature trading market follow table set period indicate high low middle market closing quotation pence share london stock exchange high low closing price dollar ad nyse ordinary share ad pence share dollar share high low high low march february january december november october september august quarter end december quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march year end december year end december year end december year end december year end december march analysis shareholding december number total total number account account share share hold share hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline bny mellon depositary company ad list nyse ordinary share represent company adr programme manage depositary register bny nominees limited march bny nominees limit hold ordinary share represent issue share capital exclude treasury share date march number holder ordinary share holding ordinary share number register holder ad holding ad certain ordinary share ad hold broker nominee result number holder record register holder representative number beneficial holder residence beneficial holdersgsk annual report strategic report governance remuneration financial statement investor information dividend financial calendar company pay dividend quarterly continue return cash event date shareholder dividend policy dividend remain quarter result announcement aprilmay essential component total shareholder return company annual general meeting committed increase dividend longterm detail dividend declare amount payment date quarter result announcement july given note financial statement dividend quarter result announcement october preliminaryquarter result announcement february gsk complete transaction novartis march annual report publication februarymarch gsk novartis create new worldleading annual report distribution march consumer healthcare business gsk acquire novartis global vaccine business gsk divest market oncology information company include share price available portfolio relate activity website wwwgskcom information available website constitute annual report gsk plan use net cash transaction proceed fund return approximately billion share shareholder result announcement special dividend pay gsk ordinary result announcement issue london stock exchange dividend payment available news service send securities exchange commission nyse issue dividend share medium available website table set dividend share ad year dividend ad translate dollar financial report applicable exchange rate company publish annual report available website date publication shareholder year dividend penny elect receive annual report contact registrar special alternatively shareholder elect receive notification email publication financial report register wwwshareviewcouk copy previous financial report available website print copy obtain registrar gsk response center page supplemental contact detail interim ordinary dividend special dividend annual general meeting receivable adr holder calculate base exchange rate april cumulative dividend receivable adr time thursday holder queen elizabeth conference centre broad sanctuary westminster london swp special dividend relate return net cash proceed novartis transaction agm company principal forum communication private shareholder addition formal business supplemental dividend relate disposal certain presentation ceo performance noncore otc brand north america pay group future development opportunity fourth quarter ordinary dividend question ask board chairman board committee question relate committee dividend fee adr holder gsk introduce dividend fee adr holder effect investor hold share nominee service arrange dividend payment authorise term nominee service appoint proxy respect amend restate deposit agreement notice provide shareholding order attend vote meeting register adr holder april adr holder wish attend meeting obtain proxy fee introduce offset cost relate bny mellon depositary notifying request sec registration include sarbanesoxley relate expense enable attend vote business administration ad facility maintenance transact adr holder instruct bny mellon nyse list fee fee expect remain place way share represent adr vote future dividend complete return voting card provide depositary annual fee currently set adr adr quarter depositary agreement gsk document display charge cent adr articles association company director service contract applicable letter appointment dividend calendar director company subsidiary ad exdividend exdividend letter relate severance term pension arrangement quarter date date record date payment date available inspection company register office available inspection agm special dividend february february february april july august august august october november november november january gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue tax information shareholder taxation capital gain shareholder liable tax gain disposal summary certain tax federal income tax share adr disposal individual subject consequence holder share adr citizen availability exemption relief annual exempt set complete analysis taxable capital gain accrue disposal share possible tax consequence purchase ownership adr tax allowable deduction sale security intend general guide shareholder taxable income tax year exceed basic holder advise consult adviser respect rate income tax limit case taxable capital gain accrue tax consequence purchase ownership sale disposal share adr tax share adr consequence state local tax combination rate corporation taxpayer entitled law implication current ukus tax indexation allowance apply reduce capital gain convention extent gain arise inflation indexation holders adr generally treat owner allowance reduce chargeable gain create underlie share purpose current usuk double allowable loss taxation convention relate income gain income tax inheritance tax convention estate gift taxis estate gift tax individual ukdomicile shareholder liable convention purpose internal revenue code inheritance tax transfer share adr tax amend code charge value shareholder shareholders estate reduce result transfer way lifetime gift summary apply resident shareholder hold disposal market value case share capital asset bequest death tax charge value share date shareholder death gift taxation dividend disposal subject inheritance tax estate different regime apply taxation dividend income payable gift tax estate gift tax convention generally resident individual tax year april provide tax pay credit tax payable tax year commence april tax year include resident stamp duty stamp duty reserve tax shareholder generally subject income tax stamp duty andor stamp duty reserve tax sdrt subject dividend pay gross tax certain exemption payable transfer share credit tax credit set individual income tax rate round near case stamp liability respect gross dividend repayable duty consideration transfer notwithstanding shareholder tax liability associate tax provide instrument execute pursuance credit extent individual income exceed basic rate agreement give rise charge sdrt limit high rate limit upper dividend rate apply instrument stamp year agreement include set gross dividend figure stamp exempt sdrt charge cancel income exceed additional rate limit sdrt pay repay additional dividend rate normally apply shareholder tax year onwards dividend tax credit summary apply shareholder citizen long apply resident individual entitle instead resident domestic corporation person dividend tax allowance subject federal income tax net income basis dividend receive tax year free tax respect share adr hold share adr dividend excess allowance tax capital asset resident tax purpose basic rate taxpayer high rate taxpayer hold share purpose trade profession additional rate taxpayer vocation carry branch agency resident shareholder corporation taxpayer summary address tax treatment holder note dividend payable ordinary share generally subject special tax rule bank taxexempt entitle exemption corporation tax entity insurance company dealer security currency person hold share adr integrate investment include straddle comprise share adr position person directly indirectly vote stock company address tax treatment applicable result international income tax treatiesgsk annual report strategic report governance remuneration financial statement investor information taxation dividend taxation capital gain gross dividend receive treat foreign generally holder subject capital gain tax source dividend income tax purpose eligible subject tax capital gain realise sale dividend receive deduction allow corporation disposal share adr gain longterm dividend adr payable dollar dividend share capital gain subject reduce rate taxation individual payable pound sterling dividend pay pound sterling holder share adr hold year include income dollar calculate date share vestedrelease shortterm capital reference exchange rate day dividend gain subject taxation rate receive holder subject certain exception shortterm longterm capital gain subject rate hedge position individual eligible holder subject state local tax rate capital gain apply taxation maximum rate respect qualified information report backup withholding dividend qualified dividend define internal dividend payment proceed sale share revenue service dividend meet follow criterion adr pay certain usrelated financial issue corporation corporation incorporate intermediary subject information reporting possession corporation eligible subject backup withholding holder benefit comprehensive income tax treaty deem corporation exempt recipient provide taxpayer satisfactory publish irs identification number certifie loss exemption occur nonus holder generally subject information dividend list irs dividend report backup withholding require provide qualify certification nonus status connection payment require dividend hold period meet share receive amount withhold allow refund own day credit holder federal income tax liability provide hold period define day period require information furnish internal revenue begin day exdividend date day service stock trade dividend price example estate gift taxis stock exdividend date october share hold estate gift tax convention shareholder day period august generally subject inheritance tax november year order count qualified dividend stamp duty stamp duty andor sdrt subject certain exemption dividend qualified subject taxation payable transfer share adr custodian federal graduate tax rate maximum rate depository rate consideration type dividend automatically exclude qualified provide transfer sale value transfer dividend meet requirement include consideration limit stamp duty sdrt payable capital gain distribution transfer agreement transfer adr dividend bank deposit dividend hold corporation employee stock ownership plan esop dividend pay taxexempt corporation state local tax rate qualify nonqualified dividend vary assess addition federal tax rate communicate gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue shareholder service contact registrar company registrar equiniti limited aspect house spencer road lance wwwshareviewcouk tel tel outside equiniti provide range service shareholder service offer participate dividend reinvestment plan alternative receive cash dividend choose drip election form download drip reinvest dividend buy gsk share wwwshareviewcouk request telephone equiniti dividend payment direct bank account currently receive dividend cheque post dividend bank mandate form bank mandate instead pay directly bank building download wwwshareviewcouk society account quick secure avoid risk request telephone equiniti cheque go astray dividend payment direct bank account instead wait sterling cheque arrive post equiniti detail service cost overseas shareholder convert dividend local currency send involve contact equiniti direct local bank account service available country worldwide electronic communication shareholder elect receive electronic notification register wwwshareviewcouk company communication include annual report dividend payment pay way bank mandate access electronic tax voucher availability online vote general meeting time gsk mail hard copy shareholder document receive email contain link document relevant website shareview portfolio service enable create free online portfolio view register wwwshareviewcouk share balance movement update address dividend payment instruction register vote agm duplicate publication mailing receive duplicate copy report mailing contact equiniti contact equiniti arrange account merge convenience avoid waste unnecessary cost share deal service shareholder trade share hold certificated form internet transaction log note market trading hour hold corporate sponsor nominee internet telephone wwwshareviewcoukdealing time postal dealing service provide equiniti financial monday friday exclude public holiday service limited telephone transaction england wale outside postal transaction request deal form corporate sponsor nominee account convenient way manage share require application form request share certificate service provide facility hold wwwshareviewcouk share nominee company sponsor company telephone equiniti continue receive dividend payment annual report attend vote company general meeting shareholder name appear publicly available share register service free join individual saving account isas company arrange equiniti financial service limit detail available provide gsk corporate isa hold gsk ordinary share wwwshareviewcouk request telephone equiniti line open deal enquiry monday friday exclude public holiday england wale line open monday friday exclude public holiday england wale provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial advisergsk annual report strategic report governance remuneration financial statement investor information adr depositary contact investor relation adr programme administer bank new york mellon investor relation contact follow bny mellon shareowner services great west road box brentford middlesex college station tel overnight correspondence send bny mellon shareowner services crescent drive quality circle suite philadelphia college station tel toll free wwwmybnymdrcom tel outside tel toll free tel outside gsk response center email shrrelationscpushareownerservicescom tel toll free depositary provide global buydirect direct ad share scam alert purchasesale dividend reinvestment plan adr holder receive unsolicited telephone offering sell buy detail enrol visit wwwmybnymdrcom share extra care caller helpline number obtain enrolment pack highly organise financial scam glaxo wellcome smithkline beecham shareholder contact financial conduct corporate pep authority information similar activity share centre limit wwwfcaorgukconsumer consumer helpline oxford house oxford road aylesbury buck tel tel tel outside wwwsharecom line open time monday friday public holiday donate share save child saturdays gsk embark ambitious global partnership save child share expertise resource responsible business supplement aim help save live million child publish responsible business supplement online outline gsk approach performance shareholder small number share value key responsible business area health behaviour make uneconomical sell wish consider donate people planet save child donate share aggregate sell save child use fund raise help reach goal obtain share donation form contact registrar equiniti manage donation sale share save child free charge provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure law regulation disclose annual report form change internal control financial reporting number provision law regulation apply period cover annual report form company share quote new york stock materially affect reasonably likely affect materially exchange nyse form adss company internal control financial reporting nyse rule disclose base recent evaluation internal general nyse rules permit company follow control financial report external auditor corporate governance practice instead apply arc significant deficiency material weaknesse provide explain significant variation design operation internal control financial reporting explanation contain form access reasonably likely affect adversely company security exchange commission sec edgar ability record process summarise report financial database website nyse rule come effect information fraud regardless materiality involve require file annual interim write affirmation person significant role company internal concern audit risk committee statement control financial report significant difference corporate governance group carry evaluation supervision sarbanesoxley act participation management include ceo follow number corporate accounting scandal cfo effectiveness design operation congress pass sarbanesoxley act group disclosure control procedure sarbanesoxley wideranging piece legislation concern december largely financial report corporate governance inherent limitation effectiveness system recommend sec company establish disclosure control procedure include possibility disclosure committee committee report ceo human error circumvention override control cfo audit risk committee chair procedure accordingly effective disclosure control company secretary member consist senior manager procedure provide reasonable assurance finance legal corporate communication investor achieve control objective relation ceo cfo expect complete certification external legal counsel external auditor internal expert report conclusion effectiveness disclosure control invite attend meeting periodically responsibility procedure march follow certificate consider materiality information timely basis file sec group form determine disclosure information responsibility section management annual report internal control timely filing report sec formal review financial report annual report form committee meet accordance requirement section sarbane time oxley follow report provide management respect sarbanesoxley require annual report form companys internal control financial reporting contain statement member audit risk define rule securities committee arc audit committee financial expert define exchange act sarbanesoxley statement relevant management responsible establish maintain member arc stacey cartwright judy lewent adequate internal control financial reporting group include audit risk committee report internal control financial reporting design provide biography additional disclosure reasonable assurance reliability financial requirement arise section section report preparation financial statement external sarbanesoxley respect disclosure control procedure purpose accordance ifrs internal control financial reporting management conduct evaluation effectiveness section corporate responsibility financial report internal control financial reporting base framework sarbanesoxley introduce requirement ceo internal control integrate framework issue cfo complete formal certification confirm committee sponsor organisation treadway review annual report form commission coso base knowledge annual report form change group internal control contain material misstatement omission financial reporting materially affect reasonably likely affect materially group internal base knowledge financial statement control financial report financial information fairly present material respect financial condition result operation cash flow management assess effectiveness internal control date period present annual report financial reporting december form conclusion file group form responsible establish maintain disclosure pricewaterhousecooper llp audit consolidated control procedure ensure material information financial statement group year end december known evaluated effectiveness assess effectiveness group internal control procedure yearend result control financial reporting auditing standard evaluation contain annual report form public company accounting oversight board united states audit report file group form responsible establish maintain internal control financial reporting provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept account principlesgsk annual report strategic report governance remuneration financial statement investor information section securities exchange act donation political organisation section securities exchange act political expenditure amend require issuer specific disclosure annual report certain type dealing iran include effect january ensure consistent approach transaction dealing governmentowne entity political contribution group introduce global dealing entity sanction activity relate policy stop voluntarily corporate political contribution terrorism proliferation weapon mass destruction period january december group activity prohibit law political donation noneu organisation involve person group legal entity base iran export certain pharmaceutical vaccine notwithstanding introduction policy accordance product iran sale nonus entity privately hold federal election campaign act continue iranian distributor group business nonus support employeeoperate political action committee pac entities jurisdiction target sanction law include facilitate voluntary political donation eligible gsk syria crimea north korea sudan employee believe group direct dealing pac control gsk decision amount iran require specific disclosure requirement recipient contribution participate employee group limit sale iran north korea syria sudan cuba exercise legal right pool resource essential medicine determine criterion set political contribution subject strict limitation world health organization group direct knowledge total identity distributor downstream customer iran donate political organisation gsk employee pac possible customer include entity agm shareholder authorise governmentowned hospital pharmacy own company donation political organisation control directly indirectly iranian government incur political expenditure provision political person entity sanction connection terrorism party election referendum act proliferation activity group direct year authority renew annually knowledge distributor customer establish company act require company continue obtain proportion gross revenue sale potentially attributable shareholder approval donation entity affiliate iranian government party sanction political organisation incur political expenditure disclosable activity result group report entire gross revenue nil net loss million intend donation group sale iran political party independent election candidate donation political organisation incur group aware hospital medical political expenditure facility lebanon affiliate control hezbollah designate united states terrorist definition political donation political expenditure organisation group deal directly political organisation legislation wide facility sell distributor group unable particular definition political organisation extend identify certainty degree nature affiliation body concern policy review law reform end customer hezbollah group unable representation business community special interest establish proportion gross revenue sale potentially group concern environment attributable reportable entity result group company subsidiary wish support result report entire gross revenue million net profit definition cover legitimate business activity million group sale lebanon ordinary sense consider political donation political expenditure activity design support political party independent election candidate authority board seek annually precautionary measure ensure company subsidiary inadvertently breach legislation gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company accordance section company act list subsidiary associate joint venture joint arrangement country incorporation effective percentage equity own december disclose state share capital disclose comprise ordinary share indirectly hold glaxosmithkline plc subsidiary company resident tax purpose country incorporation state country effective hold incorporation ownership security class share wholly own subsidiary alberta ulc canada common action potential venture capital limited england wale ordinary adechsa gmbh switzerland ordinary affymax research institute united states common alenfarma especialidade farmaceuticas limitada portugal ordinary quota allen hanbury limit england wale ordinary allen hanbury pharmaceutical nigeria limited nigeria ordinary allen farmaceutica spain ordinary allen pharmazeutika gesellschaft mbh austria ordinary aner argentina nonendorsable nominative ordinary barrier therapeutics inc united states common beecham group england wales share shares beecham pharmaceutical pte limited singapore ordinary beecham pharmaceuticals ecuador nominative beecham portuguesaprodutos farmaceuticos quimicos lda portugal ordinary quota beecham belgium ordinary biddle sawyer limited india equity biovesta ilalari ltd sti turkey nominative burrough wellcome australia pty limited australia ordinary burrough wellcome bangladesh limited bangladesh ordinary burrough wellcome international limited england wale ordinary caribbean chemical company ltd cayman islands ordinary strike cascan gmbh germany ordinary castleton investment ltd mauritius ordinary cellzome gmbh germany ordinary cellzome limited england wale ordinary cellzome therapeutics inc united states ordinary cellzome inc united states ordinary series preferred series prefer series convertible prefer series convertible prefer charles midgley limited england wale ordinary cumulative preference clarge pharmaceutical limited england wale ordinary preference colleen corporation united states share par value common corixa corporation united states common coulter pharmaceutical inc united states common dealcyber limited england wale ordinary desarrollo energia solar alternativa spain ordinary domantis limited england wale ordinary duncan flockhart australia pty limited australia ordinary duncan pharmaceuticals philippines inc philippine common edinburgh pharmaceutical industry limited scotland ordinary preference eskaylab limited england wale ordinary etex farmaceutica ltda chile social capital europharm hold romania nominative europharm romania nominative fedialis medica sas france ordinary fipar thailand ltd liquidation thailand ordinary genelabs technologies inc united states common glaxo norway ordinary glaxo group limited england wale ordinary glaxo kabushiki kaisha japan ordinary gsk annual report strategic report governance remuneration financial statement investor information group company continue country effective hold incorporation ownership security class share wholly own subsidiary continue glaxo laboratory nigeria limit nigeria ordinary glaxo laboratory limit england wale ordinary glaxo operation limited england wale ordinary glaxo property netherlands ordinary glaxo verwaltung gmbh germany ordinary glaxo wellcome australia pty ltd australia ordinary glaxo wellcome ceylon limited sri lanka ordinary ordinary glaxo wellcome farmaceutica limitada portugal ordinary quota glaxo wellcome holding limit liquidation england wale ordinary glaxo wellcome international netherlands ordinary glaxo wellcome manufacturing pte ltd singapore ordinary glaxo wellcome production sas france ordinary glaxo wellcome pst pty ltd australia ordinary glaxo wellcome limited england wale ordinary glaxo wellcome vidhyasom limited thailand ordinary glaxo wellcome spain ordinary glaxo spain ordinary glaxoallenburys nigeria limit nigeria ordinary glaxochem unlimited england wale ordinary ordinary ordinary glaxochem pte ltd singapore ordinary glaxosmithkline produtos farmaceuticos limitada portugal ordinary quota glaxosmithkline cambodia ltd cambodia ordinary glaxosmithkline china investment ltd china ordinary glaxosmithkline china company limited china equity glaxosmithkline cyprus limited cyprus ordinary glaxosmithkline gsk srl romania ordinary glaxosmithkline ireland limited ireland ordinary glaxosmithkline israel ltd israel ordinary glaxosmithkline malta limited malta ordinary glaxosmithkline private limited zimbabwe ordinary glaxosmithkline thailand limited thailand ordinary glaxosmithkline aebe greece ordinary glaxosmithkline sweden ordinary glaxosmithkline switzerland ordinary glaxosmithkline algrie spa algeria ordinary glaxosmithkline argentina argentina ordinary glaxosmithkline norway ordinary glaxosmithkline asia pvt limited india equity glaxosmithkline australia pty ltd australia ordinary glaxosmithkline netherlands ordinary glaxosmithkline beteiligung gmbh germany ordinary glaxosmithkline biological shanghai ltd china ordinary glaxosmithkline biological shenzhen ltd china ordinary glaxosmithkline biological kft hungary ordinary glaxosmithkline biological sas france ordinary glaxosmithkline biological belgium ordinary preference glaxosmithkline brasil limitada brazil ordinary glaxosmithkline business services costa rica ordinary glaxosmithkline capital inc united states ordinary glaxosmithkline capital plc england wale ordinary glaxosmithkline caribbean limited england wale ordinary glaxosmithkline chile farmaceutica limitada chile social capital glaxosmithkline colombia colombia ordinary glaxosmithkline consumer healthcare investment ireland ordinary ireland limited glaxosmithkline consumer healthcare ireland limited ireland ordinary glaxosmithkline consumer healthcare pakistan limited pakistan ordinary glaxosmithkline consumer healthcare sri lanka england wale ordinary holding limit glaxosmithkline consumer holding netherlands ordinary glaxosmithkline doo bosnia euro quota herzegovina gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue country effective hold incorporation ownership security class share wholly own subsidiary continue glaxosmithkline doo croatia equity glaxosmithkline doo beograd serbia ordinary glaxosmithkline ecuador ecuador ordinary glaxosmithkline eesti estonia ordinary glaxosmithkline ehf iceland ordinary glaxosmithkline salvador salvador ordinary glaxosmithkline eood bulgaria ordinary glaxosmithkline export limited england wale ordinary glaxosmithkline export panama panama ordinary glaxosmithkline far east netherlands ordinary glaxosmithkline finance plc england wales ordinary glaxosmithkline gmbh germany partnership capital glaxosmithkline guatemala guatemala ordinary glaxosmithkline hold norway ordinary glaxosmithkline holdings americas inc united states common glaxosmithkline holdings ireland limited england wale ordinary defer glaxosmithkline holding limited england wale ordinary glaxosmithkline holdings limited england wale ordinary glaxosmithkline holdings pty ltd australia ordinary glaxosmithkline honduras honduras ordinary glaxosmithkline ihc limited england wale ordinary glaxosmithkline ilaclari sanayi ticaret turkey nominative glaxosmithkline inc canada class common class preference glaxosmithkline insurance ltd bermuda ordinary glaxosmithkline intellectual property limited england wale ordinary glaxosmithkline intellectual property development limited england wale ordinary glaxosmithkline intellectual property holding limited england wale ordinary ordinary glaxosmithkline intellectual property limited england wale ordinary defer glaxosmithkline intellectual property management limited england wale ordinary glaxosmithkline international limited england wale ordinary glaxosmithkline investigacin desarrollo spain ordinary glaxosmithkline investment holdings limited england wale ordinary glaxosmithkline investment services limited england wale ordinary glaxosmithkline investment ireland limited ireland ordinary glaxosmithkline investment pty ltd australia ordinary glaxosmithkline japan ordinary glaxosmithkline korea limited south korea ordinary glaxosmithkline latin america panama ordinary glaxosmithkline latvia sia latvia ordinary glaxosmithkline lietuva uab lithuania ordinary glaxosmithkline limited hong kong ordinary glaxosmithkline llc united states llc interests glaxosmithkline manufacture spa italy ordinary glaxosmithkline maroc morocco ordinary glaxosmithkline medical healthcare product limit hungary ordinary quota glaxosmithkline mercury limited england wale ordinary glaxosmithkline mexico mexico ordinary ordinary glaxosmithkline limited new zealand ordinary glaxosmithkline finland ordinary glaxosmithkline peru peru ordinary glaxosmithkline pharma denmark class glaxosmithkline pharma gmbh austria ordinary glaxosmithkline pharmaceutical kenya limited kenya ordinary glaxosmithkline pharmaceutical nigeria limited nigeria ordinary glaxosmithkline pharmaceutical sdn bhd malaysia ordinary glaxosmithkline pharmaceuticals pvt ltd sri lanka ordinary glaxosmithkline pharmaceutical suzhou limited china ordinary glaxosmithkline pharmaceuticals costa rica costa rica ordinary glaxosmithkline pharmaceutical poland ordinary ordinary ordinary ordinary gsk annual report strategic report governance remuneration financial statement investor information group company continue country effective hold incorporation ownership security class share wholly own subsidiary continue glaxosmithkline pharmaceuticals belgium ordinary glaxosmithkline pharmaceutical ukraine llc ukraine charter capital glaxosmithkline philippines inc philippines common glaxosmithkline pte ltd singapore ordinary glaxosmithkline puerto rico inc puerto rico common glaxosmithkline republica dominicana dominican republic ordinary glaxosmithkline research development limited england wale ordinary glaxosmithkline spain ordinary glaxosmithkline spa italy ordinary glaxosmithkline sro czech republic ordinary glaxosmithkline services gmbh germany partnership capital glaxosmithkline services inc united states common glaxosmithkline service unlimited england wale ordinary glaxosmithkline holdings llc united states llc interest glaxosmithkline llc united states llc interest glaxosmithkline england wales partnership glaxosmithkline slovakia sro slovakia ordinary glaxosmithkline south africa pty limited south africa ordinary glaxosmithkline superannuation company pty ltd australia ordinary glaxosmithkline trading services limited ireland ordinary glaxosmithkline trading zao russia ordinary glaxosmithkline tunisia sarl tunisia ordinary glaxosmithkline limited england wale ordinary glaxosmithkline uruguay uruguay register share provisory stock glaxosmithkline venezuela venezuela ordinary glaxosmithkline vietnam limited liability company vietnam equity capital glycovaxyn switzerland common prefer prefer preferred group laboratories south africa pty limited south africa ordinary groupe glaxosmithkline sas france ordinary gsk business service centre sdn bhd malaysia ordinary gsk commercial poland ordinary gsk doo ljubljana slovenia ordinary gsk employee share plan pty ltd australia ordinary gsk kazakhstan llp kazakhstan partnership interest gsk service poland ordinary gsk vaccine gmbh germany ordinary gsk vaccines institute global health srl italy quota gsk vaccines srl italy quota gsk vaccines vertriebs gmbh germany ordinary herbridge ireland ordinary hgs france sarl france ordinary hgs luxembourg llc united states common interest horlick limited england wale ordinary human genome sciences pacific pty ltd australia ordinary human genome sciences inc united states common biomedical corporation quebec canada common biomedical corporation washington united states common instituto luso farmaco limitada portugal ordinary quota interpharma dienstleistungen gmbh austria quota technologies united states membership interest laboratoire glaxosmithkline france ordinary laboratoire pharmaceutique algrien lpa production spa algeria ordinary laboratoire pharmaceutique algrien spa algeria ordinary laboratoire paucourt france ordinary laboratoire saintgermain france ordinary laboratorios dermatologicos darier mexico ordinary ordinary laboratorios farmaceuticos stiefel portugal ltda portugal ordinary quota laboratorios phoenix sociedad anonima industrial argentina nonendorsable nominative comercial financiera ordinary share laboratorio stiefel chile cia ltda chile social capital laboratorios stiefel venezuela venezuela ordinary gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue country effective hold incorporation ownership security class share wholly own subsidiary continue laboratorios stiefel ltda brazil ordinary laboratorio wellcome portugal limitada portugal ordinary quota laboratorio wellcome liquidation uruguay ordinary maxinutrition limited liquidation england wale ordinary mixis genetic limited england wale ordinary ordinary euro montrose fine chemical company ltd scotland ordinary montrose pharma company limited hungary ordinary quota montrose pharma uab lithuania ordinary nanjing meirui pharma ltd china ordinary novartis vaccine diagnostic switzerland ordinary novartis vaccine diagnostic pty ltd australia ordinary novartis vaccine diagnostic spain ordinary okairos switzerland common prefer prefer penn labs inc united states common international netherlands ordinary limited united states unit common setfirst limited england wale ordinary smith kline french laboratory limited england wale ordinary smith kline french portuguesaprodutos portugal ordinary quota farmaceutico lda smithkline beecham australia pty ltd australia ordinary smithkline beecham bangladesh private limited bangladesh ordinary smithkline beecham cork limited ireland ordinary smithkline beecham export limited england wale ordinary smithkline beecham limited england wale noncumulative nonredeemable ordinary smithkline beecham investments limited england wale ordinary smithkline beecham manufacturing limited ireland ordinary smithkline beecham swg limited england wale ordinary smithkline beecham animal health company canada common smithkline beecham biological partnership united states partnership interest smithkline beecham egypt llc egypt quotas smithkline beecham farma spain ordinary smithkline beecham holdings australia pty limited australia ordinary ordinary smithkline beecham interamerican corporation united states share par value common smithkline beecham limited england wale ordinary smithkline beecham marketing technical services limited england wale ordinary smithkline beecham nominees limited england wale ordinary smithkline beecham overseas limited england wale ordinary smithkline beecham pension plan trustee limit england wale ordinary smithkline beecham pension trustee limit england wale ordinary smithkline beecham pharma gmbh germany partnership capital smithkline beecham pharma verwaltungs gmbh germany ordinary smithkline beecham pharmaceutical pty limited south africa ordinary smithkline beecham pharmaceuticals united states share par value common smithkline beecham port louis limited mauritius ordinary smithkline beecham retirement plan nominees australia ordinary pty limited smithkline beecham senior executive pension plan england wale ordinary trustee limit stiefel distributor ireland limited ireland ordinary stiefel dominicana srl dominican republic ordinary quota stiefel farma spain ordinary stiefel gmbh germany partnership capital stiefel india private limited india equity stiefel laboratory ireland limited ireland ordinary stiefel laboratory maidenhead ltd england wale ordinary stiefel laboratory thailand ltd liquidate jan thailand ordinary preference stiefel laboratory ltd england wale ordinary stiefel laboratory limit england wale ordinary gsk annual report strategic report governance remuneration financial statement investor information group company continue country effective hold incorporation ownership security class share wholly own subsidiary continue stiefel laboratory pte limited singapore ordinary stiefel laboratory pty ltd australia ordinary stiefel laboratory pty ltd south africa ordinary stiefel laboratory taiwan ltd liquidate jan taiwan ordinary stiefel laboratories inc united states common stiefel maroc sarl morocco ordinary stiefel polska likwidacji liquidation poland ordinary stiefel research australia holdings pty ltd australia ordinary stiefel research australia pty ltd australia ordinary stiefel research institute inc united states common stiefel sales inc united states common stiefel west coast llc united states llc interests strebor inc united states usd par value common tempero pharmaceuticals inc united states series preference series preference common sydney ross united states ordinary wellcome foundation limited england wale ordinary ucb pharma thailand ltd liquidate jan thailand ordinary ucb pharma asia pacific sdn bhd malaysia ordinary webderm inc united states common wellcome consumer healthcare limit england wale ordinary wellcome consumer product limit england wale ordinary wellcome development pty ltd australia ordinary wellcome limited england wale ordinary wellcome operation pty ltd australia ordinary subsidiary effective interest amoun pharmaceutical industry sae egypt new monetary share beecham enterprises inc united states common block drug company inc united states common british pharma group limited england wales capital block drug corporation united states common par value micln slovakia ordinary duncan consumer healthcare philippines inc philippines common exlax inc puerto rico common fondation novartis consumer health pour switzerland capital des sciences medicales biologique pharmaceutique glaxo saudi arabia limit saudi arabia ordinary glaxosmithkline tianjin ltd china ordinary glaxosmithkline bangladesh limited bangladesh ordinary glaxosmithkline brasil produtos para consumo saude ltda brazil ordinary glaxosmithkline consumer healthcare china ltd china ordinary glaxosmithkline consumer healthcare hong kong limited hong kong ordinary glaxosmithkline consumer healthcare ireland limited ireland ordinary glaxosmithkline consumer healthcare overseas limited england wales ordinary glaxosmithkline consumer healthcare thailand limited thailand ordinary glaxosmithkline consumer healthcare limited england wale ordinary glaxosmithkline consumer healthcare trading limited england wale ordinary glaxosmithkline consumer healthcare llc united states llc interest glaxosmithkline consumer healthcare denmark ordinary glaxosmithkline consumer healthcare sweden ordinary glaxosmithkline consumer healthcare switzerland ordinary glaxosmithkline consumer healthcare argentina argentina nominative non endorseable ordinary glaxosmithkline consumer healthcare australia pty ltd australia ordinary glaxosmithkline consumer healthcare netherlands ordinary glaxosmithkline consumer healthcare canada corp canada common glaxosmithkline consumer healthcare colombia sas colombia ordinary glaxosmithkline consumer healthcare czech republic sro czech republic ordinary glaxosmithkline consumer healthcare finance limited england wale ordinary glaxosmithkline consumer healthcare finland finland ordinary glaxosmithkline consumer healthcare gmbh austria ordinary glaxosmithkline consumer healthcare gmbh germany partnership capital gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue country effective hold incorporation ownership security class share subsidiary effective interest continued glaxosmithkline consumer healthcare greece societe greece ordinary anonyme glaxosmithkline consumer healthcare holding llc united states llc interest glaxosmithkline consumer healthcare holdings limited england wale ordinary ordinary glaxosmithkline consumer healthcare inc canada common prefer glaxosmithkline consumer healthcare investment ireland ordinary ireland glaxosmithkline consumer healthcare investment ireland ordinary ireland limited glaxosmithkline consumer healthcare japan japan ordinary glaxosmithkline consumer healthcare korea ltd korea ordinary glaxosmithkline consumer healthcare llc united states llc interest glaxosmithkline consumer healthcare limited india equity glaxosmithkline consumer healthcare mexico mexico ordinary glaxosmithkline consumer healthcare new zealand limited new zealand ordinary glaxosmithkline consumer healthcare norway norway ordinary glaxosmithkline consumer healthcare philippines inc philippines common glaxosmithkline consumer healthcare pte ltd singapore ordinary glaxosmithkline consumer healthcare belgium ordinary glaxosmithkline consumer healthcare spain ordinary glaxosmithkline consumer healthcare spa italy ordinary glaxosmithkline consumer healthcare sdn bhd malaysia ordinary glaxosmithkline consumer healthcare slovakia slovakia ownership interest glaxosmithkline consumer healthcare south africa pty ltd south africa ordinary glaxosmithkline consumer healthcare spzoo poland common glaxosmithkline consumer healthcare srl romania ordinary glaxosmithkline consumer healthcare united states partnership interest glaxosmithkline consumer healthcare produto para portugal ordinary quota saude higiene lda glaxosmithkline consumer nigeria plc iii nigeria ordinary glaxosmithkline consumer private limited india equity glaxosmithkline consumer trading service limited england wale ordinary glaxosmithkline costa rica costa rica ordinary glaxosmithkline dungarvan limited ireland ordinary glaxosmithkline healthcare russia ordinary glaxosmithkline healthcare gmbh germany ordinary glaxosmithkline healthcare ukraine ooo ukraine ownership interest glaxosmithkline landholde company inc philippines common glaxosmithkline limited kenya ordinary glaxosmithkline otc pvt limited pakistan ordinary glaxosmithkline pakistan limited pakistan ordinary glaxosmithkline panama panama ordinary glaxosmithkline paraguay paraguay ordinary glaxosmithkline pharmaceutical limited india equity glaxosmithkline sae egypt ordinary glaxosmithkline sante grand public sas france ordinary glaxosmithkline tuketici sagligi anonim sirketi turkey nominative glaxosmithklineconsumer hungary limited liability company hungary membership gsk consumer healthcare singapore pte ltd singapore ordinary iodosan spa italy ordinary kuhs gmbh germany equity laboratorios viiv healthcare spain ordinary modern pharma trading company llc egypt quota novartis consumer health australasia pty ltd australia ordinary redeemable preference novartis consumer health canada incnovartis sante canada common familiale canada inc novartis consumer health gmbh germany ordinary novartis consumer health llc russia participation interest gsk annual report strategic report governance remuneration financial statement investor information group company continue country effective hold incorporation ownership security class share subsidiary effective interest continued novartis consumer health belgium ordinary novartis consumer health spain ordinary novartis consumer health switzerland ordinary novartis consumer health schweiz switzerland ordinary novartis consumer health service switzerland register share novartis consumer health limited england wale ordinary novartis consumer health inc united states common novartis consumer healthgebro gmbh austria ordinary novartis sante familiale sas liquidation france ordinary smithkline beecham pharmaceutical indonesia share share sterling product indonesia indonesia share share panadol gmbh germany ordinary phivco jersey limited jersey ordinary phivco jersey limited jersey ordinary phivco limited england wale ordinary phivco limited england wale ordinary phivco llc united states llc interests phivco llc united states llc interest glaxo wellcome indonesia indonesia share share bina dentalindo liquidation indonesia ordinary shionogiviiv healthcare llc united states common interest sinoamerican tianjin smith kline french laboratories ltd china ordinary smithkline beecham private limited sri lanka ordinary smithkline beecham research limited england wale ordinary smithkline beecham spain ordinary smithkline beechambiome ooo russia participation interest staffordmiller ireland limited ireland ordinary staffordmiller limited england wale ordinary noncumulative non redeemable preference sterling drug malaya sdn berhad malaysia ordinary sterling product international incorporate united states common stiefel consumer healthcare limited england wale ordinary stiefel egypt llc egypt quota stiefel manufacturing ireland limited ireland ordinary viiv healthcare south africa proprietary limited south africa ordinary viiv healthcare netherlands ordinary viiv healthcare company united states common viiv healthcare finance limit england wale ordinary viiv healthcare finance limit england wale ordinary viiv healthcare gmbh germany ordinary viiv healthcare gmbh switzerland ordinary viiv healthcare kabushiki kaisha japan ordinary viiv healthcare limited england wale class share class share class share class preference class ordinary viiv healthcare overseas limited england wale ordinary viiv healthcare pty ltd australia ordinary viiv healthcare puerto rico llc puerto rico llc interest viiv healthcare srl italy quota viiv healthcare sas france ordinary viiv healthcare sprl belgium ordinary viiv healthcare trading llc russia participation interest viiv healthcare trading service limited england wale ordinary viiv healthcare limited jersey ordinary viiv healthcare limited england wale ordinary viiv healthcare limit england wale ordinary viiv healthcare limited england wale ordinary gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue country effective hold incorporation ownership security class share subsidiary effective interest continued viiv healthcare ulc canada common viiv healthcare venture llc united states llc interest viiv hiv healthcare unipessoal lda portugal quota winster pharmaceutical limited nigeria ordinary zhejiang tianyuan biopharmaceutical ltd china ordinary associates calci medica inc united states series junior prefer index venture life jersey united states partnership interest theravance inc innoviva inc united states common jcr pharmaceuticals ltd japan common kurma biofund fcpr france partnership interest longwood founder fund united states partnership interest river vision development corp united states series prefer joint ventures chiron panacea vaccines private ltd liquidation india japan vaccine ltd japan japan vaccine distribution ltd japan qualivax pte limited singapore qura therapeutics llc united states key directly own glaxosmithkline plc exempt provision section company act ireland accordance exemption note section act iii onsolidate subsidiary accordance section company act ground dominant influence dormant company tax resident entity expect disposed removed gsk annual report strategic report governance remuneration financial statement investor information glossary term term annual report equivalent brief description accelerate capital allowance allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr eceipt evidencing title ad gsk adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share call share capital ordinary share issue fully pay cer growth growth constant exchange rate company glaxosmithkline plc corporate integrity agreement cia company enter settlement federal government relate past sale marketing practice settlement company enter corporate integrity agreement department health human service improvement build exist compliance programme currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan ension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan equity shareholder fund shareholder equity finance lease capital lease freehold ownership absolute right perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset sset physical substance computer software brand licence patent knowhow marketing right purchase outside party novartis transaction threepart interconditional transaction novartis involve consumer healthcare vaccine oncology business complete march ordinary share fully pay ordinary share capital company profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity gsk exercise control treasury share treasury stock turnover revenue corporate governance code require list authority company disclose annual report apply good practice corporate governance provision financial reporting council corporate governance code gsk annual report strategic report governance remuneration financial statement investor information index accountability longterm incentive award accounting principle policie major restructuring cost acquisition disposal movement equity adjustment reconcile profit tax operate net debt cash flow new accounting requirement annual general meeting noncontrolle interest asset hold sale noncontrolle interest viiv healthcare associate joint venture nonexecutive director fee board governance note financial statement cash cash equivalent operate profit ceo statement intangible asset chairman statement investment commitment noncurrent asset committee report noncurrent liability competition operating income consolidate balance sheet provision consolidate cash flow statement approach risk consolidated income statement behaviour consolidated statement change equity board consolidate statement comprehensive income business consumer healthcare global marketplace consumer healthcare product competition people contingent liability planet corporate executive team strategy priority corporate governance overview total pay critical accounting policy pension postemployment benefit director senior management pharmaceutical director interest share pharmaceutical product competition director statement responsibility intellectual property dividend pipeline donation political organisation post balance sheet event political expenditure presentation financial statement earning share principal group company employee cost property plant equipment employee share scheme quarterly trend exchange rate reconciliation net cash flow movement net debt executive director remuneration registrar finance expense relate party transaction finance income relation shareholder financial instrument relate disclosure remuneration governance financial position resource remuneration policy summary financial statement glaxosmithkline plc prepare remuneration report gaap research development year record responsible business glossary term risk factor goodwill segment information group company share capital control group financial review share capital share premium account health share price independent auditor report shareholder information inventory taxation investment associate joint ventures tax information shareholder investor relation trade payable key accounting judgement estimate trade receivable key performance indicator law regulation leadership effectiveness vaccine legal proceeding viability statement gsk glaxosmithkline plc incorporate cautionary statement forwardlooke statement english public limited company december group report file furnish securities exchange commission sec include form merger document write information release oral statement public future behalf glaxo wellcome plc smithkline beecham group contain forwardlooke statement forwardlooke statement group current plc gsk acquire english company expectation forecast future event investor identify statement fact december merger relate strictly historical current fact use word anticipate estimate expect intend arrangement project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective share list london stock product product approval future performance result current anticipate product sale effort exchange new york stock exchange expense outcome contingency legal proceeding financial result accordance legal regulatory obligation include list rule disclosure transparency read wwwgskcom rule financial conduct authority group undertake obligation update forwardlooke statement result new information future event reader consult additional disclosure group document publish andor file sec reader locate note disclosure accordingly assurance give particular expectation meet shareholder caution place undue reliance forward look statement forwardlooke statement subject assumption inherent risk uncertaintie relate factor group control precise estimate group caution investor number important factor include document cause actual result differ materially express imply forwardlooke statement factor include limit discuss risk find downloadable pdfs factor page annual report forwardlooke statement behalf annual report group speak date base knowledge information available form director date annual report number adjust measure report responsible business supplement performance business measure define reconciliation core result total result set information document constitute offer sell invitation buy share glaxosmithkline plc invitation inducement engage investment activity past performance rely guide future performance annual report construe profit forecast assumption relate outlook outline expectation fiveyear period group certain assumption healthcare sector different market group operate delivery revenue financial benefit current portfolio pipeline restructuring programme group specifically period gsk brand name notice limitation expect decline sale seretideadvair brand name appear italic director liability english law introduction generic alternative advair report trade mark company act safe harbour limit factored group assessment future own andor license liability director respect statement performance group assume premature loss gsk associate company omission director report exclusivity key product period exception prolia own amgen strategic report remuneration group expectation billion revenue zofran own novartis trumenba report english law director liable annum cer basis product launch mencevax own pfizer treximet company party year include contribution current own pernix ireland lucozade report contain error result recklessness pipeline asset shingrix target expect ribena own suntory nimenrix know misstatement dishonest concealment meet year early group expect volume trade mark gsk license pfizer material fact liable page demand product increase particularly emerge inclusive comprise market acknowledgement director report page inclusive comprise print strategic report page inclusive comprise assumption group revenue earning print pureprint group iso remuneration report draw expectation assume material merger acquisition fsc certify carbon neutral present accordance reliance disposal litigation cost share repurchase english company law liability director company change group shareholding paper connection report shall subject viiv healthcare consumer healthcare assume annual report print limitation restriction provide law material change macroeconomic healthcare environment amadeus silk recycle paper fsc certification pulp website group expectation assume successful delivery deinked gsk website wwwgskcom give additional information group integration restructuring plan period postconsumer waste elemental group notwithstanding reference material cost investment new product chlorine free manufacturing mill annual report gsk website launch factor expectation hold iso ecolabel information available website constitute give expectation give constant currency certificate environmental annual report shall deem incorporate basis assume material change group management reference effective tax rate gsk annual report head office register office wwwgskcom glaxosmithkline plc great west road brentford middlesex search united kingdom tel register number